METHOD

FIELD OF THE INVENTION

The present invention relates to proline tolerant tripeptidyl peptidases for use in feed additive compositions and/or feed and/or feedstuffs and methods and/or uses encompassing the use of said proline tolerant tripeptidyl peptidases.

BACKGROUND

Proteases (synonymous with peptidases) are enzymes that are capable of cleaving peptide bonds between amino acids in substrate peptides, oligopeptides and/or proteins.

Proteases are grouped into 7 families based on their catalytic reaction mechanism and the amino acid residue involved in the active site for catalysis. The serine proteases, aspartic acid proteases, cysteine proteases and metalloprotease are the 4 major families, whilst the threonine proteases, glutamic acid proteases and ungrouped proteases make up the remaining 3 families.

The substrate specificity of a protease is usually defined in terms of preferential cleavage of bonds between particular amino acid residues in a substrate. Typically, amino acid positions in a substrate peptide are defined relative to the location of the scissile bond (i.e. the position at which a protease cleaves):

NH₂— . . . P3-P2-P1*P1′-P2′-P3′ . . . —COOH

Illustrated using the hypothetical peptide above, the scissile bond is indicated by the asterisk (*) whilst amino acid residues are represented by the letter ‘P’, with the residues N-terminal to the scissile bond beginning at P1 and increasing in number when moving away from the scissile bond towards the N-terminus. Amino acid residues C-terminal to the scissile bond begin at P1′ and increase in number moving towards the C-terminal residue.

Proteases can be also generally subdivided into two broad groups based on their substrate-specificity. The first group is that of the endoproteases, which are proteolytic peptidases capable of cleaving internal peptide bonds of a peptide or protein substrate and tending to act away from the N-terminus or C-terminus. Examples of endoproteases include trypsin, chymotrypsin and pepsin. In contrast, the second group of proteases is the exopeptidases which cleave peptide bonds between amino acid residues located towards the C or N-terminus of a protein or peptide substrate.

Certain enzymes of the exopeptidase group may have tripeptidyl peptidase activity. Such enzymes are therefore capable of cleaving 3 amino acid fragments (tripeptides) from the unsubstituted N-terminus of substrate peptides, oligopeptides and/or proteins. Tripeptidyl peptidases are known to cleave tripeptide sequences from the N-terminus of a substrate except bonds with proline at the P1 and/or P1′ position. Alternatively tripeptidyl peptidases may be proline-specific and only capable of cleaving substrates having a proline residue N-terminal to the scissile bond (i.e. in the P1 position).

Both exopeptidases and endoproteases have many applications.

Increasing protein digestibility, and therefore reducing the cost of the diet and increasing the efficiency of nutrient utilization in poultry and swine diets, as well as aqua and ruminant diets, is a big commercial area. Current commercially available proteases that are used for feed are alkaline proteases that are active at a high pH (8), which means they are active lower down in the gastrointestinal tract (the pH in the early digestive tract is more acidic, and becomes closer to neutral in the later part of the small intestine and the large intestine and caecum). By being active later (i.e. lower down) in the gastrointestinal tract, they produce oligopeptides later in the gastrointestinal tract where they appear to increase populations of microbes that excel at utilising easily digestible protein, which could lead to enteric disease challenges and reduced nutrients for the animal.

Additionally, at later parts of the gastrointestinal tract, the mucosa is less well-protected than in the tough gizzard, proventriculus or stomach and so is more easily damaged causing inflammation, a phenomenon that has been associated with protease use in young birds.

SUMMARY OF THE INVENTION

In a broad aspect the present invention provides a method of preparing a feed additive composition comprising:

(a) admixing a tripeptidyl peptidase comprising one or more amino acid sequence selected from the group consisting of SEQ ID No, 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No, 3, SEQ ID No, 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No, 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No, 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No, 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44. SEQ ID No, 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No, 49, SEQ ID No, 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof or an amino acid sequence having at least 70% identity therewith; or a tripeptidyl peptidase expressed from one or more of the nucleotide sequences selected from the group consisting of: SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No, 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No, 64, SEQ ID No, 65, SEQ ID No, 66, SEQ ID No, 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No, 76, SEQ ID No, 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No, 81, SEQ ID No, 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No, 94, SEQ ID No. 95, SEQ ID No. 96, SEQ ID No. 97 or a nucleotide sequence having at least 70% identity therewith, or which differs from these nucleotide sequences by the degeneracy of the genetic code, or which hybridises under medium or high stringency conditions; and

one or more ingredients selected from the group consisting of: a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, PVA, benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof; and

(b) optionally packaging.

According to a first aspect of the invention there is provided a method of preparing a feed additive composition comprising:

(a) admixing at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having

- (i) (A) Proline at P1; and
  - (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
- (ii) (a′) Proline at P1′; and
  - (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′; and
    
    one or more ingredients selected from the group consisting of: a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride; citrate, metabisulfite, formate or a combination thereof; and
    
    (b) optionally packaging.

In a second aspect there is provided a feed additive composition obtainable e.g. obtained) by a method of the present invention.

In a third aspect there is provided a feed additive composition or a feed ingredient comprising at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine; leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid; cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′; and
  
  one or more ingredients selected from the group consisting of: a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate; sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof.

According to a fourth aspect of the invention there is provided a kit comprising at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine; valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′; and instructions for administering same to an animal.

According to a fifth aspect of the invention there is provided a premix comprising a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention and at least one mineral and/or at least one vitamin.

In a sixth aspect there is provided a method of preparing a feedstuff comprising contacting a feed component with a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′
  
  optionally in combination with at least one endoprotease.

In a seventh aspect there is provided a feedstuff comprising a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a premix of the invention or comprising at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′.

According to an eighth aspect there is provided a method for improving a biophysical characteristic of an animal or for improving protein digestibility of an animal which method comprises administering to an animal a feed additive composition obtainable (e.g. obtained) by a method or use of the invention or a feed additive composition, feedstuff or premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′; and
  
  optionally at least one feed component and/or at least one mineral and/or at least one vitamin.

In a ninth aspect there is provided the use of a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a feedstuff or premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′
  
  for improving protein digestibility in an animal or for improving a biophysical characteristic of an animal.

In a tenth aspect there is provided the use of a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a feed feedstuff or premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (i) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′
  
  for maintaining gastrointestinal cell health of an animal; or for maintaining or improving ATP levels in gastrointestinal cells of an animal: or for maintaining or improving tight junction integrity in gastrointestinal cells of an animal.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention will now be described, by way of example only, with reference to accompanying drawings, in which:

FIG. 1 shows a plasmid map of the expression vector pTTT-pyrG-TRI083.

FIG. 2 shows a pH profile for a proline tolerant tripeptidyl peptidase.

FIG. 3 shows a graph displaying the activity of a proline tolerant tripeptidyl peptidase at various temperatures.

FIG. 4 shows enzyme activity when Alphalase® AFP (herein referred to as AFP) (an acid protease) is used in combination with a proline tolerant tripeptidyl peptidase at different dosages of each enzyme.

FIG. 5 shows the ability of a proline tolerant tripeptidyl peptidase to cleave the substrate AAPPA over time.

FIG. 6 shows the production of the cleavage product AAP from an AAPPA substrate over time.

FIG. 7 shows a plasmid map of the expression vector pTTT-pyrG13-TRI071. The endogenous signal sequence was replaced by the secretion signal sequence from the Trichoderma reesei acidic fungal protease (AFP) and an intron from a Trichoderma reesei glycoamylase gene (TrGA1) (see lower portion of FIG. 7).

FIG. 8 shows dose response of Alphalase® AFP on protein hydrolysis of corn soy feed. Dashed line represents the control where only pepsin and pancreatin were used.

FIG. 9 shows the dependence of DH on enzyme composition in the feed sample.

FIG. 10 shows the effect of feed treatment by Alphalase® AFP and proline tolerant tripeptidyl peptidase at different conditions. Solid bars represent the treatment at 40° C. for 100 min. Empty bars represent the treatment at 40° C. for 200 min.

FIG. 11 shows the effect of commercial proteases compared to a proline tolerant tripeptidyl peptidase on ileal N digestibility %.

FIG. 12 shows the effect of commercial proteases compared to a proline tolerant tripeptidyl peptidase on ileal digestiblity of energy (MJ/kg).

FIG. 13 shows the ATP content of the intestinal epithelial cells treated with proteases mixed directly with cell cultivation medium for one hour. Full bars—treatment by Commercial Protease 1; Empty bars—treatment by Commercial Protease 2; Bars with diagonal stripes —treatment by TRI083 (TRI083 as used herein mean an enzyme having the mature peptide sequence shown herein as SEQ ID No. 29); Bars with horizontal stripes—treatment by combination of TRI083 and Alphalase® AFP (dosages indicated for each enzyme).

FIG. 14 shows the ATP content of the intestinal epithelial cells treated for one hour with in vitro digested feed with proteases. Full bars—treatment by Commercial Protease 1 (plus control of digestion); Empty bars—treatment by Commercial Protease 2; Bars with diagonal stripes—treatment by TRI083; Bars with horizontal stripes—treatment by combination of TRIO83 and Alphalase® AFP (dosages indicated for each enzyme).

FIG. 15 shows FITC-Dextran permeability after four hours treatment. Full bars—treatment by Commercial Protease 1; Empty bars—treatment by Commercial Protease 2; Bars with diagonal stripes—treatment by TRIO83; Bars with horizontal stripes—treatment by combination of TRI083 and Alphalase® AFP (dosages indicated for each enzyme).

FIG. 16 shows relative changes in TEER for different treatments calculated from the value before the application of the test substances and after 4 hours of application. Full bars —treatment by Commercial Protease 1; Empty bars—treatment by Commercial Protease 2; Bars with diagonal stripes—treatment by TRI083; Bars with horizontal stripes—treatment by combination of TRI083 and Alphalase® AFP (dosages indicated for each enzyme)

FIG. 17 shows alignments between a number of proline tolerant tripeptidyl peptidase amino acid sequences. The xEANLD, y′Tzx′G and QNFSV motifs are shown (boxed).

FIG. 18 shows improvements in ileal N digestibility (%) versus the NC with supplementation of commercial proteases A+B and tripeptidyl peptidase (TRIO83).

FIG. 19 shows improvements in ileal digestible energy (MJ/kg) versus the NC with supplementation of commercial proteases A+B and tripeptidyl peptidase (TRIO83).

FIG. 20 shows the effect of supplementation of commercial proteases A+B and tripeptidyl peptidase (TRIO83) on BWG of broilers.

FIG. 21 shows the effect of supplementation of commercial proteases A+B and tripeptidyl peptidase (TRIO83) on FCR of broilers.

FIG. 22 shows the effect of pH on TRI045 (a tripeptidyl peptidase having pre-pro sequence SEQ ID No. 98 and mature protein SEQ ID No. 99) activity using AAF-pNA as substrate (values are the average of one test with 0.8 μl TRI045 (n=2).

FIG. 23 shows a plasmid map of the expression vector pTTT-pyrG13-TRI045.

FIG. 24 shows a pH profile for the tripeptidyl peptidase TRI045.

DETAILED DESCRIPTION

A seminal finding of the present invention is that a tripeptidyl peptidase can have exopeptidase activity on a substrate having proline at P1 and/or P1′ as well as any other amino acid at P1 and/or P1′. This is highly surprising as tripeptidyl peptidases that have been documented in the art typically are inhibited when proline is at P1 or are active when proline is at P1 but inactive when an amino acid other than proline is present at position P1 in the substrate, this is sometimes referred to herein as a proline-specific tripeptidyl peptidase. The inventors have shown for the first time that a proline tolerant tripeptidyl peptidase according to the present invention is highly advantageous for use in feed and feedstuffs and confers advantages to an animal fed the proline tolerant tripeptidyl peptidase or a feed additive composition comprising the same.

Advantageously, a proline tolerant tripeptidyl peptidase taught for use in the present invention is capable of acting on a wide range of peptide and/or protein substrates and due to having such a broad substrate-specificity is not readily inhibited from cleaving substrates enriched in certain amino acids (e.g. proline). The use of such a proline tolerant tripeptidyl peptidase therefore may efficiently and/or rapidly breakdown protein substrates (e.g. present in feed and/or feedstuffs). This confers the further advantage of efficiently and/or rapidly digesting a protein substrate in situ in an animal fed with such a protein substrate (e.g. as present in a feed or feedstuff) allowing rapid and/or efficient uptake of digested peptides by the animal.

Based on these findings, there is provided a method of preparing a feed additive composition comprising: (a) admixing at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having (i) (A) Proline at P1; and (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or (ii) (a′) Proline at P1′; and (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′; and one or more ingredients selected from the group consisting of: a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof; and (b) optionally packaging.

The invention also provides a feed additive composition obtainable (preferably obtained) by the method of the foregoing embodiment.

The term “admixing” as used herein refers to the mixing of one or more ingredients and/or enzymes where the one or more ingredients or enzymes are added in any order and in any combination. Suitably, admixing may relate to mixing one or more ingredients and/or enzymes simultaneously or sequentially.

In one embodiment the one or more ingredients and/or enzymes may be mixed sequentially. Preferably, the one or more ingredients and/or enzymes may be mixed simultaneously. Suitably the proline tolerant tripeptidyl peptidase for use in the methods and/or uses or comprised in any of the products of the present invention may be capable of cleaving tri-peptides from the N-terminus of peptides having proline at P1; and an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1.

Alternatively or additionally, the proline tolerant tripeptidyl peptidase for use in the methods and/or uses or comprised in any of the products of the present invention may be capable of cleaving tri-peptides from the N-terminus of peptides having proline at P1′; and an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′.

The term “proline tolerant tripeptidyl peptidase” as used herein relates to an exopeptidase which can cleave tripeptides from the N-terminus of a peptide, oligopeptide and/or protein substrate. A “proline tolerant tripeptidyl peptidase” is capable of cleaving peptide bonds where proline is at position P1 as well as cleaving peptide bonds where an amino acid other than proline is at P1 and/or capable of cleaving peptide bonds where proline is at position P1′ as well as cleaving peptide bonds where an amino acid other than proline is at P1′.

In one embodiment the proline tolerant tripeptidyl peptidase is not an endoprotease.

In another embodiment the proline tolerant tripeptidyl peptidase is not an enzyme which cleaves tetrapeptides from the N-terminus of a substrate.

In a further embodiment the proline tolerant tripeptidyl peptidase is not an enzyme which cleaves dipeptides from the N-terminus of a substrate.

In a yet further embodiment the proline tolerant tripeptidyl peptidase is not an enzyme which cleaves single amino acids from the N-terminus of a substrate.

In one embodiment the proline tolerant tripeptidyl peptidase may be capable of cleaving peptide bonds where proline is at position P1 as well as cleaving peptide bonds where an amino acid other than proline is at P1.

In another embodiment the proline tolerant tripeptidyl peptidase may be capable of cleaving peptide bonds where proline is at position P1′ as well as cleaving peptide bonds where an amino acid other than proline is at P1′.

Suitably, the proline tolerant tripeptidyl peptidase may also be able to cleave peptide bonds where the proline present at position P1 and/or P1′ is present in its cis or trans configuration. Suitably an “amino acid other than proline” may be an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids.

In another embodiment the “amino acid other than proline” may be an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine or valine.

Suitably, in such an embodiment synthetic amino acids may be excluded.

Preferably, the proline tolerant tripeptidyl peptidase may be able to cleave peptide bonds where proline is present at position P1 and P1′.

It is surprising that a tripeptidyl peptidase can act on a substrate having proline at position P1 and/or P1′. It is even more surprising that in addition to this activity a tripeptidyl peptidase may also have activity when an amino acid other than proline is present at position P1 and/or P1′.

In addition to having activity on any of the various substrates as described above the proline tolerant tripeptidyl peptidase for use in the present invention may additionally be tolerant of proline at one or more positions selected from the group consisting of: P2, P2′, P3 and P3′. Suitably the proline tolerant tripeptidyl peptidase in addition to having the activities described above may be tolerant of proline at position P2, P2′, P3 and P3′.

This is advantageous as it allows the efficient cleavage of peptide and/or protein substrates having stretches of proline and allows cleavage of a wide range of peptide and/or protein substrates.

The proline tolerant tripeptidyl peptidase may have a high activity on peptides and/or proteins having one or more of lysine, arginine or glycine in the P1 position.

The tripeptidyl peptide, e.g. proline tolerant tripeptidyl peptidase for use in the methods and/or uses of the present invention may be formulated in any appropriate manner known in the art.

In some embodiments further ingredients may be admixed with the tripeptidyl peptidase such as salts such as Na₂SO₄, maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, starch, Talc, polyvinyl alcohol (PVA), polyols such as sorbitol and glycerol, benzoate, sorbiate, sugars such as sucrose and glucose, propylene glycol, 1,3-propane diol, parabens, sodium chloride, citrate, acetate, sodium acetate, phosphate, calcium, metabisulfite, formate or mixtures thereof.

In a preferred embodiment the food additive composition or feed additive composition according to the present invention comprises the tripeptidyl peptidase according to the present invention or fermentate according to the present invention and further comprises one or more ingredients selected from the group consisting of: a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof.

In one embodiment the salt may be selected from the group consisting of: Na₂SO₄, NaH₂PO₄, Na₂HPO₄, Na₃PO₄, (NH₄)H₂PO₄, K₂HPO₄, KH₂PO₄, K₂SO₄, KHSO₄, ZnSO₄, MgSO₄, CuSO₄, Mg(NO₃)₂, (NH₄)₂SO₄, sodium borate, magnesium acetate, sodium citrate or combinations thereof.

In some embodiment polyols may be admixed with the proline tolerant tripeptidyl peptidase. Polyols such as glycerol and/or sorbitol may be admixed in amounts from 5% (w/w)-70% (w/w), preferably 10-20% (w/w), preferably 20-50% (w/w) and more preferably 10-50% (w/w) and more preferably 10-30% (w/w) with % (w/w) meaning % (weight polyol/weight solution), without wishing to be bound by theory a lower concentration of 10% polyol might help increasing the solubility and storage stability of the enzyme. However many commercial enzymes require 30% glycerol to keep the enzyme stable over time in the concentration of interest. Higher polyol at 50% might still improve stability further, but at this polyol level also the benefit of lower water activity is an advantage for microbial preservation. In particular for food enzymes this can be very important at neutral pH, where the choice of good preservatives are limited.

Sugars (in particular glucose) may be admixed with the proline tolerant tripeptidyl peptidase.

Sugars like glucose, fructose, sucrose, maltose, lactose, trehalose are all examples of substances that for many enzymes can be an alternative to using polyols. Suitably they (particularty glucose) may be used in the range 5% (w/w)-50% (w/w) either alone or in combination with polyols.

Sodium acetate may be admixed in amounts from 5% (w/w)-50% (w/w), preferably 8-40% preferably 8-12% (w/w), preferably 10-50% and more preferably 10-30% (w/w) with % (w/w) meaning % (weight sodium acetate/weight solution).

In one embodiment the proline tolerant tripeptidyl peptidase may be admixed with a preservative.

Suitably the preservative may be benzoate, such as sodium benzoate, and/or potassium sorbate. These preservatives can be typically used in a combined concentration of about 0.1-1%, suitably about 0.2-0.5%. Sodium benzoate is most efficient at pH<5.5 and sodium sorbate at pH<6.

Suitably the sugar is sorbitol.

Suitably the salt is sodium sulphate.

In one embodiment the one or more ingredients (e.g. used for the formulation of the enzyme when used in the methods and/or uses of the present invention) may be selected from the group consisting of: a wheat carrier, a polyol, a sorbitol, sodium sulphate and a preservative. Suitably the one or more ingredients (e.g. used for the formulation of the feed additive composition and/or feed and/or feedstuff and/or premix) may be selected from the group consisting of: a wheat carrier, sorbitol and sodium sulphate.

Suitably, the proline tolerant tripeptidyl peptidase may be admixed with a wheat carrier.

Suitably, the proline tolerant tripeptidyl peptidase may be admixed with sorbitol.

Suitably the proline tolerant tripeptidyl peptidase may be admixed with sodium sulphate.

In a preferred embodiment the proline tolerant tripeptidyl peptidase for use in the methods and/or uses of the present invention may be formulated with a carrier comprising (or consisting essentially of; or consisting of) a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof.

In a preferred embodiment the proline tolerant tripeptidyl peptidase for use in the methods and/or uses of the present invention may be formulated with a carrier comprising (or consisting essentially of; or consisting of) Na₂SO₄, NaH₂PO₄, Na₂HPO₄, Na₃PO₄, (NH₄)H₂PO₄, K₂HPO₄, KH₂PO₄, K₂SO₄, KHSO₄, ZnSO₄, MgSO₄, CuSO₄, Mg(NO₃)₂, (NH₄)₂SO₄, sodium borate, magnesium acetate, sodium citrate or combinations thereof.

In one embodiment, the proline tolerant tripeptidyl peptidase for use in the methods and/or uses of the present invention may be formulated with Na₂SO₄.

The feed additive composition of the present invention suitably comprises the proline tolerant tripeptidyl peptidase formulated with a carrier comprising (or consisting essentially of; or consisting of) a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof.

In one embodiment the feed additive composition of the present invention suitably comprises the proline tolerant tripeptidyl peptidase formulated with a carrier comprising (or consisting essentially of; or consisting of) Na₂SO₄, NaH₂PO₄, Na₂HPO₄, Na₃PO₄, (NH₄)H₂PO₄, K₂HPO₄. KH₂PO₄, K₂SO₄, KHSO₄, ZnSO₄, MgSO₄, CuSO₄, Mg(NO₃)₂, (NH₄)₂SO₄, sodium borate, magnesium acetate, sodium citrate or combinations thereof.

In one embodiment the feed additive composition of the present invention suitably comprises the proline tolerant tripeptidyl peptidase formulated with Na₂SO₄.

The proline tolerant tripeptidyl peptidase for use in the present invention may be a thermostable proline tolerant tripeptidyl peptidase.

The term “thermostable” means that an enzyme retains its activity when heated to temperatures of up to about 75° C. Suitably “thermostable” may mean that an enzyme retains its activity when heated to about 80° C., more suitably about 90° C.

Advantageously, a thermostable proline tolerant tripeptidyl peptidase is less prone to being denatured e.g. under the heat treatment of the feed pelleting process and/or will retain its activity for a longer period of time in e.g. an animal when compared to a non-thermostable variant.

The proline tolerant tripeptidyl peptidase may have activity in a range of about pH 2 to about pH 7. Suitably, the proline tolerant tripeptidyl peptidase may have activity in a range of about pH 4 to about pH 7, more suitably in a range of about pH 4.5 to about pH 6.5.

In another embodiment the proline tolerant tripeptidyl peptidase may have activity at an acidic pH (suitably, the proline tolerant tripeptidyl peptidase may have optimum activity at acidic pH). The proline tolerant tripeptidyl peptidase may have activity at a pH of less than about pH 6, more suitably less than about pH 5. Preferably, the proline tolerant tripeptidyl peptidase may have activity at a pH of between about 2.5 to about pH 4.0, more suitably at between about 3.0 to about 3.3. In one embodiment the proline tolerant tripeptidyl peptidase may have activity at a pH around 2.5.

Advantageously, a proline tolerant tripeptidyl peptidase having activity at an acidic pH can be active in the upper gastrointestinal tract of an animal (e.g. in the gizzard, proventriculus or stomach) and/or can digest a peptide and/or protein substrate in combination with endogenous proteases (e.g. pepsin, trypsin or chymotrypsin) that are present in the gastrointestinal tract of the animal.

Many current feeding practices involve administering an alkaline protease active at a high pH (e.g. pH 8) to animals. Alkaline proteases are therefore only active lower down (e.g. later) in the gastrointestinal tract of an animal where the gastrointestinal tract becomes more alkaline, such as in the later part of the small intestine and the large intestine and caecum. Without wishing to be bound by theory, it is believed that producing oligopeptides in the later parts of the gastrointestinal tract increases populations of microbes which utilise the oligopeptides which in turn can lead to enteric disease challenges and/or reduced nutrients available for uptake by the animal. Additionally, later in the gastrointestinal tract (i.e. lower down) the mucosa is less well-protected than in the upper portions (e.g. the gizzard, proventriculus or stomach) and so is more easily damaged leading to inflammation. Advantageously, the use of a proline tolerant tripeptidyl peptidase having activity at an acid pH alleviates this problem as it is capable of digesting its substrate in the upper gastrointestinal tract thereby not substantially increasing populations of microbes and/or increasing the amount of nutrient (e.g. amino acids/peptides) available for uptake by an animal and/or reducing inflammation. Chicken peptide transporter PEPT1 is most highly expressed in the duodenum compared to the jejunum and ileum (Chen et al (2009) J. Anim. Sci. 77:1277-1283 the teaching of which is incorporated herein by reference), therefore the inventors have identified that a proline tolerant tripeptidyl peptidase having activity at an acid pH may facilitate the uptake of peptides by an animal as the digestion of the protein and/or peptide substrate (e.g. present in a feed and/or feedstuff) will be available for uptake by the animal, early in the gastrointestinal tract, in the duodenum. This is in contrast to alkaline proteases which are not active early on in the gastrointestinal tract.

In one embodiment at least one endoprotease may be used in combination with the proline tolerant tripeptidyl peptidase for any of the applications herein. At least one endoprotease may also be comprised in the feed additive composition, feedstuff, kit or premix described herein.

The term “endoprotease” as used herein is synonymous with the term “endopeptidase” and refers to an enzyme which is a proteolytic peptidase capable of cleaving internal peptide bonds of a peptide or protein substrate (e.g. not located towards the C or N-terminus of the peptide or protein substrate). Such endoproteases may be defined as one that tends to act away from the N-terminus or C-terminus.

In one embodiment the endoprotease may be one or more selected from the group consisting of: a serine protease, an aspartic acid protease, a cysteine protease, a metalloprotease, a threonine protease, a glutamic acid protease and a protease selected from the family of ungrouped proteases.

In one embodiment the endoprotease may be one or more selected from the group consisting of: an acid fungal protease, a subtilisin, a chymotrypsin, a trypsin, a pepsin, papain, bromalin, thermostable bacterial neutral metalloendopeptidase, metalloneutral endopeptidase, alkaline serine protease, fungal endoprotease or from the group of commercial protease products Alphalase® AFP, Alphalase® FP2, Alphalase® NP.

Suitably, the endoprotease may be an acid endoprotease.

Preferably the endoprotease may be an acid fungal protease.

Advantageously, the use of an endoprotease in combination with a proline tolerant tripeptidyl peptidase can increase the efficiency of substrate cleavage. Without wishing to be bound by theory, it is believed that an endoprotease is able to cleave a peptide and/or protein substrate at multiple regions away from the C or N-terminus, thereby producing more N-terminal ends for the proline tolerant tripeptidyl peptidase to use as a substrate, thereby advantageously increasing reaction efficiency and/or reducing reaction times.

The use of an acid endoprotease and a proline tolerant tripeptidyl peptidase having activity at an acid pH is highly advantageous as the two enzymes can co-operate to digest a peptide and/or protein substrate in the upper gastrointestinal tract (e.g. gizzard, proventriculus or stomach) of an animal and can be active in combination with other endogenous proteases (e.g. pepsin) present in the animal.

The proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be an “in-feed” proline tolerant tripeptidyl peptidase.

The term “in-feed” as used herein means that the enzyme (e.g. the proline tolerant tripeptidyl peptidase and/or endoprotease) is functional, preferably primarily functional, more preferably solely functional, in the gastrointestinal tract (GIT) of the animal. In other words, the term “in-feed” as used herein means that the enzyme is substantially inactive (or is inactive) in the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix prior to feeding the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix to an animal.

There term “primarily functional” means that the enzyme mainly functions on its substrate once it enters the GIT. In other words, prior to entering the GIT the level of enzyme activity defined as the amount of cleavage of peptide and/or protein substrates to tripeptides is less than about 20%, suitably less than about 10%, preferably less than about 5%, of the level of enzyme activity after it enters the GIT (particularly, after it enters the gizzard, proventriculus or stomach of the animal).

Suitably, the proline tolerant tripeptidyl peptidase and/or the endoprotease is/are active in the duodenum and parts of the gastrointestinal tract of the animal preceding the duodenum (e.g. parts of the GIT that feed encounters earlier in the digestion process).

The term “solely functional” as used herein means that the enzyme is inactive before entering the GIT and is activated upon entering the GIT.

The term “inactive” as used herein means that the enzyme is not active. This may mean that the enzyme's activity is somehow inhibited or that the enzyme is in an environment in which it is inactive or that the enzyme is presented to its substrate immediately prior to feeding to the animal such that there is not enough time to be active. The “inactivity” of the enzyme may be in any event reversible once it enters the GIT of an animal.

Therefore, suitably the proline tolerant tripeptidyl peptidase (optionally in combination with an endoprotease) is admixed with the at least one protein or portion thereof immediately prior to feeding the feed additive composition to an animal.

The term “substantially inactive” as used herein means that the enzyme has low activity compared with its activity once it has entered the GIT (e.g. in the gizzard, proventriculus or stomach of the animal). For instance, substantially inactive may mean that the enzyme in the feed additive composition and/or feed and/or feedstuff and/or feed ingredient and/or premix has less than 10% of its activity when compared with its activity in the GIT (particularly, in the gizzard, proventriculus or stomach of the animal).

Maintaining the “in-feed” enzyme in an inactive or substantially inactive state in the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix can be achieved in a number of ways known to one skilled in the art.

By way of example only maintaining the water content (wt %) of the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix at less than 15%, preferably less than 10%, is sufficient to ensure that the in-feed enzyme is inactive or substantially inactive in the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix.

In one embodiment the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix, post-admixing the in-feed enzyme, are (maintained and/or stored) in a dry state or substantially dry state.

The term “dry state” as used herein means that the in-feed enzyme and/or the feed additive composition contains no or only a very low amount of water. In other words the term “dry state” as used herein may mean that the in-feed enzyme and/or the feed additive composition comprises less than 5%, preferably less than 1%, water content (wt %).

In one embodiment the proline tolerant tripeptidyl peptidase and/or endoprotease for use in the methods and/or uses and/or products of the present invention may in a dry or substantially dry state.

In another embodiment a proline tolerant tripeptidyl peptidase for use in any of the methods and/or uses and/or products of the invention may be admixed with a composition comprising at least one protein or at least a portion of a protein, wherein the composition, the proline tolerant tripeptidyl peptidase or combinations thereof are in a dry or substantially dry state when admixed. Suitably an endoprotease may be further admixed.

The term “dry or substantially dry state” when used herein means that the composition, proline tolerant tripeptidyl peptidase, endoprotease or combinations thereof contains only a very low amount of water. In other words the term “substantially dry state” as used herein may mean that the composition, proline tolerant tripeptidyl peptidase, endoprotease or combinations thereof comprises less than 15%, preferably less than 10%, water content (wt %).

In one embodiment, the composition, proline tolerant tripeptidyl peptidase, endoprotease or combinations thereof may be dried prior to, during or after (preferably prior to) use in the methods and/or uses of the invention.

In another embodiment the composition, proline tolerant tripeptidyl peptidase, endoprotease or combinations thereof either before or after use in the methods and/or uses of the invention comprises less than 15 wt % moisture content.

The proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof may be maintained in an inactive or substantially inactive state in the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix by physically preventing the enzyme from interacting with its substrate. For example the proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof may be encapsulated prior to its use in the methods and/or uses feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix of the invention.

When the proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof is physically prevented from interacting with its substrate in the feed additive composition and/or feedstuff and/or feed and/or feed ingredient and/or premix, then once in the GIT the physical barrier is removed thus allowing the interaction of the proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof with its substrate.

By way of example only, the encapsulation may be removed by passage of the encapsulated proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof through the gizzard, proventriculus or stomach of an animal. The gizzard, proventriculus or stomach of an animal is at very low (acidic) pH (e.g. pH 2-4). This acidity can be used to activate encapsulated enzymes.

In one embodiment the enzyme may be encapsulated by a polymer, such as chitin or chitosans, gelatin, gum arabic or wax for example. By way of example only the polymer may be a gelatin or gum arabic as taught in Xue et al Food Funct. 2013, Apr. 25; 6 Feb. (epub); 4 (4) 610-7. Alternatively, the polymer may a chitosan-based hydrogel as taught in Zhang et al Biomacromolecules 2011, 12,2894-2901.

In one embodiment the proline tolerant tripeptidyl peptidase (e.g. “in-feed” proline tolerant tripeptidyl peptidase), endoprotease or combinations thereof may be activated by feeding the enzyme to an animal.

The term “inactive” as used herein may mean that the enzyme is presented to its substrate immediately prior to feeding to the animal such that there is not enough time to be active before it enters the GIT of the animal.

In one embodiment the proline tolerant tripeptidyl peptidase for use in the present invention is part of a fermentate.

As used herein the term “fermentate” refers to the mixture of constituents present following (e.g. at the end of) the culturing of a host cell which fermentate includes the tripeptidyl peptidase (e.g. proline tolerant tripeptidyl peptidase), e.g. expressed by the host cell. The fermentate may comprises as well as the tripeptidyl peptidase in accordance with the present invention other components such as particulate matter, solids, substrates not utilised during culturing, debris, media, cell waste, etc. In one aspect, host cells (and particularly any spores) are removed from the fermentate and/or inactivated to provide a cell-free fermentate.

In other embodiments the proline tolerant tripeptidyl peptidase for use in the present invention is isolated or purified.

The present enzymes, including combinations of 3PP and an endoprotease, are also useful in a starch conversion process, particularly in a saccharification and fermentation process of gelatinized, raw, and or granular starch that has undergone liquefaction. The desired end-product (often referred to as an “end-of-fermentation” or “EOF” product) may be any product that may be produced by the enzymatic conversion of the starch substrate. For example, the desired product may be a syrup rich in glucose and maltose, which can be used in other processes, such as the preparation of high-fructose corn syrup (HFCS), or which can be converted into a number of other useful products, such as an ascorbic acid intermediates (e.g., gluconate; 2-keto-L-gulonic acid; 5-keto-gluconate; and 2,5-diketogluconate); 1,3-propanediol; amino acids (e.g., tyrosine, serine, lysine, glutamic acid, glycine, phenylalanine and tryptophan); organic acids (e.g., lactate, pyruvate, succinate, citrate, isocitrate, gluconate, itaconate, and oxaloacetate); antibiotics; antimicrobials; enzymes; vitamins; hormones; ethanol, butanol, and other alcohols; glucono delta-lactone; sodium erythorbate; omega-3 fatty acid; isoprene; and other biochemicals and biomaterials. One skilled in the art is aware of various fermentation conditions that may be used in the production of these EOF products.

Those of skill in the art are well aware of available methods that may be used to prepare starch substrates for conversion. Useful starch substrates may be obtained from tubers, roots, stems, legumes, cereals or whole grain. More specifically, the granular starch may be obtained from corn, cobs, wheat, barley, rye, triticale, milo, sago, millet, cassava, tapioca, sorghum, rice, peas, bean, banana, or potatoes. The starch substrate can be a crude starch from milled whole grain, which contains non-starch fractions, e.g., germ residues and fibers. Liquefaction generally involves gelatinization of starch simultaneously with or followed by the addition of an α-amylase, although additional liquefaction-inducing enzymes optionally may be added. In some cases, liquefaction of starch is performed at or below the gelatinization temperature, typically requires similar classes of enzymes with different performance criteria. The liquefied starch can be saccharified into a syrup with a lower degree of polymerization (DP) using α-amylases, optionally in the presence of other enzymes. The exact composition of the products of saccharification depends on the combination of enzymes used, as well as the type of granular starch processed.

The present enzymes may be added during liquefaction and/or saccharification as an isolated enzyme solution, dried or granular enzyme, clarified broth, ultrafiltrate concentrate, or whole cell broth, optionally as part of a blend. The present enzymes can be also added in the form of a cultured cell material produced by host cells expressing the enzymes. The present enzymes may also be secreted by a host cell into the reaction medium during the fermentation or simultaneous saccharification and fermentation (SSF) process, such that the enzyme is provided continuously into the reaction (see, below). The host cell producing and secreting the present enzymes may also express an additional enzyme, such as a glucoamylase and/or α-amylase. The host cell can be engineered to express a broad spectrum of various saccharolytic enzymes.

The soluble starch hydrolysate produced by treatment with amylase can be converted into high fructose starch-based syrup, such as high fructose corn syrup (HFCS). This conversion can be achieved using a glucose isomerase, particularly a glucose isomerase immobilized on a solid support.

Soluble starch hydrolysate, particularly a glucose rich syrup, can be fermented by contacting the starch hydrolysate with a fermenting organism. Ethanologenic microorganisms include yeast, such as Saccharomyces cerevisiae and bacteria, e.g., Zymomonas mobilis, expressing alcohol dehydrogenase and pyruvate decarboxylase. Commercial sources of yeast include ETHANOL REDÒ (LeSaffre); THERMOSACCÒ (Lallemand); RED STARÒ (Red Star); FERMIOLÒ (DSM Specialties); and SUPERSTARTÒ (Alltech). Microorganisms that produce other EOF (such as those mentioned, above) are also known in the art. As mentioned, above, the saccharification and fermentation processes may be carried out as an SSF process, wherein the fermenting organism expresses the present enzymes, optionally with one or more additional enzymes, such as a glucoamylase and/or α-amylase. Fermentation may comprise subsequent enrichment, purification, and recovery of the EOF.

Kits

In one aspect there is provided a kit comprising at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

- (i) (A) Proline at P1; and
  - (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
- (ii) (a′) Proline at P1′; and
  - (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′: and instructions for administering same to an animal.

Suitably the proline tolerant tripeptidyl peptidase may be capable of cleaving tri-peptides from the N-terminus of peptides having:

- (i) (A) Proline at P1; and
  - (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; and
- (ii) (a′) Proline at P1′; and
  - (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′.

More suitably, the proline tolerant tripeptidyl peptidase may be capable of cleaving tri-peptides from the N-terminus of peptides having proline at position P1 and at position P1′. Suitably the kit may further comprise at least one endoprotease.

The endoprotease may be compartmentalised separately to the proline tolerant tripeptidyl peptidase or the two enzymes may be mixed.

The proline tolerant tripeptidyl peptidase and/or endoprotease may be formulated in any manner as described herein or known to the person skilled in the art.

Suitably when the kit comprises a proline tolerant tripeptidyl peptidase in combination with at least one endoprotease the instructions may be instructions for co-administering the same.

The term “co-administering” as used herein means administering one or more ingredients and/or enzyme either separately (e.g. sequentially) or together (e.g. simultaneously).

Activity and Assays

The proline tolerant tripeptidyl peptidase for use in the present invention predominantly has exopeptidase activity.

The term “exopeptidase” activity as used herein means that the proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of a substrate, such as a protein and/or peptide substrate.

The term “predominantly has exopeptidase activity” as used herein means that the tripeptidyl peptidase has no or substantially no endoprotease activity.

“Substantially no endoprotease activity” means that the proline tolerant tripeptidyl peptidase or exo-peptidase of the S53 family has less than about 100 U endoprotease activity in the “Endoprotease Assay” taught herein when compared to 1000 nkat of exopeptidase activity in the “Exopeptidase Broad-Specificity Assay (EBSA)” taught herein. Suitably, “substantially no endoprotease activity” means that the proline tolerant tripeptidyl peptidase has less than about 100 U endoprotease activity in the “Endoprotease Assay” taught herein when compared to 1000 nkat of exopeptidase activity in the “Exopeptidase Broad-Specificity Assay” taught herein.

Preferably the proline tolerant tripeptidyl peptidase or exo-peptidase of the S53 family may have less than about 10 U endoprotease activity in the “Endoprotease Assay” taught herein when compared to 1000 nkat of exopeptidase activity in the “Exopeptidase Broad-Specificity Assay” taught herein, more preferably less than about 1 U endoprotease activity in the “Endoprotease Assay” taught herein when compared to 1000 nkat of exopeptidase activity in the “Exopeptidase Broad-Specificity Assay” taught herein. Even more preferably the proline tolerant tripeptidyl peptidase or exo-tripeptidyl peptidase may have less than about 0.1 U endoprotease activity in the “Endoprotease Assay” taught herein when compared to 1000 nkat of exopeptidase activity in the “Exopeptidase Broad-Specificity Assay” taught herein.

“Endoprotease Assay”
Azoscasein Assay for Endoprotease Activity

A modified version of the endoprotease assay described by Iversen and Jørgensen, 1995 (Biotechnology Techniques 9, 573-576) is used. An enzyme sample of 50 μl is added to 250 μl of azocasein (0.25% w/v; from Sigma) in 4 times diluted McIlvaine buffer, pH 5 and incubated for 15 min at 40° C. with shaking (800 rpm). The reaction is terminated by adding 50 μl of 2 M trichloroacetic acid (TCA) (from Sigma Aldrich, Denmark) and centrifugation for 5 min at 20,000 g. To a 195 μl sample of the supernatant 65 μl of 1 M NaOH is added and absorbance at 450 nm is measured. One unit of endoprotease activity is defined as the amount which yields an increase in absorbance of 0.1 in 15 min at 40° C. at 450 nm.

“Exopeptidase Assay”

There are two parts to the assay:

Part 1—“Exopeptidase Broad-Specificity Assay” (EBSA)

10 μL of the chromogenic peptide solution (10 mM H-Ala-Ala-Ala-pNA dissolved in dimethyl sulfoxide (DMSO); MW=387.82; Bachem, Switzerland) were added to 130 μl Na-acetate (20 mM, adjusted to pH 4.0 with acetic acid) in a microtiter plate and heated for 5 minutes at 40° C. 10 μL of appropriately diluted enzyme was added and the absorption was measured in a MTP reader (Versa max, Molecular Devices, Denmark) at 405 nm. One katal of proteolytic activity was defined as the amount of enzyme required to release 1 mole of p-nitroaniline per second.

Part 2 (1)—P1 Proline Assay

(a) Dissolve the substrate H-Arg-Gly-Pro-Phe-Pro-Ile-Ile-Val (MW=897.12; from Schafer-N, Copenhagen in 10 times diluted McIlvain buffer, pH=4.5 at 1 mg/ml concentration.

(b) Incubate 1000 ul of the substrate solution with 10 ug of proline tolerant tripeptidyl peptidase solution at 40° C.

(c) Take 100 ul samples at seven time points (0, 30, 60, 120, 720 and 900 min), dilute with 50 ul 5% TFA, heat inactivate (10 min at 80° C.) and keep at −20° C. until LC-MS analysis;

(d) Perform LC-MC/MS analysis using an Agilent 1100 Series Capillary HPLC system (Agilent Technologies, Santa Clara. Calif.) interfaced to a LTQ Orbitrap Classic hybrid mass spectrometer (Thermo Scientific, Bremen, Germany);

(e) Load samples onto a 50 mm Fortis™ C18 column with an inner diameter of 2.1 mm and a practical size of 1.7 μm

(f) Perform separation at a flow rate of 200 μL/min using a 14 min gradient of 2-28% Solvent B (H2O/CH3CN/HCOOH (50/950/0.65 v/v/v)) into the IonMAX source—The LTQ Orbitrap Classic instrument was operated in a data-dependent MS/MS mode;

(g) Measure the peptide masses by the Orbitrap (obtain MS scans with a resolution of 60.000 at m/z 400), and select up to 2 of the most intense peptide m/z and subject to fragmentation using CID in the linear ion trap (LTQ). Enable dynamic exclusion with a list size of 500 masses, duration of 40 s, and an exclusion mass width of ±10 ppm relative to masses on the list;

(h) Use the open source program Skyline 1.4.0.4421 (available from MacCoss Lab Software, University of Washington, Department of Genome Sciences, 3720 15^thAve NE Seattle, Wash., US) to access the RAW files and extract MS1 intensities to build chromatograms. Set the precursor isotopic import filter to a count of three, (M, M+1, and M+2) at a resolution of 60,000 and use the most intense charge state;

(i) Peptide sequences of the substrate and cleavage products were typed into Skyline and intensities were calculated in each sample (0, 30, 60, 120, 720 and 900 min hydrolysis).

(j) One unit of activity is defined as the amount of enzyme which in this assay will hydrolyse 50% of the substrate within 720 min while releasing Arg-Gly-Pro.

Part 2 (11)—P1′ Proline Assay

(a) Dissolve the peptide H-Ala-Ala-Phe-Pro-Ala-NH2 (MW=474.5; from Schafer-N, Copenhagen) in 10 times diluted McIlvain buffer, pH=4.5 at 0.1 mg/ml concentration.

(b) Incubate 1000 ul of the substrate solution with 10 ug proline tolerant tripeptidyl peptidase solution at 40° C.

(c) Take 100 ul samples at seven time points (0, 30, 60, 120, 720 and 900 min), dilute with 50 ul 5% TFA, heat inactivate (10 min at 80° C.) and keep at −20° C. until LC-MS analysis;

(d) Perform LC-MC/MS analysis using a Agilent 1100 Series Capillary HPLC system (Agilent Technologies, Santa Clara, Calif.) interfaced to a LTQ Orbitrap Classic hybrid mass spectrometer (Thermo Scientific, Bremen, Germany);

(e) Load samples onto a 50 mm Fortis™ C18 column with an inner diameter of 2.1 mm and a practical size of 1.7 μm

(f) Perform separation at a flow rate of 200 μL/min using a 14 min gradient of 2-28% Solvent B (H2O/CH3CN/HCOOH (50/950/0.65 v/v/v)) into the IonMAX source—The LTQ Orbitrap Classic instrument was operated in a data-dependent MS/MS mode;

(g) Measure the peptide masses by the Orbitrap (obtain MS scans with a resolution of 60.000 at m/z 400), and select up to 2 of the most intense peptide m/z and subject to fragmentation using CID in the linear ion trap (LTQ). Enable dynamic exclusion with a list size of 500 masses, duration of 40 s, and an exclusion mass width of ±10 ppm relative to masses on the list.

(h) Use the open source program Skyline 1.4.0.4421 (available from MacCoss Lab Software, University of Washington, Department of Genome Sciences, 3720 15^thAve NE Seattle, Wash., US) to access the RAW files and extract MS1 intensities to build chromatograms. Set the precursor isotopic import filter to a count of three, (M, M+1, and M+2) at a resolution of 60,000 and use the most intense charge state;

(i) Peptide sequences of the substrate as well as cleavage products were typed into Skyline and intensities were calculated in each sample.

(j) One unit of activity is defined as the amount of enzyme which in this assay will hydrolyse 50% of the substrate within 720 min while releasing Ala-Ala-Phe.

In one embodiment a proline tolerant tripeptidyl peptidase in accordance with the present invention has an activity of at least 50 nkat in Part 1 of the activity taught herein and at least 100 U activity in Part 2(i) or Part 2(ii) of the assay taught herein per mg of protein.

In one embodiment a proline tolerant tripeptidyl peptidase in accordance with the present invention has an activity of between about 50-2000 nkat in Part 1 of the activity taught herein and between about 1-500 units activity in Part 2(i) or Part 2(i) of the assay taught herein per mg of protein. Note the protein measurement is described in Example 2.

“P1 and P1′ Proline Activity Assay”

Suitably the tripeptidyl peptidase for use in the present invention may be able to cleave substrates having proline at position P1 and P1′. This can be assessed using the assay taught below.

In this assay a tripeptidyl peptidase is examined for its ability to hydrolyse a synthetic substrate AAPPA by LC-MS and label free quantification.

(a) Dissolve the peptide H-AAPPA-NH2 (MW=424.3, from Schafer-N, Copenhagen) in 20 mM MES buffer, pH=4.0 (1 mg/ml);

(b) Incubate 1000 ul of the H-AAPPA-NH2 solution with 200 ul proline tolerant tripeptidyl peptidase solution (40 ug/ml) (substrate/enzyme 100:0.8) at room temperature;

(c) Take 100 ul samples at seven time points (0, 5, 15, 60, 180, 720 and 1440 min), dilute with 50 ul 5% TFA, heat inactivate (10 min at 80° C.) and keep at −20° C. until LC-MS analysis;

(d) Perform Nano LC-MS/MS analyses using an Easy LC system (Thermo Scientific, Odense, DK) interfaced to a LTQ Orbitrap Classic hybrid mass spectrometer (Thermo Scientific, Bremen, Germany);

(e) Load samples onto a custom-made 2 cm trap column (100 μm i.d., 375 μm o.d., packed with Reprosil C18, 5 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) connected to a 10 cm analytical column (75 μm i.d., 375 μm o.d., packed with Reprosil C18, 3 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) with a steel needle;

(f) Perform separation at a flow rate of 300 nL/min using a 10 min gradient of 0-34% Solvent B (H2O/CH3CN/TFE/HCOOH (100/800//100/1 v/v/v/v)) into the nanoelectrospray ion source (Thermo Scientific, Odense, DK)—operate the LTQ Orbitrap Classic instrument in a data-dependent MS/MS mode;

(g) Measure the peptide masses by the Orbitrap (obtain MS scans with a resolution of 60 000 at m/z 400), and select up to 2 of the most intense peptide m/z and subject to fragmentation using CID in the linear ion trap (LTQ). Enable dynamic exclusion with a list size of 500 masses, duration of 40 s, and an exclusion mass width of ±10 ppm relative to masses on the list;

(h) Use the open source program Skyline 1.4.0.4421 (available from MacCoss Lab Software, University of Washington, Department of Genome Sciences, 3720 15^thAve NE Seattle, Wash., US) to access the RAW files which program can use the MS1 intensities to build chromatograms. Set the precursor isotopic import filter to a count of three, (M, M+1, and M+2) at a resolution of 60,000 and use the most intense charge state;

(i) Peptide sequences of the substrate as cleavage products were typed into Skyline and intensities were calculated in each sample.

(j) One unit of activity is defined as the amount of enzyme which in this assay will hydrolyse 50% of the substrate within 24 h while releasing AAP.

In one embodiment a proline tolerant tripeptidyl peptidase in accordance with the present invention has an activity of between about 50-2000 nkat in Part 1 of the activity taught herein and between about 1-500 units activity in Part 2(i) or Part 2(i) of the assay taught herein per mg of protein (protein concentration is calculated as in Example 2).

In one embodiment a proline tolerant tripeptidyl peptidase for use in the present invention may have at least 10 U activity in the “P1 and P1′ Proline Activity Assay” taught herein per mg of protein.

In one embodiment a proline tolerant tripeptidyl peptidase in accordance with the present invention has an activity of between about 1 U-500 U activity in the “P1 and P1′ Proline Activity Assay” taught herein per mg of protein.

In addition to the above, the proline tolerant tripeptidyl peptidase may also have activity in accordance with Part 1 of the “Exopeptidase Activity Assay” taught above.

In one embodiment the proline tolerant tripeptidyl peptidase for use in the present invention may have at least 10 U activity in the “P1 and P1′ Proline Activity Assay” taught herein and at least 50 nkatal in Part 1 of the “Exopeptidase Activity Assay” taught herein per mg of protein.

In another embodiment a proline tolerant tripeptidyl peptidase in accordance with the present invention has an activity of between about 1 U-500 U activity in the “P1 and P1′ Proline Activity Assay” taught herein and between about 50 U-2000 U katal in Part 1 of the “Exopeptidase Activity Assay” taught herein per mg of protein.

Amino Acid and Nucleotide Sequences

The proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from any source so long as it has the activity described herein.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Trichoderma.

Suitably from Trichoderma reesei, more suitably, Trichoderma reesei QM6A.

Suitably from Trichoderma virens, more suitably, Trichoderma virens Gv29-8.

Suitably from Trichoderma atroviride. More suitably, Trichoderma atroviride IMI 206040.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Aspergillus.

Suitably from Aspergillus fumigatus, more suitably Aspergillus fumigatus CAE17675.

Suitably from Aspergillus kawachii, more suitably from Aspergillus kawachii IFO 4308.

Suitably from Aspergillus nidulans, more suitably from Aspergillus nidulans FGSC A4.

Suitably from Aspergillus oryzae, more suitably Aspergillus oryzae RIB40.

Suitably from Aspergillus ruber, more suitably Aspergillus ruber CBS135680.

Suitably from Aspergillus terreus, more suitably from Aspergillus terreus NIH2624.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Bipolaris, suitably from Bipolaris maydis, more suitably Bipolaris maydis C5.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Togninia, suitably from Togninia minima more suitably Togninia minima UCRPA7.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Talaromyces, suitably from Talaromyces stipitatus more suitably Talaromyces stipitatus ATCC 10500.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Arthroderma, suitably from Arthroderma benhamiae more suitably Arthroderma benhamiae CBS 112371.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Magnaporthe, suitably from Magnaporthe oryzae more suitably Magnaporthe oryzae 70-1.

In another embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Fusarium.

Suitably from Fusarium oxysporum, more suitably from Fusarium oxysporum f. sp. cubense race 4.

Suitably from Fusarium graminearum, more suitably Fusarium graminearum PH-1.

In a further embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Phaeosphaeria, suitably from Phaeosphaeria nodorum more suitably Phaeosphaeria nodorum SN15.

In a yet further embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Agaricus, suitably from Agaricus bisporus more suitably Agaricus bisporus var. burnettii JB137-S8.

In a yet further embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Acremonium, suitably from Acremonium alcalophilum.

In a yet further embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Sodiomyces, suitably from Sodiomyces alkalinus.

In one embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Penicillium.

Suitably the proline tolerant tripeptidyl peptidase may be obtainable from Penicillium digitatum, more suitably from Penicillium digitatum Pd1.

Suitably the proline tolerant tripeptidyl peptidase may be obtainable from Penicillium oxalicum, more suitably from Penicillium oxalicum 114-2.

Suitably the proline tolerant tripeptidyl peptidase may be obtainable from Penicillium roqueforti, more suitably from Penicillium roqueforti FM164.

Suitably the proline tolerant tripeptidyl peptidase may be obtainable from Penicillium rubens, more suitably from Penicillium rubens Wisconsin 54-1255.

In another embodiment the proline tolerant tripeptidyl peptidase for use in accordance with the present invention may be obtainable (e.g. obtained) from Neosartorya.

Suitably the proline tolerant tripeptidyl peptidase may be obtainable from Neosartorya fischeri, more suitably from Neosartorya fischeri NRRL181.

In one embodiment the tripeptidyl peptidase (e.g. proline tolerant tripeptidyl peptidase) for use in accordance with the present invention is not obtainable (e.g. obtained) from Aspergillus niger.

SEQ

ID

No.:
Sequence
Origin

1

MAKLSTLRLASLLSLVSVQVSASVHLLESLEKLPHGWKAAETPSPS

Trichoderma

SQIVLQVALTQQNIDQLESRLAAVSTPTSSTYGKYLDVDEINSIFAP

reesei QM6a

SDASSSAVESWLQSHGVTSYTKQGSSIWFQTNISTANAMLSTNFH

TYSDLTGAKKVRTLKYSIPESLIGHVDLISPTTYFGTTKAMRKLKSS

GVSPAADALAARQEPSSCKGTLVFEGETENVFQPDCLRTEYSVDG

YTPSVKSGSRIGEGSFLNESASFADQALFEKHENIPSQNFSVVLING

GTDLPQPPSDANDGEANLDAQTILTIAHPLPITEFITAGSPPYFPDP

VEPAGTPNENEPYLQYYEELLSKSNAEIPQVITNSYGDEEQTVPRS

YAVRVONLIGLLGLRGISVLEISSGDEGVGASCVATNSTTPQFNPIF

PATCPYVTSVGGTVSENPEVAWAGSSGGESYYFSRPWYQQEAV

GTYLEKYVSAETKKYYGPYVDFSGRGFPDVAAHSVSPDYPVFQG

GELTPSGGTSAASPVVAAIVALLNDARLREGKPTLGELNPLIYLHAS

KGFTDITSGQSEGCNGNNTQTGSPLPGAGFIAGAHWNATKGWDP

TTGEGVPNLKKLLALVRF

2
SVHLLESLEKLPHGWKAAETPSPSSQIVLQVALTQQNIDQLESRLA

Trichoderma

AVSTPTSSTYGKYLDVDEINSIFAPSDASSSAVESWLQSHGVTSYT

reesei QM6a

KQGSSIWFQTNISTANAMLSTNEHTYSDLTGAKKVRTLKYSIPESLI

GHVDLISPTTYFGTTKAMRKLKSSGVSPAADALAARQEPSSCKGT

LVFEGETENVFQPDCLRTEYSVDGYTPSVKSGSRIGEGSFLNESA

SFADQALFEKHFNIPSQNFSVVLINGGTDLPQPPSDANDGEANLDA

QTILTIAHPLPITEFITAGSPPYFPDPVEPAGTPNENEPYLQYYEFLL

SKSNAEIPQVITNSYGDEEQTVPRSYAVRVCNLIGLLGLRGISVLHS

SGDEGVGASCVATNSTTPQFNPIFPATCPYVTSVGGTVSFNPEVA

WAGSSGGFSYYFSRPWYQQEAVGTYLEKYVSAETKKYYGPYVDF

SGRGFPDVAAHSVSPDYPVFQGGELTPSGGTSAASPVVAAIVALL

NDARLREGKPTLGELNPLIYLHASKGFTDITSGQSEGCNGNNTQT

GSPLPGAGFIAGAHWNATKGWDPTTGEGVPNLKKLLALVRF

3
EAFEKLSAVPKGWHYSSTPKGNTEVCLKIALAQKDPAGFEKTVLE

Aspergillus

MSDPDHPSYGQHFTTHDEMKRMLLPRDDTVDAVRQWLENGGVT

oryzae RIB40

DETQDADWINFCTTVDTANKLLNAQFKWYVSDVKHIRRLRTLQYD

VPESVTPHINTIQPTTRFGKISPKKAVTHSKPSQLDVTALAAAVVAK

NISHCDSIITPTCLKELYNIGDYQADANSGSKIAFASYLEEYARYADL

ENFENYLAPWAKGQNFSVTTENGGLNDQNSSSDSGEANLDLQYIL

GVSAPLPVTEFSTGGRGPLVPDLTQPDPNSNSNEPYLEFFQNVLK

LDQKDLPQVISTSYGENEQEIPEKYARTVCNLIAQLGSRGVSVLFS

SGDSGVGEGCMTNDGTNRTHEPPQFPAACPWVTSVGATEKTTPE

RGTYFSSGGESDYWPRPEWQDEAVSSYLETIGDTFKGLYNSSGR

AFPDVAAQGMNFAVYDKGILGEFDGTSASAPAFSAVIALLNDARL

RAGKPTLGELNPWLYKTGRQGLQDITLGASIGCTGRAREGGAPDG

GPVVPYASWNATQGWDPVTGLGTPDFAELKKLALGN

4
EPFEKLFSTPEGWKMQGLATNEQIVKLQIALQQGDVAGFEQHVIDI

Phaeosphaeria

STPSHPSYGAHYGSHEEMKRMIQPSSETVASVSAWLKAAGINDAE

nodorum

IDSDWVTEKTTVGVANKMLDTKFAWYVSEEAKPRKVLRTLEYSVP
SN15

DDVAEHINLIQPTTRFAAIRQNHEVAHEIVGLQFAALANNTVNCDAT

ITPQCLKTLYKIDYKADPKSGSKVAFASYLEQYARYNDLALFEKAFL

PEAVGQNFSVVQFSGGLNDQNTTQDSGEANLDLQYIVGVSAPLPV

TEFSTGGRGPWVADLDQPDEADSANEPYLEFLQGVLKLPQSELP

QVISTSYGENEQSVPKSYALSVCNLFAQLGSRGVSVIESSGDSGP

GSACQSNDGKNTTKFQPQYPAACPFVTSVGSTRYLNETATGESS

GGESDYWKRPSYQDDAVKAYFHHLGEKEKPYFNRHGRGFPDVAT

QGYGFRVYDQGKLKGLQGTSASAPAFAGVIGLLNDARLKAKKPTL

GELNPLLYSNSDALNDIVLGGSKGCDGHARENGPPNGSPVIPYAG

WNATAGWDPVTGLGTPNFPKLLKAAVPSRYRA

5
NAAVLLDSLDKVPVGWQAASAPAPSSKITLQVALTQQNIDQLESKL

Trichoderma

AAVSTPNSSNYGKYLDVDEINQIFAPSSASTAAVESWLKSYGVDYK

atroviride

VQGSSIWFQTDVSTANKMLSTNFHTYTDSVGAKKVRTLQYSVPET
IMI 206040

LADHIDLISPTTYFGTSKAMRALKIQNAASAVSPLAARQEPSSCKGT

IEFENRIFNVFQPDCLRTEYSVNGYKPSAKSGSRIGFGSFLNQSAS

SSDLALFEKHFGFASQGFSVELINGGSNPQPPTDANDGEANLDAQ

NIVSFVQPLPITEFIAGGTAPYFPDPVEPAGTPDENEPYLEYYEYLL

SKSNKELPQVITNSYGDEEQTVPQAYAVRVCNLIGLMGLRGISILES

SGDEGVGASCLATNSTTTPQFNPIFPATCPYVTSVGGTVSFNPEV

AWDGSSGGFSYYFSRPWYQEAAVGTYLNKYVSEETKEYYKSYVD

FSGRGFPDVAAHSVSPDYPVFQGGELTPSGGTSAASPIVASVIALL

NDARLRAGKPALGFLNPLIYGYAYKGFTDITSGQAVGCNGNNTQT

GGPLPGAGVIPGAFWNATKGWDPTTGFGVPNFKKLLELVRY

6
KPTPGASHKVIEHLDFVPEGWQMVGAADPAAIIDFWLAIERENPEK

Arthroderma

LYDTIYDVSTPGRAQYGKHLKREELDDLLRPRAETSESIINWLTNG

benhamiae

GVNPQHIRDEGDWVRFSTNVKTAETLMNTRFNVFKDNLNSVSKIR
CBS 112371

TLEYSVPVAISAHVQMIQPTTLFGRQKPQNSLILNPLTKDLESMSVE

EFAASQCRSLVTTACLRELYGLGDRVTQARDDNRIGVSGFLEEYA

QYRDLELFLSRFEPSAKGFNFSEGLIAGGKNTQGGPGSSTEANLD

MQYVVGLSHKAKVTYYSTAGRGPLIPDLSQPSQASNNNEPYLEQL

RYLVKLPKNQLPSVLTTSYGDTEQSLPASYTKATCDLFAQLGTMG

VSVIFSSGDTGPGSSCQTNDGKNATRFNPIYPASCPFVTSIGGTVG

TGPERAVSFSSGGFSDRFPRPQYQDNAVKDYLKILGNQWSGLFD

PNGRAFPDIAAQGSNYAVYDKGRMTGVSGTSASAPAMAAIIAQLN

DFRLAKGSPVLGFLNPWIYSKGFSGFTDIVDGGSRGCTGYDIYSGL

KAKKVPYASWNATKGWDPVTGFGTPNFQALTKVLP

7
KSYSHHAEAPKGWKVDDTARVASTGKQQVFSIALTMQNVDQLES

Fusarium

KLLDLSSPDSKNYGQWMSQKDVTTAFYPSKEAVSSVTKWLKSKG

graminearum

VKHYNVNGGFIDFALDVKGANALLDSDYQYYTKEGQTKLRTLSYSI
PH-1

PDDVAEHVQFVDPSTNFGGTLAFAPVTHPSRTLTERKNKPTKSTV

DASCQTSITPSCLKQMYNIGDYTPKVESGSTIGFSSFLGESAIYSDV

FLFEEKFGIPTQNFTTVLINNGTDDQNTAHKNFGEADLDAENIVGIA

HPLPFTQYITGGSPPFLPNIDQPTAADNQNEPYVPFFRYLLSQKEV

PAVVSTSYGDEEDSVPREYATMTCNLIGLLGLRGISVIFSSGDIGVG

AGCLGPDHKTVEFNAIFPATCPYLTSVGGTVDVTPEIAWEGSSGG

FSKYFPRPSYQDKAVKTYMKTVSKQTKKYYGPYTNWEGRGFPDV

AGHSVSPNYEVIYAGKQSASGGTSAAAPVWAAIVGLLNDARFRAG

KPSLGWLNPLVYKYGPKVLTDITGGYAIGCDGNNTQSGKPEPAGS

GIVPGARWNATAGWDPVTGYGTPDFGKLKDLVLSF

8
AVVIRAAVLPDAVKLMGKAMPDDIISLQFSLKQQNIDQLETRLRAVS

Acremonium

DPSSPEYGQYMSESEVNEFFKPRDDSFAEVIDWVAASGFQDIHLT

alcalophilum

PQAAAINLAATVETADQLLGANFSWFDVDGTRKLRTLEYTIPDRLA

DHVDLISPTTYFGRARLDGPRETPTRLDKRQRDPVADKAYFHLKW

DRGTSNCDLVITPPCLEAAYNYKNYMPDPNSGSRVSFTSFLEQAA

QQSDLTKFLSLTGLDRLRPPSSKPASFDTVLINGGETHQGTPPNKT

SEANLDVQWLAAVIKARLPITQWITGGRPPFVPNLRLRHEKDNTNE

PYLEFFEYLVRLPARDLPQVISNSYAEDEQTVPEAYARRVCNLIGIM

GLRGVTVLTASGDSGVGAPCRANDGSDRLEFSPQFPTSCPYITAV

GGTEGWDPEVAWEASSGGFSHYFLRPWYQANAVEKYLDEELDP

ATRAYYDGNGFVQFAGRAYPDLSAHSSSPRYAYIDKLAPGLTGGT

SASCPVVAGIVGLLNDARLRRGLPTMGFINPWLYTRGFEALQDVT

GGRASGCQGIDLQRGTRVPGAGIIPWASWNATPGWDPATGLGLP

DFWAMRGLALGRGT

9
AVVIRAAPLPESVKLVRKAAAEDGINLQLSLKRQNMDQLEKFLRAV

Sodiomyces

SDPFSPKYGQYMSDAEVHEIFRPTEDSFDQVIDWLTKSGEGNLHIT

alkalinus

PQAAAINVATTVETADQLFGANFSWEDVDGTPKLRTGEYTIPDRLV

EENDLVSPTTYFGRMRPPPRGDGVNDWITENSPEQPAPLNKRDT

KTESDQARDHPSWDSRTPDCATIITPPCLETAYNYKGYIPDPKSGS

RVSFTSFLEQAAQQADLTKELSLTRLEGFRTPASKKKTEKTVLING

GESHEGVHKKSKTSEANLDVQWLAAVTQTKLPITQWITGGRPIDEV

PNLRIPTPEANTNEPYLEFLEYLERLPDKDLPQVISNSYAEDEQSVP

EAYARRVCGLLGIMGLRGVTVLTASGDSGVGAPCRANDGSGREE

FSPQFPSSCPYITTVGGTQAWDPEVAWKGSSGGFSNYFPRPWYQ

VAAVEKYLEEQLDPAAREYYEENGFVRFAGRAFPDLSAHSSSPKY

AWDKRVPGLTGGTSASCPWAGIVGLLNDARLRRGLIDTMGFINP

WLYAKGYQALEDVTGGAAVGCQGIDIQTGKRVPGAGIIPGASWNA

TPDWDPATGLGLPNFWAMRELALED

10
VVHEKLAAVPSGWHHLEDAGSDHQISLSIALARKNLDQLESKLKDL

Aspergillus

STPGESQYGQWLDQEEVDTLFPVASDKAVISWIRSANITHIARQG

kawachii IFO

SLVNFATTVDKVNKLLNTTFAYYQRGSSQRLRTTEYSIPDDLVDSID
4308

LISPTTFFGKEKTSAGLTQRSQKVDNHVAKRSNSSSCADTITLSCL

KEMYNEGNYTPSASSGSKLGFASELNESASYSDLAKFERLFNLPS

QNFSVELINGGVNDQNQSTASLTEADLDVELLVGVGHPLPVTEFIT

SGEPPFIPDPDEPSAADNENEPYLQYYEYLLSKPNSALPQVISNSY

GDDEQTVPEYYAKRVCNLIGLVGLRGISVLESSGDEGIGSGCRTTD

GTNSTQFNPIFPATCPYVTAVGGTMSYAPEIAWEASSGGESNYFE

RAWFQKEAVQNYLANHITNETKQYYSQFANFSGRGFPDVSAHSF

EPSYEVIFYGARYGSGGTSAACPLFSALVGMLNDARLRAGKSTLG

FLNPLLYSKGYKALTDVTAGQSIGCNGIDPQSDEAVAGAGIIPWAH

WNATVGWDPVTGLGLPDFEKLRQLVLSL

11
AAALVGHESLAALPVGWDKVSTPAAGTNIQLSVALALQNIEQLEDH

Talaromyces

LKSVSTPGSASYGQYLDSDGIAAQYGPSDASVEAVTNWLKEAGVT

stipitatus

DIYNNGQS1HFATSVSKANSLLGADENYYSDGSATKLRTLAYSVPS
ATCC 10500

DLKEAIDLVSPTTYFGKTTASRSIQAYKNKRASTTSKSGSSSVQVS

ASCQTSITPACLKQMYNVGNYTPSVAHGSRVGFGSFLNQSAIFDD

LFTYEKVNDIPSQNFTKVIIANASNSQDASDGNYGEANLDVQNIVGI

SHPLPVTEFLTGGSPIDEVASLDTPTNQNEPYIPYYEYLLSQKNEDL

PQVISNSYGDDEQSVPYKYAIRACNLIGLTGLRGISVLESSGDLGV

GAGCRSNDGKNKTQFDPIFPATCPYVTSVGGTQSVTPEIAWVASS

GGESNYFPRTWYQEPAIQTYLGLLDDETKTYYSQYTNFEGRGFPD

VSAHSLTPDYQVVGGGYLQPSGGTSAASPVFAGIIALLNDARLAAG

KPTLGELNPFFYLYGYKGLNDITGGQSVGCNGINGQTGAPVPGGG

IVPGAAWNSTTGWDPATGLGTPDFQKLKELVLSF

12
KSFSHHAEAPQGWQVQKTAKVASNTQHVFSLALTMQNVDQLESK

Fusarium

LLDLSSPDSANYGNWLSHDELTSTESPSKEAVASVIKWLKSKGIK

oxysporum f.

HYKVNGAFIDFAADVEKANTLLGGDYQYYTKDGQTKLRTLSYSIPD
sp. cubense

DVAGHVQFVDPSTNEGGTVAFNPVPHPSRTLQERKVSPSKSTVD
race 4

ASCQTSITPSCLKQMYNIGDYTPDAKSGSEIGESSFLGQAAIYSDVF

KFEELEGIPKQNYTTILINNGTDDQNTAHGNEGEANLDAENIVGIAH

PLPFKQYITGGSPPFVPNIDQPTEKDNQNEPYVPFFRYLLGQKDLP

AVISTSYGDEEDSVPREYATLTCNMIGLLGLRGISVIFSSGDIGVGS

GCLAPDYKTVEFNAIFPATCPYLTSVGGTVDVIPEIAWEGSSGGES

KYFPRPSYQDKAIKKYMKTVSKETKKYYGPYTNWEGRGFPDVAG

HSVAPDYEVIYNGKQARSGGTSAAAPVWAAIVGLLNDARFKAGKK

SLGWLNPLIYKHGPKVLTDITGGYAIGCDGNNTQSGKPEPAGSGL

VPGARWNATAGWDPTTGYGTPNFQKLKDLVLSL

13
SVLVESLEKLPHGWKAASAPSPSSQITLQVALTQQNIDQLESRLAA

Trichoderma

VSTPNSKTYGNYLDLDEINEIFAPSDASSAAVESWLHSHGVTKYTK

virens

QGSSIVVFQTEVSTANAMLSTNFHTYSDAAGVKKLRTLQYSIPESLV
Gv29-8

GHVDLISPTTYFGTSNAMRALRSKSVASVAQSVAARQEPSSCKGT

LVFEGRTFNVFQPDCLRTEYNVNGYTPSAKSGSRIGFGSFLNQSA

SFSDLALFEKHFGFSSQNFSVVLINGGTDLPQPPSDDNDGEANLD

VQNILTIAHPLPITEFITAGSPPYFPDPVEPAGTPDENEPYLQYFEYL

LSKPNRDLPQVITNSYGDEEQTVPQAYAVRVCNLIGLMGLRGISILE

SSGDEGVGASCVATNSTTPQFNPIFPATCPYVTSVGGTVNFNPEV

AWDGSSGGFSYYFSRPWYQEEAVGNYLEKHVSAETKKYYGPYV

DFSGRGFPDVAAHSVSPDYPVFQGGQLTPSGGTSAASPWASIIA

LLNDARLREGKPTLGFLNPLIYQYAYKGFTDITSGQSDGCNGNNTQ

TDAPLPGAGVVLGAHWNATKGWDPTTGFGVPNFKKLLELIRYI

14
AVLVESLKQVPNGWNAVSTPDPSTSIVLQIALAQQNIDELEWRLAA

Trichoderma

VSTPNSGNYGKYLDIGEIEGIFAPSNASYKAVASWLQSHGVKNFVK

atroviride

QAGSIWFYTTVSTANKMLSTDFKHYSDPVGIEKLRTLQYSIPEELV
IMI 206040

GHVIDLISPITYFGNNHPATARTPNMKAINVTYQIFHPDCLKTKYGV

DGYAPSPRCGSRIGFGSFLNETASYSDLAQFEKYFDLPNQNLSTLL

INGAIDVQPPSNKNDSEANMDVQTILTFVQPLPITEFVVAGIPPYIPD

AALPIGDPVQNEPWLEYFEFLMSRTNAELPQVIANSYGDEEQTVP

QAYAVRVCNQIGLLGLRGISVIASSGDTGVGMSCMASNSTTPQFN

PMFPASCPYITTVGGTQHLDNEIAWELSSGGFSNYFTRPWYQEDA

AKTYLERHVSTETKAYYERYANFLGRGFPDVAALSLNPDYPVIIGG

ELGPNGGTSPAAPVVASIIALLNDARLCLGKPALGFLNPLIYQYADK

GGFTDITSGQSWGCAGNTTQTGPPPPGAGVIPGAHWNATKGWD

PVTGFGTPNFKKLLSLALSV

15
SPLARRWDDFAEKHAWVEVPRGWEMVSEAPSDHTFDLRIGVKSS

Agaricus

GMEQLIENLMQTSDPTHSRYGQHLSKEELHDFVQPHPDSTGAVE

bisporus var.

AWLEDFGISDDFIDRTGSGNWVTVRVSVAQAERMLGTKYNVYRH

burnettii

SESGESVVRTMSYSLPSELHSHIDVVAPTTYFGTMKSMRVISFLQ
JB137-S8

PEIEPVDPSAKPSAAPASCLSTTVITPDCLRDLYNTADYVPSATSRN

AIGIAGYLDRSNRADLQTFFRRFRPDAVGFNYTTVQLNGGGDDQN

DPGVEANLDIQYAAGIAFPTPATYWSTGGSPPFIPDTQTPTNTNEP

YLDWINFVLGQDEIPQVISTSYGDDEQTVPEDYATSVONLFAQLGS

RGVTVFFSSGDFGVGGGDCLTNDGSNQVLFQPAFPASCPFVTAV

GGTVRLDPEIAVSFSGGGFSRYFSRPSYQNQTVAQFVSNLGNTFN

GLYNKNGRAYPDLAAQGNGFQVVIDGIVRSVGGTSASSPTVAGIF

ALLNDFKLSRGQSTLGFINPLIYSSATSGFNDIRAGINPGCGTRGF

TAGTGWDPVTGLGTPDFLRLQGLI

16
RVFDSLPHPPRGWSYSHAAESTEPLTLRIALRQQNAAALEQWLQ

Magnaporthe

VSNPRHANYGQHLTRDELRSYTAPTPRAVRSVTSWLVDNGVDDY

oryzae 70-15

TVEHDWVTLRTTVGAADRLLGADFAWYAGPGETLQLRTLSYGVD

DSVAPHVDLVQPTTRFGGPVGQASHIFKQDDFDEQQLKTLSVGFQ

VMADLPANGPGSIKAACNESGVTPLCLRTLYRVNYKPATTGNLVA

FASFLEQYARYSDQQAFTQRVLGPGVPLQNFSVETVNGGANDQQ

SKLDSGEANLDLQYVMAMSHPIPILEYSTGGRGPLVPTLDQPNAN

NSSNEPYLEFLTYLLAQPDSAIPQTLSVSYGEEEQSVPRDYAIKVC

NMFMQLGARGVSVMFSSGDSGPGNDCVRASDNATFFGSTFPAG

CPYVTSVGSTVGFEPERAVSFSSGGFSIYHARPDYQNEVVPKYIES

IKASGYEKFFDGNGRGIPDVAAQGARFVVIDKGRVSLISGTSASSP

AFAGMVALVNAARKSKDMPALGFLNPMLYQNAAAMTDIVNGAGIG

CRKQRTEFPNGARFNATAGWDPVTGLGTPLFDKLLAVGAPGVPN

A

17
SDVVLESLREVPQGWKRLRDADPEQSIKLRIALEQPNLDLFEQTLY

Togninia

DISSPDHPKYGQHLKSHELRDIMAPREESTAAVIAVVLQDAGLSGS

minima

QIEDDSDWINIQTTVAQANDMLNTTFGLFAQEGTEVNRIRALAYSV
UCRPA7

PEEIVPHVKMIAPIIRFGQLRPQMSHIFSHEKVEETPSIGTIKAAAI

PSVDLNVTACNASITPECLRALYNVGDYEADPSKKSLFGVCGYLEQY

AKHDQLAKFEQTYAPYAIGADFSVVTINGGGDNQTSTIDDGEANLD

MQYAVSMAYKTIPITYYSTGGRGPLVPDLDQPDPNDVSNEPYLDFV

SYLLKLPDSKLPQTITTSYGEDEQSVPRSYVEKVCTMFGALGARG

VSVIFSSGDTGVGSACQTNDGKNTTRFLPIFPAACPYVTSVGGTRY

VDPEVAVSFSSGGFSDIFPTPLYQKGAVSGYLKILGDRWKGLYNP

HGRGFPDVSGQSVRYHVFDYGKDVMYSGTSASAPMFAALVSLLN

NARLAKKLPPMGFLNPWLYTVGFNGLTDIVFIGGSTGCTGTDVYSG

LPTPFVPYASWNATVGWDPVTGLGTPLFDKLLNLSTPNFHLPHIG

GH

18
STTSHVEGEVVERLHGVPEGWSQVGAPNPDQKLRFRIAVRSADS

Bipolaris

ELFERTLMEVSSPSHPRYGQHLKRHELKDLIKPRAKSTSNILNWLQ

maydis C5

ESGIEARDIQNDGEWISFYAPVKRAEQMMSTTFKTYQNEARANIKK

IRSLDYSVPKHIRDDIDIIQPTTRFGQIQPERSQVFSQEEVPFSALVV

NATCNKKITPDCLANLYNFKDYDASDANVTIGVSGFLEQYARFDDL

KQFISTFQPKAAGSTFQVTSVNAGPFDQNSTASSVEANLDIQYTTG

LVAPD1ETRYFTVPGRGILIPDLDQPTESDNANEPYLDYFTYLNNLE

DEELPDVLTTSYGESEQSVPAEYAKKVCNLIGQLGARGVSVIFSSG

DTGPGSACQTNDGKNTTRFLPIFPASCPYVTSVGGTVGVEPEKAV

SFSSGGFSDLWPRPAYQEKAVSEYLEKLGDRWNGLYNPQGRGF

PDVAAQGQGFQVFDKGRLISVGGTSASAPVFASVVALLNNARKAA

GMSSLGFLNPWIYEQGYKGLTDIVAGGSTGCTGRSIYSGLPAPLVP

YASWNATEGWDPVTGYGTPDFKQLLTLATAPKSGERRVRRGGLG

GQA

19

MLSSFLSQGAAVSLALLSLLPSPVAAEIFEKLSGVPNGWRYANNPH

Aspergillus

GNEVIRLQIALQQHDVAGFEQAVMDMSTPGHADYGKHFRTHDEM

kawachii IFO

KRMLLPSDTAVDSVRDWLESAGVHNIQVDADWVKFHTTVNKANA
4308

LLDADFKWYVSEAKHIRRLRTLQYSIPDALVSHINMIQPTTRFGQIQ

PNRATMRSKPKHADETFLTAATLAQNTSHCDSIITPHCLKQLYNIG

DYQADPKSGSKVGFASYLEEYARYADLERFEQHLAPNAIGQNFSV

VQFNGGLNDQLSLSDSGEANLDLQYILGVSAPVPVTEYSTGGRGE

LVPDLSSPDPNDNSNEPYLDFLQGILKLDNSDLPQVISTSYGEDEQ

TIPVPYARTVCNLYAQLGSRGVSVIFSSGDSGVGAACLTNDGTNR

THFPPQFPASCPWVTSVGATSKTSPEQAVSFSSGGFSDLWPRPS

YQQAAVQTYLTQHLGNKFSGLFNASGRAFPDVAAQGVNYAVYDK

GMLGQFDGTSCSAPTFSGVIALLNDARLRAGLPVMGFLNPFLYGV

GSESGALNDIVNGGSLGCDGRNRFGGTPNGSPVVPFASWNATTG

WDPVSGLGTPDFAKLRGVALGEAKAYGN

20
MAATGRFTAFWNVASVPALIGILPLAGSHLRAVLCPVCIWRHSKAV

Aspergillus

CAPDTLQAMRAFTRVTAISLAGFSCFAAAAAAAFESLRAVPDGWIY

nidulans

ESTPDPNQPLRLRIALKQHNVAGFEQALLDMSTPGHSSYGQHFGS
FGSC A4

YHEMKQLLLPTEEASSSVRDWLSAAGVEFEQDADWINFRTTVDQA

NALLDADFLWYTTTGSTGNPTRILRTLSYSVPSELAGYVNMIQPTT

RFGGTHANRATVRAKPIFLETNRQLINAISSGSLEHCEKAITPSCLA

DLYNTEGYKASNRSGSKVAFASFLEEYARYDDLAEFEETYAPYAIG

QNFSVISINGGLNDQDSTADSGEANLDLQYIIGVSSPLPVTEFTTGG

RGKLIPDLSSPDPNDNTNEPFLDFLEAVLKLDQKDLPQVISTSYGE

DEQTIPEPYARSVCNLYAQLGSRGVSVLFSSGDSGVGAACQTND

GKNTTHFPPQFPASCPWVTAVGGTNGTAPESGVYFSSGGFSDYW

ARPAYQNAAVESYLRKLGSTQAQYFNRSGRAFPDVAAQAQNFAV

VDKGRVGLFDGTSCSSPVFAGIVALLNDVRLKAGLPVLGFLNPWL

YQDGLNGLNDIVDGGSTGCDGNNRENGSPNGSPVIPYAGWNATE

GWDPVTGLGTPDFAKLKALVLDA

21

MLSFVRRGALSLALVSLLTSSVAAEVFEKLHVVPEGWRYASTPNP

Aspergillus

KQPIRLQIALQQHDVTGFEQSLLEMSTPDHPNYGKHFRTHDEMKR

ruber CBS

MLLPNENAVHAVREWLQDAGISDIEEDADWVRFHTTVDQANDLLD
135680

ANFLWYAHKSHRNTARLRTLEYSIPDSIAPQVNVIQPTTRFGQIRAN

RATHSSKPKGGLDELAISQAATADDDSICDQITTPHCLRKLYNVNG

YKADPASGSKIGFASFLEEYARYSDLVLFEENLAPFAEGENFTVVM

YNGGKNDQNSKSDSGEANLDLQYIVGMSAGAPVTEFSTAGRAPVI

PDLDQPDPSAGTNEPYLEFLQNVLHMDQEHLPQVISTSYGENEQT

IPEKYARTVCNMYAQLGSRGVSVIFSSGDSGVGSACMTNDGTNRT

HFPPQFPASCPWVTSVGATEKMAPEQATYFSSGGFSDLFPRPKY

QDAAVSSYLQTLGSRYQGLYNGSNRAFPDVSAQGTNFAVYDKGR

LGQFDGTSCSAPAFSGIIALLNDVRLQNNKPVLGFLNPWLYGAGSK

GLNDVVHGGSTGCDGQERFAGKANGSPVVPYASWNATQGWDP

VTGLGTPDFGKLKDLALSA

22

MLPSLVNNGALSLAVLSLLTSSVAGEVFEKLSAVPKGWHFSHAAQ

Aspergillus

ADAPINLKIALKQHDVEGFEQALLDMSTPGHENYGKHFHEHDEMK

terreus

RMLLPSDSAVDAVQTWLTSAGITDYDLDADWINLRTTVEHANALLD
NIH2624

TQFGWYENEVRHITRLRTLQYSIPETVAAHINMVQPTTRFGQIRPD

RATFHAHHTSDARILSALAAASNSTSCDSVITPKCLKDLYKVGDYE

ADPDSGSQVAFASYLEEYARYADMVKFQNSLAPYAKGQNFSVVL

YNGGVNDQSSSADSGEANLDLQTIMGLSAPLPITEYITGGRGKLIP

DLSQPNPNDNSNEPYLEFLQNILKLDQDELPQVISTSYGEDEQTIP

RGYAESVCNMLAQLGSRGVSVVFSSGDSGVGAACQTNDGRNQT

HENPQFPASCPWVTSVGATIKTNPEQAVYFSSGGESDFWKRPKY

QDEAVAAYLDTLGDKFAGLFNKGGRAFPDVAAQGMNYAIYDKGTL

GRLDGTSCSAPAFSAIISLLNDARLREGKPTMGFLNPWLYGEGRE

ALNDVVVGGSKGCDGRDRFGGKPNGSPVVPFASWNATQGWDPV

TGLGTPNFAKMLELAP

23

MIASLFNRRALTLALLSLFASSATADVFESLSAVPQGWRYSRTPSA

Penicillium

NQPLKLQIALAQGDVAGFEAAVIDMSTPDHPSYGNHFNTHEEMKR

digitatum

MLQPSAESVDSIRNWLESAGISKIEQDADWMTFYTTVKTANELLAA
Pd1

NFQFYINGVKKIERLRTLKYSVPDALVSHINMIQPTTRFGQLRAQRA

ILHTEVKDNDEAFRSNAMSANPDCNSIITPQCLKDLYSIGDYEADPT

NGNKVAFASYLEEYARYSDLALFEKNIAPFAKGQNFSWQYNGGG

NDQQSSSGSSEANLDLQYIVGVSSPVPVTEFSTGGRGELVPDLDQ

PNPNDNNNEPYLEFLQNVLKLHKKDLPQVISTSYGEDEQSVPEKY

ARAVCNLYSQLGSRGVSVIFSSGDSGVGAACQTNDGRNATHFPP

QFPAACPWVTSVGATTHTAPERAVYFSSGGESDLWDRPTWQEDA

VSEYLENLGDRWSGLFNPKGRAFPDVAAQGENYAIYDKGSLISVD

GTSCSAPAFAGVIALLNDARIKANRPPMGFLNPWLYSEGRSGLNDI

VNGGSTGCDGHGRFSGPTNGGTSIPGASWNATKGWDPVSGLGS

PNFAAMRKLANAE

24

MHVPLLNQGALSLAVVSLLASTVSAEVEDKLVAVPEGWRFSRTPS

Penicillium

GDQPIRLQVALTQGDVEGFEKAVLDMSTPDHPNYGKHFKSHEEVK

oxalicum

RMLQPAGESVEAIHQWLEKAGITHIQQDADWMTFYTTVEKANNLL
114-2

DANFQYYLNENKQVERLRTLEYSVPDELVSHINLVTPTTRFGQLHA

EGVTLFIGKSKDVDEQFRQAATSPSSDCNSAITPQCLKDLYKVGDY

KASASNGNKVAFTSYLEQYARYSDLALFEQNIAPYAQGQNFTVIQY

NGGLNDQSSPADSSEANLDLQYIIGTSSPVPVTEFSTGGRGPLVP

DLDQPDINDNNNEPYLDFLQNVIKMSDKDLPQVISTSYGEDEQSVP

ASYARSVCNLIAQLGGRGVSVIFSSGDSGVGSACQTNDGKNTTRF

PAQFPAACPWVTSVGATTGISPERGVFFSSGGESDLWSRPSWQS

HAVKAYLFIKLGKRQDGLENREGRAFPDVSAQGENYAIYAKGRLGK

VDGTSCSAPAFAGLVSLLNDARIKAGKSSLGFLNPWLYSHPDALN

DITVGGSTGCDGNAREGGRPNGSPVVPYASWNATEGWDPVTGL

GTPNFQKLLKSAVKQK

25

MIASLFSRGALSLAVLSLLASSAAADVFESLSAVPQGWRYSRRPRA

Penicillium

DQPLKLQIALTQGDTAGFEEAVMEMSTPDHPSYGHHFTTHEEMKR

roqueforti

MLQPSAESAESIRDWLEGAGITRIEQDADWMTFYTTVETANELLAA
FM164

NFQFYVSNVRHIERLRTLKYSVPKALVPHINMIQPTTRFGQLRAHR

GILHGQVKESDEAFRSNAVSAQPDCNSIITPQCLKDIYNIGDYQAN

DTNGNKVGFASYLEEYARYSDLALFEKNIAPSAKGQNFSVTRYNG

GLNDQSSSGSSSEANLDLQYIVGVSSPVPVTEFSVGGRGELVPDL

DQPDPNDNNNEPYLEFLQNVLKLDKKDLPQVISTSYGEDEQSIPEK

YARSVCNLYSQLGSRGVSVIFSSGDSGVGSACLTNDGRNATREPP

QFPAACPWVTSVGATTHTAPEQAVYFSSGGESDLWARPKWQEE

AVSEYLEILGNRWSGLENPKGRAFPDVTAQGRNYAIYDKGSLTSV

DGTSCSAPAFAGVVALLNDARLKVNKPPMGFLNPWLYSTGRAGL

KDIVDGGSTGCDGKSREGGANNGGPSIPGASWNATKGWDPVSG

LGSPNFATMRKLANAE

26

MIASLFNRGALSLAVLSLLASSASADVFESLSAVPQGWRYSRRPR

Penicillium

ADQPLKLQIALAQGDTAGFEEAVMDMSTPDHPSYGNHFHTHEEM

rubens

KRMLQPSAESADSIRDWLESAGINRIEQDADWMTFYTTVETANELL
Wisconsin

AANFQFYANSAKHIERLRTLQYSVPEALMPHINMIQPTTRFGQLRV
54-1255

QGAILHTQVKETDEAFRSNAVSTSPDCNSIITPQCLKNMYNVGDYQ

ADDDNGNKVGFASYLEEYARYSDLELFEKNVAPFAKGQNFSVIQY

NGGLNDQHSSASSSEANLDLQYIVGVSSPVPVTEFSVGGRGELVP

DLDQPDPNDNNNEPYLEFLQNVLKMEQQDLPQVISTSYGENEQSV

PEKYARTVCNLFSQLGSRGVSVIFASGDSGVGAACQTNDGRNAT

REPAQFPAACPWVTSVGATTHTAPEKAVYFSSGGESDLWDRPKW

QEDAVSDYLDTLGDRWSGLFNPKGRAFPDVSAQGQNYAIYDKGS

LTSVDGTSCSAPAFAGVIALLNDARLKANKPPMGFLNPWLYSTGR

DGLNDIVHGGSTGCDGNAREGGPGNGSPRVPGASWNATKGWDP

VSGLGSPNFATMRKLANGE

27

MLSSTLYAGLLCSLAAPALGVVHEKLSAVPSGWTLVEDASESDTTT

Neosartorya

LSIALARQNLDQLESKLTTLATPGNAEYGKWLDQSDIESLFPTASD

fischeri

DAVIQWLKDAGVTQVSRQGSLVNFATTVGTANKLFDTKESYYRNG
NRRL 181

ASQKLRTTQYSIPDSLTESIDLIAPTVFFGKEQDSALPPHAVKLPAL

PRRAATNSSCANLITPDCLVEMYNLGDYKPDASSGSRVGFGSFLN

QSANYADLAAYEQLFNIPPQNFSVELINGGANDQNWATASLGEAN

LDVELIVAVSHALPWEFITGGSPPFVPNVDEPTAADNQNEPYLQY

YEYLLSKPNSHLPQVISNSYGDDEQTVPEYYARRVCNLIGLMGLR

GITVLESSGDTGIGSACMSNDGTNTPQFTPTFPGTCPFITAVGGTQ

SYAPEVAWDASSGGESNYFSRPWYQYFAVENYLNNHITKDTKKY

YSQYTNFKGRGFPDVSAHSLTPDYEVVLTGKHYKSGGTSAACPVF

AGIVGLLNDARLRAGKSTLGFLNPLLYSILAEGFTDITAGSSIGCN

GINPQTGKPVPGGGIIPYAHWNATAGWDPVTGLGVPDFMKLKELV

LSL

28

MLSSTLYAGWLLSLAAPALCVVQEKLSAVPSGWTLIEDASESDTIT

Aspergillus

LSIALARQNLDQLESKLTTLATPGNPEYGKWLDQSDIESLFPTASD

fumigatus

DAVLQWLKAAGITQVSRQGSLVNFATTVGTANKLFDTKFSYYRNG
CAE17675

ASQKLRTTQYSIPDHLTESIDLIAPTVFFGKEQNSALSSHAVKLPAL

PRRAATNSSCANLITPDCLVEMYNLGDYKPDASSGSRVGFGSFLN

ESANYADLAAYEQLFNIPPQNFSVELINRGVNDQNWATASLGEAN

LDVELIVAVSHPLPVVEFITGALPPVLRVLALQTQLPSSSGDFQLTV

PEYYARRVCNLIGLMGLRGITVLESSGDTGIGSACMSNDGTNKPQ

FTPTFPGTCPFITAVGGTQSYAPEVAWDGSSGGFSNYFSRPWYQ

SFAVDNYLNNHITKDTKKYYSQYTNFKGRGFPDVSAHSLTPYYEV

VLTGKHYKSGGTSAASPVFAGIVGLLNDARLRAGKSTLGFLNPLLY

SILAEGFTDITAGSSIGCNGINPQTGKPVPGGGIIPYAHWNATAGW

DPVTGLGVPDFMKLKELVLSL

29
QEPSSCKGTLVFEGETFNVFQPDCLRTEYSVDGYTPSVKSGSRIG

Trichoderma

FGSFLNESASFADQALFEKHFNIPSQNFSVVLINGGTDLPQPPSDA

reesei QM6a

NDGEANLDAQTILTIAHPLPITEFITAGSPPYFPDPVEPAGTPNENE

PYLQYYEFLLSKSNAEIPQVITNSYGDEEQTVPRSYAVRVCNLIGLL

GLRGISVLHSSGDEGVGASCVATNSTTPQFNPIFPATCPYVTSVG

GTVSFNPEVAWAGSSGGFSYYFSRPWYQQEAVGTYLEKYVSAET

KKYYGPYVDFSGRGFPDVAAHSVSPDYPVFQGGELTPSGGTSAA

SPVVAAIVALLNDARLREGKPTLGFLNPLIYLHASKGFTDITSGQSE

GCNGNNTQTGSPLPGAGFIAGAHWNATKGWDPTTGFGVPNLKKL

LALVRF

30
CDSIITPTCLKELYNIGDYQADANSGSKIAFASYLEEYARYADLENF

Aspergillus

ENYLAPWAKGQNFSVTTFNGGLNDQNSSSDSGEANLDLQYILGVS

oryzae RIB40

APLPVTEFSTGGRGPLVPDLTQPDPNSNSNEPYLEFFQNVLKLDQ

KDLPQVISTSYGENEQEIPEKYARTVCNLIAQLGSRGVSVLFSSGD

SGVGEGCMTNDGTNRTHFPPQFPAACPWVTSVGATFKTTPERGT

YFSSGGFSDYWPRPEWQDEAVSSYLETIGDTFKGLYNSSGRAFP

DVAAQGMNFAVYDKGTLGEFDGTSASAPAFSAVIALLNDARLRAG

KPILGFLNPWLYKTGRQGLQDITLGASIGCTGRARFGGAPDGGPV

VPYASWNATQGWDPVTGLGTPDFAELKKLA

31
CDATITPQCLKTLYKIDYKADPKSGSKVAFASYLEQYARYNDLALFE

Phaeosphaeria

KAFLPEAVGQNFSVVQFSGGLNDQNTTQDSGEANLDLQYIVGVSA

nodorum

PLPVTEFSTGGRGPWVADLDQPDEADSANEPYLEFLQGVLKLPQS
SN15

ELPQVISTSYGENEQSVPKSYALSVCNLFAQLGSRGVSVIFSSGDS

GPGSACQSNDGKNTTKFQPQYPAACPFVTSVGSTRYLNETATGF

SSGGFSDYWKRPSYQDDAVKAYFHHLGEKFKPYFNRHGRGFPDV

ATQGYGFRVYDQGKLKGLQGTSASAPAFAGVIGLLNDARLKAKKP

TLGFLNPLLYSNSDALNDIVLGGSKGCDGHARFNGPPNGSPVIPYA

GWNATAGWDPVTGLGTPNFPKLLKAA

32
VFQPDCLRTEYSVNGYKPSAKSGSRIGFGSFLNQSASSSDLALFE

Trichoderma

KHFGFASQGFSVELINGGSNPQPPTDANDGEANLDAQNIVSFVQP

atroviride IMI

LPITERAGGTAPYFPDPVEPAGTPDENEPYLEYYEYLLSKSNKELP
206040

QVITNSYGDEEQTVPQAYAVRVCNLIGLMGLRGISILESSGDEGVG

ASCLATNSTTTPQFNPIFPATCPYVTSVGGIVSFNPEVAWDGSSG

GFSYYFSRPWYQEAAVGTYLNKYVSEETKEYYKSYVDFSGRGFP

DVAAHSVSPDYPVFQGGELTPSGGTSAASPIVASVIALLNDARLRA

GKPALGFLNPLIYGYAYKGFTDITSGQAVGCNGNNTQTGGPLPGA

GVIPGAFWNATKGWDPTTGFGVPNFKKLLELV

33
CRSLVTTACLRELYGLGDRVTQARDDNRIGVSGFLEEYAQYRDLE

Arthroderma

LFLSRFEPSAKGFNFSEGLIAGGKNTQGGPGSSTEANLDMQYVVG

benhamiae

LSHKAKVTYYSTAGRGPLIPDLSQPSQASNNNEPYLEQLRYLVKLP
CBS 112371

KNQLPSVLTTSYGDTEQSLPASYTKATCDLFAQLGTMGVSVIFSSG

DTGPGSSCQTNDGKNATRFNPIYPASCPFVTSIGGTVGTGPERAV

SFSSGGFSDRFPRPQYQDNAVKDYLKILGNQWSGLFDPNGRAFP

DIAAQGSNYAVYDKGRMTGVSGTSASAPAMAAIIAQLNDFRLAKG

SPVLGFLNPWIYSKGFSGFTDIVDGGSRGCTGYDIYSGLKAKKVPY

ASWNATKGWDPVTGFGTPNFQALTKVL

34
CQTSITPSCLKQMYNIGDYTPKVESGSTIGFSSFLGESAIYSDVFLF

Fusarium

EEKFGIPTQNFTTVLINNGTDDQNTAHKNFGEADLDAENIVGIAHPL

graminearum

PFTQYITGGSPPFLPNIDQPTAADNQNEPYVPFFRYLLSQKEVPAV
PH-1

VSTSYGDEEDSVPREYATMTCNLIGLLGLRGISVIFSSGDIGVGAG

CLGPDHKTVEFNAIFPATCPYLTSVGGTVDVTPEIAWEGSSGGFSK

YFPRPSYQDKAVKTYMKTVSKQTKKYYGPYTNWEGRGFPDVAGH

SVSPNYEVIYAGKQSASGGTSAAAPVWAAIVGLLNDARFRAGKPS

LGWLNPLVYKYGPKVLTDITGGYAIGCDGNNTQSGKPEPAGSGIV

PGARWNATAGWDPVTGYGTPDFGKLKDLVLS

35
CDLVITPPCLEAAYNYKNYMPDPNSGSRVSFTSFLEQAAQQSDLT

Acremonium

KFLSLTGLDRLRPPSSKPASFDTVLINGGETHQGTPPNKTSEANLD

alcalophilum

VQWLAAVIKARLPITQWITGGRPPFVPNLRLRHEKDNTNEPYLEFF

EYLVRLPARDLPQVISNSYAEDEQTVPEAYARRVCNLIGIMGLRGV

TVLTASGDSGVGAPCRANDGSDRLEFSPQFPTSCPYITAVGGTEG

WDPEVAWEASSGGFSHYFLRPWYQANAVEKYLDEELDPATRAYY

DGNGFVQFAGRAYPDLSAHSSSPRYAYIDKLAPGLTGGTSASCPV

VAGIVGLLNDARLRRGLPTMGFINPWLYTRGFEALQDVTGGRASG

CQGIDLQRGTRVPGAGIIPWASWNATPGWDPATGLGLPDFWAMR

GL

36
CATIITPPCLETAYNYKGYIPDPKSGSRVSFTSFLEQAAQQADLTKF

Sodiomyces

LSLTRLEGFRTPASKKKTFKTVLINGGESHEGVHKKSKTSEANLDV

alkalinus

QWLAAVTQTKLPITQWITGGRPPFVPNLRIPTPEANTNEPYLEFLE

YLFRLPDKDLPQVISNSYAEDEQSVPEAYARRVCGLLGIMGLRGVT

VLTASGDSGVGAPCRANDGSGREEFSPQFPSSCPYITTVGGTQA

WDPEVAWKGSSGGFSNYFPRPWYQVAAVEKYLEEQLDPAAREY

YEENGFVRFAGRAFPDLSAHSSSPKYAYVDKRVPGLTGGTSASCP

VVAGIVGLLNDARLRRGLPTMGFINPWLYAKGYQALEDVTGGAAV

GCQGIDIQTGKRVPGAGIIPGASWNATPDWDPATGLGLPNFWAMR

ELA

37
CADTITLSCLKEMYNFGNYTPSASSGSKLGFASFLNESASYSDLAK

Aspergillus

FERLFNLPSQNFSVELINGGVNDQNQSTASLTEADLDVELLVGVG

kawachii IFO

HPLPVTEFITSGEPPFIPDPDEPSAADNENEPYLQYYEYLLSKPNSA
4308

LPQVISNSYGDDEQTVPEYYAKRVCNLIGLVGLRGISVLESSGDEGI

GSGCRITDGTNSTQFNPIFPATCPYVTAVGGTMSYAPEIAWEASS

GGFSNYFERAWFQKEAVQNYLANHITNETKQYYSQFANFSGRGF

PDVSAHSFEPSYEVIFYGARYGSGGTSAACPLFSALVGMLNDARL

RAGKSTLGFLNPLLYSKGYKALTDVTAGQSIGCNGIDPQSDEAVAG

AGIIPWAHWNATVGWDPVTGLGLPDFEKLRQLVLS

38
CQTSITPACLKQMYNVGNYTPSVAHGSRVGFGSFLNQSAIFDDLF

Talaromyces

TYEKVNDIPSQNFTKVIIANASNSQDASDGNYGEANLDVQNIVGISH

stipitatus

PLPVTEFLTGGSPPFVASLDTPINQNEPYIPYYEYLLSQKNEDLPQ
ATCC 10500

VISNSYGDDEQSVPYKYAIRACNLIGLTGLRGISVLESSGDLGVGA

GCRSNDGKNKTQFDPIFPATCPYVTSVGGIQSVTPEIAWVASSGG

FSNYFPRTWYQEPAIQTYLGLLDDETKTYYSQYTNFEGRGFPDVS

AHSLTPDYQVVGGGYLQPSGGTSAASPVFAGIIALLNDARLAAGKP

TLGFLNPFFYLYGYKGLNDITGGQSVGCNGINGQTGAPVPGGGIV

PGAAWNSTTGVVDPATGLGTPDFQKLKELVLS

39
CQTSITPSCLKQMYNIGDYTPDAKSGSEIGFSSFLGQAAIYSDVFKF

Fusarium

EELFGIPKQNYTTILINNGTDDQNTAHGNFGEANLDAENIVGIAHPL

oxysporum f.

PFKQYITGGSPPFVPNIDQPTEKDNQNEPYVPFFRYLLGQKDLPAV
sp. cubense

ISTSYGDEEDSVPREYATLTCNMIGLLGLRGISVIFSSGDIGVGSGC
race 4

LAPDYKTVEFNAIFPATCPYLTSVGGIVDVTPEIAWEGSSGGFSKY

FPRPSYQDKAIKKYMKTVSKETKKYYGPYTNWEGRGFPDVAGHS

VAPDYEVIYNGKQARSGGTSAAAPVWAAIVGLINDARFKAGKKSL

GWLNPLIYKHGPKVLTDITGGYAIGCDGNNTQSGKPEPAGSGLVP

GARWNATAGWDPTTGYGTPNFQKLKDLVLS

40
VFQPDCLRTEYNVNGYTPSAKSGSRIGFGSFLNQSASFSDLALFE

Trichoderma

KHFGFSSQNFSVVLINGGTDLPQPPSDDNDGEANLDVQNILTIAHP

virens

LPITEFITAGSPPYFPDPVEPAGTPDENEPYLQYFEYLLSKPNRDLP
Gv29-8

QVITNSYGDEEQTVPQAYAVRVCNLIGLMGLRGISILESSGDEGVG

ASCVATNSTTPQFNPIFPATCPYVTSVGGTVNFNPEVAWDGSSGG

FSYYFSRPWYQEEAVGNYLEKHVSAETKKYYGPYVDFSGRGFPD

VAAHSVSPDYPVFQGGQLTPSGGTSAASPWASIIALLNDARLREG

KPTLGFLNPLIYQYAYKGFTDITSGQSDGCNGNNTQTDAPLPGAG

VVLGAHWNATKGWDPTTGFGVPNFKKLLELI

41
QIFHPDCLKTKYGVDGYAPSPRCGSRIGFGSFLNETASYSDLAQFE

Trichoderma

KYFDLPNQNLSTLLINGAIDVQPPSNKNDSEANMDVQTILTFVQPLP

atroviride IMI

ITEFVVAGIPPYIPDAALPIGDPVQNEPWLEYFEFLMSRTNAELPQVI
206040

ANSYGDEEQTVPQAYAVRVCNQIGLLGLRGISVIASSGDTGVGMS

CMASNSTTPQFNPMFPASCPYITTVGGTQHLDNEIAWELSSGGFS

NYFTRPWYQEDAAKTYLERHVSTETKAYYERYANFLGRGFPDVAA

LSLNPDYPVIIGGELGPNGGTSAAAPVVASIIALLNDARLCLGKPAL

GFLNPLIYQYADKGGFTDITSGQSWGCAGNTTQTGPPPPGAGVIP

GAHWNATKGWDPVTGFGTPNFKKLLSLALS

42
TVITPDCLRDLYNTADYVPSATSRNAIGIAGYLDRSNRADLQTFFRR

Agaricus

FRPDAVGFNYTTVQLNGGGDDQNDPGVEANLDIQYAAGIAFPTPA

bisporus var.

TYWSTGGSPPFIPDTQTPTNTNEPYLDWINFVLGQDEIPQVISTSY

burnettii

GDDEQTVPEDYATSVCNLFAQLGSRGVTVFFSSGDFGVGGGDCL
JB137-S8

TNDGSNQVLFQPAFPASCPFVTAVGGTVRLDPEIAVSFSGGGFSR

YFSRPSYQNQTVAQFVSNLGNTFNGLYNKNGRAYPDLAAQGNGF

QVVIDGIVRSVGGTSASSPTVAGIFALLNDFKLSRGQSTLGFINPLIY

SSATSGFNDIRAGTNPGCGTRGFTAGTGWDPVTGLGTPDFLRLQ

43
GVTPLCLRTLYRVNYKPATTGNLVAFASFLEQYARYSDQQAFTQR

Magnaporthe

VLGPGVPLQNFSVETVNGGANDQQSKLDSGEANLDLQYVMAMSH

oryzae 70-15

PIPILEYSTGGRGPLVPTLDQPNANNSSNEPYLEFLTYLLAQPDSAI

PQTLSVSYGEEEQSVPRDYAIKVCNMFMQLGARGVSVMFSSGDS

GPGNDCVRASDNATFFGSTFPAGCPYVTSVGSTVGFEPERAVSF

SSGGFSIYHARPDYQNEVVPKYIESIKASGYEKFFDGNGRGIPDVA

AQGARFVVIDKGRVSLISGTSASSPAFAGMVALVNAARKSKDMPA

LGFLNPMLYQNAAAMTDIVNGAGIGCRKQRTEFPNGARFNATAG

WDPVTGLGTPLFDKLLA

44
CNASITPECLRALYNVGDYEADPSKKSLFGVCGYLEQYAKHDQLA

Togninia

KFEQTYAPYAIGADFSVVTINGGGDNQTSTIDDGEANLDMQYAVS

minima

MAYKTPITYYSTGGRGPLVPDLDQPDPNDVSNEPYLDFVSYLLKLP
UCRPA7

DSKLPQTITTSYGEDEQSVPRSYVEKVCTMFGALGARGVSVIFSS

GDTGVGSACQTNDGKNTTRFLPIFPAACPYVTSVGGTRYVDPEVA

VSFSSGGFSDIFPTPLYQKGAVSGYLKILGDRWKGLYNPHGRGFP

DVSGQSVRYHVFDYGKDVMYSGTSASAPMFAALVSLLNNARLAK

KLPPMGFLNPWLYTVGFNGLTDIVHGGSTGCTGTDVYSGLPTPFV

PYASWNATVGWDPVTGLGTPLFDKLLNL

45
CNKKITPDCLANLYNFKDYDASDANVTIGVSGFLEQYARFDDLKQF

Bipolaris

ISTFQPKAAGSTFQVTSVNAGPFDQNSTASSVEANLDIQYTTGLVA

maydis C5

PDIETRYFTVPGRGILIPDLDQPTESDNANEPYLDYFTYLNNLEDEE

LPDVLTTSYGESEQSVPAEYAKKVCNLIGQLGARGVSVIFSSGDTG

PGSACQTNDGKNTTRFLPIFPASCPYVTSVGGTVGVEPEKAVSFS

SGGFSDLWPRPAYQEKAVSEYLEKLGDRWNGLYNPQGRGFPDV

AAQGQGFQVFDKGRLISVGGTSASAPVFASVVALLNNARKAAGMS

SLGFLNPWIYEQGYKGLTDIVAGGSTGCTGRSIYSGLPAPLVPYAS

WNATEGWDPVTGYGTPDFKQLLTLAT

46
CDSIITPHCLKQLYNIGDYQADPKSGSKVGFASYLEEYARYADLER

Aspergillus

FEQHLAPNAIGQNFSVVQFNGGLNDQLSLSDSGEANLDLQYILGV

kawachii IFO

SAPVPVTEYSTGGRGELVPDLSSPDPNDNSNEPYLDFLQGILKLD
4308

NSDLPQVISTSYGEDEQTIPVPYARTVCNLYAQLGSRGVSVIFSSG

DSGVGAACLTNDGTNRTHFPPQFPASCPWVTSVGATSKTSPEQA

VSFSSGGFSDLWPRPSYQQAAVQTYLTQHLGNKFSGLFNASGRA

FPDVAAQGVNYAVYDKGMLGQFDGTSCSAPTFSGVIALLNDARLR

AGLPVMGFLNPFLYGVGSESGALNDIVNGGSLGCDGRNRFGGTP

NGSPVVPFASWNATTGWDPVSGLGTPDFAKLRGV

47
CEKAITPSCLADLYNTEGYKASNRSGSKVAFASFLEEYARYDDLAE

Aspergillus

FEETYAPYAIGQNFSVISINGGLNDQDSTADSGEANLDLQYIIGVSS

nidulans

PLPVTEFTTGGRGKLIPDLSSPDPNDNTNEPFLDFLEAVLKLDQKD
FGSC A4

LPQVISTSYGEDEQTIPEPYARSVCNLYAQLGSRGVSVLFSSGDSG

VGAACQTNDGKNTTHFPPQFPASCPWVTAVGGTNGTAPESGVYF

SSGGFSDYWARPAYQNAAVESYLRKLGSTQAQYFNRSGRAFPDV

AAQAQNFAVVDKGRVGLFDGTSCSSPVFAGIVALLNDVRLKAGLP

VLGFLNPWLYQDGLNGLNDIVDGGSTGCDGNNRFNGSPNGSPVI

PYAGWNATEGWDPVTGLGTPDFAKLKALVL

48
CDQITTPHCLRKLYNVNGYKADPASGSKIGFASFLEEYARYSDLVL

Aspergillus

FEENLAPFAEGENFTVVMYNGGKNDQNSKSDSGEANLDLQYIVG

ruber CBS

MSAGAPVTEFSTAGRAPVIPDLDQPDPSAGTNEPYLEFLQNVLHM
135680

DQEHLPQVISTSYGENEQTIPEKYARTVCNMYAQLGSRGVSVIFSS

GDSGVGSACMTNDGTNRTHFPPQFPASCPWVTSVGATEKMAPE

QATYFSSGGFSDLFPRPKYQDAAVSSYLQTLGSRYQGLYNGSNR

AFPDVSAQGTNFAVYDKGRLGQFDGTSCSAPAFSGIIALLNDVRLQ

NNKPVLGFLNPWLYGAGSKGLNDVVHGGSTGCDGQERFAGKAN

GSPVVPYASWNATQGWDPVTGLGTPDFGKLKDLAL

49
CDSVITPKCLKDLYKVGDYEADPDSGSQVAFASYLEEYARYADMV

Aspergillus

KFQNSLAPYAKGQNFSVVLYNGGVNDQSSSADSGEANLDLQTIM

terreus

GLSAPLPITEYITGGRGKLIPDLSQPNPNDNSNEPYLEFLQNILKLD
NIH2624

QDELPQVISTSYGEDEQTIPRGYAESVCNMLAQLGSRGVSVVFSS

GDSGVGAACQTNDGRNQTHFNPQFPASCPWVTSVGATTKTNPE

QAVYFSSGGFSDFWKRPKYQDEAVAAYLDTLGDKFAGLFNKGGR

AFPDVAAQGMNYAIYDKGTLGRLDGTSCSAPAFSAIISLLNDARLR

EGKPTMGFLNPWLYGEGREALNDVVVGGSKGCDGRDRFGGKPN

GSPVVPFASWNATQGWDPVTGLGTPNFAKMLELA

50
CNSIITPQCLKDLYSIGDYEADPTNGNKVAFASYLEEYARYSDLALF

Penicillium

EKNIAPFAKGQNFSVVQYNGGGNDQQSSSGSSEANLDLQYIVGVS

digitatum

SPVPVTEFSTGGRGELVPDLDQPNPNDNNNEPYLEFLQNVLKLHK
Pd1

KDLPQVISTSYGEDEQSVPEKYARAVCNLYSQLGSRGVSVIFSSG

DSGVGAACQTNDGRNATHFPPQFPAACPWVTSVGATTHTAPERA

VYFSSGGFSDLWDRPTWQEDAVSEYLENLGDRWSGLFNPKGRA

FPDVAAQGENYAIYDKGSLISVDGTSCSAPAFAGVIALLNDARIKAN

RPPMGFLNPWLYSEGRSGLNDIVNGGSTGCDGHGRFSGPTNGG

TSIPGASWNATKGWDPVSGLGSPNFAAMRKLA

51
CNSAITPQCLKDLYKVGDYKASASNGNKVAFTSYLEQYARYSDLAL

Penicillium

FEQNIAPYAQGQNFTVIQYNGGLNDQSSPADSSEANLDLQYIIGTS

oxalicum

SPVPVTEFSTGGRGPLVPDLDQPDINDNNNEPYLDFLQNVIKMSD
114-2

KDLPQVISTSYGEDEQSVPASYARSVCNLIAQLGGRGVSVIFSSGD

SGVGSACQTNDGKNTTRFPAQFPAACPWVTSVGATTGISPERGV

FFSSGGFSDLWSRPSWQSHAVKAYLHKLGKRQDGLFNREGRAFP

DVSAQGENYAIYAKGRLGKVDGTSCSAPAFAGLVSLLNDARIKAG

KSSLGFLNPWLYSHPDALNDITVGGSTGCDGNARFGGRPNGSPV

VPYASWNATEGWDPVTGLGTPNFQKLLKSAV

52
CNSIITPQCLKDIYNIGDYQANDTNGNKVGFASYLEEYARYSDLALF

Penicillium

EKNIAPSAKGQNFSVTRYNGGLNDQSSSGSSSEANLDLQYIVGVS

roqueforti

SPVPVTEFSVGGRGELVPDLDQPDPNDNNNEPYLEFLQNVLKLDK
FM164

KDLPQVISTSYGEDEQSIPEKYARSVCNLYSQLGSRGVSVIFSSGD

SGVGSACLTNDGRNATRFPPQFPAACPWVTSVGATTHTAPEQAV

YFSSGGFSDLWARPKWQEEAVSEYLEILGNRWSGLFNPKGRAFP

DVTAQGRNYAIYDKGSLTSVDGTSCSAPAFAGVVALLNDARLKVN

KPPMGFLNPWLYSTGRAGLKDIVDGGSTGCDGKSRFGGANNGG

PSIPGASWNATKGWDPVSGLGSPNFATMRKLA

53
CNSIITPQCLKNMYNVGDYQADDDNGNKVGFASYLEEYARYSDLE

Penicillium

LFEKNVAPFAKGQNFSVIQYNGGLNDQHSSASSSEANLDLQYIVG

rubens

VSSPVPVTEFSVGGRGELVPDLDQPDPNDNNNEPYLEFLQNVLK
Wisconsin

MEQQDLPQVISTSYGENEQSVPEKYARTVCNLFSQLGSRGVSVIF
54-1255

ASGDSGVGAACQTNDGRNATRFPAQFPAACPWVTSVGATTHTAP

EKAVYFSSGGFSDLWDRPKWQEDAVSDYLDTLGDRWSGLFNPK

GRAFPDVSAQGQNYAIYDKGSLTSVDGTSCSAPAFAGVIALLNDA

RLKANKPPMGFLNPWLYSTGRDGLNDIVHGGSTGCDGNARFGGP

GNGSPRVPGASWNATKGWDPVSGLGSPNFATMRKLA

54
CANLITPDCLVEMYNLGDYKPDASSGSRVGFGSFLNQSANYADLA

Neosartorya

AYEQLFNIPPQNFSVELINGGANDQNWATASLGEANLDVELIVAVS

fischeri

HALPVVEFITGGSPPFVPNVDEPTAADNQNEPYLQYYEYLLSKPNS
NRRL 181

HLPQVISNSYGDDEQTVPEYYARRVCNLIGLMGLRGITVLESSGDT

GIGSACMSNDGTNTPQFTPTFPGTCPFITAVGGTQSYAPEVAWDA

SSGGFSNYFSRPWYQYFAVENYLNNHITKDTKKYYSQYTNFKGR

GFPDVSAHSLTPDYEVVLTGKHYKSGGTSAACPVFAGIVGLLNDA

RLRAGKSTLGFLNPLLYSILAEGFTDITAGSSIGCNGINPQTGKPVP

GGGIIPYAHWNATAGWDPVTGLGVPDFMKLKELVLS

55
CANLITPDCLVEMYNLGDYKPDASSGSRVGFGSFLNESANYADLA

Aspergillus

AYEQLFNIPPQNFSVELINRGVNDQNWATASLGEANLDVELIVAVS

fumigatus

HPLPVVEFITGALPPVLRVLALQTQLPSSSGDFQLTVPEYYARRVC
CAE17675

NLIGLMGLRGITVLESSGDTGIGSACMSNDGTNKPQFTPTFPGTCP

FITAVGGTQSYAPEVAWDGSSGGFSNYFSRPWYQSFAVDNYLNN

HITKDTKKYYSQYTNFKGRGFPDVSAHSLTPYYEVVLTGKHYKSG

GTSAASPVFAGIVGLLNDARLRAGKSTLGFLNPLLYSILAEGFTDIT

AGSSIGCNGINPQTGKPVPGGGIIPYAHWNATAGWDPVTGLGVPD

FMKLKELVLS

56
ATGGCAAAGTTGAGCACTCTCCGGCTTGCGAGCCTTCTTTCCCT

Trichoderma

TGTCAGTGTGCAGGTATCTGCCTCTGTCCATCTATTGGAGAGTC

reesei QM6a

TGGAGAAGCTGCCTCATGGATGGAAAGCAGCTGAAACCCCGAG

CCCTTCGTCTCAAATCGTCTTGCAGGTTGCTCTGACGCAGCAGA

ACATTGACCAGCTTGAATCGAGGCTCGCAGCTGTATCCACACC

CACTTCTAGCACCTACGGCAAATACTTGGATGTAGACGAGATCA

ACAGCATCTTCGCTCCAAGTGATGCTAGCAGTTCTGCCGTCGA

GTCTTGGCTTCAGTCCCACGGAGTGACGAGTTACACCAAGCAA

GGCAGCAGCATTTGGTTTCAAACAAACATCTCCACTGCAAATGC

GATGCTCAGCACCAATTTCCACACGTACAGCGATCTCACCGGC

GCGAAGAAGGTGCGCACTCTCAAGTACTCGATCCCGGAGAGCC

TCATCGGCCATGTCGATCTCATCTCTCCCACGACCTATTTTGGC

ACGACAAAGGCCATGAGGAAGTTGAAATCCAGTGGCGTGAGCC

CAGCCGCTGATGCTCTAGCCGCTCGCCAAGAACCTTCCAGCTG

CAAAGGAACTCTAGTCTTTGAGGGAGAAACGTTCAATGTCTTTC

AGCCAGACTGTCTCAGGACCGAGTATAGTGTTGATGGATACAC

CCCGTCTGTCAAGTCTGGCAGCAGAATTGGGTTTGGTTCCTTTC

TCAATGAGAGCGCAAGCTTCGCAGATCAAGCACTCTTTGAGAA

GCACTTCAACATCCCCAGTCAAAACTTCTCCGTTGTCCTGATCA

ACGGTGGAACGGATCTCCCTCAGCCGCCTTCTGACGCCAACGA

TGGCGAAGCCAACCTGGACGCTCAAACCATTTTGACCATCGCA

CATCCTCTCCCCATCACCGAATTCATCACCGCCGGCAGTCCGC

CATACTTCCCCGATCCAGTTGAACCTGCGGGAACACCCAACGA

GAACGAGCCTTATTTACAGTATTACGAATTTCTGTTGTCCAAGTC

CAACGCTGAAATTCCGCAAGTCATTACCAACTCCTACGGCGAC

GAGGAGCAAACTGTGCCGCGGTCATATGCCGTTCGAGTTTGCA

ATCTGATTGGTCTGCTAGGACTACGCGGTATCTCTGTCCTTCAT

TCCTCGGGCGACGAGGGTGTGGGCGCCTCTTGCGTTGCTACC

AAACAGCACCACGCCTCAGTTTAACCCCATCTTTCCTGTAGGTCT

TCTACGTCAACACTTCCAGACAACCATTTTCTCCTACTAACCACT

CTACCCTACTCTCTGTTCACATAGGCTACATGTCCTTATGTTACA

AGTGTTGGCGGAACCGTGAGCTTCAATCCCGAGGTTGCCTGGG

CTGGTTCATCTGGAGGTTTCAGCTACTACTTCTCTAGACCCTGG

TACCAGCAGGAAGCTGTGGGTACTTACCTTGAGAAATATGTCAG

TGCTGAGACAAAGAAATACTATGGACCTTATGTCGATTTCTCCG

GACGAGGTTTCCCCGATGTTGCAGCCCACAGCGTCAGCCCCGA

GTGAGTTCTATTCCTACCTATGCAAATCATAGAATGTATGCTAAC

TCGCCATGAAGCTATCCTGTGTTTCAGGGCGGTGAACTCACCC

CAAGCGGAGGCACTTCAGCAGCCTCTCCTGTCGTAGCAGCCAT

CGTGGCGCTGTTGAACGATGCCCGTCTCCGCGAAGGAAAACCC

ACGCTTGGATTTCTCAATCCGCTGATTTACCTACACGCCTCCAA

AGGGTTCACCGACATCACCTCGGGCCAATCTGAAGGGTGCAAC

GGCAATAACACCCAGACGGGCAGTCCTCTCCCAGGAGTATGCA

GAACATCAAGAAGCCTTCTATCAGACGCCAATGCTAACTTGTGG

ATAGGCCGGCTTCATTGCAGGCGCACACTGGAACGCGACCAAG

GGATGGGACCCGACGACTGGATTTGGTGTTCCAAACCTCAAAA

AGCTCCTCGCACTTGTCCGGTTCTAA

57
ATGTTCTTCAGTCGTGGAGCGCTTTCGCTCGCAGTGCTTTCACT

Aspergillus

GCTCAGCTCCTCCGCCGCAGGGGAGGCTTTTGAGAAGCTGTCT

oryzae RIB40

GCCGTTCCAAAAGGGATGGCACTATTCTAGTACCCCTAAAGGCA

ACACTGAGGTTTGTCTGAAGATCGCCCTCGCGCAGAAGGATGC

TGCTGGGTTCGAAAAGACCGTCTTGGAGATGTCGGATCCCGAC

CACCCCAGCTACGGCCAGCACTTCACCACCCACGACGAGATGA

AGCGCATGCTTCTTCCCAGAGATGACACCGTTGATGCCGTTCG

ACAATGGCTCGAAAACGGCGGCGTGACCGACTTTACCCAGGAT

GCCGACTGGATCAACTTCTGTACTACCGTCGATACCGCGAACA

AACTCTTGAATGCCCAGTTCAAATGGTACGTCAGCGATGTGAAG

CACATCCGCCGTCTCAGAACACTGCAGTACGACGTCCCCGAGT

CGGTCACCCCTCACATCAACACCATCCAACCGACCACCCGTTTT

GGCAAGATTAGCCCCAAGAAGGCCGTTACCCACAGCAAGCCCT

CCCAGTTGGACGTGACCGCCCTTGCTGCCGCTGTCGTTGCAAA

GAACATCTCGCACTGTGATTCTATCATTACCCCCACCTGTCTGA

AGGAGCTTTACAACATTGGTGATTACCAGGCCGATGCAAACTCG

GGCAGCAAGATCGCCTTCGCCAGCTATCTGGAGGAGTACGCGC

GCTACGCTGACCTGGAGAACTTTGAGAACTACCTTGCTCCCTG

GGCTAAGGGCCAGAACTTCTCCGTTACCACCTTCAACGGCGGT

CTCAATGATCAGAACTCCTCGTCCGATAGCGGTGAGGCCAACC

TGGACCTGCAGTACATTCTTGGTGTCAGCGCTCCACTGCCCGT

TACTGAATTCAGCACCGGAGGCCGTGGTCCCCTCGTTCCTGAT

CTGACCCAGCCGGATCCCAACTCTAACAGCAATGAGCCGTACC

TTGAGTTCTTCCAGAATGTGTTGAAGCTCGACCAGAAGGACCTC

CCCCAGGTCATCTCGACCTCCTATGGAGAGAACGAACAGGAAA

TCCCCGAAAAAGTACGCTCGCACCGTCTGCAACCTGATCGCTCA

GCTTGGCAGCCGCGGTGTCTCCGTTCTCTTCTCCTCCGGTGAC

TCTGGTGTTGGCGAGGGCTGCATGACCAACGACGGCACCAACC

GGACTCACTTCCCACCCCAGTTCCCCGCCGCTTGCCCGTGGGT

CACCTCCGTCGGCGCCACCTTCAAGACCACTCCCGAGCGCGG

CACCTACTTCTCCTCGGGCGGTTTCTCCGACTACTGGCCCCGT

CCCGAATGGCAGGATGAGGCCGTGAGCAGCTACCTCGAGACG

ATCGGCGACACTTTCAAGGGCCTCTACAACTCCTCCGGCCGTG

CTTTCCCCGACGTCGCAGCCCAGGGCATGAACTTCGCCGTCTA

CGACAAGGGCACCTTGGGCGAGTTCGACGGCACCTCCGCCTC

CGCCCCGGCCTTCAGCGCCGTCATCGCTCTCCTGAACGATGCC

CGTCTCCGCGCCGGCAAGCCCACTCTCGGCTTCCTGAACCCCT

GGTTGTACAAGACCGGCCGCCAGGGTCTGCAAAGATATCACCCT

CGGTGCTAGCATTGGCTGCACCGGTCGCGCTCGCTTCGGCGG

CGCCCCTGACGGTGGTCCCGTCGTGCCTTACGCTAGCTGGAAC

GCTACCCAGGGCTGGGATCCCGTCACTGGTCTCGGAACTCCCG

ATTTCGCCGAGCTCAAGAAGCTTGCCCTTGGCAACTAA

58
ATGGCGCCCATCCTCTCGTTCCTTGTTGGCTCTCTCCTGGCGG

Phaeosphaeria

TTCGCGCTCTTGCTGAGCCATTTGAGAAGCTGTTCAGCACCCC

nodorum

GGAAGGATGGAAGATGCAAGGTCTTGCTACCAATGAGCAGATC
SN15

GTCAAGCTCCAGATTGCTCTTCAGCAAGGCGATGTTGCAGGTTT

CGAGCAACATGTGATTGACATCTCAACGCCTAGCCACCCGAGC

TATGGTGCTCACTATGGCTCGCATGAGGAGATGAAGAGGATGA

TCCAGCCAAGCAGCGAGACAGTCGCTTCTGTGTCTGCATGGCT

GAAGGCCGCCGGTATCAACGACGCTGAGATTGACAGCGACTG

GGTCACCTTCAAGACGACCGTTGGCGTTGCCAACAAGATGCTC

GACACCAAGTTCGCTTGGTACGTGAGCGAGGAGGCCAAGCCC

CGCAAGGTCCTTCGCACACTCGAGTACTCTGTACCAGATGATGT

TGCAGAACACATCAACTTGATCCAGCCCACTACTCGGTTTGCTG

CGATCCGCCAAAACCACGAGGTTGCGCACGAGATTGTTGGTCT

TCAGTTCGCTGCTCTTGCCAACAACACCGTTAACTGCGATGCCA

CCATCACTCCCCAGTGCTTGAAGACTCTTTACAAGATTGACTAC

AAGGCCGATCCCAAGAGTGGTTCCAAGGTCGCTTTTGCTTCGT

ATTTGGAGCAGTACGCGCGTTACAATGACCTCGCCCTCTTCGA

GAAGGCCTTCCTCCCCGAAGCAGTTGGCCAGAACTTCTCTGTC

GTCCAGTTCAGCGGCGGTCTCAACGACCAGAACACCACGCAAG

ACAGTGGCGAGGCCAACTTGGACTTGCAGTACATTGTCGGTGT

CAGCGCTCCTCTTCCCGTCACCGAGTTCAGCACCGGTGGTCGC

GGCCCATGGGTCGCTGACCTAGACCAACCTGACGAGGCGGAC

AGCGCCAACGAGCCCTACCTTGAATTCCTTCAGGGTGTGCTCA

AACTTCCCCAGTCTGAGCTACCTCAGGTCATCTCCACATCCTAT

GGCGAGAATGAGCAGAGTGTACCTAAGTCATACGCTCTCTCCG

TCTGCAACTTGTTCGCCCAACTCGGTTCCCGTGGCGTCTCCGT

CATCTTCTCTTCTGGTGACAGCGGCCCTGGATCCGCATGCCAG

AGCAACGACGGCAAGAACACGACCAAGTTCCAGCCTCAGTACC

CCGCTGCCTGCCCCTTTGTCACCTCGGTTGGATCGACTCGCTA

CCTCAACGAGACCGCAACCGGCTTCTCATCTGGTGGTTTCTCC

GACTACTGGAAGCGCCCATCGTACCAGGACGATGCTGTTAAGG

CGTATTTCCACCACCTCGGTGAGAAATTCAAGCCATACTTCAAC

CGCCACGGCCGTGGATTCCCCGACGTTGCAACCCAGGGATATG

GCTTCCGCGTCTACGACCAGGGCAAGCTCAAGGGTCTCCAAGG

TACTTCTGCCTCCGCGCCTGCATTCGCCGGTGTGATTGGTCTC

CTCAACGACGCGCGATTGAAGGCGAAGAAGCCTACCTTGGGAT

TCCTAAACCCACTGCTTTACTCTAACTCAGACGCGCTAAATGAC

ATTGTTCTCGGTGGAAGCAAGGGATGCGATGGTCATGCTCGCT

TTAACGGGCCGCCAAATGGCAGCCCAGTAATCCCATATGCGGG

ATGGAACGCGACTGCTGGGTGGGATCCAGTGACTGGTCTTGGA

ACGCCGAACTTCCCCAAGCTTCTTAAGGCTGCGGTGCCTAGCC

GGTACAGGGCGTGA

59
ATGGCGAAACTGACAGCTCTTGCCGGTCTCCTGACCCTTGCCA

Trichoderma

GCGTGCAGGCAAATGCCGCCGTGCTCTTGGACAGCCTCGACAA

atroviride

GGTGCCTGTTGGATGGCAGGCTGCTTCGGCCCCGGCCCCGTC
IMI 206040

ATCCAAGATCACCCTCCAAGTTGCCCTCACGCAGCAGAACATTG

ATCAGTTGGAATCAAAGCTCGCTGCCGTCTCCACGCCCAACTC

CAGCAACTATGGAAAGTACCTGGATGTCGATGAGATTAACCAAA

TCTTCGCTCCCAGCAGCGCCAGCACCGCTGCTGTTGAGTCCTG

GCTCAAGTCGTACGGCGTGGACTACAAGGTGCAGGGCAGCAG

CATCTGGTTCCAGACGGATGTCTCCACGGCCAACAAGATGCTC

AGCACAAACTTCCACACTTACACCGACTCGGTTGGTGCCAAGAA

AGTGCGAACTCTCCAGTACTCGGTCCCCGAGACCCTGGCCGAC

CACATCGATCTGATTTCGCCCACAACCTACTTTGGCACGTCCAA

GGCCATGCGGGCGTTGAAGATCCAGAACGCGGCCTCTGCCGT

CTCGCCCCTGGCTGCTCGTCAGGAGCCCTCCAGCTGCAAGGG

CACAATTGAGTTTGAGAACCGCACATTCAACGTCTTCCAGCCCG

ACTGTCTCAGGACCGAGTACAGCGTCAACGGATACAAGCCCTC

AGCCAAGTCCGGTAGCAGGATTGGCTTCGGCTCTTTCCTGAAC

CAGAGCGCCAGCTCCTCAGATCTCGCTCTGTTCGAGAAGCACT

TTGGCTTTGCCAGCCAGGGCTTCTCCGTCGAGCTCATCAATGG

CGGATCAAACCCCCAGCCGCCCACAGACGCCAATGACGGCGA

GGCCAACCTGGACGCCCAGAACATTGTGTCGTTTGTGCAGCCT

CTGCCCATCACCGAGTTTATTGCTGGAGGAACTGCGCCGTACT

TCCCAGACCCCGTTGAGCCGGCTGGAACTCCCGATGAGAACGA

GCCTTACCTCGAGTACTACGAGTACCTGCTCTCCAAGTCAAACA

AGGAGCTTCCCCAAGTCATCACCAACTCCTACGGTGATGAGGA

GCAGACTGTTCCCCAGGCATATGCCGTCCGCGTGTGCAACCTC

ATTGGATTGATGGGCCTTCGTGGTATCTCTATCCTCGAGTCATC

CGGTGATGAGGGTGTTGGTGCCTCTTGTCTCGCTACCAACAGC

ACCACCACTCCCCAGTTCAACCCCATCTTCCCGGCTACATGCC

CCTATGTCACCAGTGTTGGTGGAACCGTCAGCTTCAACCCCGA

GGTTGCCTGGGACGGCTCATCCGGAGGCTTCAGCTACTACTTC

TCAAGACCTTGGTACCAGGAGGCCGCAGTCGGCACATACCTTA

ACAAGTATGTCAGCGAGGAGACCAAGGAATACTACAAGTCGTAT

GTCGACTTTTCCGGACGTGGCTTCCCCGATGTTGCAGCTCACA

GCGTGAGCCCCGATTACCCCGTGTTCCAAGGCGGCGAGCTTAC

CCCCAGCGGCGGTACTTCTGCGGCCTCTCCCATCGTGGCCAGT

GTTATTGCCCTCCTGAACGATGCTCGTCTCCGTGCAGGCAAGC

CTGCTCTCGGATTCTTGAACCCTCTGATCTACGGATATGCCTAC

AAGGGCTTTACCGATATCACGAGTGGCCAAGCTGTCGGCTGCA

ACGGCAACAACACTCAAACTGGAGGCCCTCTTCCTGGTGCGGG

TGTTATTCCAGGTGCTTTCTGGAACGCGACCAAGGGCTGGGAT

CCTACAACTGGATTCGGTGTCCCCAACTTCAAGAAGCTGCTTGA

GCTTGTCCGATACATTTAG

60
ATGCGTCTTCTCAAATTTGTGTGCCTGTTGGCATCAGTTGCCGC

Arthroderma

CGCAAAGCCTACTCCAGGGGCGTCACACAAGGTCATTGAACAT

benhamiae

CTTGACTTTGTTCCAGAAGGATGGCAGATGGTTGGTGCCGCGG
CBS 112371

ACCCTGCTGCTATCATTGATTTCTGGCTTGCCATCGAGCGCGAA

AACCCAGAAAAGCTCTACGACACCATCTATGACGTCTCCACCCC

TGGACGCGCACAATATGGCAAACATTTGAAGCGTGAGGAATTG

GATGACTTACTACGCCCAAGGGCAGAGACGAGTGAGAGCATCA

TCAACTGGCTCACCAATGGTGGAGTCAACCCACAACATATTCGG

GATGAAGGGGACTGGGTCAGATTCTCTACCAATGTCAAGACTG

CCGAAACGTTGATGAATACCCGCTTCAACGTCTTCAAGGACAAC

CTAAATTCCGTTTCAAAAATTCGAACTTTGGAGTATTCCGTCCCT

GTAGCTATATCAGCTCATGTCCAAATGATCCAGCCAACTACCTT

ATTTGGACGACAGAAGCCACAGAACAGTTTGATCCTAAACCCCT

TGACCAAGGATCTAGAATCCATGTCCGTTGAAGAATTTGCTGCT

TCTCAGTGCAGGTCCTTAGTGACTACTGCCTGCCTTCGAGAATT

GTACGGACTTGGTGACCGTGTCACTCAGGCTAGGGATGACAAC

CGTATTGGAGTATCCGGCTTTTTGGAGGAGTACGCCCAATACC

GCGATCTTGAGCTCTTCCTCTCTCGCTTTGAGCCATCCGCCAAA

GGATTTAATTTCAGTGAAGGCCTTATTGCCGGAGGAAAGAACAC

TCAGGGTGGTCCTGGAAGCTCTACTGAGGCCAACCTTGATATG

CAATATGTCGTCGGTCTGTCCCACAAGGCAAAGGTCACCTATTA

CTCCACCGCTGGCCGTGGCCCATTAATTCCCGATCTATCTCAG

CCAAGCCAAGCTTCAAACAACAACGAACCATACCTTGAACAGCT

GCGGTACCTCGTAAAGCTCCCCAAGAACCAGCTTCCATCTGTAT

TGACAACTTCCTATGGAGACACAGAACAGAGCTTGCCCGCCAG

CTATACCAAAGCCACTTGCGACCTCTTTGCTCAGCTAGGAACTA

TGGGTGTGTCTGTTATCTTCAGCAGTGGTGATACCGGGCCCGG

AAGCTCATGCCAGACCAACGATGGCAAGAATGCGACTCGCTTC

AACCCTATCTACCCAGCTTCTTGCCCGTTTGTGACCTCCATCGG

TGGAACCGTTGGTACCGGTCCTGAGCGTGCAGTTTCATTCTCCT

CTGGTGGCTTCTCAGACAGGTTCCCCCGCCCACAATATCAGGA

TAACGCTGTTAAAGACTACCTGAAAATTTTGGGCAACCAGTGGA

GCGGATTGTTTGACCCCAACGGCCGTGCTTTCCCAGATATCGC

AGCTCAGGGATCAAATTATGCTGTCTATGACAAGGGAAGGATGA

CTGGAGTCTCCGGCACCAGTGCATCCGCCCCTGCCATGGCTGC

CATCATTGCCCAGCTTAACGATTTCCGACTGGCAAAGGGCTCTC

CTGTGCTGGGATTCTTGAACCCATGGATATATTCCAAGGGTTTC

TCTGGCTTTACAGATATTGTTGATGGCGGTTCCAGGGGTTGCAC

TGGTTACGATATATACAGCGGCTTGAAAGCGAAGAAGGTTCCCT

ACGCAAGCTGGAATGCAACTAAGGGATGGGACCCAGTAACGGG

ATTTGGTACTCCCAACTTCCAAAGCTCTCACTAAAGTGCTGCCCT

AA

61
ATGTATATCACCTCATCCCGCCTCGTGCTGGCCTTAGCGGCACT

Fusarium

TCCGACAGCATTTGGTAAATCATACTCCCACCATGCCGAAGCAC

graminearum

CAAAGGGATGGAAGGTCGACGACACCGCTCGTGTTGCCTCCAC
PH-1

CGGTAAACAACAGGTCTTCAGCATCGCACTGACCATGCAAAATG

TTGATCAGCTCGAGTCCAAGCTCCTTGACCTCTCCAGCCCCGA

CAGCAAGAACTATGGCCAGTGGATGTCTCAAAAGGACGTAAACA

ACTGCTTTCTATCCTTCGAAAGAAGCTGTTTCCAGTGTGACAAA

GTGGCTCAAGTCCAAGGGTGTCAAGCACTACAACGTCAACGGT

GGTTTCATTGACTTTGCTCTCGATGTCAAGGGTGCCAATGCGCT

ACTTGATAGTGACTATCAATACTACACCAAAGAGGGCCAGACCA

AGTTGCGAACTCTGTCTTACTCTATCCCTGATGATGTAGCCGAA

CACGTTCAGTTCGTCGACCCAAGCACCAACTTTGGCGGCACAC

TGGCTTTCGCCCCTGTCACTCACCCATCGCGTACTCTAACCGA

GCGCAAGAACAAGCCCACCAAGAGCACAGTCGATGCTTCATGC

CAAACCAGCATCACACCCTCATGCTTGAAGCAGATGTACAACAT

TGGTGACTACACTCCCAAGGTCGAGTCTGGAAGCACTATTGGTT

TCAGCAGCTTCCTTGGCGAGTCCGCCATCTACTCCGATGTTTTC

CTGTTTGAGGAGAAGTTTGGAATTCCCACGCAGAACTTTACCAC

TGTTCTCATCAACAACGGCACTGATGACCAGAACACTGCTCACA

AGAACTTTGGCGAGGCTGACTTGGATGCCGAGAACATTGTTGG

AATTGCCCACCCTCTTCCCTTCACCCAGTACATCACTGGCGGTT

CACCACCTTTTCTTCCCAACATCGATCAGCCAACTGCTGCCGAT

AACCAGAACGAGCCTTATGTGCCTTTCTTCCGCTACCTTCTATC

GCAGAAGGAAGTCCCTGCAGTTGTCTCTACCTCGTATGGTGAC

GAAGAAGATAGCGTCCCTCGCGAATATGCTACCATGACCTGCA

ACCTGATTGGTCTTCTCGGACTTCGAGGAATCAGTGTCATCTTC

TCCTCTGGCGATATCGGCGTTGGTGCTGGATGTCTCGGCCCTG

ACCACAAGACTGTCGAGTTCAACGCCATCTTCCCTGCCACCTG

CCCTTACCTCACCTCCGTCGGCGGTACCGTTGATGTCACCCCC

GAAATCGCCTGGGAAGGTTCTTCTGGTGGTTTCAGCAAGTACTT

CCCCCGACCCAGCTACCAGGACAAGGCTGTCAAGACGTACATG

AAGACTGTCTCCAAGCAGACAAAGAAGTACTACGGCCCTTACAC

CAACTGGGAAGGCCGAGGCTTCCCTGATGTTGCTGGCCACAGT

GTCTCTCCCAACTATGAGGTTATCTATGCTGGTAAGCAGAGTGC

AAGCGGAGGTACCAGTGCTGCTGCTCCTGTTTGGGCTGCCATT

GTCGGTCTGCTCAACGATGCCCGTTTCAGAGCTGGGAAGCCAA

GCTTGGGATGGTTGAACCCTCTTGTTTACAAGTATGGACCAAAG

GTGTTGACTGACATCACTGGTGGTTACGCCATTGGATGTGATG

GCAACAACACCCAGTCCGGAAAGCCTGAGCCTGCAGGATCCG

GTATTGTGCCCGGTGCCAGATGGAATGCCACTGCCGGATGGGA

TCCTGTCACTGGTTATGGTACACCCGACTTTGGAAAGTTGAAGG

ATTTGGTTCTTAGCTTCTAA

62
ATGCGTTCCTCCGGTCTTTACGCAGCACTGCTGTGCTCTCTGG

Aspergillus

CCGCATCGACCAACGCAGTTGTTCATGAGAAGCTCGCCGCGGT

kawachii IFO

CCCCTCGGGCTGGCACCATCTCGAAGATGCTGGCTCCGATCAC
4308

CAGATTAGCCTGTCGATCGCATTGGCACGCAAGAACCTCGATC

AGCTTGAATCCAAGCTGAAAGACTTGTCCACACCAGGTGAATCG

CAGTATGGCCAGTGGCTGGATCAAGAGGAAGTCGACACACTGT

TCCCAGTGGCCAGCGACAAGGCCGTGATCAGCTGGTTGCGCA

GCGCCAACATCACCCATATTGCCCGGCAGGGCAGCTTGGTGAAA

CTTTGCGACCACCGTCGACAAGGTGAACAAGCTTCTCAACACC

ACTTTTGCTTACTACCAAAGAGGTTCTTCCCAGAGACTGCGCAC

GACAGAGTACTCCATTCCCGATGATCTGGTCGACTCGATCGAC

CTCATCTCCCCGACAACCTTTTTCGGCAAGGAAAAGACCAGTGC

TGGCCTGACCCAGCGGTCGCAGAAAGTCGACAACCATGTGGCC

AAACGCTCCAACAGCTCGTCCTGCGCCGATACCATCACGTTATC

CTGCCTGAAGGAGATGTACAACTTTGGCAACTACACTCCCAGC

GCCTCGTCAGGAAGCAAGCTGGGATTCGCCAGCTTCCTGAACG

AGTCCGCCTCGTATTCCGATCTTGCCAAGTTCGAGAGACTGTTC

AACTTGCCGTCTCAGAACTTCTCCGTGGAGCTGATCAACGGCG

GCGTCAATGACCAGAACCAATCGACGGCTTCTCTGACCGAGGC

TGACCTCGATGTGGAATTGCTCGTTGGCGTAGGTCATCCTCTTC

CGGTGACCGAGTTTATCACTTCTGGCGAACCTCCTTTCATTCCC

GACCCCGATGAGCCGAGTGCCGCCGATAATGAGAATGAGCCTT

ACCTTCAGTACTACGAGTACCTCCTCTCCAAGCCCAACTCGGCC

CTGCCCCAAGTGATTTCCAACTCCTACGGTGACGACGAACAGA

CCGTTCCAGAATACTACGCCAAGCGAGTCTGCAACCTGATCGG

ACTGGTCGGCCTGCGCGGCATCAGCGTCCTGGAATCATCCGGT

GACGAAGGAATTGGATCTGGCTGCCGCACCACCGACGGCACTA

ACAGCACCCAATTCAATCCCATCTTCCCCGCCACCTGTCCCTAC

GTGACCGCCGTAGGAGGCACCATGTCCTACGCGCCCGAAATTG

CCTGGGAAGCCAGTTCCGGTGGTTTCAGCAACTACTTCGAGCG

AGCCTGGTTCCAGAAGGAAAGCCGTGCAGAACTACCTGGCGAAAC

CACATCACCAACGAGACGAAGCAGTATTACTCACAATTCGCTAA

CTTTAGCGGTCGCGGATTTCCCGATGTTTCGGCCCATAGCTTTG

AGCCTTCGTACGAAGTTATCTTCTACGGCGCCCGTTACGGCTC

CGGCGGTACTTCCGCCGCATGTCCTCTGTTCTCTGCGCTAGTG

GGCATGTTGAACGATGCTCGTCTGCGGGCGGGCAAGTCCACG

CTTGGTTTCTTGAACCCCCTGCTGTACAGTAAGGGGTACAAGG

CGCTGACAGATGTCACGGCGGGACAATCGATCGGGTGCAATG

GCATTGATCCGCAGAGTGATGAGGCTGTTGCGGGCGCGGGCA

TTATCCCGTGGGCGCATTGGAATGCCACAGTCGGATGGGATCC

GGTGACGGGATTGGGACTTCCTGATTTTGAGAAGTTGAGGCAG

TTGGTGCTGTCGTTGTAG

63
ATGAGTCGAAATCTCCTCGTTGGTGCTGGCCTGTTGGCCCTCG

Talaromyces

CCCAATTGAGCGGTCAAGCTCTCGCTGCCGCTGCCCTCGTCGG

stipitatus

CCATGAATCCCTAGCTGCGCTGCCAGTTGGCTGGGATAAGGTC
ATCC 10500

AGCACGCCAGCTGCAGGGACGAACATTCAATTGTCCGTCGCCC

TCGCTCTGCAAAACATCGAGCAGCTGGAAGACCACTTGAAGTC

TGTGTCAACCCCCGGTTCTGCCAGCTACGGTCAGTACCTGGAT

TCCGACGGTATTGCCGCTCAATACGGTCCCAGCGACGCATCCG

TTGAGGCTGTCACCAACTGGCTGAAGGAGGCCGGTGTCACTGA

CATCTACAACAACGGCCAGTCGATTCACTTCGCAACCAGTGTCA

GCAAGGCCAACAGCTTGCTCGGGGCCGATTTCAACTACTATTCT

GATGGTAGTGCGACCAAGTTGCGTACCTTAGCTTATTCCGTTCC

CAGTGACCTCAAAGAGGCCATCGACCTTGTCTCGCCCACCACC

TATTTCGGCAAGACCACTGCTTCTCGTAGCATCCAGGCTTACAA

GAACAAGCGCGCCTCTACTACTTCCAAGTCTGGATCGAGCTCT

GTGCAAGTATCTGCTTCCTGCCAGACCAGCATCACTCCTGCCT

GCTTGAAACAGATGTACAATGTTGGCAACTACACACCCAGCGTC

GCTCACGGCAGTCGTGTCGGATTCGGTAGCTTCTTGAATCAATC

TGCCATCTTTGACGACTTGTTCACCTACGAAAAGGTCAATGATA

TTCCATCACAGAATTTCACTAAGGTGATTATTGCAAATGCATCCA

ACAGCCAAGATGCCAGCGATGGCAACTACGGCGAAGCCAACCT

TGACGTGCAAAACATTGTCGGCATCTCTCATCCTCTCCCCGTGA

CTGAATTCCTCACTGGTGGCTCACCTCCCTTCGTTGCTAGCCTC

GACACCCCTACCAACCAGAACGAGCCATATATTCCTTACTACGA

ATATCTTTTGTCTCAGAAGAACGAGGATCTCCCCCAGGTCATTT

CCAACTCTTACGGAGACGACGAGCAGTCTGTGCCGTACAAGTA

TGCCATCCGTGCATGCAACCTGATCGGCCTGACAGGTTTACGA

GGTATCTCGGTCTTGGAATCCAGCGGTGATCTCGGCGTTGGAG

CCGGCTGTCGCAGCAACGATGGCAAGAACAAGACTCAATTTGA

CCCCATCTTCCCTGCCACTTGCCCCTACGTTACCTCTGTTGGTG

GTACCCAATCCGTTACCCCTGAAATTGCCTGGGTCGCCAGCTC

CGGTGGTTTCAGCAACTACTTCCCTCGTACCTGGTACCAGGAA

CCCGCAATTCAGACCTATCTCGGACTCCTTGACGATGAGACCAA

GACATACTATTCTCAATACACCAACTTTGAAGGCCGTGGTTTCC

CCGATGTTTCCGCCCACAGCTTGACCCCTGATTACCAGGTCGT

CGGTGGTGGCTATCTCCAGCCAAGCGGTGGTACTTCCGCTGCT

TCTCCTGTCTTTGCCGGCATCATTGCGCTTTTGAACGACGCTCG

TCTCGCTGCTGGCAAGCCCACTCTTGGCTTCTTGAACCCGTTCT

TCTACCTTTATGGATACAAGGGTTTAAACGATATCACTGGAGGA

CAGTCAGTGGGTTGCAACGGTATCAACGGCCAAACTGGGGCTC

CTGTTCCCGGTGGTGGCATTGTTCCTGGAGCGGCCTGGAACTC

TACTACTGGCTGGGACCCAGCCACTGGTCTCGGAACACCCGAC

TTCCAGAAGTTGAAAGAACTCGTACTTAGCTTTTAA

64
ATGTATATCTCCTCCCAAAATCTGGTACTCGCCTTATCGGCGCT

Fusarium

GCCTTCAGCATTTGGCAAATCCTTCTCTCACCATGCTGAAGCTC

oxysporum f.

CTCAAGGCTGGCAAGTCCAAAAGACTGCCAAAGTCGCTTCCAA
sp. cubense

CACGCAGCATGTCTTCAGTCTTGCACTAACCATGCAAAACGTGG
race 4

ATCAGCTCGAATCCAAGCTTCTTGACCTCTCCAGCCCCGACAG

CGCCAACTACGGTAACTGGCTCTCCCACGATGAGCTCACAAGC

ACTTTCTCTCCTTCCAAGGAGGCGGTGGCTAGTGTGACAAAGT

GGCTCAAGTCAAAGGGCATCAAGCACTACAAGGTCAACGGTGC

TTTCATTGACTTTGCTGCTGATGTTGAGAAGGCCAATACGCTTC

TCGGAGGTGATTACCAGTACTACACTAAGGATGGTCAGACGAA

GCTGAGAACGCTGTCTTACTCCATTCCTGATGATGTCGCCGGTC

ACGTTCAATTTGTTGATCCTAGCACAAACTTCGGTGGCACCGTT

GCGTTCAACCCTGTGCCTCACCCCTCGCGCACCCTCCAAGAGC

GCAAGGTCTCTCCCTCCAAGAGCACCGTTGATGCTTCATGCCA

GACAAGCATCACCCCTTCTTGCCTCAAGCAGATGTACAACATTG

GAGACTACACTCCCGATGCCAAGTCTGGAAGTGAGATTGGTTT

CAGCAGCTTTCTCGGCCAGGCTGCTATTTACTCTGATGTCTTCA

AGTTTGAGGAGCTGTTTGGTATTCCTAAGCAGAACTACACCACT

ATTCTGATCAACAATGGCACCGATGATCAGAATACTGCGCATGG

AAACTTTGGAGAGGCTAACCTTGATGCTGAGAACATTGTTGGAA

TCGCTCATCCTCTTCCTTTCAAGCAGTACATTACTGGAGGTTCA

CCACCTTTCGTTCCCAACATCGATCAGCCCACCGAGAAGGATAA

CCAGAACGAGCCCTACGTGCCTTTCTTCCGTTACCTCTTGGGC

CAGAAGGATCTCCCAGCCGTCATCTCCACTTCCTACGGCGATG

AAGAAGACAGCGTTCCTCGTGAGTATGCTACACTCACCTGCAAC

ATGATCGGTCTTCTCGGTCTCCGTGGCATCAGTGTCATCTTCTC

TTCCGGTGACATCGGTGTCGGTTCCGGCTGCCTTGCTCCCGAC

TACAAGACCGTCGAGTTCAATGCCATCTTCCCCGCCACATGCC

CCTACCTCACCTCCGTCGGCGGTACCGTCGACGTCACCCCCGA

GATCGCCTGGGAGGGATCCTCCGGCGGATTCAGCAAGTACTTC

CCCCGACCCAGCTACCAGGACAAGGCCATCAAGAAGTACATGA

AGACAGTCTCCAAGGAGACCAAGAAGTACTACGGCCCTTACAC

CAACTGGGAGGGCCGAGGTTTCCCTGATGTCGCTGGACACAGT

GTTGCGCCTGACTACGAGGTTATCTACAATGGTAAGCAGGCTC

GAAGTGGAGGTACCAGCGCTGCTGCCCCTGTTTGGGCTGCTAT

CGTTGGTCTGTTGAACGATGCCCGCTTCAAGGCTGGTAAGAAG

AGCTTGGGATGGTTGAACCCTCTTATCTACAAGCATGGACCCAA

GGTCTTGACTGACATCACCGGTGGCTATGCTATTGGATGTGAC

GGTAACAACACTCAGTCTGGAAAGCCCGAGCCCGCTGGATCTG

GTCTTGTTCCCGGTGCTCGATGGAACGCCACAGCTGGATGGGA

TCCTACCACTGGCTATGGAACTCCCAACTTCCAGAAGTTGAAGG

ACTTGGTTCTCAGCTTGTAA

65
ATGCCTAAGTCCACAGCGCTTCGGCTTGTTAGCCTCCTTTCCCT

Trichoderma

GGCCAGTGTGCCGATATCTGCCTCCGTCCTTGTGGAAAGTCTC

virens

GAAAAGCTGCCTCACGGATGGAAAGCTGCTTCGGCTCCTAGCC
Gv29-8

CTTCCTCCCAGATAACCCTACAAGTCGCTCTTACGCAGCAGAAC

ATCGATCAGCTGGAATCGAGGCTCGCGGCTGTATCCACACCAA

ATTCCAAGACATACGGAAATTATCTGGATCTTGATGAGATCAAT

GAGATCTTCGCGCCAAGCGATGCCAGCAGCGCAGCCGTGGAG

TCTTGGCTCCATTCTCACGGTGTGACAAAATACACGAAGCAAGG

CAGCAGTATCTGGTTCCAAACCGAAGTTTCTACAGCAAATGCAA

TGTTGAGCACAAACTTCCACACTTACAGTGATGCTGCTGGCGTT

AAGAAGTTGCGAACTCTTCAGTATTCAATTCCGGAGAGTCTTGT

GGGCCATGTCGATCTCATCTCACCCACGACCTACTTTGGCACCT

CTAACGCTATGAGAGCTTTGAGATCTAAAAGCGTGGCTTCAGTT

GCTCAAAGTGTGGCAGCCCGCCAAGAACCTTCTAGCTGCAAGG

GAACTCTGGTTTTCGAAGGAAGAACGTTCAATGTCTTCCAACCA

GATTGTCTTAGGACAGAGTACAATGTCAATGGATACACTCCATC

AGCCAAGTCTGGTAGTAGAATAGGATTTGGTTCCTTCTTAAACC

AAAGTGCAAGCTTTTCAGACCTCGCACTCTTTGAAAAACACTTT

GGGTTTTCCAGCCAAAATTTCTCCGTCGTTCTGATCAATGGTGG

AACGGACCTGCCCCAACCACCCTCTGACGACAACGATGGCGAG

GCCAATTTGGATGTCCAAAACATTTTGACAATCGCACACCCTCT

GCCCATCACTGAATTCATCACTGCCGGAAGCCCGCCGTACTTC

CCAGATCCCGTTGAACCTGCAGGAACTCCCGATGAGAACGAGC

CTTACTTGCAGTACTTTGAGTATCTGTTGTCGAAGCCCAACAGA

GATCTTCCTCAGGTCATTACCAACTCTTACGGTGATGAGGAGCA

AACAGTACCTCAGGCTTATGCTGTCCGAGTGTGCAACCTAATTG

GATTGATGGGACTGCGTGGTATCAGTATCCTCGAGTCCTCCGG

CGATGAGGGAGTGGGTGCTTCCTGCGTTGCTACCAACAGCACC

ACTCCTCAATTTAACCCCATTTTCCCGGCAACATGCCCCTATGT

CACTAGCGTAGGTGGAACTGTGAACTTCAACCCAGAAGTTGCC

TGGGACGGTTCATCTGGAGGTTTCAGCTACTATTTCTCCAGGCC

ATGGTACCAAGAGGAAGCAGTTGGAAACTACCTAGAGAAGCAT

GTCAGCGCCGAAACAAAGAAGTACTACGGGCCTTATGTCGATTT

CTCTGGACGTGGCTTCCCTGATGTTGCAGCTCACAGCGTGAGC

CCCGATTATCCTGTGTTCCAAGGCGGCCAGCTCACTCCTAGCG

GAGGCACTTCTGCGGCTTCTCCCGTCGTAGCCAGTATCATTGC

CCTTCTGAACGATGCACGCCTCCGTGAAGGCAAGCCCACACTT

GGGTTCCTGAACCCGCTGATTTACCAATATGCTTACAAGGGTTT

CACGGATATCACATCCGGCCAGTCTGATGGCTGCAATGGCAAC

AACACCCAAACGGATGCCCCTCTTCCTGGAGCTGGCGTTGTCC

TAGGAGCACACTGGAATGCGACCAAAGGATGGGATCCTACGAC

AGGATTTGGTGTCCCTAACTTTAAGAAGCTACTCGAGCTGATCC

GATATATATAG

66
ATGGCTAAACTGACGGCACTTCGGCTCGTCAGCCTTCTTTGCCT

Trichoderma

TGCGGCTGCGCAGGCCTCTGCTGCTGTGCTCGTGGAAAGCCTC

atroviride IMI

AAACAAGTGCCCAACGGGTGGAATGCAGTCTCGACCCCAGACC
206040

CTTCGACATCGATTGTCTTGCAAATCGCCCTCGCGCAACAGAAT

ATCGATGAATTGGAATGGCGTCTCGCGGCTGTATCCACGCCCA

ACTCTGGCAATTATGGCAAATACCTGGATATTGGAGAGATTGAA

GGAATTTTCGCCCCAAGCAATGCCTCTTACAAAGCCGTGGCATC

GTGGCTCCAGTCTCATGGGGTGAAGAACTTCGTCAAACAAGCC

GGCAGTATTTGGTTCTACACTACTGTCTCTACCGCAAACAAGAT

GCTTAGCACAGATTTCAAACACTATAGCGATCCTGTTGGCATTG

AGAAGCTGCGTACTCTTCAGTACTCGATCCCAGAAGAACTAGTC

GGCCATGTTGATCTCATCTCGCCTACAACATATTTTGGAAACAA

CCACCCCGCGACAGCGAGAACACCCAACATGAAGGCCATTAAC

GTAACCTACCAAATCTTTCACCCAGACTGCCTTAAAACGAAAATA

CGGCGTTGATGGCTATGCCCCATCTCCAAGATGTGGCAGCAGG

ATTGGTTTTGGCTCATTCCTCAACGAAACTGCCAGTTATTCGGA

TCTTGCGCAGTTTGAGAAGTACTTTGACCTTCCCAACCAAAACC

TTTCCACCTTATTGATCAATGGCGCAATCGACGTTCAGCCACCT

TCCAACAAAAAACGACAGCGAGGCCAACATGGACGTTCAGACCA

TCTTGACCTTTGTCCAACCTCTTCCTATTACTGAGTTTGTTGTTG

CCGGAATCCCGCCGTATATTCCTGATGCGGCTTTGCCGATCGG

CGACCCTGTCCAAAACGAGCCGTGGCTGGAATACTTTGAGTTTT

TGATGTCCAGGACCAACGCAGAGCTTCCCCAGGTCATTGCCAA

CTCATACGGTGACGAGGAACAAACGGTACCACAGGCGTATGCC

GTCCGAGTATGCAACCAGATTGGGCTGTTGGGCCTTCGCGGTA

TATCCGTTATCGCATCATCTGGCGATACGGGTGTTGGAATGTCT

TGTATGGCTTCGAACAGCACTACTCCTCAGTTTAACCCCATGTT

CCCGGCTTCGTGTCCTTATATCACCACTGTCGGTGGAACTCAG

CACCTTGATAATGAGATTGCTTGGGAGCTTTCATCGGGAGGCTT

CAGTAACTATTTCACAAGGCCATGGTATCAAGAAGACGCAGCCA

AAACATATCTTGAACGTCATGTCAGCACCGAGACAAAGGCATAT

TACGAACGTTACGCCAATTTCTTGGGACGCGGCTTTCCCGACG

TTGCAGCACTTAGTCTCAACCCCGATTATCCAGTGATTATTGGC

GGAGAACTTGGTCCCAATGGAGGCACTTCTGCGGCCGCACCC

GTCGTCGCTAGTATTATTGCACTCTTGAACGATGCACGCCTTTG

CCTAGGCAAACCTGCCCTTGGGTTCTTGAACCCCCTGATCTATC

AATATGCTGATAAGGGTGGCTTCACGGATATCACGTCCGGCCA

GTCTTGGGGCTGTGCCGGAAATACCACTCAGACGGGGCCTCCT

CCCCCTGGAGCTGGTGTCATTCCGGGGGCACACTGGAATGCG

ACCAAGGGATGGGATCCTGTAACAGGATTTGGAACCCCGAACT

TCAAGAAATTACTCTCACTGGCCCTGTCCGTCTAA

67
ATGTTTTGGCGTCCAGCTTTTGTCCTTCTTCTCGCTCAGCTTGT

Agaricus

CACTGCTAGTCCTTTAGCTCGACGCTGGGATGATTTCGCAGAAA

bisporus var.

AACATGCCTGGGTTGAAGTTCCTCGCGGGTGGGAAATGGTCTC

burnettii

CGAGGCTCCCAGTGACCATACCTTTGATCTTCGCATTGGAGTAA
JB137-S8

AGTCAAGTGGCATGGAGCAGCTCATTGAAAACTTGATGCAAACC

AGCGATCCTACTCATTCCAGATATGGTCAACATCTTAGTAAAGA

AGAGCTCCATGATTTCGTTCAGCCTCATCCTGATTCTACCGGAG

CGGTCGAAGCATGGCTTGAAGATTTCGGTATCTCCGATGATTTC

ATTGATCGTACTGGAAGTGGCAACTGGGTTACTGTTCGAGTTTC

AGTAGCCCAGGCTGAACGTATGCTTGGTACCAAGTATAACGTCT

ACCGCCATTCTGAATCAGGGGAATCGGTTGTACGAACAATGTCT

TATTCGCTTCCCAGCGAACTTCACTCCCACATAGATGTTGTCGC

ACCCACCACTTATTTCGGCACGATGAAAAGCATGCGGGTGACC

AGCTTCTTACAGCCGGAAATAGAGCCTGTTGACCCAAGCGCTA

AACCATCGGCTGCTCCAGCTTCCTGTTTGAGTACCACTGTCATA

ACCCCCGATTGCCTCCGTGACCTTTATAATACGGCTGACTACGT

TCCTTCCGCCACTTCACGGAATGCCATTGGTATTGCTGGGTACT

TGGATCGTTCAAATCGTGCAGATCTTCAGACTTTCTTCCGACGC

TTCCGGCCCGATGCCGTTGGCTTCAATTACACGACTGTCCAACT

AAATGGCGGAGGAGACGACCAGAATGATCCCGGTGTAGAGGC

CAACCTCGATATTCAATACGCCGCTGGTATTGCTTTCCCCACAC

CAGCTACATACTGGAGTACTGGCGGCTCTCCACCTTTCATTCCA

GATACTCAAACCCCGACAAACACCAATGAGCCCTACCTGGATTG

GATCAATTTTGTCCTAGGCCAGGACGAGATTCCACAGGTGATTT

CAACGTCCTATGGTGACGACGAGCAAACAGTTCCTGAAGATTAC

GCTACTAGCGTGTGTAATCTCTTCGCGCAACTCGGCAGCCGTG

GCGTTACAGTATTCTTCTCCAGCGGTGACTTTGGTGTTGGTGGT

GGAGATTGCCTCACGAATGATGGCTCAAACCAAGTCCTTTTCCA

GCCGGCTTTCCCCGCTTCCTGCCCATTCGTAACAGCTGTTGGC

GGAACTGTCAGGCTTGATCCTGAGATTGCTGTCAGTTTCTCTGG

AGGAGGCTTTTCCCGTTACTTCTCCAGGCCATCGTACCAGAATC

AAACTGTGGCTCAATTTGTTTCTAATCTTGGGAATACATTCAACG

GACTCTACAATAAAAATGGAAGGGCCTACCCAGATCTTGCAGCA

CAGGGCAATGGCTTCCAAGTTGTTATAGACGGCATCGTCCGTT

CGGTTGGAGGGACCAGCGCCAGCTCTCCGACGGTTGCCGGTA

TCTTTGCGCTTTTGAATGACTTCAAGCTCTCAAGAGGCCAGTCG

ACACTCGGATTTATCAACCCACTTATATACTCCTCCGCTACATCC

GGCTTCAATGACATCAGGGCGGGTACAAACCCTGGTTGTGGTA

CTCGCGGATTTACCGCTGGTACTGGTTGGGATCCGGTCACTGG

TCTGGGCACTCCCGATTTTTTGAGGCTTCAGGGACTTATTTAA

68
ATGCTCGACCGTATCCTTCTCCCCCTCGGCCTCCTGGCCTCCC

Magnaporthe

TTGCCACCGCTCGTGTCTTTGACAGCCTACCCCACCCTCCCCG

oryzae 70-15

AGGCTGGTCATACTCGCACGCGGCGGAATCGACGGAGCCGCT

GACCCTGCGCATCGCCCTCCGCCAGCAAAATGCCGCCGCCCT

GGAGCAGGTGGTGCTGCAGGTCTCGAACCCCAGGCACGCCAA

TTACGGCCAGCACCTGACGCGCGACGAGCTGCGCAGCTACAC

GGCGCCCACGCCGCGGGCCGTCCGCAGCGTGACGTCGTGGCT

GGTCGACAACGGCGTCGACGACTACACGGTCGAGCACGACTG

GGTGACGCTGCGCACGACGGTCGGGGCCGCGGACAGGCTGCT

CGGCGCAGACTTTGCCTGGTATGCCGGCCCGGGCGAGACGCT

GCAGCTGCGGACGCTCTCGTACGGCGTCGACGACTCGGTGGC

GCCGCACGTCGACCTCGTGCAGCCCACGACGCGGTTTGGCGG

TCCCGTCGGGCAGGCGTCGCACATCTTCAAGCAGGACGACTTT

GACGAGCAGCAGCTCAAGACCTTGTCGGTGGGGTTCCAGGTCA

TGGCTGACCTGCCGGCCAACGGGCCTGGGTCGATCAAGGCGG

CATGTAACGAGTCTGGCGTGACGCCCCTGTGCCTGCGAACTCT

GTACAGGGTCAACTACAAGCCGGCAACCACGGGGAACCTGGTC

GCTTTCGCGTCGTTCCTGGAGCAGTACGCCAGGTACAGTGATC

AGCAGGCATTCACTCAGCGGGTCCTTGGCCCTGGTGTTCCGTT

GCAGAACTTTTCGGTCGAAACGGTCAACGGTGGAGCCAATGAC

CAGCAGAGCAAAACTTGACAGCGGCGAGGCGAACCTCGATCTGC

AGTACGTCATGGCAATGAGCCACCCTATTCCAATTTTGGAGTAC

AGCACTGGAGGCAGAGGACCCCTCGTCCCAACTCTGGACCAG

CCCAACGCCAACAACAGCAGCAATGAGCCTTACCTGGAGTTCC

TGACGTACCTCCTGGCCCAACCCGACTCAGCCATCCCTCAGAC

CCTGTCGGTGTCGTATGGCGAGGAGGAACAGTCGGTGCCGCG

CGACTACGCCATCAAGGTTTGCAACATGTTCATGCAGCTCGGC

GCCCGCGGCGTGTCGGTTATGTTTTCGTCGGGCGACTCGGGC

CCGGGTAATGACTGTGTTCGAGCCTCGGACAACGCAACCTTTTT

TGGCTCAACATTCCCCGCAGGCTGCCCCTACGTCACGTCGGTG

GGCTCCACCGTCGGCTTCGAGCCGGAGCGCGCCGTCTCCTTTT

CCTCGGGCGGCTTCAGCATTTACCACGCTCGCCCCGACTACCA

AAACGAAGTGGTCCCCAAGTACATTGAATCGATCAAGGCTTCG

GGCTACGAAAAGTTCTTTGACGGCAACGGCCGCGGAATTCCCG

ACGTGGCTGCCCAGGGCGCCCGCTTCGTCGTCATCGACAAGG

GCCGCGTTTCTCTAATCTCGGGGACCAGCGCCAGCTCACCTGC

GTTTGCTGGCATGGTGGCGCTCGTCAACGCCGCCCGCAAGTCA

AAGGACATGCCGGCCTTGGGCTTCCTCAACCCCATGCTGTACC

AGAACGCCGCGGCCATGACGGACATTGTCAACGGCGCTGGCA

TCGGCTGCAGGAAGCAACGTACAGAATTCCCGAATGGCGCCAG

GTTCAACGCCACGGCCGGCTGGGATCCCGTCACAGGGCTGGG

GACGCCGTTGTTTGACAAGCTGCTGGCTGTTGGCGCACCTGGA

GTTCCCAACGCGTGA

69
ATGCGTAGCCAGTTGCTCTTCTGCACAGCATTTGCTGCTCTCCA

Togninia

GTCGCTTGTGGAGGGCAGCGATGTGGTGTTGGAGTCATTGCGA

minima

GAGGTCCCTCAGGGCTGGAAGAGGCTTCGAGATGCGGACCCC
UCRPA7

GAGCAGTCCATCAAGCTGCGCATTGCGCTTGAGCAGCCTAACC

TGGACCTGTTCGAGCAGACCCTCTACGACATCTCGTCACCGGA

TCACCCAAAATATGGCCAGCATCTCAAGAGCCACGAGTTACGG

GATATTATGGCACCTCGCGAGGAGTCAACTGCTGCTGTCATCG

CTTGGCTGCAAGACGCTGGGCTTTCTGGCTCGCAGATTGAGGA

CGACAGCGACTGGATCAACATCCAGACGACAGTCGCCCAAGCC

AACGACATGCTGAACACGACTTTCGGTCTCTTCGCCCAGGAAG

GCACCGAGGTCAATCGAATTCGAGCTCTGGCATATTCCGTGCC

TGAGGAGATCGTCCCTCACGTCAAGATGATTGCTCCCATCATCC

GCTTCGGTCAGTTGAGACCTCAGATGAGCCACATCTTCTCGCAT

GAGAAAGTCGAGGAGACCCCGTCTATTGGCACCATCAAGGCCG

CCGCTATCCCATCTGTGGATCTTAACGTCACCGCTTGCAATGCC

AGCATCACCCCCGAGTGCCTCCGAGCGCTTTACAACGTTGGTG

ATTACGAGGCGGACCCATCGAAGAAGTCTCTTTTCGGAGTCTGT

GGCTACTTGGAGCAATATGCCAAGCACGATCAGCTGGCCAAGT

TTGAGCAGACCTACGCTCCGTATGCTATCGGTGCCGACTTCAG

CGTCGTGACCATCAATGGCGGAGGCGACAACCAGACCAGTACG

ATCGATGATGGAGAAGCCAACCTGGATATGCAGTATGCTGTCA

GCATGGCATACAAGACGCCAATCACATACTATTCAACTGGGGGT

CGAGGACCTCTTGTTCCAGATCTCGACCAACCTGATCCCAACG

ACGTCTCAAACGAGCCGTACCTTGATTTTGTGAGCTACCTTCTC

AAGCTGCCCGACTCCAAATTGCCGCAGACCATCACAACTTCGTA

CGGAGAGGATGAGCAATCCGTTCCACGCTCCTACGTGGAGAAG

GTCTGCACCATGTTCGGCGCGCTCGGTGCCCGAGGCGTGTCT

GTGATCTTCTCCTCTGGTGATACCGGTGTCGGCTCAGCGTGCC

AGACCAACGACGGCAAGAACACCACCCGCTTCCTGCCTATATT

CCCTGCTGCGTGCCCTTATGTGACCTCGGTTGGAGGCACTCGC

TATGTCGACCCGGAAGTCGCTGTGTCCTTCTCGTCTGGAGGCT

TCTCGGACATCTTCCCTACGCCACTCTACCAGAAGGGCGCTGT

CTCTGGCTACCTGAAGATCCTCGGCGATCGCTGGAAGGGCCTC

TATAACCCTCACGGCCGCGGTTTCCCTGACGTCTCCGGACAGA

GTGTCAGATACCACGTCTTCGACTACGGCAAGGACGTCATGTA

CTCTGGCACAAGTGCCTCTGCACCGATGTTCGCCGCGCTTGTC

TCGCTGCTGAACAACGCCCGTCTCGCAAAGAAGTTGCCGCCCA

TGGGATTCCTGAATCCCTGGCTGTATACCGTTGGTTTTAACGGG

CTGACGGATATTGTGCACGGTGGATCTACTGGGTGCACTGGCA

CAGACGTGTACAGCGGCCTGCCCACACCTTTCGTTCCGTATGC

GTCTTGGAACGCAACCGTGGGATGGGACCCCGTTACTGGACTT

GGCACGCCTCTCTTTGATAAGCTGCTCAATTTGAGCACGCCAAA

CTTCCACTTGCCGCACATTGGCGGTCACTAG

70
ATGAAGTACAACACACTCCTCACCGGCCTGCTGGCTGTTGCCC

Bipolaris

ATGGCAGTGCCGTTTCCGCTTCAACTACTTCACATGTCGAGGGT

maydis C5

GAAGTTGTCGAGCGACTTCATGGCGTTCCTGAGGGTTGGAGTC

AAGTGGGCGCCCCCAATCCAGACCAGAAGCTGCGCTTTCGCAT

CGCAGTACGCTCGGTGAGTAATTGCTTTTGTGAACCCATGTTTG

AATCTTGCGGTGCTTTTTACTGAACATAACAGGCGGATAGCGAG

CTGTTTGAGAGGACGCTTATGGAGGTTTCTTCTCCCAGCCATCC

TCGCTACGGACAGCACCTAAAGCGACACGAACTCAAGGACCTC

ATCAAACCGCGCGCCAAGTCAACTTCAAACATCCTGAACTGGCT

GCAAGAGTCTGGAATTGAGGCCAGAGATATCCAGAACGATGGC

GAGTGGATCAGCTTCTATGCTCCGGTTAAACGTGCCGAGCAAA

TGATGAGCACTACATTCAAGACCTATCAGAACGAGGCCCGAGC

GAATATCAAGAAGATCCGCTCTCTAGACTACTCGGTGCCGAAG

CACATTCGAGATGACATCGACATCATCCAGCCTACGACTCGCTT

CGGCCAGATCCAACCGGAGCGTAGCCAAGTCTTTAGTCAAGAA

GAGGTCCCATTCTCAGCGCTTGTTGTCAATGCGACGTGTAACAA

GAAAATCACTCCCGACTGCCTCGCCAACCTCTACAACTTCAAAG

ACTATGATGCCAGCGATGCCAATGTCACTATCGGAGTCAGCGG

CTTCCTGGAGCAATATGCTCGCTTTGACGACTTGAAGCAATTCA

TCAGCACTTTCCAACCAAAAGCAGCTGGTTCCACATTCCAAGTT

ACATCTGTCAATGCAGGGCCTTTTGACCAGAACTCGACAGCCA

GCAGTGTTGAAGCCAATCTTGACATTCAGTACACAACAGGTCTT

GTTGCGCCCGACATTGAAACCCGCTACTTCACTGTTCCCGGTC

GCGGTATCCTGATCCCTGATCTGGACCAGCCTACGGAGAGCGA

CAACGCTAATGAGCCGTATCTGGATTACTTTACATATCTTAATAA

CCTCGAAGACGAAGAACTCCCCGACGTGCTGACCACATCTTAC

GGCGAGAGCGAGCAGAGTGTACCCGCCGAATATGCAAAAAAG

GTGTGCAATTTGATCGGCCAGTTGGGTGCTCGTGGTGTGTCCG

TCATCTTCTCCAGCGGTGATACTGGCCCTGGCTCTGCATGCCA

AACCAATGATGGAAAAAACACGACACGTTTCTTGCCCATCTTCC

CTGCTTCTTGCCCCTACGTCACTTCGGTTGGCGGCACTGTTGG

TGTTGAGCCCGAAAAGGCTGTCAGCTTCTCTTCGGGCGGCTTT

TCTGACCTATGGCCTCGACCCGCTTATCAAGAGAAGGCCGTAT

CAGAATATCTTGAAAAGCTCGGAGACCGCTGGAACGGGCTTTA

CAACCCTCAAGGACGCGGATTTCCTGATGTAGCTGCTCAGGGC

CAAGGCTTCCAGGTGTTTGACAAGGGCAGGCTGATTTCGGTCG

GAGGAACGAGCGCTTCAGCTCCTGTTTTCGCATCCGTAGTCGC

ACTCCTGAACAATGCTCGCAAGGCTGCCGGCATGTCTTCACTC

GGCTTCTTGAACCCATGGATCTACGAGCAAGGCTACAAGGGCT

TGACCGATATCGTTGCTGGAGGCTCGACAGGATGCACAGGAAG

ATCCATCTATTCAGGCCTCCCAGCACCACTCGTGCCGTATGCTT

CTTGGAATGCCACCGAAGGATGGGATCCGGTGACGGGCTATG

GTACACCTGATTTCAAGCAATTGCTCACCCTCGCGACGGCACC

CAAGTCTGGCGAGCGTCGCGTTCGTCGTGGCGGTCTCGGTGG

CCAGGCTTAG

71
ATGTTATCTTCCTTCCTTAGCCAGGGAGCAGCCGTATCCCTCGC

Aspergillus

GTTATTGTCGCTGCTCCCTTCGCCTGTAGCCGCGGAGATCTTC

kawachii IFO

GAGAAGCTGTCCGGCGTCCCCAATGGCTGGAGATACGCCAACA
4308

ATCCTCACGGCAACGAGGTCATTCGCCTTCAAATCGCCCTTCAG

CAGCACGATGTTGCCGGTTTCGAACAAGCCGTGATGGACATGT

CCACCCCCGGTCACGCCGACTATGGAAAGCATTTCCGCACACA

TGATGAGATGAAGCGCATGCTGCTCCCCAGCGACACTGCCGTC

GACTCAGTTCGCGACTGGCTGGAATCCGCCGGAGTCCACAATA

TCCAGGTCGACGCCGACTGGGTCAAGTTCCATACCACCGTCAA

CAAGGCCAATGCCCTGCTGGATGCCGACTTCAAGTGGTATGTC

AGCGAGGCCAAGCACATTCGTCGTCTACGCACCCTGCAATACT

CCATCCCCGACGCCCTGGTCTCGCACATCAACATGATCCAGCC

CACCACTCGCTTTGGCCAGATCCAGCCGAACCGTGCCACCATG

CGCAGCAAGCCCAAGCACGCCGACGAGACATTCCTGACCGCA

GCCACCTTGGCCCAGAACACCTCCCACTGCGACTCCATCATCA

CGCCGCACTGTCTGAAGCAGCTCTACAACATCGGTGACTACCA

GGCCGACCCCAAGTCCGGTAGCAAGGTCGGCTTCGCCAGCTA

CCTCGAAGAATACGCCCGGTATGCCGATCTCGAAAGGTTCGAG

CAGCACCTGGCTCCCAACGCCATCGGCCAGAACTTCAGCGTCG

TTCAATTCAACGGCGGCCTCAACGACCAGCTTTCATTGAGCGAC

AGCGGCGAAGCCAACCTCGACCTGCAGTACATCCTGGGCGTCA

GCGCTCCCGTCCCGGTCACTGAATACAGCACTGGCGGACGCG

GCGAACTGGTCCCCGACCTGAGCTCCCCGGACCCCAACGACA

ACAGCAACGAGCCCTACCTCGACTTCCTCCAGGGTATTCTCAAA

CTCGACAATTCCGACCTCCCCCAAGTCATCTCTACCTCCTACGG

CGAAGACGAACAGACCATCCCCGTCCCCTACGCCCGCACAGTC

TGCAATCTCTACGCCCAACTCGGCAGCCGCGGTGTCTCCGTGA

TCTTCTCGAGCGGCGACTCCGGCGTCGGCGCCGCCTGCCTCA

CCAACGACGGCACCAACCGCACCCACTTCCCTCCTCAATTCCC

GGCCTCCTGCCCCTGGGTAACCTCCGTCGGTGCCACCAGCAAA

ACCTCCCCGGAGCAAGCCGTCTCCTTCTCCTCAGGAGGCTTCT

CCGACCTCTGGCCCCGCCCCTCCTACCAACAGGCTGCCGTCCA

AACCTACCTCACCCAGCACCTGGGCAACAAGTTCTCAGGCCTC

TTCAACGCCTCCGGCCGCGCCTTCCCCGACGTCGCCGCGCAG

GGCGTCAACTACGCCGTCTACGACAAGGGCATGCTTGGCCAGT

TCGATGGAACCAGTTGCTCCGCGCCGACGTTCAGTGGTGTCAT

TGCCTTGTTGAATGACGCCAGACTGAGGGCGGGTTTGCCCGTT

ATGGGATTCCTGAACCCGTTCCTCTATGGAGTTGGTAGTGAGA

GTGGCGCGTTGAATGATATTGTCAACGGCGGGAGCCTGGGTTG

TGATGGTAGGAATCGATTTGGAGGCACGCCCAATGGAAGTCCC

GTTGTGCCGTTTGCTAGTTGGAATGCGACCACCGGGTGGGATC

CGGTTTCTGGGCTGGGAACGCCGGATTTTGCGAAGTTGAGGGG

TGTGGCGTTGGGTGAAGCTAAGGCGTATGGTAATTAA

72
AUGGCAGCGACUGGACGAUUCACUGCCUUCUGGAAUGUCGC

Aspergillus

GAGCGUGCCCGCCUUGAUUGGCAUUCUCCCCCUUGCUGGAU

nidulans

CUCAUUUAAGAGCUGUCCUUUGCCCUGUCUGUAUCUGGCGUC
FGSC A4

ACUCGAAGGCCGUUUGUGCACCAGACACUUUGCAAGCCAUGC

GCGCCUUCACCCGUGUAACGGCCAUCUCCCUGGCCGGUUUC

UCCUGCUUCGCUGCUGCGGCGGCUGCGGCUUUUGAGAGCCU

GCGAGCUGUCCCUGACGGCUGGAUCUACGAGAGCACCCCCG

ACCCUAACCAACCGCUGCGUCUACGCAUCGCGCUGAAACAGC

ACAAUGUCGCCGGCUUCGAGCAGGCACUGCUGGAUAUGUCCA

CACCCGGUCACUCCAGCUACGGGCAGCAUUUCGGCUCCUACC

ACGAGAUGAAGCAGCUGCUUCUCCCUACCGAGGAGGCGUCCU

CCUCGGUGCGAGACUGGCUCUCGGCGGCGGGCGUUGAGUUC

GAACAGGACGCCGACUGGAUCAACUUCCGCACGACCGUCGAC

CAGGCUAACGCCCUCCUCGACGCCGAUUUCCUCUGGUACACA

ACGACCGGCUCGACGGGCAACCCGACGCGGAUCCUCCGAACC

CUCUCCUACAGCGUUCCCAGCGAGCUCGCUGGAUACGUCAAC

AUGAUCCAGCCGACUACGCGUUUCGGCGGCACGCAUGCCAAC

CGGGCCACCGUUCGCGCGAAGCCGAUCUUCCUCGAGACCAAC

CGGCAGCUCAUCAACGCCAUCUCCUCUGGCUCGCUCGAGCAC

UGCGAGAAGGCCAUCACCCCAUCGUGCCUGGCGGAUCUGUAC

AACACUGAAGGGUACAAGGCGUCCAACCGCAGCGGGAGCAAG

GUGGCCUUUGCCUCCUUCCUCGAAGAGUACGCGCGCUACGA

CGAUCUCGCCGAGUUCGAGGAGACCUACGCUCCCUAUGCGAU

CGGGCAGAACUUCUCGGUUAUCUCCAUCAACGGCGGCCUCAA

CGACCAGGACUCCACGGCCGACAGCGGCGAGGCGAACCUCGA

CCUGCAGUACAUCAUCGGCGUCUCGUCGCCGCUACCUGUGAC

CGAGUUCACAACCGGUGGCCGCGGCAAGCUCAUUCCUGACCU

CUCCUCCCCCGACCCGAAUGACAACACCAACGAGCCUUUCCU

UGACUUCCUUGAGGCCGUCCUCAAGCUCGAUCAGAAAGACCU

GCCCCAGGUCAUCUCGACCUCCUACGGCGAGGACGAGCAGAC

AAUCCCUGAGCCGUACGCCCGCUCCGUCUGCAACCUGUACGC

UCAGCUCGGUUCCCGCGGCGUGUCUGUGCUCUUCUCCUCGG

GUGACUCUGGCGUCGGCGCCGCCUGCCAGACCAACGAUGGC

AAAAACACGACGCACUUCCCGCCGCAGUUCCCGGCCUCUUGC

CCCUGGGUGACCGCCGUCGGCGGCACGAACGGCACAGCGCC

CGAAUCCGGUGUAUACUUCUCCAGCGGCGGGUUCUCCGACUA

CUGGGCGCGCCCGGCGUACCAGAACGCCGCGGUUGAGUCAU

ACCUGCGCAAACUCGGUAGCACACAGGCGCAGUACUUCAACC

GCAGCGGACGCGCCUUCCCGGACGUCGCAGCGCAGGCGCAG

AACUUCGCUGUCGUCGACAAGGGCCGUGUCGGUCUCUUCGA

CGGAACGAGCUGCAGUUCGCCUGUAUUUGCGGGCAUCGUGG

CGUUGCUCAACGACGUGCGUCUGAAGGCAGGCCUGCCCGUG

CUGGGAUUCCUCAACCCUUGGCUCUACCAGGAUGGCCUGAAC

GGGCUCAACGAUAUCGUGGAUGGAGGGAGCACCGGCUGCGA

CGGGAACAACCGGUUUAACGGAUCGCCAAAUGGGAGCCCCGU

AAUCCCGUAUGCGGGUUGGAACGCGACGGAGGGGUGGGAUC

CUGUGACGGGGCUGGGAACGCCGGAUUUCGCGAAGCUGAAA

GCGCUCGUGCUUGAUGCUUAG

73
ATGTTGTCATTTGTTCGTCGGGGAGCTCTCTCCCTCGCTCTCGT

Aspergillus

TTCGCTGTTGACCTCGTCTGTCGCCGCCGAGGTCTTCGAGAAG

ruber CBS

CTGCATGTTGTGCCCGAAGGTTGGAGATATGCCTCCACTCCTAA
135680

CCCCAAACAACCCATTCGTCTTCAGATCGCTCTGCAGCAGCAC

GATGTCACCGGTTTCGAACAGTCCCTCTTGGAGATGTCGACTC

CCGACCATCCCAACTACGGAAAACACTTCCGCACCCACGATGA

GATGAAGCGCATGCTTCTCCCCAATGAAAATGCCGTTCACGCC

GTCCGCGAATGGCTGCAAGACGCCGGAATCAGCGACATCGAA

GAAGACGCCGATTGGGTCCGTTTCCACACCACCGTGGACCAGG

CCAACGACCTCCTCGACGCCAACTTCCTCTGGTACGCGCACAA

GAGCCATCGTAACACGGCGCGTCTCCGCACTCTCGAGTACTCG

ATCCCAGACTCTATTGCGCCGCAGGTCAACGTGATCCAGCCAA

CCACGCGATTCGGACAGATCCGTGCCAACCGGGCTACGCATAG

CAGCAAGCCCAAGGGTGGGCTTGACGAGTTGGCTATCTCGCAG

GCAGCTACGGCGGATGATGATAGCATTTGTGACCAGATCACCA

CCCCACACTGTCTGCGGAAGCTGTACAATGTCAATGGCTACAA

GGCCGATCCCGCTAGTGGTAGCAAGATCGGTTTTGCTAGTTTC

CTGGAGGAATACGCGCGGTACTCTGATCTGGTACTGTTCGAGG

AGAACCTGGCACCGTTTGCGGAGGGTGAGAACTTTACTGTCGT

CATGTACAACGGCGGCAAGAATGACCAGAACTCCAAGAGCGAC

AGCGGCGAGGCCAACCTCGATCTGCAGTACATCGTGGGAATGA

GCGCGGGCGCGCCCGTGACCGAGTTCAGCACCGCCGGTCGC

GCACCCGTCATCCCGGACCTGGACCAGCCCGACCCCAGCGCC

GGTACCAACGAGCCGTACCTCGAGTTCCTGCAGAACGTGCTAC

ACATGGACCAGGAGCACCTGCCGCAGGTGATCTCTACTTCCTA

CGGTGAGAACGAACAGACCATCCCCGAAAAGTACGCCCGCACC

GTTTGCAACATGTACGCGCAGCTGGGCAGCCGCGGTGTGTCG

GTGATTTTCTCGTCGGGCGACTCCGGCGTCGGCTCTGCCTGTA

TGACCAACGACGGTACAAACCGCACCCACTTCCCCCCGCAGTT

CCCGGCGTCCTGCCCCTGGGTGACATCGGTCGGGGCCACTGA

GAAGATGGCCCCCGAGCAAGCGACATATTTCTCCTCGGGCGGC

TTCTCTGACCTCTTCCCGCGCCCAAAGTACCAGGACGCTGCTG

TCAGCAGCTACCTTCAGACCCTCGGATCCCGGTACCAGGGCTT

GTACAACGGTTCCAACCGTGCATTCCCTGACGTCTCGGCGCAG

GGTACCAACTTTGCTGTGTACGACAAGGGCCGTCTAGGCCAGT

TCGATGGTACTTCTTGCTCTGCTCCCGCGTTTAGCGGTATCATC

GCCTTGCTCAACGACGTCCGTCTCCAGAACAACAAGCCCGTCC

TGGGCTTCTTGAACCCCTGGTTGTATGGCGCTGGGAGCAAGGG

CCTGAACGACGTCGTGCACGGTGGCAGTACAGGATGCGATGG

ACAGGAGCGGTTTGCAGGAAAGGCCAATGGAAGCCCCGTCGT

GCCGTACGCTAGCTGGAATGCTACGCAAGGCTGGGATCCAGTC

ACTGGCCTTGGAACGCCGGATTTCGGCAAGTTGAAGGATTTGG

CTCTGTCGGCTTAA

74
AUGUUGCCCUCUCUUGUAAACAACGGGGCGCUGUCCCUGGC

Aspergillus

UGUGCUUUCGCUGCUCACCUCGUCCGUCGCCGGCGAGGUGU

terreus

UUGAGAAGCUGUCGGCCGUGCCGAAAGGAUGGCACUUCUCC
NIH2624

CACGCUGCCCAGGCCGACGCCCCCAUCAACCUGAAGAUCGCC

CUGAAGCAGCAUGAUGUCGAGGGCUUCGAGCAGGCCCUGCU

GGACAUGUCCACCCCGGGCCACGAGAACUACGGCAAGCACUU

CCACGAGCACGACGAGAUGAAACGCAUGCUGCUCCCCAGCGA

CUCCGCCGUCGACGCCGUCCAGACCUGGCUGACCUCCGCCG

GCAUCACCGACUACGACCUCGACGCCGACUGGAUCAACCUGC

GCACCACCGUCGAGCACGCCAACGCCCUGCUGGACACGCAGU

UCGGCUGGUACGAGAACGAAGUGCGCCACAUCACGCGCCUGC

GCACCCUGCAAUACUCCAUCCCCGAGACCGUCGCCGCGCACA

UCAACAUGGUGCAGCCGACCACGCGCUUUGGCCAGAUCCGGC

CCGACCGCGCGACCUUCCACGCGCACCACACCUCCGACGCGC

GCAUCCUGUCCGCCCUGGCCGCCGCCAGCAACAGCACCAGCU

GCGACUCAGUCAUCACCCCCAAGUGCCUCAAGGACCUCUACA

AGGUCGGCGACUACGAGGCCGACCCGGACUCGGGCAGCCAG

GUCGCCUUCGCCAGCUACCUCGAGGAAUACGCCCGCUACGCC

GACAUGGUCAAGUUCCAGAACUCGCUCGCCCCCUACGCCAAG

GGCCAGAACUUCUCGGUCGUCCUGUACAACGGCGGCGUCAAC

GACCAGUCGUCCAGCGCCGACUCCGGCGAGGCCAACCUCGAC

CUGCAGACCAUCAUGGGCCUCAGCGCGCCGCUCCCCAUCACC

GAGUACAUCACCGGCGGCCGCGGCAAGCUCAUCCCCGAUCUC

AGCCAGCCCAACCCCAACGACAACAGCAACGAGCCCUACCUC

GAGUUCCUCCAGAACAUCCUCAAGCUGGACCAGGACGAGCUG

CCGCAGGUGAUCUCGACCUCCUACGGCGAGGACGAGCAGACA

AUCCCCCGUGGCUACGCCGAAUCCGUCUGCAACAUGCUGGCC

CAGCUCGGCAGCCGCGGCGUGUCGGUGGUCUUCUCGUCAGG

CGAUUCGGGCGUCGGCGCCGCCUGCCAGACCAACGACGGCC

GCAACCAAACCCACUUCAACCCGCAGUUCCCGGCCAGCUGCC

CGUGGGUGACGUCGGUCGGGGCCACGACCAAGACCAACCCG

GAGCAGGCGGUGUACUUCUCGUCGGGCGGGUUCUCGGACUU

CUGGAAGCGCCCGAAGUACCAGGACGAGGCGGUGGCCGCGU

ACCUGGACACGCUGGGCGACAAGUUCGCGGGGCUGUUCAAC

AAGGGCGGGCGCGCGUUCCCGGACGUCGCGGCGCAGGGCAU

GAACUACGCCAUCUACGACAAGGGCACGCUGGGCCGGCUGGA

CGGCACCUCGUGCUCGGCGCCGGCCUUCUCGGCCAUCAUCU

CGCUGCUGAACGAUGCGCGCCUGCGCGAGGGUAAGCCGACC

AUGGGCUUCUUGAACCCGUGGCUGUAUGGUGAGGGCCGCGA

GGCGCUGAAUGAUGUUGUCGUGGGUGGGAGCAAGGGCUGUG

AUGGGCGCGACCGGUUUGGCGGCAAGCCCAAUGGGAGCCCU

GUCGUGCCUUUUGCUAGCUGGAAUGCUACGCAGGGCUGGGA

CCCGGUUACUGGGCUGGGGACGCCGAACUUUGCGAAGAUGU

UGGAGCUGGCGCCAUAG

75
ATGATTGCATCATTATTCAACCGTAGGGCATTGACGCTCGCTTT

Penicillium

ATTGTCACTTTTTGCATCCTCTGCCACAGCCGATGTTTTTGAGA

digitatum

GTTTGTCTGCTGTTCCTCAGGGATGGAGATATTCTCGCACACCG
Pd1

AGTGCTAATCAGCCCTTGAAGCTACAGATTGCTCTGGCTCAGG

GAGATGTTGCTGGGTTCGAGGCAGCTGTGATCGATATGTCAAC

CCCCGACCACCCCAGTTACGGGAACCACTTCAACACCCACGAG

GAAATGAAGCGGATGCTGCAGCCTAGCGCGGAGTCCGTAGACT

CGATCCGTAACTGGCTCGAAAGTGCCGGTATTTCCAAGATCGA

ACAGGACGCTGACTGGATGACCTTCTATACCACCGTGAAGACA

GCGAATGAGCTGCTGGCAGCCAACTTCCAGTTCTACATCAATG

GAGTCAAGAAAATAGAGCGTCTCCGCACACTCAAGTACTCTGTC

CCGGACGCTTTGGTGTCCCACATTAACATGATCCAGCCAACCA

CCCGTTTCGGCCAGCTGCGCGCCCAGCGCGCCATTTTACACAC

CGAGGTCAAGGATAACGACGAGGCTTTCCGCTCAAATGCCATG

TCCGCTAATCCGGACTGCAACAGCATCATCACTCCCCAGTGTCT

CAAGGATTTGTACAGTATCGGTGACTATGAGGCCGACCCCACC

AATGGGAACAAGGTCGCGTTTGCCAGCTACCTAGAGGAGTATG

CCCGATACTCCGATCTCGCATTATTTGAGAAAAACATCGCCCCC

TTTGCCAAGGGACAGAATTTCTCCGTTGTCCAGTATAACGGCGG

TGGTAATGATCAACAATCGAGCAGTGGCAGTAGTGAGGCGAAT

CTTGACTTGCAGTACATCGTTGGAGTCAGCTCTCCTGTTCCCGT

TACAGAGTTTAGCACTGGAGGTCGCGGTGAACTTGTTCCGGAT

CTCGACCAGCCGAATCCCAATGACAACAACAACGAGCCATACC

TTGAATTCCTCCAGAACGTGCTCAAGTTGCACAAGAAGGACCTC

CCCCAGGTGATTTCCACCTCTTATGGCGAGGACGAGCAGAGCG

TTCCAGAGAAGTACGCCCGCGCCGTTTGCAACCTGTACTCCCA

ACTCGGTAGCCGTGGTGTGTCCGTAATCTTTTCATCCGGCGACT

CTGGCGTTGGCGCCGCGTGTCAGACGAACGACGGCCGGAACG

CGACCCACTTCCCACCCCAGTTCCCGGCCGCCTGCCCCTGGGT

GACATCAGTCGGTGCGACAACCCACACTGCGCCCGAACGAGC

CGTTTACTTCTCATCTGGCGGTTTCTCCGATCTCTGGGATCGCC

CTACGTGGCAAGAAGATGCTGTGAGTGAGTACCTCGAGAACCT

GGGCGACCGCTGGTCTGGCCTCTTCAACCCTAAGGGCCGTGC

CTTCCCCGACGTCGCAGCCCAGGGTGAAAACTACGCCATCTAC

GATAAGGGTTCTTTGATCAGCGTCGATGGCACCTCTTGCTCGG

CACCTGCGTTTGCCGGAGTCATCGCCCTCCTCAACGACGCCCG

CATCAAGGCCAATAGACCACCCATGGGCTTCCTCAACCCTTGG

CTGTACTCTGAAGGCCGCAGCGGCCTAAACGACATTGTCAACG

GCGGTAGCACTGGCTGCGACGGTCATGGCCGCTTCTCCGGCC

CCACTAACGGTGGTACGTCGATTCCAGGTGCCAGCTGGAACGC

TACTAAGGGCTGGGACCCTGTCTCCGGTCTTGGATCGCCCAAC

TTTGCTGCCATGCGCAAACTCGCCAACGCTGAGTAG

76
ATGCATGTTCCTCTGTTGAACCAAGGCGCGCTGTCGCTGGCCG

Penicillium

TCGTCTCGCTGTTGGCCTCCACGGTCTCGGCCGAAGTATTCGA

oxalicum

CAAGCTTGTCGCTGTCCCTGAAGGATGGCGATTCTCCCGCACT
114-2

CCCAGTGGAGACCAGCCCATCCGACTGCAGGTTGCCCTCACAC

AGGGTGACGTTGAGGGCTTCGAGAAGGCCGTTCTGGACATGTC

AACTCCCGACCACCCCAACTATGGCAAGCACTTCAAGTCACAC

GAGGAAGTTAAGCGCATGCTGCAGCCTGCAGGCGAGTCCGTC

GAAGCCATCCACCAGTGGCTCGAGAAGGCCGGCATCACCCACA

TTCAACAGGATGCCGACTGGATGACCTTCTACACCACCGTTGA

GAAGGCCAACAACCTGCTGGATGCCAACTTCCAGTACTACCTC

AACGAGAACAAGCAGGTCGAGCGTCTGCGCACCTTGGAGTACT

CGGTTCCTGACGAGCTCGTCTCGCACATTAACCTTGTCACCCC

GACCACTCGCTTCGGCCAGCTGCACGCCGAGGGTGTGACGCT

GCACGGCAAGTCTAAGGACGTCGACGAGCAATTCCGCCAGGCT

GCTACTTCCCCTAGCAGCGACTGCAACAGTGCTATCACCCCGC

AGTGCCTCAAGGACCTGTACAAGGTCGGCGACTACAAGGCCAG

TGCCTCCAATGGCAACAAGGTCGCCTTCACCAGCTACCTGGAG

CAGTACGCCCGGTACTCGGACCTGGCTCTGTTTGAGCAGAACA

TTGCCCCCTATGCTCAGGGCCAGAACTTCACCGTTATCCAGTAC

AACGGTGGTCTGAACGACCAGAGCTCGCCTGCGGACAGCAGC

GAGGCCAACCTGGATCTCCAGTACATTATCGGAACGAGCTCTC

CCGTCCCCGTGACTGAGTTCAGCACCGGTGGTCGTGGTCCCTT

GGTCCCCGACTTGGACCAGCCTGACATCAACGACAACAACAAC

GAGCCTTACCTCGACTTCTTGCAGAATGTCATCAAGATGAGCGA

CAAGGATCTTCCCCAGGTTATCTCCACCTCGTACGGTGAGGAC

GAGCAGAGCGTCCCCGCAAGCTACGCTCGTAGCGTCTGCAACC

TCATCGCTCAGCTCGGCGGCCGTGGTGTCTCCGTGATCTTCTC

ATCTGGTGATTCCGGTGTGGGCTCTGCCTGTCAGACCAACGAC

GGCAAGAACACCACTCGCTTCCCCGCTCAGTTCCCCGCCGCCT

GCCCCTGGGTGACCTCTGTTGGTGCTACTACCGGTATCTCCCC

CGAGCGCGGTGTCTTCTTCTCCTCCGGTGGCTTCTCCGACCTC

TGGAGCCGCCCCTCGTGGCAAAGCCACGCCGTCAAGGCCTAC

CTTCACAAGCTTGGCAAGCGTCAAGACGGTCTCTTCAACCGCG

AAGGCCGTGCGTTCCCCGACGTGTCAGCCCAGGGTGAGAACTA

CGCTATCTACGCGAAGGGTCGTCTCGGCAAGGTTGACGGCACT

TCCTGCTCGGCTCCCGCTTTCGCCGGTCTGGTTTCTCTGCTGA

ACGACGCTCGCATCAAGGCGGGCAAGTCCAGCCTCGGCTTCCT

GAACCCCTGGTTGTACTCGCACCCCGATGCCTTGAACGACATC

ACCGTCGGTGGAAGCACCGGCTGCGACGGCAACGCTCGCTTC

GGTGGTCGTCCCAACGGCAGTCCCGTCGTCCCTTACGCTAGCT

GGAACGCTACTGAGGGCTGGGACCCCGTCACCGGTCTGGGTA

CTCCCAACTTCCAGAAGCTGCTCAAGTCTGCCGTTAAGCAGAA

GTAA

77
ATGATTGCATCCCTATTTAGTCGTGGAGCATTGTCGCTCGCGGT

Penicillium

CTTGTCGCTTCTCGCGTCCTCTGCTGCAGCCGATGTATTTGAGA

roqueforti

GTTTGTCTGCTGTTCCTCAAGGATGGAGATATTCTCGCAGGCCG
FM164

CGTGCTGATCAGCCCTTGAAGTTACAGATCGCTCTGACACAGG

GGGATACTGCCGGCTTCGAAGAGGCTGTGATGGAGATGTCAAC

CCCCGATCACCCTAGCTACGGGCACCACTTCACCACCCACGAA

GAAATGAAGCGGATGCTACAGCCCAGTGCGGAGTCCGCGGAG

TCAATCCGTGACTGGCTCGAAGGCGCGGGTATTACCAGGATCG

AACAGGATGCAGATTGGATGACCTTCTACACCACCGTGGAGAC

GGCAAATGAGCTGCTGGCAGCCAATTTCCAGTTCTACGTCAGTA

ATGTCAGGCACATTGAGCGTCTTCGCACACTCAAGTACTCAGTC

CCGAAGGCTCTGGTGCCACACATCAACATGATCCAGCCAACCA

CCCGTTTCGGCCAGCTGCGCGCCCATCGGGGCATATTACACGG

CCAGGTCAAAGGAATCCGACGAGGCTTTCCGCTCAAACGCCGTG

TCCGCTCAGCCGGATTGCAACAGTATCATCACTCCTCAGTGTCT

CAAGGATATATATAATATCGGTGATTACCAGGCCAASGATACCA

ATGGGAACAAGGTCGGGTTTGCCAGCTACCTAGAGGAGTATGC

ACGATACTCCGATCTGGCACTATTTGAGAAAAATATCGCGCCCT

CTGCCAAAGGGCCAGAACTTCTCCGTCACCAGGTACAAACGGCGG

TCTTAATGATCAAAGTTCCAGCGGTAGCAGCAGCGAGGCGAAC

CTGGACTTGCAGTACATTGTTGGAGTCAGCTCTCCTGTTCCCGT

CACCGAATTTAGCGTTGGCGGCCGTGGTGAACTTGTTCCCGAT

CTCGACCAGCCTGATCCCAATGATAACAACAACGAGCCATACCT

TGAATTCCTCCAGAACGTGCTCAAGCTGGACAAAAAGGACCTTC

CCCAGGTGATTTCTACCTCCTATGGTGAGGACGAGCAGAGCAT

TCCCGAGAAGTACGCCCGCAGTGTTTGCAACTTGTACTCGCAG

CTCGGTAGCCGTGGTGTATCCGTCATTTTCTCATCTGGCGACTC

CGGCGTTGGGTCCGCGTGCCTGACGAACGACGGCAGGAACGC

GACCCGCTTCCCACCCCAGTTCCCCGCCGCCTGCCCGTGGGT

GACATCAGTCGGCGCGACAACCCATACCGCGCCCGAACAGGC

CGTGTACTTCTCGTCCGGCGGCTTTTCCGATCTCTGGGCTCGC

CCGAAATGGCAAGAGGAGGCCGTGAGTGAGTACCTCGAGATCC

TGGGTAACCGCTGGTCTGGCCTCTTCAACCCTAAGGGTCGTGC

CTTCCCCGATGTCACAGCCCAAGGTCGCAATTACGCTATATACG

ATAAGGGCTCGTTGACCAGCGTCGACGGCACCTCCTGCTCGGC

ACCTGCCTTCGCCGGAGTCGTCGCCCTCCTCAACGACGCTCGC

CTCAAAGTCAACAAACCACCAATGGGCTTCCTTAATCCTTGGCT

GTACTCGACAGGGCGCGCCGGCCTAAAGGACATTGTCGATGG

CGGCAGCACGGGTTGCGATGGCAAGAGCCGCTTCGGTGGTGC

CAATAACGGTGGTCCGTCGATCCCAGGTGCTAGCTGGAACGCT

ACTAAGGGTTGGGACCCTGTTTCTGGTCTCGGGTCGCCCAACT

TTGCTACCATGCGCAAGCTTGCGAACGCTGAGTAG

78
AUGAUUGCAUCUCUAUUUAACCGUGGAGCAUUGUCGCUCGCG

Penicillium

GUAUUGUCGCUUCUCGCGUCUUCGGCUUCCGCUGAUGUAUU

rubens

UGAGAGUUUGUCUGCUGUUCCUCAAGGAUGGAGAUAUUCUCG
Wisconsin

CAGACCGCGUGCUGAUCAGCCCCUGAAGCUACAGAUUGCUCU
54-1255

GGCACAAGGGGAUACUGCCGGAUUCGAAGAGGCUGUGAUGG

ACAUGUCAACCCCUGAUCACCCCAGCUACGGGAACCACUUCC

ACACCCACGAGGAAAUGAAGCGGAUGCUGCAGCCCAGCGCGG

AGUCCGCAGACUCGAUCCGUGACUGGCUUGAAAGUGCGGGU

AUCAAUAGAAUUGAACAGGAUGCCGACUGGAUGACAUUCUAC

ACCACCGUCGAGACGGCAAAUGAGCUGCUGGCAGCCAAUUUC

CAGUUCUAUGCCAACAGUGCCAAGCACAUUGAGCGUCUUCGC

ACACUCCAGUACUCCGUCCCGGAGGCUCUGAUGCCACACAUC

AACAUGAUCCAGCCAACCACUCGUUUCGGCCAGCUGCGCGUC

CAGGGGGCCAUAUUGCACACCCAGGUCAAGGAAACCGACGAG

GCUUUCCGCUCAAACGCCGUGUCCACUUCACCGGACUGCAAC

AGUAUCAUCACUCCUCAGUGUCUCAAGAAUAUGUACAAUGUG

GGUGACUACCAGGCCGACGACGACAAUGGGAACAAGGUCGGA

UUUGCCAGCUACCUAGAGGAGUAUGCACGGUACUCCGAUUUG

GAACUAUUUGAGAAAAAUGUCGCACCCUUCGCCAAGGGCCAG

AACUUCUCCGUCAUCCAGUAUAACGGCGGUCUUAACGAUCAA

CACUCGAGUGCUAGCAGCAGCGAGGCGAACCUUGACUUACAG

UACAUUGUUGGAGUUAGCUCUCCUGUUCCAGUUACAGAGUUU

AGCGUUGGCGGUCGUGGUGAACUUGUUCCCGAUCUUGACCA

GCCUGAUCCCAAUGAUAACAACAACGAGCCAUACCUUGAAUU

CCUCCAGAACGUGCUCAAGAUGGAACAACAGGACCUCCCCCA

GGUGAUUUCCACCUCUUAUGGCGAGAACGAGCAGAGUGUUCC

CGAGAAAUACGCCCGCACCGUAUGCAACUUGUUCUCGCAGCU

UGGCAGCCGUGGUGUGUCCGUCAUCUUCGCAUCUGGCGACU

CCGGCGUUGGCGCCGCGUGCCAGACGAAUGACGGCAGGAAC

GCGACCCGCUUCCCGGCCCAGUUCCCUGCUGCCUGCCCAUG

GGUGACAUCGGUCGGCGCGACAACCCACACCGCGCCCGAGAA

GGCCGUGUACUUCUCGUCCGGUGGCUUCUCCGAUCUUUGGG

AUCGCCCGAAAUGGCAAGAAGACGCCGUGAGUGACUACCUCG

ACACCCUGGGCGACCGCUGGUCCGGCCUCUUCAAUCCUAAGG

GCCGUGCCUUCCCCGACGUCUCAGCCCAAGGUCAAAACUACG

CCAUAUACGAUAAGGGCUCGUUGACCAGCGUCGACGGCACCU

CGUGCUCGGCACCCGCCUUCGCCGGUGUCAUCGCCCUCCUC

AACGACGCCCGCCUCAAGGCCAACAAACCACCCAUGGGCUUC

CUCAAUCCCUGGCUGUACUCGACAGGCCGUGACGGCCUGAAC

GACAUUGUUCAUGGCGGCAGCACUGGCUGUGAUGGCAACGC

CCGCUUCGGCGGCCCCGGUAACGGCAGUCCGAGGGUUCCAG

GUGCCAGCUGGAACGCUACUAAGGGCUGGGACCCUGUUUCU

GGUCUUGGAUCACCCAACUUUGCUACCAUGCGCAAGCUCGCG

AACGGUGAGUAG

79
AUGCUGUCCUCGACUCUCUACGCAGGGUUGCUCUGCUCCCU

Neosartorya

CGCAGCCCCAGCCCUUGGUGUGGUGCACGAGAAGCUCUCAG

fischeri

CUGUUCCUAGUGGCUGGACACUCGUCGAGGAUGCAUCGGAG
NRRL 181

AGCGACACGACCACUCUCUCAAUUGCCCUUGCUCGGCAGAAC

CUCGACCAGCUCGAGUCCAAGUUGACCACACUGGCGACCCCA

GGGAACGCGGAGUACGGCAAGUGGCUGGACCAGUCCGACAU

UGAGUCCCUAUUUCCUACUGCAAGCGAUGACGCUGUUAUCCA

AUGGCUCAAGGAUGCCGGGGUCACCCAAGUGUCUCGUCAGG

GCAGCUUGGUGAACUUUGCCACCACUGUGGGAACGGCGAACA

AGCUCUUUGACACCAAGUUCUCCUACUACCGCAAUGGUGCUU

CCCAGAAACUGCGUACCACGCAGUACUCCAUUCCCGAUAGCC

UGACAGAGUCGAUCGAUCUGAUUGCCCCCACUGUCUUCUUUG

GCAAGGAGCAAGACAGCGCACUGCCACCUCACGCAGUGAAGC

UUCCAGCCCUUCCCAGGAGGGCAGCCACCAACAGUUCUUGCG

CCAACCUGAUCACUCCCGACUGCCUAGUGGAGAUGUACAACC

UCGGCGACUACAAGCCUGAUGCAUCUUCGGGCAGUCGAGUC

GGCUUUGGUAGCUUCUUGAAUCAGUCAGCCAACUAUGCAGAU

CUGGCUGCUUAUGAGCAACUGUUCAACAUCCCACCCCAGAAU

UUCUCAGUCGAAUUGAUUAACGGAGGCGCCAAUGAUCAGAAU

UGGGCCACUGCUUCCCUCGGCGAGGCCAAUCUGGACGUGGA

GUUGAUUGUAGCCGUCAGCCACGCCCUGCCAGUAGUGGAGU

UUAUCACUGGCGGUUCACCUCCGUUUGUUCCCAAUGUCGACG

AGCCAACCGCUGCGGACAACCAGAAUGAGCCCUACCUCCAGU

ACUACGAGUACUUGCUCUCCAAACCCAACUCCCAUCUUCCUC

AGGUGAUUUCCAACUCGUAUGGUGACGAUGAACAGACUGUUC

CCGAGUACUACGCCAGGAGAGUUUGCAACUUGAUCGGCUUGA

UGGGUCUUCGUGGUAUCACUGUGCUCGAGUCCUCUGGUGAU

ACCGGAAUCGGCUCGGCGUGCAUGUCCAAUGACGGCACCAAC

ACGCCUCAGUUCACUCCUACAUUCCCUGGCACCUGCCCCUUC

AUCACCGCAGUUGGUGGUACACAGUCCUAUGCUCCUGAAGUU

GCCUGGGACGCCAGCUCGGGUGGAUUCAGCAACUACUUCAG

CCGUCCCUGGUACCAGUAUUUCGCGGUGGAGAACUACCUCAA

UAAUCACAUUACCAAGGACACCAAGAAGUACUAUUCGCAGUAC

ACCAACUUCAAGGGCCGUGGAUUCCCUGAUGUUUCUGCCCAU

AGCUUGACCCCUGACUACGAGGUCGUCCUAACUGGCAAACAU

UACAAGUCCGGUGGCACAUCGGCCGCCUGCCCCGUCUUUGC

UGGUAUCGUCGGCCUGUUGAAUGACGCCCGUCUGCGCGCCG

GCAAGUCCACCCUUGGCUUCCUGAACCCAUUGCUGUAUAGCA

UACUCGCGGAAGGAUUCACCGAUAUCACUGCCGGAAGUUCUA

UCGGUUGUAAUGGUAUCAACCCACAGACCGGAAAGCCAGUCC

CCGGUGGUGGUAUCAUCCCCUACGCUCACUGGAACGCUACUG

CCGGCUGGGAUCCUGUUACAGGUCUUGGGGUUCCUGAUUUC

AUGAAGUUGAAGGAGUUGGUUUUGUCGUUGUAA

80
AUGCUGUCCUCGACUCUCUACGCAGGGUGGCUCCUCUCCCU

Aspergillus

CGCAGCCCCAGCCCUUUGUGUGGUGCAGGAGAAGCUCUCAG

fumigatus

CUGUUCCUAGUGGCUGGACACUCAUCGAGGAUGCAUCGGAGA
CAE17675

GCGACACGAUCACUCUCUCAAUUGCCCUUGCUCGGCAGAACC

UCGACCAGCUUGAGUCCAAGCUGACCACGCUGGCGACCCCAG

GGAACCCGGAGUACGGCAAGUGGCUGGACCAGUCCGACAUU

GAGUCCCUAUUUCCUACUGCAAGCGAUGAUGCUGUUCUCCAA

UGGCUCAAGGCGGCCGGGAUUACCCAAGUGUCUCGUCAGGG

CAGCUUGGUGAACUUCGCCACCACUGUGGGAACAGCGAACAA

GCUCUUUGACACCAAGUUCUCUUACUACCGCAAUGGUGCUUC

CCAGAAACUGCGUACCACGCAGUACUCCAUCCCCGAUCACCU

GACAGAGUCGAUCGAUCUGAUUGCCCCCACUGUCUUCUUUGG

CAAGGAGCAGAACAGCGCACUGUCAUCUCACGCAGUGAAGCU

UCCAGCUCUUCCUAGGAGGGCAGCCACCAACAGUUCUUGCGC

CAACCUGAUCACCCCCGACUGCCUAGUGGAGAUGUACAACCU

CGGCGACUACAAACCUGAUGCAUCUUCGGGAAGUCGAGUCGG

CUUCGGUAGCUUCUUGAAUGAGUCGGCCAACUAUGCAGAUUU

GGCUGCGUAUGAGCAACUCUUCAACAUCCCACCCCAGAAUUU

CUCAGUCGAAUUGAUCAACAGAGGCGUCAAUGAUCAGAAUUG

GGCCACUGCUUCCCUCGGCGAGGCCAAUCUGGACGUGGAGU

UGAUUGUAGCCGUCAGCCACCCCCUGCCAGUAGUGGAGUUUA

UCACUGGCGCCCUACCUCCAGUACUACGAGUACUUGCUCUCC

AAACCCAACUCCCAUCUUCCUCAGGUGAUUUCCAACUCACUG

UUCCCGAGUACUACGCCAGGAGAGUUUGCAACUUGAUCGGCU

UGAUGGGUCUUCGUGGCAUCACGGUGCUCGAGUCCUCUGGU

GAUACCGGAAUCGGCUCGGCAUGCAUGUCCAAUGACGGCACC

AACAAGCCCCAAUUCACUCCUACAUUCCCUGGCACCUGCCCC

UUCAUCACCGCAGUUGGUGGUACUCAGUCCUAUGCUCCUGAA

GUUGCUUGGGACGGCAGUUCCGGCGGAUUCAGCAACUACUU

CAGCCGUCCCUGGUACCAGUCUUUCGCGGUGGACAACUACCU

CAACAACCACAUUACCAAGGAUACCAAGAAGUACUAUUCGCAG

UACACCAACUUCAAGGGCCGUGGAUUCCCUGAUGUUUCCGCC

CAUAGUUUGACCCCUUACUACGAGGUCGUCUUGACUGGCAAA

CACUACAAGUCUGGCGGCACAUCCGCCGCCAGCCCCGUCUUU

GCCGGUAUUGUCGGUCUGCUGAACGACGCCCGUCUGCGCGC

CGGCAAGUCCACUCUUGGCUUCCUGAACCCAUUGCUGUAUAG

CAUCCUGGCCGAAGGAUUCACCGAUAUCACUGCCGGAAGUUC

AAUCGGUUGUAAUGGUAUCAACCCACAGACCGGAAAGCCAGU

UCCUGGUGGUGGUAUUAUCCCCUACGCUCACUGGAACGCUAC

UGCCGGCUGGGAUCCUGUUACUGGCCUUGGGGUUCCUGAUU

UCAUGAAAUUGAAGGAGUUGGUUCUGUCGUUGUAA

81

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Phaeosphaeria

CGGCCTGGCCGCGGCCGAGCCCTTCGAGAAGCTCTTTAGCAC

nodorum

CCCCGAGGGCTGGAAGATGCAGGGCCTCGCCACCAACGAGCA
SN15

GATCGTCAAGCTCCAGATCGCCCTCCAGCAGGGCGACGTGGC

CGGCTTTGAGCAGCACGTCATCGACATCAGCACCCCCAGCCAC

CCCAGCTACGGCGCTCACTACGGCAGCCACGAAGAGATGAAG

CGCATGATCCAGCCCAGCAGCGAGACTGTCGCCAGCGTCAGC

GCCTGGCTCAAGGCCGCTGGCATCAACGACGCCGAGATCGAC

AGCGACTGGGTCACCTTCAAGACCACCGTCGGCGTCGCCAACA

AGATGCTCGACACCAAGTTCGCCTGGTACGTCAGCGAGGAAGC

CAAGCCCCGCAAGGTCCTCCGCACCCTTGAGTACAGCGTCCCC

GACGACGTCGCCGAGCACATCAACCTCATCCAGCCCACCACCC

GCTTCGCCGCCATCCGCCAGAACCACGAGGTCGCCCACGAGA

TCGTCGGCCTCCAGTTTGCCGCCCTCGCCAACAACACCGTCAA

CTGCGACGCCACCATCACCCCCCAGTGCCTCAAGACCCTCTAC

AAGATCGACTACAAGGCCGACCCCAAGAGCGGCAGCAAGGTC

GCCTTCGCCAGCTACCTTGAGCAGTACGCCCGCTACAACGACC

TCGCCCTCTTCGAGAAGGCCTTCCTGCCTGAGGCCGTCGGCCA

GAACTTCAGCGTCGTCCAGTTCTCTGGCGGCCTCAACGACCAG

AACACCACCCAGGATAGCGGCGAGGCCAACCTCGACCTCCAGT

ACATCGTCGGCGTCAGCGCCCCTCTGCCCGTCACCGAGTTTAG

CACTGGCGGCCGAGGCCCTTGGGTCGCCGATCTCGATCAGCC

TGACGAGGCCGACAGCGCCAACGAGCCCTACCTTGAGTTCCTC

CAGGGCGTCCTCAAGCTCCCCCAGAGCGAGCTGCCCCAGGTC

ATCAGCACCTCGTACGGCGAGAACGAGCAGAGCGTCCCCAAGA

GCTACGCCCTCAGCGTCTGCAACCTCTTCGCCCAGCTTGGCTC

TCGCGGCGTCAGCGTCATCTTCAGCAGCGGCGATAGCGGCCC

TGGCAGCGCCTGCCAGTCTAACGACGGCAAGAACACCACCAAG

TTCCAGCCCCAGTACCCTGCCGCCTGCCCCTTCGTCACTAGCG

TCGGCTCTACCCGCTACCTCAACGAGACTGCCACCGGCTTCAG

CTCCGGCGGCTTCAGCGACTACTGGAAGCGCCCCAGCTACCA

GGACGACGCCGTCAAGGCCTACTTCCACCACCTCGGCGAGAA

GTTCAAGCCCTACTTCAACCGCCACGGCCGAGGCTTCCCTGAC

GTCGCCACTCAGGGCTACGGCTTCCGCGTCTACGACCAGGGC

AAGCTCAAGGGCCTCCAGGGCACTTCTGCCAGCGCCCCTGCCT

TCGCCGGCGTCATTGGCCTGCTCAACGACGCCCGCCTCAAGG

CCAAGAAGCCCACCCTCGGCTTTCTCAACCCCCTGCTCTACAG

CAACAGCGACGCCCTCAACGACATCGTCCTCGGCGGCTCCAAG

GGCTGCGACGGCCACGCTAGGTTTAACGGCCCTCCCAACGGC

AGCCCCGTCATCCCTTACGCCGGCTGGAACGCCACTGCCGGCT

GGGACCCTGTTACCGGCCTCGGCACCCCCAACTTCCCCAAGCT

CCTCAAGGCCGCCGTCCCCTCTCGATACCGCGCTTAA

82

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Trichoderma

CGGCCTGGCCGCGGCCAACGCTGCTGTCCTCCTCGACAGCCT

atroviride

CGACAAGGTCCCCGTCGGCTGGCAGGCTGCTTCTGCCCCTGCT
IMI 206040

CCCAGCAGCAAGATCACCCTCCAGGTCGCCCTCACCCAGCAGA

ACATCGACCAGCTTGAGAGCAAGCTCGCCGCCGTCAGCACCCC

CAACAGCAGCAACTACGGCAAGTACCTCGACGTCGACGAGATC

AACCAGATCTTCGCCCCCAGCAGCGCCAGCACTGCCGCTGTCG

AGAGCTGGCTCAAGAGCTACGGCGTCGACTACAAGGTCCAGG

GCAGCAGCATCTGGTTCCAGACCGACGTCAGCACGGCCAACAA

GATGCTCAGCACCAACTTCCACACCTACACCGACAGCGTCGGC

GCCAAGAAGGTCCGCACCCTCCAGTACAGCGTCCCCGAGACTC

TCGCCGACCACATCGACCTCATCAGCCCCACCACCTACTTCGG

CACCAGCAAGGCCATGCGAGCCCTCAAGATCCAGAACGCCGC

CAGCGCCGTCAGCCCTCTCGCTGCTCGACAAGAGCCCAGCAG

CTGCAAGGGCACCATCGAGTTCGAGAACCGCACCTTCAACGTC

TTTCAGCCCGACTGCCTCCGCACCGAGTACAGCGTCAACGGCT

ACAAGCCCAGCGCCAAGAGCGGCAGCCGAATCGGCTTCGGCA

GCTTCCTCAACCAGAGCGCCAGCAGCAGCGACCTCGCCCTCTT

CGAGAAGCACTTCGGCTTCGCCAGCCAGGGCTTCAGCGTCGA

GCTGATCAACGGCGGCAGCAACCCCCAGCCTCCCACCGATGCT

AACGACGGCGAGGCCAACCTCGACGCCCAGAACATCGTCAGCT

TCGTCCAGCCCCTGCCCATCACCGAGTTTATCGCTGGCGGCAC

CGCCCCCTACTTCCCCGATCCTGTTGAGCCTGCCGGCACCCCC

GACGAGAACGAGCCCTACCTTGAGTACTACGAGTACCTCCTCA

GCAAGAGCAACAAGGAACTCCCCCAGGTCATCACCAACAGCTA

CGGCGACGAGGAACAGACCGTCCCCCAGGCCTACGCCGTCCG

CGTCTGCAACCTCATCGGCCTCATGGGCCTCCGCGGCATCAGC

ATCCTTGAGAGCAGCGGCGACGAGGGCGTCGGCGCTTCTTGC

CTCGCCACCAACAGCACCACCACCCCCCAGTTCAACCCCATCT

TCCCCGCCACGTGCCCCTACGTCACTAGCGTCGGCGGCACCG

TCAGCTTCAACCCCGAGGTCGCTTGGGACGGCAGCAGCGGCG

GCTTCAGCTACTACTTCAGCCGCCCCTGGTATCAAGAGGCCGC

CGTCGGCACCTACCTCAACAAGTACGTCAGCGAGGAAACGAAG

GAATATTACAAGAGCTACGTCGACTTCAGCGGCCGAGGCTTCC

CTGACGTCGCCGCTCACTCTGTCAGCCCCGACTACCCCGTCTT

TCAGGGCGGCGAGCTGACTCCTTCTGGCGGCACTTCTGCCGC

CAGCCCCATCGTCGCCAGCGTCATTGCCCTGCTCAACGACGCC

CGACTCCGAGCCGGCAAGCCTGCCCTCGGCTTTCTCAACCCCC

TCATCTACGGCTACGCCTACAAGGGCTTCACCGACATCACCTC

CGGCCAGGCCGTTGGCTGCAACGGCAACAACACCCAGACCGG

CGGACCCCTTCCTGGCGCTGGCGTTATCCCTGGCGCCTTCTGG

AACGCCACCAAGGGCTGGGACCCCACCACCGGCTTTGGCGTC

CCCAACTTCAAGAAGCTCCTTGAGCTGGTCCGCTACATC

83

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Arthroderma

CGGCCTGGCCGCGGCCAAGCCTACTCCTGGCGCTTCCCACAA

benhamiae

GGTCATCGAGCACCTCGACTTCGTCCCCGAGGGCTGGCAGATG
CBS 112371

GTCGGCGCTGCTGACCCTGCCGCCATCATCGACTTTTGGCTCG

CCATCGAGCGCGAGAACCCCGAGAAGCTCTACGACACCATCTA

CGACGTCAGCACCCCCGGACGCGCCCAGTACGGCAAGCACCT

CAAGCGCGAGGAACTCGACGACCTCCTCCGCCCTCGCGCCGA

GACTAGCGAGAGCATCATCAACTGGCTCACCAACGGCGGCGTC

AACCCCCAGCACATTCGCGACGAGGGCGACTGGGTCCGCTTCA

GCACCAACGTCAAGACCGCCGAGACTCTCATGAACACCCGCTT

CAACGTCTTTAAGGACAACCTCAACAGCGTCAGCAAGATCCGC

ACCCTTGAGTACAGCGTCCCCGTCGCCATCAGCGCCCACGTCC

AGATGATCCAGCCCACCACCCTCTTCGGCCGCCAGAAGCCCCA

GAACAGCCTCATCCTCAACCCCCTCACCAAGGACCTTGAGAGC

ATGAGCGTCGAAGAGTTCGCCGCCAGCCAGTGCCGCAGCCTC

GTCACTACTGCCTGCCTCCGCGAGCTGTACGGCCTCGGCGATC

GAGTCACCCAGGCCCGCGACGACAACCGAATTGGCGTCAGCG

GCTTCCTCGAAGAGTACGCCCAGTACCGCGACCTTGAGCTGTT

CCTCAGCCGCTTCGAGCCCAGCGCCAAGGGCTTCAACTTCAGC

GAGGGCCTGATCGCTGGCGGCAAGAACACCCAGGGTGGCCCT

GGCTCTAGCACCGAGGCCAACCTCGACATGCAGTACGTCGTCG

GCCTCAGCCACAAGGCCAAGGTCACCTACTACAGCACTGCCGG

CCGAGGCCCCCTCATCCCTGATCTCTCACAGCCCAGCCAGGCC

AGCAACAACAACGAGCCCTACCTTGAGCAGCTCCGCTACCTCG

TCAAGCTCCCCAAGAACCAGCTCCCCAGCGTCCTCACCACCAG

CTACGGCGACACCGAGCAGAGCCTCCCCGCCAGCTACACCAA

GGCCACGTGCGACCTCTTCGCCCAGCTCGGCACTATGGGCGT

CAGCGTCATCTTCAGCAGCGGCGACACTGGCCCTGGCAGCTC

GTGCCAGACCAACGACGGCAAGAACGCCACGCGCTTCAACCC

CATCTACCCCGCCAGCTGCCCCTTCGTCACCAGCATTGGCGGC

ACCGTCGGCACCGGCCCTGAGCGAGCTGTCAGCTTTAGCAGC

GGCGGCTTCAGCGACCGCTTCCCTCGCCCTCAGTACCAGGACA

ACGCCGTCAAGGACTACCTCAAGATCCTCGGCAACCAGTGGTC

CGGCCTCTTCGACCCTAACGGCCGAGCCTTCCCCGACATTGCC

GCCCAGGGCAGCAACTACGCCGTCTACGACAAGGGCCGCATG

ACCGGCGTTAGCGGCACTTCTGCTTCCGCCCCTGCTATGGCCG

CCATCATTGCCCAGCTCAACGACTTCCGCCTCGCCAAGGGCAG

CCCCGTCCTCGGCTTTCTCAACCCCTGGATCTACAGCAAGGGC

TTCAGCGGCTTCACCGACATCGTCGACGGCGGCTCTAGGGGCT

GCACCGGCTACGACATCTACAGCGGCCTCAAGGCCAAGAAGGT

CCCCTACGCCAGCTGGAACGCCACCAAGGGCTGGGACCCCGT

CACCGGCTTTGGCACCCCCAACTTCCAGGCCCTGACCAAGGTC

CTGCCCTAA

84

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Fusarium

CGGCCTGGCCGCGGCCAAGAGCTACTCTCACCACGCCGAGGC

graminearum

CCCCAAGGGCTGGAAGGTCGACGATACTGCCCGCGTCGCCAG
PH-1

CACCGGCAAGCAGCAGGTCTTTTCGATCGCCCTGACCATGCAG

AACGTCGACCAGCTTGAGAGCAAGCTCCTCGACCTCAGCAGCC

CCGACAGCAAGAACTACGGCCAGTGGATGAGCCAGAAGGACG

TCACCACCGCCTTCTACCCCAGCAAGGAAGCCGTCAGCAGCGT

CACCAAGTGGCTCAAGAGCAAGGGCGTCAAGCACTACAACGTC

AACGGCGGCTTCATCGACTTCGCCCTCGACGTGAAGGGCGCCA

ACGCCCTCCTCGACAGCGACTACCAGTACTACACCAAGGAAGG

CCAGACCAAGCTCCGCACCCTCAGCTACAGCATCCCCGACGAC

GTCGCCGAGCACGTCCAGTTCGTCGACCCCAGCACCAACTTCG

GCGGCACCCTCGCCTTTGCCCCCGTCACTCACCCTAGCCGCAC

CCTCACCGAGCGCAAGAACAAGCCCACCAAGAGCACCGTCGAC

GCCAGCTGCCAGACCAGCATCACCCCCAGCTGCCTCAAGCAGA

TGTACAACATCGGCGACTACACCCCCAAGGTCGAGAGCGGCAG

CACGATCGGCTTCAGCAGCTTCCTCGGCGAGAGCGCTATCTAC

AGCGACGTCTTTCTGTTCGAGGAAAAGTTCGGCATCCCCACCC

AGAACTTCACCACCGTCCTCATCAACAACGGCACCGACGACCA

GAACACCGCCCACAAGAACTTCGGCGAGGCCGACCTCGACGC

CGAGAACATCGTCGGCATTGCCCACCCCCTGCCCTTCACCCAG

TACATCACTGGCGGCAGCCCCCCCTTCCTGCCCAACATCGATC

AGCCCACTGCCGCCGACAACCAGAACGAGCCCTACGTCCCCTT

CTTCCGCTACCTCCTCAGCCAGAAGGAAGTCCCCGCCGTCGTC

AGCACCAGCTACGGCGACGAAGAGGACAGCGTCCCCCGCGAG

TACGCCACCATGACCTGCAACCTCATCGGCCTGCTCGGCCTCC

GCGGCATCAGCGTCATCTTCAGCAGCGGCGACATCGGCGTCG

GCGCTGGCTGTCTTGGCCCCGACCACAAGACCGTCGAGTTCAA

CGCCATCTTCCCCGCCACGTGCCCCTACCTCACTAGCGTCGGC

GGCACGGTCGACGTCACCCCCGAGATTGCTTGGGAGGGCAGC

AGCGGCGGCTTCAGCAAGTACTTCCCTCGCCCCAGCTACCAGG

ACAAGGCCGTCAAGACCTACATGAAGACCGTCAGCAAGCAGAC

CAAGAAGTACTACGGCCCCTACACCAACTGGGAGGGCCGAGG

CTTTCCTGACGTCGCCGGCCACAGCGTCAGCCCCAACTACGAG

GTCATCTACGCCGGCAAGCAGAGCGCCTCTGGCGGCACTTCTG

CTGCCGCCCCTGTCTGGGCTGCCATCGTCGGCCTGCTCAACGA

CGCCCGATTCCGAGCCGGCAAGCCTAGCCTCGGCTGGCTCAA

CCCCCTCGTCTACAAGTACGGCCCCAAGGTCCTCACCGACATC

ACCGGCGGCTACGCCATTGGCTGCGACGGCAACAACACCCAG

AGCGGCAAGCCCGAGCCTGCCGGCTCTGGCATTGTCCCTGGC

GCCCGATGGAACGCCACTGCCGGATGGGACCCTGTCACCGGC

TACGGCACCCCCGACTTCGGCAAGCTCAAGGACCTCGTCCTCA

GCTTCTAA

85

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Acremonium

CGGCCTGGCCGCGGCCGCCGTCGTCATTCGCGCCGCCGTCCT

alcalophilum

CCCCGACGCCGTCAAGCTGATGGGCAAGGCCATGCCCGACGA

CATTATTTCCCTCCAGTTTTCCCTGAAGCAGCAGAACATCGACC

AGCTGGAGACCCGCCTCCGCGCCGTCTCGGACCCCAGCTCCC

CCGAGTACGGCCAGTACATGAGCGAGTCCGAGGTCAACGAGTT

CTTTAAGCCCCGCGACGACTCGTTCGCCGAGGTCATTGACTGG

GTCGCCGCCAGCGGCTTTCAGGACATCCACCTGACGCCCCAG

GCTGCCGCCATTAACCTCGCCGCCACCGTCGAGACGGCCGAC

CAGCTCCTGGGCGCCAACTTCAGCTGGTTTGACGTCGACGGCA

CCCGCAAGCTCCGCACCCTGGAGTACACGATCCCCGACCGCCT

CGCCGACCACGTCGACCTGATTTCCCCCACCACGTACTTCGGC

CGCGCCCGACTGGACGGCCCCCGCGAGACCCCCACGCGCCTC

GACAAGCGCCAGCGCGACCCCGTCGCCGACAAGGCCTACTTC

CACCTCAAGTGGGACCGCGGCACCAGCAACTGCGACCTGGTC

ATCACGCCCCCCTGCCTGGAGGCCGCCTACAACTACAAGAACT

ACATGCCCGACCCCAACTCGGGCAGCCGCGTCTCGTTCACCAG

CTTTCTGGAGCAGGCCGCCCAGCAGAGCGACCTCACCAAGTTC

CTCTCCCTGACGGGCCTCGACCGCCTGCGCCCCCCCAGCAGC

AAGCCCGCCAGCTTCGACACGGTCCTGATCAACGGCGGCGAG

ACCCACCAGGGCACGCCCCCCAACAAGACCTCCGAGGCCAAC

CTCGACGTCCAGTGGCTGGCCGCCGTCATTAAGGCCCGACTCC

CCATCACCCAGTGGATTACGGGCGGCCGCCCCCCCTTCGTCCC

CAACCTCCGCCTGCGCCACGAGAAGGACAACACGAACGAGCC

CTACCTGGAGTTCTTTGAGTACCTCGTCCGCCTGCCCGCCCGC

GACCTCCCCCAGGTCATCTCCAACTCGTACGCCGAGGACGAGC

AGACCGTCCCCGAGGCCTACGCCCGACGCGTCTGCAACCTCAT

CGGCATTATGGGCCTGCGCGGCGTCACCGTCCTCACGGCCTC

CGGCGACTCGGGCGTCGGCGCCCCCTGCCGCGCCAACGACG

GCAGCGACCGCCTGGAGTTCTCCCCCCAGTTTCCCACCTCGTG

CCCCTACATCACCGCCGTCGGCGGCACGGAGGGCTGGGACCC

CGAGGTCGCCTGGGAGGCCTCCTCGGGCGGCTTCAGCCACTA

CTTTCTCCGCCCCTGGTACCAGGCCAACGCCGTCGAGAAGTAC

CTCGACGAGGAGCTGGACCCCGCCACCCGCGCCTACTACGAC

GGCAACGGCTTCGTCCAGTTTGCCGGCCGAGCCTACCCCGAC

CTGTCCGCCCACAGCTCCTCGCCCCGCTACGCCTACATCGACA

AGCTCGCCCCCGGCCTGACCGGCGGCACGAGCGCCTCCTGCC

CCGTCGTCGCCGGCATCGTCGGCCTCCTGAACGACGCCCGAC

TCCGCCGCGGCCTGCCCACGATGGGCTTCATTAACCCCTGGCT

GTACACGCGCGGCTTTGAGGCCCTCCAGGACGTCACCGGCGG

CCGCGCCTCGGGCTGCCAGGGCATCGACCTCCAGCGCGGCAC

CCGCGTCCCCGGCGCCGGCATCATTCCCTGGGCCTCCTGGAA

CGCCACCCCCGGCTGGGACCCCGCCACGGGCCTCGGCCTGCC

CGACTTCTGGGCCATGCGCGGCCTCGCCCTGGGCCGCGGCAC

CTAA

86

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Sodiomyces

CGGCCTGGCCGCGGCCGCCGTCGTCATTCGCGCCGCCCCCCT

alkalinus

CCCCGAGAGCGTCAAGCTCGTCCGCAAGGCCGCCGCCGAGGA

CGGCATTAACCTCCAGCTCTCCCTGAAGCGCCAGAACATGGAC

CAGCTGGAGAAGTTCCTCCGCGCCGTCAGCGACCCCTTTTCCC

CCAAGTACGGCCAGTACATGTCGGACGCCGAGGTCCACGAGAT

CTTCCGCCCCACCGAGGACTCCTTTGACCAGGTCATTGACTGG

CTCACCAAGTCGGGCTTCGGCAACCTGCACATCACGCCCCAGG

CTGCCGCCATTAACGTCGCCACCACGGTCGAGACCGCCGACCA

GCTGTTTGGCGCCAACTTCTCCTGGTTTGACGTCGACGGCACG

CCCAAGCTCCGCACCGGCGAGTACACGATCCCCGACCGCCTC

GTCGAGCACGTCGACCTGGTCAGCCCCACCACGTACTTCGGCC

GCATGCGCCCCCCCCCTCGCGGCGACGGCGTCAACGACTGGA

TCACCGAGAACTCGCCCGAGCAGCCCGCCCCCCTGAACAAGC

GCGACACCAAGACGGAGAGCGACCAGGCCCGCGACCACCCCT

CCTGGGACTCGCGCACCCCCGACTGCGCCACCATCATTACGCC

CCCCTGCCTGGAGACGGCCTACAACTACAAGGGCTACATCCCC

GACCCCAAGTCCGGCTCGCGCGTCAGCTTCACCAGCTTCCTGG

AGCAGGCCGCCCAGCAGGCCGACCTGACCAAGTTCCTCAGCC

TGACGCGCCTGGAGGGCTTTCGCACCCCCGCCAGCAAGAAGA

AGACCTTCAAGACGGTCCTGATCAACGGCGGCGAGTCCCACGA

GGGCGTCCACAAGAAGTCGAAGACCAGCGAGGCCAACCTCGA

CGTCCAGTGGCTGGCCGCCGTCACCCAGACGAAGCTGCCCAT

CACCCAGTGGATTACGGGCGGCCGCCCCCCCTTCGTCCCCAA

CCTCCGCATCCCCACCCCCGAGGCCAACACGAACGAGCCCTAC

CTGGAGTTCCTGGAGTACCTCTTTCGCCTGCCCGACAAGGACC

TCCCCCAGGTCATCAGCAACTCCTACGCCGAGGACGAGCAGAG

CGTCCCCGAGGCCTACGCCCGACGCGTCTGCGGCCTCCTGGG

CATTATGGGCCTCCGCGGCGTCACCGTCCTGACGGCCTCCGG

CGACTCGGGCGTCGGCGCCCCCTGCCGCGCCAACGACGGCTC

GGGCCGCGAGGAGTTCAGCCCCCAGTTTCCCAGCTCCTGCCC

CTACATCACCACGGTCGGCGGCACCCAGGCCTGGGACCCCGA

GGTCGCCTGGAAGGGCAGCAGCGGCGGCTTCTCCAACTACTTT

CCCCGCCCCTGGTACCAGGTCGCCGCCGTCGAGAAGTACCTG

GAGGAGCAGCTGGACCCCGCCGCCCGCGAGTACTACGAGGAG

AACGGCTTCGTCCGCTTTGCCGGCCGAGCCTTCCCCGACCTGA

GCGCCCACAGCAGCAGCCCCAAGTACGCCTACGTCGACAAGC

GCGTCCCCGGCCTCACCGGCGGCACGTCGGCCAGCTGCCCCG

TCGTCGCCGGCATCGTCGGCCTCCTGAACGACGCCCGACTCC

GCCGCGGCCTGCCCACGATGGGCTTCATTAACCCCTGGCTCTA

CGCCAAGGGCTACCAGGCCCTGGAGGACGTCACCGGCGGCGC

CGCCGTCGGCTGCCAGGGCATCGACATTCAGACGGGCAAGCG

CGTCCCCGGCGCCGGCATCATTCCCGGCGCCAGCTGGAACGC

CACCCCCGACTGGGACCCCGCCACGGGCCTCGGCCTGCCCAA

CTTCTGGGCCATGCGCGAGCTCGCCCTGGAGGACTAA

87

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Aspergillus

CGGCCTGGCCGCGGCCGTCGTCCATGAGAAGCTCGCTGCTGT

kawachii IFO

CCCCAGCGGCTGGCACCACCTTGAGGATGCCGGCAGCGACCA
4308

CCAGATCAGCCTCTCGATTGCCCTCGCCCGCAAGAACCTCGAC

CAGCTTGAGAGCAAGCTCAAGGACCTCAGCACCCCTGGCGAGA

GCCAGTACGGCCAGTGGCTCGACCAAGAGGAAGTCGACACCC

TGTTCCCCGTCGCCAGCGACAAGGCCGTCATCAGCTGGCTCCG

CAGCGCCAACATCACCCACATTGCCCGCCAGGGCAGCCTCGTC

AACTTCGCCACCACCGTCGACAAGGTCAACAAGCTCCTCAACA

CCACCTTCGCCTACTACCAGCGCGGCAGCTCTCAGCGCCTCCG

CACCACCGAGTACAGCATCCCCGACGACCTCGTCGACAGCATC

GACCTGATCAGCCCCACCACGTTCTTCGGCAAGGAAAAGACCT

CTGCCGGCCTCACCCAGCGCAGCCAGAAGGTCGATAACCACGT

CGCCAAGCGCAGCAACAGCAGCAGCTGCGCCGACACCATCAC

CCTCAGCTGCCTCAAGGAAATGTACAACTTCGGCAACTACACCC

CCAGCGCCAGCAGCGGCAGCAAGCTCGGCTTCGCCAGCTTCC

TCAACGAGAGCGCCAGCTACAGCGACCTCGCCAAGTTCGAGCG

CCTCTTCAACCTCCCCAGCCAGAACTTCAGCGTCGAGCTGATC

AACGGCGGCGTCAACGACCAGAACCAGAGCACCGCCAGCCTC

ACCGAGGCCGACCTCGATGTCGAGCTGCTTGTCGGCGTCGGC

CACCCCCTGCCCGTCACCGAGTTTATCACCAGCGGCGAGCCCC

CCTTCATCCCCGACCCTGATGAGCCTTCTGCCGCCGACAACGA

GAACGAGCCCTACCTCCAGTACTACGAGTACCTCCTCAGCAAG

CCCAACAGCGCCCTGCCCCAGGTCATCAGCAACAGCTACGGC

GACGACGAGCAGACCGTCCCCGAGTACTACGCCAAGCGCGTC

TGCAACCTCATCGGCCTCGTCGGCCTCCGCGGCATCAGCGTCC

TTGAGTCTAGCGGCGACGAGGGCATCGGCTCTGGCTGCCGAA

CCACCGACGGCACCAACAGCACCCAGTTCAACCCCATCTTCCC

CGCCACGTGCCCCTACGTCACTGCCGTCGGCGGCACCATGAG

CTACGCCCCCGAGATTGCTTGGGAGGCCAGCTCCGGCGGCTT

CAGCAACTACTTCGAGCGAGCCTGGTTCCAGAAGGAAGCCGTC

CAGAACTACCTCGCCAACCACATCACCAACGAGACTAAGCAGT

ACTACAGCCAGTTCGCCAACTTCAGCGGCCGAGGCTTCCCCGA

CGTCAGCGCCCACAGCTTCGAGCCCAGCTACGAGGTCATCTTC

TACGGCGCTCGCTACGGCAGCGGCGGCACTTCTGCTGCCTGC

CCCCTGTTTTCTGCCCTCGTCGGCATGCTCAACGACGCCCGAC

TCCGAGCCGGCAAGTCGACCCTCGGCTTCCTCAACCCCCTGCT

CTACAGCAAGGGCTACAAGGCCCTCACCGACGTCACCGCTGGC

CAGAGCATTGGCTGCAACGGCATCGACCCCCAGAGCGACGAG

GCTGTCGCTGGCGCTGGCATCATTCCCTGGGCCCACTGGAACG

CCACCGTCGGCTGGGACCCTGTCACTGGCCTTGGCCTCCCCG

ACTTCGAGAAGCTCCGCCAGCTCGTCCTCAGCCTCTAA

88

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Talaromyces

CGGCCTGGCCGCGGCCGCTGCTGCTCTTGTTGGCCACGAGTC

stipitatus

TCTCGCCGCCCTCCCTGTCGGCTGGGACAAGGTCAGCACTCCT
ATCC 10500

GCCGCTGGCACCAACATCCAGCTCAGCGTCGCCCTCGCCCTCC

AGAACATCGAGCAGCTTGAGGACCACCTCAAGAGCGTCAGCAC

CCCCGGCTCTGCCAGCTACGGCCAGTACCTCGACAGCGACGG

CATTGCCGCCCAGTACGGCCCTTCTGACGCCAGCGTCGAGGC

CGTCACCAACTGGCTCAAGGAAGCCGGCGTCACCGACATCTAC

AACAACGGCCAGAGCATCCACTTCGCCACCAGCGTCAGCAAGG

CCAACAGCCTCCTCGGCGCCGACTTCAACTACTACAGCGACGG

CTCCGCCACCAAGCTCCGCACCCTCGCTTACAGCGTCCCCAGC

GACCTGAAGGAAGCCATCGACCTCGTCAGCCCCACCACCTACT

TCGGCAAGACCACCGCCAGCCGCAGCATCCAGGCCTACAAGAA

CAAGCGAGCCAGCACCACCAGCAAGAGCGGCAGCAGCAGCGT

CCAGGTCAGCGCCTCTTGCCAGACCAGCATCACCCCCGCCTGC

CTCAAGCAGATGTACAACGTCGGCAACTACACCCCCAGCGTCG

CCCACGGCTCTCGCGTTGGCTTCGGCAGCTTCCTCAACCAGAG

CGCCATCTTCGACGACCTCTTCACCTACGAGAAGGTCAACGAC

ATCCCCAGCCAGAACTTCACCAAGGTCATCATTGCCAACGCCA

GCAACAGCCAGGACGCCAGCGACGGCAACTACGGCGAGGCCA

ACCTCGACGTCCAGAACATTGTCGGCATCAGCCACCCCCTGCC

CGTCACCGAGTTTCTCACTGGCGGCAGCCCACCCTTCGTCGCC

AGCCTCGACACCCCCACCAACCAGAACGAGCCCTACATCCCCT

ACTACGAGTACCTCCTCAGCCAGAAGAACGAGGACCTCCCCCA

GGTCATCAGCAACAGCTACGGCGACGACGAGCAGAGCGTCCC

CTACAAGTACGCCATCCGCGCCTGCAACCTCATCGGCCTCACT

GGCCTCCGCGGCATCAGCGTCCTTGAGAGCAGCGGCGATCTC

GGCGTTGGCGCTGGCTGCCGATCCAACGACGGCAAGAACAAG

ACCCAGTTCGACCCCATCTTCCCCGCCACGTGCCCCTACGTCA

CTAGCGTCGGCGGCACCCAGAGCGTCACCCCCGAGATTGCTT

GGGTCGCTTCCAGCGGCGGCTTCAGCAACTACTTCCCCCGCAC

CTGGTATCAAGAGCCCGCCATCCAGACCTACCTCGGCCTCCTC

GACGACGAGACTAAGACCTACTACAGCCAGTACACCAACTTCG

AGGGCCGAGGCTTCCCCGACGTCAGCGCCCATTCTCTCACCCC

CGACTACCAGGTCGTCGGCGGAGGCTACCTTCAGCCTTCTGGC

GGCACTTCTGCCGCCAGCCCTGTCTTTGCCGGCATCATTGCCC

TGCTCAACGACGCCCGACTCGCCGCTGGCAAGCCCACCCTCG

GCTTTCTCAACCCCTTCTTCTACCTCTACGGCTACAAGGGCCTC

AACGACATCACTGGCGGCCAGAGCGTCGGCTGCAACGGCATC

AACGGCCAGACTGGCGCCCCTGTTCCCGGCGGAGGAATTGTC

CCTGGCGCCGCTTGGAACAGCACCACCGGATGGGACCCTGCC

ACCGGCCTTGGCACCCCCGACTTTCAGAAGCTCAAGGAACTCG

TCCTCAGCTTCTAA

89

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Fusarium

CGGCCTGGCCGCGGCCAAGTCGTTTTCCCACCACGCCGAGGC

oxysporum f.

CCCCCAGGGCTGGCAGGTCCAGAAGACCGCCAAGGTCGCCTC
sp. cubense

CAACACGCAGCACGTCTTTAGCCTCGCCCTGACCATGCAGAAC
race 4

GTCGACCAGCTGGAGTCGAAGCTCCTGGACCTGAGCTCCCCC

GACAGCGCCAACTACGGCAACTGGCTCAGCCACGACGAGCTG

ACCTCCACGTTCTCGCCCAGCAAGGAGGCCGTCGCCTCGGTCA

CCAAGTGGCTGAAGAGCAAGGGCATCAAGCACTACAAGGTCAA

CGGCGCCTTCATTGACTTTGCCGCCGACGTCGAGAAGGCCAAC

ACCCTCCTGGGCGGCGACTACCAGTACTACACGAAGGACGGC

CAGACCAAGCTGCGCACGCTCTCCTACTCGATCCCCGACGACG

TCGCCGGCCACGTCCAGTTCGTCGACCCCAGCACCAACTTCGG

CGGCACGGTCGCCTTTAACCCCGTCCCCCACCCCTCCCGCACC

CTCCAGGAGCGCAAGGTCTCCCCCTCCPAGTCGACGGTCGAC

GCCTCCTGCCAGACCTCGATCACGCCCAGCTGCCTGAAGCAGA

TGTACAACATTGGCGACTACACCCCCGACGCCAAGAGCGGCTC

CGAGATCGGCTTCAGCAGCTTCCTCGGCCAGGCCGCCATTTAC

AGCGACGTCTTCAAGTTTGAGGAGCTCTTCGGCATCCCCAAGC

AGAACTACACCACGATCCTGATTAACAACGGCACCGACGACCA

GAACACGGCCCACGGCAACTTTGGCGAGGCCAACCTCGACGC

CGAGAACATCGTCGGCATTGCCCACCCCCTGCCCTTCAAGCAG

TACATCACCGGCGGCAGCCCCCCCTTTGTCCCCAACATTGACC

AGCCCACGGAGAAGGACAACCAGAACGAGCCCTACGTCCCCTT

CTTTCGCTACCTCCTGGGCCAGAAGGACCTGCCCGCCGTCATC

TCGACCAGCTACGGCGACGAGGAGGACTCCGTCCCCCGCGAG

TACGCCACCCTCACGTGCAACATGATCGGCCTCCTGGGCCTGC

GCGGCATCTCCGTCATTTTCTCCTCGGGCGACATTGGCGTCGG

CTCGGGCTGCCTCGCCCCCGACTACAAGACCGTCGAGTTCAAC

GCCATCTTTCCCGCCACCTGCCCCTACCTGACGTCCGTCGGCG

GCACCGTCGACGTCACGCCCGAGATTGCCTGGGAGGGCAGCT

CCGGCGGCTTCTCCAAGTACTTTCCCCGCCCCTCGTACCAGGA

CAAGGCCATCAAGAAGTACATGAAGACCGTCTCGAAGGAGACG

AAGAAGTACTACGGCCCCTACACCAACTGGGAGGGCCGCGGC

TTCCCCGACGTCGCCGGCCACTCCGTCGCCCCCGACTACGAG

GTCATCTACAACGGCAAGCAGGCCCGATCCGGCGGCACCAGC

GCCGCCGCCCCCGTCTGGGCCGCCATCGTCGGCCTCCTGAAC

GACGCCCGATTCAAGGCCGGCAAGAAGAGCCTGGGCTGGCTC

AACCCCCTGATCTACAAGCACGGCCCCAAGGTCCTCACCGACA

TCACGGGCGGCTACGCCATTGGCTGCGACGGCAACAACACCC

AGAGCGGCAAGCCCGAGCCCGCCGGCTCCGGCCTGGTCCCCG

GCGCCCGATGGAACGCCACCGCCGGCTGGGACCCCACCACGG

GCTACGGCACGCCCAACTTCCAGAAGCTCAAGGACCTCGTCCT

GTCCCTCTAA

90

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Trichoderma

CGGCCTGGCCGCGGCCGTCGTCCATGAGAAGCTCGCTGCTGT

virens

CCCCAGCGGCTGGCACCACCTTGAGGATGCCGGCAGCGACCA
Gv29-8

CCAGATCAGCCTCTCGATTGCCCTCGCCCGCAAGAACCTCGAC

CAGCTTGAGAGCAAGCTCAAGGACCTCAGCACCCCTGGCGAGA

GCCAGTACGGCCAGTGGCTCGACCAAGAGGAAGTCGACACCC

TGTTCCCCGTCGCCAGCGACAAGGCCGTCATCAGCTGGCTCCG

CAGCGCCAACATCACCCACATTGCCCGCCAGGGCAGCCTCGTC

AACTTCGCCACCACCGTCGACAAGGTCAACAAGCTCCTCAACA

CCACCTTCGCCTACTACCAGCGCGGCAGCTCTCAGCGCCTCCG

CACCACCGAGTACAGCATCCCCGACGACCTCGTCGACAGCATC

GACCTGATCAGCCCCACCACGTTCTTCGGCAAGGAAAAGACCT

CTGCCGGCCTCACCCAGCGCAGCCAGAAGGTCGATAACCACGT

CGCCAAGCGCAGCAACAGCAGCAGCTGCGCCGACACCATCAC

CCTCAGCTGCCTCAAGGAAATGTACAACTTCGGCAACTACACCC

CCAGCGCCAGCAGCGGCAGCAAGCTCGGCTTCGCCAGCTTCC

TCAACGAGAGCGCCAGCTACAGCGACCTCGCCAAGTTCGAGCG

CCTCTTCAACCTCCCCAGCCAGAACTTCAGCGTCGAGCTGATC

AACGGCGGCGTCAACGACCAGAACCAGAGCACCGCCAGCCTC

ACCGAGGCCGACCTCGATGTCGAGCTGCTTGTCGGCGTCGGC

CACCCCCTGCCCGTCACCGAGTTTATCACCAGCGGCGAGCCCC

CCTTCATCCCCGACCCTGATGAGCCTTCTGCCGCCGACAACGA

GAACGAGCCCTACCTCCAGTACTACGAGTACCTCCTCAGCAAG

CCCAACAGCGCCCTGCCCCAGGTCATCAGCAACAGCTACGGC

GACGACGAGCAGACCGTCCCCGAGTACTACGCCAAGCGCGTC

TGCAACCTCATCGGCCTCGTCGGCCTCCGCGGCATCAGCGTCC

TTGAGTCTAGCGGCGACGAGGGCATCGGCTCTGGCTGCCGAA

CCACCGACGGCACCAACAGCACCCAGTTCAACCCCATCTTCCC

CGCCACGTGCCCCTACGTCACTGCCGTCGGCGGCACCATGAG

CTACGCCCCCGAGATTGCTTGGGAGGCCAGCTCCGGCGGCTT

CAGCAACTACTTCGAGCGAGCCTGGTTCCAGAAGGAAGCCGTC

CAGAACTACCTCGCCAACCACATCACCAACGAGACTAAGCAGT

ACTACAGCCAGTTCGCCAACTTCAGCGGCCGAGGCTTCCCCGA

CGTCAGCGCCCACAGCTTCGAGCCCAGCTACGAGGTCATCTTC

TACGGCGCTCGCTACGGCAGCGGCGGCACTTCTGCTGCCTGC

CCCCTGTTTTCTGCCCTCGTCGGCATGCTCAACGACGCCCGAC

TCCGAGCCGGCAAGTCGACCCTCGGCTTCCTCAACCCCCTGCT

CTACAGCAAGGGCTACAAGGCCCTCACCGACGTCACCGCTGGC

CAGAGCATTGGCTGCAACGGCATCGACCCCCAGAGCGACGAG

GCTGTCGCTGGCGCTGGCATCATTCCCTGGGCCCACTGGAACG

CCACCGTCGGCTGGGACCCTGTCACTGGCCTTGGCCTCCCCG

ACTTCGAGAAGCTCCGCCAGCTCGTCCTCAGCCTCTAA

91

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Trichoderma

CGGCCTGGCCGCGGCCGCTGTCCTTGTCGAGTCTCTCAAGCA

atroviride

GGTCCCCAACGGCTGGAACGCCGTCAGCACCCCTGACCCCAG
IMI 206040

CACCAGCATCGTCCTCCAGATCGCCCTCGCCCAGCAGAACATC

GACGAGCTTGAGTGGCGCCTCGCCGCCGTGTCTACCCCCAACT

CTGGCAACTACGGCAAGTACCTCGACATCGGCGAGATCGAGGG

CATCTTCGCCCCCAGCAACGCCAGCTACAAGGCCGTCGCTTCC

TGGCTCCAGAGCCACGGCGTCAAGAACTTCGTCAAGCAGGCCG

GCAGCATCTGGTTCTACACCACCGTCAGCACCGCCAACAAGAT

GCTCAGCACCGACTTCAAGCACTACAGCGACCCCGTCGGCATC

GAGAAGCTCCGCACCCTCCAGTACAGCATCCCCGAGGAACTCG

TCGGCCACGTCGACCTCATCAGCCCCACCACCTACTTCGGCAA

CAACCACCCTGCCACCGCCCGCACCCCCAACATGAAGGCCATC

AACGTCACCTACCAGATCTTCCACCCCGACTGCCTCAAGACCAA

GTACGGCGTCGACGGCTACGCCCCCTCACCTCGATGCGGCAG

CCGAATCGGCTTCGGCAGCTTCCTCAACGAGACTGCCAGCTAC

AGCGACCTCGCCCAGTTCGAGAAGTACTTCGACCTCCCCAACC

AGAACCTCAGCACCCTCCTCATCAACGGCGCCATCGACGTCCA

GCCCCCCAGCAAACAAAGAACGACAGCGAGGCCAACATGGACGT

CCAGACCATCCTCACCTTCGTCCAGCCCCTGCCCATCACCGAG

TTCGTCGTCGCCGGCATCCCCCCCTACATTCCCGATGCCGCCC

TCCCCATTGGCGACCCCGTTCAGAACGAGCCCTGGCTTGAGTA

CTTCGAGTTCCTCATGAGCCGCACCAACGCCGAGCTGCCCCAG

GTCATTGCCAACAGCTACGGCGACGAGGAACAGACCGTCCCCC

AGGCCTACGCCGTCCGCGTCTGCAACCAGATTGGCCTCCTCGG

CCTCCGCGGCATCAGCGTCATTGCCTCTAGCGGCGACACCGG

CGTCGGCATGTCTTGCATGGCCAGCAACAGCACCACCCCCCAG

TTCAACCCCATGTTCCCCGCCAGCTGCCCCTACATCACCACCG

TCGGCGGCACCCAGCACCTCGACAACGAGATCGCCTGGGAGC

TGAGCAGCGGCGGCTTCAGCAACTACTTCACCCGCCCCTGGTA

TCAAGAGGACGCCGCCAAGACCTACCTTGAGCGCCACGTCAGC

ACCGAGACTAAGGCCTACTACGAGCGCTACGCCAACTTCCTGG

GCCGAGGCTTTCCTGACGTCGCCGCCCTCAGCCTCAACCCCGA

CTACCCCGTCATCATCGGCGGCGAGCTTGGCCCTAACGGCGG

CACTTCTGCTGCCGCCCCTGTCGTCGCCAGCATCATTGCCCTG

CTCAACGACGCCCGCCTCTGCCTCGGCAAGCCTGCCCTCGGCT

TTCTCAACCCCCTCATCTACCAGTACGCCGACAAGGGCGGCTT

CACCGACATCACCAGCGGCCAGTCTTGGGGCTGCGCCGGCAA

CACCACTCAGACTGGACCTCCCCCTCCTGGCGCTGGCGTCATT

CCTGGCGCTCACTGGAACGCCACCAAGGGCTGGGACCCCGTC

ACCGGCTTTGGCACCCCCAACTTCAAGAAGCTCCTCAGCCTCG

CCCTCAGCGTCTAA

92

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Agaricus

CGGCCTGGCCGCGGCCTCTCCTCTTGCTCGACGCTGGGACGA

bisporus var.

CTTCGCCGAGAAGCACGCCTGGGTCGAGGTTCCTCGCGGCTG

burnettii

GGAGATGGTCAGCGAGGCCCCTAGCGACCACACCTTCGACCTC
JB137-S8

CGCATCGGCGTCAAGAGCAGCGGCATGGAACAGCTCATCGAG

AACCTCATGCAGACCAGCGACCCCACCCACAGCCGCTACGGCC

AGCACCTCAGCAAGGAAGAACTCCACGACTTCGTCCAGCCCCA

CCCCGACTCTACTGGCGCCGTCGAGGCCTGGCTTGAGGACTTC

GGCATCAGCGACGACTTCATCGACCGCACCGGCAGCGGCAAC

TGGGTCACCGTCCGAGTCTCTGTCGCCCAGGCCGAGCGAATG

CTCGGCACCAAGTACAACGTCTACCGCCACAGCGAGAGCGGC

GAGTCCGTCGTCCGCACCATGAGCTACAGCCTCCCCAGCGAGC

TGCACAGCCACATCGACGTCGTCGCCCCCACCACCTACTTCGG

CACCATGAAGTCGATGCGCGTCACCTCGTTCCTCCAGCCCGAG

ATCGAGCCCGTCGACCCCTCTGCCAAGCCTTCTGCTGCTCCCG

CCAGCTGCCTCAGCACCACCGTCATTACCCCCGACTGCCTCCG

CGACCTCTACAACACCGCCGACTACGTCCCCAGCGCCACCAGC

CGCAACGCCATTGGCATTGCCGGCTACCTCGACCGCAGCAACC

GAGCCGACCTCCAGACCTTCTTCCGCCGCTTTCGCCCTGACGC

CGTCGGCTTCAACTACACCACCGTCCAGCTCAACGGCGGAGGC

GACGACCAGAAACGACCCTGGCGTCGAGGCCAACCTCGACATC

CAGTACGCCGCTGGCATTGCCTTCCCCACCCCCGCCACCTACT

GGTCTACTGGCGGCAGCCCCCCCTTCATCCCCGACACCCAGAC

CCCCACCAACACCAACGAGCCCTACCTCGACTGGATCAACTTC

GTCCTCGGCCAGGATGAGATCCCCCAGGTCATCAGCACCAGCT

ACGGCGACGACGAGCAGACCGTCCCCGAGGACTACGCCACCA

GCGTCTGCAACCTCTTCGCCCAGCTTGGCTCTCGCGGCGTCAC

CGTCTTTTTCAGCAGCGGCGACTTCGGCGTCGGCGGTGGCGA

CTGCCTCACTAACGACGGCAGCAACCAGGTCCTCTTCCAGCCC

GCCTTCCCTGCCAGCTGCCCCTTTGTCACTGCCGTCGGCGGCA

CCGTCCGACTCGACCCTGAGATCGCCGTCAGCTTCAGCGGCG

GTGGCTTCAGCCGCTACTTCAGCCGCCCCAGCTACCAGAACCA

GACCGTCGCCCAGTTCGTCAGCAACCTCGGCAAACACCTTCAAC

GGCCTCTACAACAAGAACGGCCGAGCCTACCCCGACCTCGCC

GCTCAGGGCAACGGCTTCCAGGTCGTCATCGACGGCATCGTCC

GATCGGTCGGCGGCACTTCTGCCAGCAGCCCTACCGTCGCCG

GCATCTTCGCCCTGCTCAACGACTTCAAGCTCTCTCGCGGCCA

GAGCACCCTCGGCTTCATCAACCCCCTCATCTACAGCAGCGCC

ACCTCCGGCTTCAACGACATCCGAGCCGGCACCAACCCTGGCT

GTGGCACCCGAGGCTTTACCGCCGGCACTGGCTGGGACCCTG

TCACCGGACTCGGCACCCCTGACTTTCTCCGCCTCCAGGGCCT

CATCTAA

93

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Magnaporthe

CGGCCTGGCCGCGGCCCGCGTCTTTGATTCTCTCCCTCACCCC

oryzae 70-15

CCTCGCGGCTGGTCCTACTCTCACGCCGCTGAGAGCACCGAG

CCCCTCACCCTCCGAATTGCCCTCCGCCAGCAGAACGCCGCTG

CCCTTGAGCAGGTCGTCCTCCAGGTCAGCAACCCCCGCCACGC

CAACTACGGCCAGCACCTCACCCGAGATGAGCTGCGCTCTTAC

ACCGCCCCTACCCCTCGCGCTGTCCGCTCTGTCACTAGCTGGC

TCGTCGACAACGGCGTCGACGACTACACCGTCGAGCACGACTG

GGTCACCCTCCGCACCACTGTCGGCGCTGCCGATCGACTCCTC

GGCGCCGACTTTGCCTGGTACGCTGGCCCTGGCGAGACTCTC

CAGCTCCGCACTCTCAGCTACGGCGTGGACGACAGCGTCGCC

CCTCACGTCGATCTCGTCCAGCCCACCACCCGCTTTGGCGGCC

CTGTTGGCCAGGCCAGCCACATCTTCAAGCAGGACGACTTCGA

CGAGCAGCAGCTCAAGACCCTCAGCGTCGGCTTCCAGGTCATG

GCCGACCTCCCTGCTAACGGCCCTGGCAGCATTAAGGCCGCCT

GCAACGAGAGCGGCGTCACCCCTCTCTGCCTCCGCACCCTCTA

CCGCGTCAACTACAAGCCCGCCACCACCGGCAACCTCGTCGCC

TTCGCCAGCTTCCTTGAGCAGTACGCCCGCTACAGCGACCAGC

AGGCCTTCACCCAGCGAGTCCTTGGCCCTGGCGTCCCGCTCCA

GAACTTCAGCGTCGAGACTGTCAACGGCGGAGCCAACGACCAG

CAGAGCAAGCTCGATAGCGGCGAGGCCAACCTCGACCTCCAGT

ACGTCATGGCCATGTCCCACCCCATCCCCATCCTTGAGTACAG

CACTGGCGGCCGAGGCCCCCTCGTCCCTACTCTCGATCAGCCC

AACGCCAACAACAGCAGCAACGAGCCCTACCTTGAGTTCCTCA

CCTACCTGCTCGCCCAGCCCGACAGCGCCATTCCCCAGACTCT

CAGCGTGAGCTACGGCGAGGAAGAACAGAGCGTCCCCCGCGA

CTACGCCATCAAGGTCTGCAACATGTTCATGCAGCTCGGCGCT

CGCGGCGTCAGCGTCATGTTTAGCAGCGGCGATAGCGGCCCT

GGCAACGACTGCGTCCGAGCCTCTGACAACGCCACCTTCTTCG

GCAGCACCTTCCCTGCCGGCTGCCCCTACGTCACTAGCGTCGG

CAGCACCGTCGGCTTCGAGCCTGAGCGAGCCGTCAGCTTTAGC

TCCGGCGGCTTCAGCATCTACCACGCCCGACCCGACTACCAGA

ACGAGGTCGTCCCCAAGTACATCGAGAGCATCAAGGCCAGCGG

CTACGAGAAGTTCTTCGACGGCAACGGCCGAGGCATCCCCGAT

GTCGCTGCTCAGGGCGCTCGCTTCGTCGTCATCGACAAGGGCC

GCGTCAGCCTCATCAGCGGCACTAGCGCTTCCAGCCCCGCCTT

CGCTGGCATGGTCGCCCTCGTCAACGCCGCTCGCAAGAGCAA

GGATATGCCCGCCCTCGGCTTCCTCAACCCCATGCTCTACCAG

AACGCTGCCGCCATGACCGACATCGTCAACGGCGCTGGCATCG

GCTGCCGCAAGCAGCGCACCGAGTTTCCCAACGGTGCCCGCTT

CAACGCCACCGCCGGATGGGACCCTGTCACTGGCCTTGGCAC

CCCCCTGTTCGACAAGCTCCTCGCCGTTGGCGCTCCCGGCGTC

CCTAACGCCTAA

94

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Togninia

CGGCCTGGCCGCGGCCTCCGATGTCGTCCTTGAGTCTCTCCGC

minima

GAGGTCCCCCAGGGCTGGAAGCGACTCCGAGATGCCGACCCC
UCRPA7

GAGCAGAGCATCAAGCTCCGCATTGCCCTTGAGCAGCCCAACC

TCGACCTCTTCGAGCAGACCCTCTACGACATCAGCAGCCCCGA

CCACCCCAAGTACGGCCAGCACCTCAAGAGCCACGAGCTGCG

CGACATCATGGCCCCTCGCGAGGAATCCACTGCCGCCGTCATT

GCCTGGCTCCAGGATGCTGGCCTCAGCGGCAGCCAGATCGAG

GACGACAGCGACTGGATCAACATCCAGACCACCGTCGCCCAGG

CCAACGACATGCTCAACACCACCTTCGGCCTCTTCGCCCAAGA

GGGCACCGAGGTCAACCGCATTCGCGCCCTCGCCTACAGCGT

CCCCGAGGAAATTGTCCCCCACGTCAAGATGATCGCCCCCATC

ATCCGCTTCGGCCAGCTCCGCCCTCAGATGAGCCACATCTTCA

GCCACGAGAAGGTCGAGGAAACCCCCAGCATCGGCACCATCAA

GGCCGCTGCCATCCCCAGCGTCGACCTCAACGTCACCGCCTG

CAACGCCAGCATCACCCCCGAGTGCCTCCGCGCCCTCTACAAC

GTCGGCGACTACGAGGCCGACCCCAGCAAGAAGTCCCTCTTCG

GCGTCTGCGGCTACCTTGAGCAGTACGCCAAGCACGACCAGCT

CGCCAAGTTCGAGCAGACGTACGCCCCCTACGCCATCGGCGC

CGACTTCAGCGTCGTCACCATCAACGGCGGAGGCGACAACCAG

ACCAGCACCATCGACGACGGCGAGGCCAACCTCGACATGCAGT

ACGCCGTCAGCATGGCCTACAAGACCCCCATCACCTACTACAG

CACTGGCGGCCGAGGCCCCCTCGTCCCTGATCTCGATCAGCC

CGACCCCAACGACGTCAGCAACGAGCCCTACCTCGACTTCGTC

AGCTACCTCCTCAAGCTCCCCGACAGCAAGCTCCCCCAGACCA

TCACCACCAGCTACGGCGAGGACGAGCAGAGCGTCCCCCGCA

GCTACGTCGAGAAGGTCTGCACCATGTTCGGCGCCCTTGGCGC

CCGAGGCGTCAGCGTCATTTTCAGCTCTGGCGACACCGGCGTC

GGCAGCGCCTGCCAGACTAACGACGGCAAGAACACCACCCGC

TTTCTGCCCATCTTCCCTGCCGCCTGCCCCTACGTCACTAGCGT

CGGCGGCACCCGCTACGTCGATCCTGAGGTCGCCGTCAGCTT

CAGCAGCGGCGGCTTCAGCGACATCTTCCCCACCCCCCTGTAC

CAGAAGGGCGCCGTCAGCGGCTACCTCAAGATCCTCGGCGAC

CGCTGGAAGGGCCTCTACAACCCTCACGGCCGAGGCTTCCCTG

ACGTCAGCGGCCAGTCTGTCCGCTACCACGTCTTTGACTACGG

CAAGGACGTCATGTACAGCGGCACCAGCGCCAGCGCCCCCAT

GTTTGCTGCTCTCGTCAGCCTCCTCAACAACGCCCGCCTCGCC

AAGAAGCTCCCCCCTATGGGCTTCCTCAACCCCTGGCTCTACA

CCGTCGGCTTCAACGGCCTCACCGACATCGTCCACGGCGGCTC

TACTGGCTGCACCGGCACCGATGTCTACAGCGGCCTGCCTACC

CCCTTCGTCCCCTACGCCTCTTGGAACGCCACCGTCGGCTGGG

ACCCTGTCACTGGCCTTGGCACCCCCCTGTTCGACAAGCTCCT

CAACCTCAGCACCCCCAACTTCCACCTCCCCCACATCGGCGGC

CACTAA

95

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCTCGCCGCCAG

Bipolaris

CGGCCTGGCCGCGGCCTCTACCACTTCTCACGTCGAGGGCGA

maydis C5

GGTCGTCGAGCGCCTTCATGGCGTCCCTGAGGGCTGGTCACA

GGTCGGCGCTCCCAACCCCGACCAGAAGCTCCGCTTCCGCATT

GCCGTCCGCAGCGCCGACAGCGAGCTGTTCGAGCGCACCCTC

ATGGAAGTCAGCAGCCCCAGCCACCCCCGCTACGGCCAGCAC

CTCAAGCGCCACGAGCTGAAGGACCTCATCAAGCCTCGCGCCA

AGAGCACCAGCAACATCCTCAACTGGCTCCAAGAGAGCGGCAT

CGAGGCCCGCGACATCCAGAACGACGGCGAGTGGATCAGCTT

CTACGCCCCCGTCAAGCGAGCCGAGCAGATGATGAGCACCAC

CTTCAAGACCTACCAGAACGAGGCCCGAGCCAACATCAAGAAG

ATCCGCAGCCTCGACTACAGCGTCCCCAAGCACATCCGCGACG

ACATCGACATCATCCAGCCCACCACGCGCTTCGGCCAGATCCA

GCCTGAGCGCAGCCAGGTCTTTAGCCAAGAGGAAGTCCCCTTC

AGCGCCCTCGTCGTCAACGCCACGTGCAACAAGAAGATCACCC

CCGACTGCCTCGCCAACCTCTACAACTTCAAGGACTACGACGC

CAGCGACGCCAACGTCACGATCGGCGTCAGCGGCTTCCTTGAG

CAGTACGCCCGCTTCGACGACCTCAAGCAGTTCATCAGCACCT

TCCAGCCCAAGGCCGCTGGCTCCACCTTCCAGGTCACCAGCGT

CAACGCTGGCCCCTTCGACCAGAACAGCACCGCCTCTAGCGTC

GAGGCCAACCTCGACATCCAGTACACCACCGGCCTCGTCGCCC

CCGACATCGAGACTCGCTACTTCACCGTCCCCGGACGCGGCAT

CCTCATCCCCGACCTCGACCAGCCTACCGAGAGCGACAACGCC

AACGAGCCCTACCTCGACTACTTCACCTACCTCAACAACCTTGA

GGACGAGGAACTCCCCGACGTCCTCACCACCAGCTACGGCGA

GAGCGAGCAGAGCGTCCCTGCCGAGTACGCCAAGAAGGTCTG

CAACCTCATCGGCCAGCTCGGCGCTCGCGGCGTCAGCGTCATT

TTCAGCAGCGGCGACACCGGCCCTGGCAGCGCCTGCCAGACT

AACGACGGCAAGAACACCACCCGCTTTCTGCCCATCTTCCCCG

CCAGCTGCCCCTACGTCACTAGCGTCGGCGGCACTGTCGGCG

TCGAGCCTGAGAAGGCCGTCAGCTTTAGCAGCGGCGGCTTCAG

CGACCTCTGGCCCCGACCTGCCTACCAAGAGAAGGCCGTGAG

CGAGTACCTTGAGAAGCTCGGCGACCGCTGGAACGGCCTCTAC

AACCCTCAGGGCCGAGGCTTCCCTGACGTCGCTGCTCAGGGC

CAGGGCTTCCAGGTCTTTGACAAGGGCCGCCTCATCTCGGTCG

GCGGCACATCTGCTTCCGCCCCTGTCTTTGCCAGCGTCGTCGC

CCTCCTCAACAACGCCCGAAAGGCTGCCGGAATGAGCAGCCTC

GGCTTCCTCAACCCCTGGATCTACGAGCAGGGCTACAAGGGCC

TCACCGACATCGTCGCTGGCGGCTCTACTGGCTGCACCGGCC

GCTCTATCTACAGCGGCCTCCCTGCCCCCCTGGTCCCTTACGC

TTCTTGGAACGCCACCGAGGGCTGGGACCCCGTCACTGGCTAT

GGCACCCCCGACTTCAAGCAGCTCCTCACCCTCGCCACCGCCC

CCAAGTCTGGCGAGCGACGAGTTCGACGAGGCGGCCTTGGAG

GCCAGGCTTAA

SEQ

ID

No.:
Description
Sequence
Origin

96
TRI045
ATGCGTCTTCTCAAATTTGTGTGCCTGTTGGCATC
Human skin

Genomic
AGTTGCCGCCGCAAAGCCTACTCCAGGGGCGTC
fungus

sequence
ACACAAGGTCATTGAACATCTTGACTTTGTTCCAG

Arthroderma

CDS
AAGGATGGCAGATGGTTGGTGCCGCGGACCCTG

benhamiae

CTGCTATCATTGATTTCTGGCTTGCCATCGAGCGC

GAAAACCCAGAAAAGCTCTACGACACCATCTATG

ACGTCTCCACCCCTGGACGCGCACAATATGGCAA

ACATTTGAAGCGTGAGGAATTGGATGACTTACTAC

GCCCAAGGGCAGAGACGAGTGAGAGCATCATCA

ACTGGCTCACCAATGGTGGAGTCAACCCACAACA

TATTCGGGATGAAGGGGACTGGGTCAGATTCTCT

ACCAATGTCAAGACTGCCGAAACGTTGATGAATA

CCCGCTTCAACGTCTTCAAGGACAACCTAAATTCC

GTTTCAAAAATTCGAACTTTGGAGTATTCCGTCCC

TGTAGCTATATCAGCTCATGTCCAAATGATCCAGC

CAACTACCTTATTTGGACGACAGAAGCCACAGAA

CAGTTTGATCCTAAACCCCTTGACCAAGGATCTAG

AATCCATGTCCGTTGAAGAATTTGCTGCTTCTCAG

TGCAGGTCCTTAGTGACTACTGCCTGCCTTCGAG

AATTGTACGGACTTGGTGACCGTGTCACTCAGGC

TAGGGATGACAACCGTATTGGAGTATCCGGCTTT

TTGGAGGAGTACGCCCAATACCGCGATCTTGAGC

TCTTCCTCTCTCGCTTTGAGCCATCCGCCAAAGG

ATTTAATTTCAGTGAAGGCCTTATTGCCGGAGGAA

AGAACACTCAGGGTGGTCCTGGAAGCTCTACTGA

GGCCAACCTTGATATGCAATATGTCGTCGGTCTG

TCCCACAAGGCAAAGGTCACCTATTACTCCACCG

CTGGCCGTGGCCCATTAATTCCCGATCTATCTCA

GCCAAGCCAAGCTTCAAACAACAACGAACCATAC

CTTGAACAGCTGOGGTACCTCGTAAAGCTCCCCA

AGAACCAGCTTCCATCTGTATTGACAACTTCCTAT

GGAGACACAGAACAGAGCTTGCCCGCCAGCTATA

CCAAAGCCACTTGCGACCTCTTTGCTCAGCTAGG

AACTATGGGTGTGTCTGTTATCTTCAGCAGTGGTG

ATACCGGGCCCGGAAGCTCATGCCAGACCAACG

ATGGCAAGAATGCGACTCGCTTCAACCCTATCTA

CCCAGCTTCTTGCCCGTTTGTGACCTCCATCGGT

GGAACCGTTGGTACCGGTCCTGAGCGTGCAGTTT

CATTCTCCTCTGGTGGCTTCTCAGACAGGTTCCC

COGCOCACAATATCAGGATAACGCTGTTAAAGAC

TACCTGAAAATTTTGGGCAACCAGTGGAGCGGAT

TGTTTGACCCCAACGGCCGTGCTTTCCCAGATAT

CGCAGCTCAGGGATCAAATTATGCTGTCTATGAC

AAGGGAAGGATGACTGGAGTCTCCGGCACCAGT

GCATCCGCOCCTGCCATGGCTGCCATCATTGCCC

AGCTTAACGATTTCCGACTGGCAAAGGGCTCTCC

TGTGCTGGGATTCTTGAACCCATGGATATATTCCA

AGGGTTTCTCTGGCTTTACAGATATTGTTGATGGC

GGTTCCAGGGGTTGCACTGGTTACGATATATACA

GCGGCTTGAAAGCGAAGAAGGTTCCCTACGCAAG

CTGGAATGCAACTAAGGGATGGGACCCAGTAACG

GGATTTGGTACTCCCAACTTCCAAGCTCTCACTAA

AGTGCTGCCCTAA

97
TRI045

ATGCAGACCTTCGGTGCTTTTCTCGTTTCCTTCCT

Human skin

Synthetic

CGCCGCCAGCGGCCTGGCCGCGGCCAAGCCTAC
fungus

Gene
TCCTGGCGCTTCCCACAAGGTCATCGAGCACCTC

Arthroderma

optimized for
GACTTCGTCCCCGAGGGCTGGCAGATGGTCGGC

benhamiae

expression in
GCTGCTGACCCTGCCGCCATCATCGACTTTTGGC

trichoderma
TCGCCATCGAGCGCGAGAACCCCGAGAAGCTCTA

with
CGACACCATCTACGACGTCAGCACCCCCGGACG

trichoderma
CGCCCAGTACGGCAAGCACCTCAAGCGCGAGGA

signal
ACTCGACGACCTCCTCCGCCCTCGCGCCGAGACT

sequence
AGCGAGAGCATCATCAACTGGCTCACCAACGGCG

underlined
GCGTCAACCCCCAGCACATTCGCGACGAGGGCG

ACTGGGTCCGCTTCAGCACCAACGTCAAGACCGC

CGAGACTCTCATGAACACCCGCTTCAACGTCTTTA

AGGACAACCTCAACAGCGTCAGCAAGATCCGCAC

CCTTGAGTACAGCGTCCCCGTCGCCATCAGCGCC

CACGTCCAGATGATCCAGCCCACCACCCTCTTCG

GCCGCCAGAAGCCCCAGAACAGCCTCATCCTCAA

CCCCCTCACCAAGGACCTTGAGAGCATGAGCGTC

GAAGAGTTCGCCGCCAGCCAGTGCCGCAGCCTC

GTCACTACTGCCTGCCTCCGCGAGCTGTACGGCC

TCGGCGATCGAGTCACCCAGGCCCGCGACGACA

ACCGAATTGGCGTCAGCGGCTTCCTCGAAGAGTA

CGCCCAGTACCGCGACCTTGAGCTGTTCCTCAGC

CGCTTCGAGCCCAGCGCCAAGGGCTTCAACTTCA

GCGAGGGCCTGATCGCTGGCGGCAAGAACACCC

AGGGTGGCCCTGGCTCTAGCACCGAGGCCAACC

TCGACATGCAGTACGTCGTCGGCCTCAGCCACAA

GGCCAAGGTCACCTACTACAGCACTGCCGGCCG

AGGCCCCCTCATCCCTGATCTCTCACAGCCCAGC

CAGGCCAGCAACAACAACGAGCCCTACCTTGAGC

AGCTCCGCTACCTCGTCAAGCTCCCCAAGAACCA

GCTCCCCAGCGTCCTCACCACCAGCTACGGCGA

CACCGAGCAGAGCCTCCCCGCCAGCTACACCAA

GGCCACGTGCGACCTCTTCGCCCAGCTCGGCAC

TATGGGCGTCAGCGTCATCTTCAGCAGCGGCGAC

ACTGGCCCTGGCAGCTCGTGCCAGACCAACGAC

GGCAAGAACGCCACGCGCTTCAACCCCATCTACC

CCGCCAGCTGCCCCTTCGTCACCAGCATTGGCG

GCACCGTCGGCACCGGCCCTGAGCGAGCTGTCA

GCTTTAGCAGCGGCGGCTTCAGCGACCGCTTCCC

TCGCCCTCAGTACCAGGACAACGCCGTCAAGGAC

TACCTCAAGATCCTCGGCAACCAGTGGTCCGGCC

TCTTCGACCCTAACGGCCGAGCCTTCCCCGACAT

TGCCGCCCAGGGCAGCAACTACGCCGTCTACGA

CAAGGGCCGCATGACCGGCGTTAGCGGCACTTC

TGCTTCCGCCCCTGCTATGGCCGCCATCATTGCC

CAGCTCAACGACTTCCGCCTCGCCAAGGGCAGC

CCCGTCCTCGGCTTTCTCAACCCCTGGATCTACA

GCAAGGGCTTCAGCGGCTTCACCGACATCGTCGA

CGGCGGCTCTAGGGGCTGCACCGGCTACGACAT

CTACAGCGGCCTCAAGGCCAAGAAGGTCCCCTAC

GCCAGCTGGAACGCCACCAAGGGCTGGGACCCC

GTCACCGGCTTTGGCACCCCCAACTTCCAGGCCC

TGACCAAGGTCCTGCCCTAA

98
TRI045
KPTPGASHKVIEHLDFVPEGWQMVGAADPAAIIDFW
Human skin

pre_pro
LAIERENPEKLYDTIYDVSTPGRAQYGKHLKREELD
fungus

amino acid
DLLRPRAETSESIINWLTNGGVNPQHIRDEGDWVRF

Arthroderma

sesquence
STNVKTAETLMNTRFNVFKDNLNSVSKIRTLEYSVP

benhamiae

VAISAHVQMIQPTTLFGRQKPQNSLILNPLTKDLES

MSVEEFAASQCRSLVTTACLRELYGLGDRVTQARDD

NRIGVSGFLEEYAQYRDLELFLSRFEPSAKGFNFSE

GLIAGGKNTQGGPGSSTEANLDMQYVVGLSHKAKV

TYYSTAGRGPLIPDLSQPSQASNNNEPYLEQLRYLV

KLPKNQLPSVLTTSYGDTEQSLPASYTKATCDLFAQ

LGTMGVSVIFSSGDTGPGSSCQTNDGKNATRFNPIY

PASCPFVTSIGGTVGTGPERAVSFSSGGFSDRFPR

PQYQDNAVKDYLKILGNQWSGLFDPNGRAFPDIAA

QGSNYAVYDKGRMTGVSGTSASAPAMAAIIAQLND

FRLAKGSPVLGFLNPWIYSKGFSGFTDIVDGGSRGC

TGYDIYSGLKAKKVPYASWNATKGWDPVTGFGTPN

FQALTKVLP

99
TRI045
CRSLVTTACLRELYGLGDRVTQARDDNRIGVSGFLE
Human skin

mature
EYAQYRDLELFLSRFEPSAKGFNFSEGLIAGGKNTQ
fungus

Interpro
GGPGSSTEANLDMQYVVGLSHKAKVTYYSTAGRGP

Arthroderma

domain
LIPDLSQPSQASNNNEPYLEQLRYLVKLPKNQLPSV

benhamiae

IPR000209
LTTSYGDTEQSLPASYTKATCDLFAQLGTMGVSVIF

Peptidase
SSGDTGPGSSCQTNDGKNATRFNPIYPASCPFVTSI

S8/S53 dom
GGTVGTGPERAVSFSSGGFSDRFPRPQYQDNAVK

DYLKILGNQWSGLFDPNGRAFPDIAAQGSNYAVYD

KGRMTGVSGTSASAPAMAAIIAQLNDFRLAKGSPVL

GFLNPWIYSKGFSGFTDIVDGGSRGCTGYDIYSGLK

AKKVPYASWNATKGWDPVTGFGTPNFQALTKVLP

The at least one proline tolerant tripeptidyl peptidase may:

- (a) comprise the amino acid sequence SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40. SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof;
- (b) comprise an amino acid having at least 70% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15. SEQ ID No. 16, SEQ ID No. 17. SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof;
- (c) be encoded by a nucleotide sequence comprising the sequence SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 96 or SEQ ID No. 97;
- (d) be encoded by a nucleotide sequence comprising at least about 70% sequence identity to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61. SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 96 or SEQ ID No. 97;
- (e) be encoded by a nucleotide sequence which hybridises to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65. SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 96 or SEQ ID No. 97 under medium stringency conditions; or
- (f) be encoded by a nucleotide sequence which differs from SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 96 or SEQ ID No. 97 due to degeneracy of the genetic code.

The proline tolerant tripeptidyl peptidase may be expressed as a polypeptide sequence which undergoes further post-transcriptional and/or post-translational modification.

In one embodiment the proline tolerant tripeptidyl peptidase may comprise the amino acid sequence SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3. SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15. SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 98 or a functional fragment thereof.

In another embodiment the proline tolerant tripeptidyl peptidase comprise an amino acid having at least 70% identity to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 98 or a functional fragment thereof.

In one embodiment the proline tolerant tripeptidyl peptidase may comprise the amino acid sequence SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 98 or a functional fragment thereof.

In another embodiment the proline tolerant tripeptidyl peptidase comprise an amino acid having at least 70% identity to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4. SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 98 or a functional fragment thereof.

In another embodiment the proline tolerant tripeptidyl peptidase may be a “mature” proline tolerant tripeptidyl peptidase which has undergone post-transcriptional and/or post-translational modification (e.g. post-translational cleavage). Suitably such modification may lead to an activation of the enzyme.

Suitably the proline tolerant tripeptidyl peptidase may comprise the amino acid sequence SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35. SEQ ID No. 36. SEQ ID No. 37. SEQ ID No. 38. SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 99 or a functional fragment thereof.

In another embodiment the proline tolerant tripeptidyl peptidase comprise an amino acid having at least 70% identity to SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33. SEQ ID No. 34. SEQ ID No. 35. SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50. SEQ ID No. 51. SEQ ID No. 52. SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 99 or a functional fragment thereof.

In a yet further embodiment the proline tolerant tripeptidyl peptidase may comprise the amino acid sequence SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39. SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 99 or a functional fragment thereof.

In another embodiment the proline tolerant tripeptidyl peptidase comprise an amino acid having at least 70% identity to SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41. SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 99 or a functional fragment thereof.

The term “functional fragment” is a portion of an amino acid sequence that retains its peptidase enzyme activity. Therefore, a functional fragment of a proline tolerant tripeptidyl peptidase is a portion of a proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; and/or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′. Alternatively or additionally a functional fragment of a proline tolerant tripeptidyl peptidase is a portion of a proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity and capable of cleaving tri-peptides from the N-terminus of peptides having proline at P1 and P1′.

The “portion” is any portion that still has the activity as defined above, suitably a portion may be at least 50 amino acids in length, more suitably at least 100. In other embodiments the portion may be about 150 or about 200 amino acids in length.

In one embodiment the functional fragment may be portion of a proline tolerant tripeptidyl peptidase following post transcriptional and/or post-translational modification (e.g. cleavage). Suitably the functional fragment may comprise a sequence shown as: SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54. SEQ ID No. 55 or SEQ ID NO: 98.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 1, or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 1 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 2, or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 2 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 3 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 3 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 4 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 4 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 5 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 5 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 6 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 6 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 7 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 7 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 8 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 8 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 9 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 9 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 10 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 10 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 11 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 11 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 12 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 12 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 13 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 13 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 14 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 14 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 15 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 15 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 16 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 16 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 17 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 17 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 18 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 18 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 19 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 19 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 20 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 20 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 21 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 21 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 22 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 22 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 23 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 23 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 24 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 24 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 25 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 25 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 26 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 26 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 27 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 27 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 28, or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 28 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 29, or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 29 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 30 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 30 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 31 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 31 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 32 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 32 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 33 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 33 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 34 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 34 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 35 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 35 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 36 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 36 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 37 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 37 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 38 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 38 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 39 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 39 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 40 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 40 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 41 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 41 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 42 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 42 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 43 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 43 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 44 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 44 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 45 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 45 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 46 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 46 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 47 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 47 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 48 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 48 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 49 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 49 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 50 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 50 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 51 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 51 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 52 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 52 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 53 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 53 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 54 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 54 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 55 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 55 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 98 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 98 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise one or more amino acid sequence selected from SEQ ID No. 99 or a functional fragment thereof.

The proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 70% identity to SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 80% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31. SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43. SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 85% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 90% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40. SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 95% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31. SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43. SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 97% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

Suitably the proline tolerant tripeptidyl peptidase may comprise an amino acid having at least 99% identity to SEQ ID No. 29, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40. SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 98, SEQ ID No. 99 or a functional fragment thereof.

In one embodiment the proline tolerant tripeptidyl peptidase may comprise an amino acid sequence selected from one more of the group consisting of: SEQ ID No. 29, SEQ ID No. 1. SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27. SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40. SEQ ID No. 41, SEQ ID No. 42. SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45, SEQ ID No. 46, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54. SEQ ID No. 55, SEQ ID No. 98 and SEQ ID No. 99.

The proline tolerant tripeptidyl peptidase may comprise an amino acid sequence selected from one more of the group consisting of: SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 98, and SEQ ID No. 99 or a sequence having at least 70% identity thereto, suitably a sequence having at least 80% thereto or at least 90% thereto. In some embodiments it may be suitable that the proline tolerant tripeptidyl peptidase may comprise an amino acid sequence selected from the group consisting of SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 30 and SEQ ID No. 31, or a sequence having at least 70% identity thereto, suitably a sequence having at least 80% thereto or at least 90% thereto.

In some embodiments it may be suitable that the proline tolerant tripeptidyl peptidase may comprise an amino acid sequence selected from the group consisting of SEQ ID No. 98 and SEQ ID No. 99, or a sequence having at least 70% identity thereto, suitably a sequence having at least 80% thereto or at least 90% thereto.

Advantageously these particular amino acid sequences may be particularly suited to cleaving peptide and/or protein substrates enriched in lysine, arginine and/or glycine. Particularly where lysine, arginine and/or glycine are present at the P1 position.

Suitably, the proline tolerant tripeptidyl peptidase may comprise an amino acid sequence selected from one more of the group consisting of: SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 29, SEQ ID No. 32, SEQ ID No. 33 and SEQ ID No. 34, or a sequence having at least 70% identity thereto, suitably a sequence having at least 80% thereto or at least 90% thereto.

Suitably the proline tolerant tripeptidyl peptidase may have the sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 29.

The proline tolerant tripeptidyl peptidase may comprise one or more of the sequence motifs selected from the group consisting of: xEANLD, y′Tzx′G and QNFSV.

Suitably, the proline tolerant tripeptidyl peptidase may comprise xEANLD.

x may be one or more amino acid selected from the group consisting of: G, T, S and V.

In another embodiment the proline tolerant tripeptidyl peptidase may comprise y′Tzx′G.

y′ may be one or more amino acid selected from the group consisting of: I, L and V.

z may be one or more amino acid selected from the group consisting of: S and T.

x′ may be one or more amino acid selected from the group consisting of: I and V.

In another embodiment the proline tolerant tripeptidyl peptidase may comprise the sequence motif QNFSV.

In a further embodiment the proline tolerant tripeptidyl peptidase may comprise the sequence motifs xEANLD and y′Tzx′G or xEANLD and QNFSV.

In a yet further embodiment the proline tolerant tripeptidyl peptidase may comprise the sequence motifs y′Tzx′G and QNFSV.

Suitably the proline tolerant tripeptidyl peptidase may comprise the sequence motifs xEANLD, y′Tzx′G and QNFSV.

One or more of the motifs are present in the proline tolerant tripeptidyl peptidases for use in the present invention. FIG. 17 indicates the positioning of these motifs.

In one embodiment the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence shown as SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63. SEQ ID No. 64, SEQ ID No. 65. SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96, SEQ ID No. 97 or a nucleotide sequence having at least 70% identity thereto, suitably a sequence having at least 80% thereto or at least 90% thereto.

Preferably the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence having at least 95% sequence identity to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96 or SEQ ID No. 97, more preferably at least 99% identity to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96 or SEQ ID No. 97.

In another embodiment the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence which hybridises to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78. SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96 or SEQ ID No. 97 under medium stringency conditions. Suitably, a nucleotide sequence which hybridises to SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72. SEQ ID No. 73. SEQ ID No. 74. SEQ ID No. 75. SEQ ID No. 76. SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96 or SEQ ID No. 97 under high stringency conditions.

In a further embodiment, the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence which differs from SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72. SEQ ID No. 73. SEQ ID No. 74. SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 96 or SEQ ID No. 97 due to degeneracy of the genetic code.

In one embodiment the nucleotide sequence comprising a nucleotide sequence shown as SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62, SEQ ID No. 63, SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No. 68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 71, SEQ ID No. 72, SEQ ID No. 73, SEQ ID No. 74, SEQ ID No. 75, SEQ ID No. 76, SEQ ID No. 77, SEQ ID No. 78, SEQ ID No. 79, SEQ ID No. 80, SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88. SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 96 or SEQ ID No. 97 may be a DNA, cDNA, synthetic DNA and/or RNA sequence.

Preferably the sequence is a DNA sequence, more preferably a cDNA sequence coding for the proline tolerant tripeptidyl peptidase of the present invention.

In one aspect, preferably the amino acid and/or nucleotide sequence for use in the present invention is in an isolated form. The term “isolated” means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature. The amino acid and/or nucleotide sequence for use in the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.

In one aspect, preferably the amino acid and/or nucleotide sequence for use in the present invention is in a purified form. The term “purified” means that a given component is present at a high level. The component is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.

Enzymes

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 1, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 1. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 1.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 2, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 2. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 2.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 3, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 3. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 3.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 4, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 4. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 4.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 5, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 5. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 5.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 6, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 6. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 6.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 7, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 7. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 7.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 8, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 8. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 8.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 9, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 9. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 9.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 10, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 10. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 10.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 11, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 11. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 11.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 12, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 12. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 12.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 13, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 13. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 13.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 14, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 14. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 14.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 15, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 15. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 15.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 16, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 16. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 16.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 17, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 17. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 17.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 18, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 18. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 18.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 19, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 19. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 19.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 20, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 20. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 20.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 21, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 21. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 21.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 22, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 22. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 22.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 23, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 23. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 23.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 24, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 24. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 24.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 25, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 25. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 25.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 26, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 26. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 26.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 27, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 27. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 27.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 28, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 28. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 28.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 29, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 29. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 29.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 30, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 30. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 30.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 31, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 31. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 31.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 32, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 32. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 32.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 33, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 33. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 33.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 34, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 34. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 34.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 35, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 35. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 35.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 36, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 36. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 36.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 37, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 37. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 37.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 38, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 38. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 38.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 39, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 39. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 39.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 40, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 40. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 40.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 41, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 41. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 41.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 42, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 42. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 42.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 43, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 43. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 43.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 44, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 44. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 44.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 45, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 45. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 45.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 46, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 46. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 46.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 47, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 47. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 47.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 48, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 48. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 48.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 49, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 49. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 49.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 50, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 50. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 50.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 51, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 51. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 51.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 52, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 52. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 52.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 53, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 53. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 53.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 54, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 54. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 54.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 55, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 55. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 55.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 98, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 98. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 98.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase comprising SEQ ID No. 99, a functional fragment thereof or a sequence having at least 70% identity to SEQ ID No. 99. Suitably the enzyme may have at least 80%, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity to SEQ ID No. 99.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 56 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 57 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 58 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 59 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 60 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 61 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 62 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 63 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 64 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 65 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 66 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 67 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 68 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 69 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 70 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 71 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 72 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 73 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 74 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 75 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 76 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 77 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 78 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 79 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 80 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 81 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 82 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 83 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 84 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 85 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 86 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 87 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 88 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 89 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 90 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 91 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 92 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 93 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 94 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 95 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 96 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

In one embodiment the enzyme for use in the present invention may be a tripeptidyl peptidase encoded by a nucleotide sequence comprising the sequence shown as SEQ ID No. 97 or a sequence having at least 70% identity thereto. Suitably at least 80% identity, suitably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97%, suitably at least 99% identity thereto.

Nucleotide Sequence

The scope of the present invention encompasses nucleotide sequences encoding proteins having the specific properties as defined herein.

The term “nucleotide sequence” as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti-sense strand.

The term “nucleotide sequence” in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention.

In a preferred embodiment, the nucleotide sequence when relating to and when encompassed by the per se scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the “non-native nucleotide sequence”. In this regard, the term “native nucleotide sequence” means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. However, the amino acid sequence encompassed by scope the present invention can be isolated and/or purified post expression of a nucleotide sequence in its native organism. Preferably, however, the amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

Typically, the nucleotide sequence encompassed by the scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers M H et al., (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al., (1980) Nuc Acids Res Symp Ser 225-232).

Preparation of the Nucleotide Sequence

A nucleotide sequence encoding either a protein which has the specific properties as defined herein or a protein which is suitable for modification may be identified and/or isolated and/or purified from any cell or organism producing said protein. Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PCR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.

By way of further example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the enzyme. If the amino acid sequence of the enzyme is known, labelled oligonucleotide probes may be synthesised and used to identify enzyme-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify enzyme-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

Alternatively, enzyme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar plates containing a substrate for enzyme (i.e. maltose), thereby allowing clones expressing the enzyme to be identified.

In a yet further alternative, the nucleotide sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S. L. et al., (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al., (1984) EMBO J. 3, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in U.S. Pat. No. 4,683,202 or in Saiki R K et al., (Science (1988) 239, pp 487-491).

Amino Acid Sequences

The scope of the present invention also encompasses amino acid sequences of enzymes having the specific properties as defined herein.

As used herein, the term “amino acid sequence” is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”.

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

The protein encompassed in the present invention may be used in conjunction with other proteins, particularly enzymes. Thus the present invention also covers a combination of proteins wherein the combination comprises the protein/enzyme of the present invention and another protein/enzyme, which may be another protein/enzyme according to the present invention. This aspect is discussed in a later section.

Preferably the amino acid sequence when relating to and when encompassed by the per se scope of the present invention is not a native enzyme. In this regard, the term “native enzyme” means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence.

Isolated

In one aspect, preferably the amino acid sequence, or nucleic acid, or enzyme according to the present invention is in an isolated form. The term “isolated” means that the sequence or enzyme or nucleic acid is at least substantially free from at least one other component with which the sequence, enzyme or nucleic acid is naturally associated in nature and as found in nature. The sequence, enzyme or nucleic acid of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.

Purified

In one aspect, preferably the sequence, enzyme or nucleic acid according to the present invention is in a purified form. The term “purified” means that the given component is present at a high level. The component is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 80% said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration. Suitably it may be present at a level of at least about 90%, or at least about 95, or at least about 98% said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.

Sequence Identity or Sequence Homology

The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a “homologous sequence(s)”). Here, the term “homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term “homology” can be equated with “identity”.

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

In the present context, a homologous sequence is taken to include an amino acid or a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence for instance. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

In one embodiment, a homologous sequence is taken to include an amino acid sequence or nucleotide sequence which has one or several additions, deletions and/or substitutions compared with the subject sequence.

In one embodiment the present invention relates to a protein whose amino acid sequence is represented herein or a protein derived from this (parent) protein by substitution, deletion or addition of one or several amino acids, such as 2, 3, 4, 5, 6, 7, 8, 9 amino acids, or more amino acids, such as 10 or more than 10 amino acids in the amino acid sequence of the parent protein and having the activity of the parent protein.

Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably over at least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids, preferably over at least 100 contiguous amino acids, preferably over at least 200 contiguous amino acids.

In one embodiment the present invention relates to a nucleic acid sequence (or gene) encoding a protein whose amino acid sequence is represented herein or encoding a protein derived from this (parent) protein by substitution, deletion or addition of one or several amino acids, such as 2, 3, 4, 5, 6, 7, 8, 9 amino acids, or more amino acids, such as 10 or more than 10 amino acids in the amino acid sequence of the parent protein and having the activity of the parent protein.

In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence).

Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.

However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible—reflecting higher relatedness between the two compared sequences—will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons.

Calculation of maximum % homology or % identity therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector NTI (Invitrogen Corp.). Examples of software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed-Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50: FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60), such as for example in the GenomeQuest search tool (www.genomequest.com).

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix—the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI package.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins D G & Sharp P M (1988), Gene 73(1), 237-244).

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used for pairwise alignment:

FOR BLAST

GAP OPEN
9

GAP EXTENSION
2

FOR CLUSTAL
DNA
PROTEIN

Weight Matrix
IUB
Gonnet 250

GAP OPENING
15
10

GAP EXTEND
6.66
0.1

In one embodiment, CLUSTAL may be used with the gap penalty and gap extension set as defined above.

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 100 contiguous nucleotides, preferably over at least 200 contiguous nucleotides, preferably over at least 300 contiguous nucleotides, preferably over at least 400 contiguous nucleotides, preferably over at least 500 contiguous nucleotides, preferably over at least 600 contiguous nucleotides, preferably over at least 700 contiguous nucleotides, preferably over at least 800 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

Suitably, the degree of identity with regard to a protein (amino acid) sequence is determined over at least 100 contiguous amino acids, preferably over at least 200 contiguous amino acids, preferably over at least 300 contiguous amino acids.

Suitably, the degree of identity with regard to an amino acid or protein sequence may be determined over the whole sequence taught herein.

In the present context, the term “query sequence” means a homologous sequence or a foreign sequence, which is aligned with a subject sequence in order to see if it falls within the scope of the present invention. Accordingly, such query sequence can for example be a prior art sequence or a third party sequence.

In one preferred embodiment, the sequences are aligned by a global alignment program and the sequence identity is calculated by identifying the number of exact matches identified by the program divided by the length of the subject sequence.

In one embodiment, the degree of sequence identity between a query sequence and a subject sequence is determined by 1) aligning the two sequences by any suitable alignment program using the default scoring matrix and default gap penalty, 2) identifying the number of exact matches, where an exact match is where the alignment program has identified an identical amino acid or nucleotide in the two aligned sequences on a given position in the alignment and 3) dividing the number of exact matches with the length of the subject sequence.

In yet a further preferred embodiment, the global alignment program is selected from the group consisting of CLUSTAL and BLAST (preferably BLAST) and the sequence identity is calculated by identifying the number of exact matches identified by the program divided by the length of the subject sequence.

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC
Non-polar
G A P

I L V

Polar - uncharged
C S T M

N Q

Polar - charged
D E

K R

AROMATIC

H F W Y

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as omithine (hereinafter referred to as Z), diaminobutyric acid omithine (hereinafter referred to as B), norleucine omithine (hereinafter referred to as 0), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

Replacements may also be made by synthetic amino acids (e.g. unnatural amino acids) include; alpha* and alpha-disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids such as trifluorotyrosine*, p-Cl-phenylalanine*, p-Br-phenylalanine*, p-l-phenylalanine*, L-allyl-glycine*, β-alanine*, L-α-amino butyric acid*, L-γ-amino butyric acid*, L-α-amino isobutyric acid*, L-ε-amino caproic acid^#, 7-amino heptanoic acid*, L-methionine sulfone^#*, L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline^#, L-thioproline*, methyl derivatives of phenylalanine (Phe) such as 4-methyl-Phe*, pentamethyl-Phe*, L-Phe (4-amino)^#, L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L-diaminopropionic acid^# and L-Phe (4-benzyl)*. The notation * has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #* indicates amphipathic characteristics.

Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or β-alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, “the peptoid form” is used to refer to variant amino acid residues wherein the α-carbon substituent group is on the residue's nitrogen atom rather than the α-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon R J et al., PNAS (1992) 89(20), 9367-9371 and Horwell D C, Trends Biotechnol. (1995) 13(4), 132-134.

The nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3′ and/or 5′ ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences of the present invention.

The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.

Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other homologues may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention. Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used. The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

Hybridisation

The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto. The term “hybridisation” as used herein shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.

The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.

The term “variant” also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.

Preferably, the term “variant” encompasses sequences that are complementary to sequences that are capable of hybridising under medium stringency conditions (e.g. 50° C. and 0.2×SSC {1×SSC=0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}) to the nucleotide sequences presented herein.

More preferably, the term “variant” encompasses sequences that are complementary to sequences that are capable of hybridising under high stringency conditions (e.g. 65° C. and 0.1×SSC {1×SSC=0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}) to the nucleotide sequences presented herein.

The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under medium stringency conditions (e.g. 50° C. and 0.2×SSC {1×SSC=0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}).

In a more preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g. 65° C. and 0.1×SSC {1×SSC=0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}).

Preferably hybridisation is analysed over the whole of the sequences taught herein.

Molecular Evolution

As a non-limiting example, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded polypeptide by various means.

In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wildtype or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide. The production of new preferred variants can be achieved by various methods well established in the art, for example the Error Threshold Mutagenesis (WO 92/18645), oligonucleotide mediated random mutagenesis (U.S. Pat. No. 5,723,323), DNA shuffling (U.S. Pat. No. 5,605,793), exo-mediated gene assembly WO00/58517. The application of these and similar random directed molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or in vitro, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability, altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature. pH, substrate.

Site-Directed Mutagenesis

Once a protein-encoding nucleotide sequence has been isolated, or a putative protein-encoding nucleotide sequence has been identified, it may be desirable to mutate the sequence in order to prepare a protein of the present invention.

Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

A suitable method is disclosed in Morinaga et al., (Biotechnology (1984) 2, p 646-649).

Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151).

Recombinant

In one aspect the sequence for use in the present invention is a recombinant sequence—i.e. a sequence that has been prepared using recombinant DNA techniques.

These recombinant DNA techniques are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press.

Synthetic

In one aspect the sequence for use in the present invention is a synthetic sequence—i.e. a sequence that has been prepared by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, sequences made with optimal codon usage for host organisms—such as the methylotrophic yeasts Pichia and Hansenula.

Expression of Enzymes

The nucleotide sequence for use in the present invention may be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in protein/enzyme form, in and/or from a compatible host cell.

Expression may be controlled using control sequences e.g. regulatory sequences.

The protein produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences may be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

Expression Vector

The term “expression vector” means a construct capable of in vivo or in vitro expression.

In one embodiment the proline tolerant tripeptidyl peptidase and/or endoprotease for use in the present invention may be encoded by a vector. In other words the vector may comprise a nucleotide sequence encoding the proline tolerant tripeptidyl peptidase.

Preferably, the expression vector is incorporated into the genome of a suitable host organism. The term “incorporated” preferably covers stable incorporation into the genome.

The nucleotide sequence of the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host organism.

The vectors for use in the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide of the present invention.

The choice of vector e.g. a plasmid, cosmid, or phage vector will often depend on the host cell into which it is to be introduced.

The vectors for use in the present invention may contain one or more selectable marker genes—such as a gene, which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Alternatively, the selection may be accomplished by co-transformation (as described in WO91/17243).

Vectors may be used in vitro, for example for the production of RNA or used to transfect, transform, transduce or infect a host cell.

Thus, in a further embodiment, the invention provides a method of making nucleotide sequences of the present invention by introducing a nucleotide sequence of the present invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.

The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

Codon Optimisation

The nucleotide sequence and/or vector encoding the proline tolerant tripeptidyl peptidase and/or the endoprotease may be codon optimised for expression in a particular host organism.

The nucleotide sequence and/or vector encoding the proline tolerant tripeptidyl peptidase and/or the endoprotease may be codon optimised for expression in a prokaryotic or eukaryotic cell. Suitably, the nucleotide sequence and/or vector encoding the proline tolerant tripeptidyl peptidase and/or the endoprotease may be codon optimised for expression in a fungal host organism (e.g. Trichoderma, preferably Trichoderma reesei).

Codon optimisation refers to a process of modifying a nucleic acid sequence for enhanced expression in a host cell of interest by replacing at least one codon (e.g. at least about more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, 60, 70, 80 or 100 codons) of the native sequence with codons that are more frequently used in the genes of the host cell, whilst maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, amongst other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis.

Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimisation. A nucleotide sequence and/vector that has undergone this tailoring can be referred to therefore as a “codon optimised” nucleotide sequence and/or vector.

Codon usage tables are readily available, for example, at the “Codon Usage Database”, and these tables can be adapted in a number of ways. See Nakamura, Y., et al. “Codon usage tabulated from the international DNA sequence databases: status for the year 2000” Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimising a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, Pa.). In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a proline tolerant tripeptidyl peptidase and/or endoprotease for use in the present invention correspond to the most frequently used codon for a particular amino acid.

In one embodiment the nucleotide sequence encoding the proline tolerant tripeptidyl peptidase may be a nucleotide sequence which has been codon optimised for expression in Trichoderma reesei.

In one embodiment the codon optimised sequence may comprise a nucleotide sequence shown as SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92. SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, SEQ ID No. 97 or a nucleotide sequence having at least 70% identity thereto. Suitably a sequence having at least 80% thereto or at least 90% thereto.

Preferably the codon optimised sequence may comprise a nucleotide sequence having at least 95% sequence identity to SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95, more preferably at least 99% identity to SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 or SEQ ID No. 97.

In one embodiment the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence which hybridises to SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85. SEQ ID No. 86. SEQ ID No. 87. SEQ ID No. 88, SEQ ID No. 89. SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 or SEQ ID No. 97 under medium stringency conditions. Suitably, a nucleotide sequence which hybridises to SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 or SEQ ID No. 97 under high stringency conditions.

In a further embodiment, the proline tolerant tripeptidyl peptidase may be encoded by a nucleotide sequence which differs from SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 or SEQ ID No. 97 due to degeneracy of the genetic code.

There is also provided a vector (e.g. plasmid) comprising one or more of the sequences selected from the group consisting of: SEQ ID No. 81, SEQ ID No. 82, SEQ ID No. 83, SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 86, SEQ ID No. 87, SEQ ID No. 88, SEQ ID No. 89, SEQ ID No. 90, SEQ ID No. 91, SEQ ID No. 92, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 or SEQ ID No. 97.

Regulatory Sequences

In some applications, the nucleotide sequence for use in the present invention is operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.

The term “operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The term “regulatory sequences” includes promoters and enhancers and other expression regulation signals.

The term “promoter” is used in the normal sense of the art, e.g. an RNA polymerase binding site.

Enhanced expression of the nucleotide sequence encoding the enzyme of the present invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.

Preferably, the nucleotide sequence according to the present invention is operably linked to at least a promoter.

Other promoters may even be used to direct expression of the polypeptide of the present invention.

Examples of suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art.

The promoter can additionally include features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box.

Constructs

The term “construct”—which is synonymous with terms such as “conjugate”, “cassette” and “hybrid”—includes a nucleotide sequence for use according to the present invention directly or indirectly attached to a promoter.

An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term “fused” in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

The construct may even contain or express a marker, which allows for the selection of the genetic construct.

For some applications, preferably the construct of the present invention comprises at least the nucleotide sequence of the present invention operably linked to a promoter.

Host Cells

The term “host cell”—in relation to the present invention includes any cell that comprises either the nucleotide sequence or an expression vector as described above and which is used in the recombinant production of a protein having the specific properties as defined herein.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence that expresses the protein of the present invention.

The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

Examples of suitable bacterial host organisms are gram positive or gram negative bacterial species.

Depending on the nature of the nucleotide sequence encoding the polypeptide of the present invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.

The use of suitable host cells—such as yeast, fungal and plant host cells—may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

The host cell may be a protease deficient or protease minus strain. This may for example be the protease deficient strain Aspergillus oryzae JaL 125 having the alkaline protease gene named “alp” deleted. This strain is described in WO97/35956.

Suitably, the host cell may be a Trichoderma host cell, preferably a Trichoderma reesei host cell. In other embodiments, the host cell may be any member belonging to the genera Escherichia, Bacillus, Thermomyces, Acremonium, Aspergillus, Penicillium, Mucor, Neurospora, Humicola and the like.

Organism

The term “organism” in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the polypeptide according to the present invention and/or products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention when present in the organism.

Suitable organisms may include a prokaryote, fungus, yeast or a plant.

The term “transgenic organism” in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the polypeptide according to the present invention and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

The term “transgenic organism” does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the polypeptide according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention, or the products thereof.

For example the transgenic organism may also comprise the nucleotide sequence coding for the polypeptide of the present invention under the control of a heterologous promoter.

Transformation of Host Cells/Organism

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include E. coli and Bacillus spp., including Bacillus subtilis and B. licheniformis.

Teachings on the transformation of prokaryotic hosts are well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation—such as by removal of introns.

Filamentous fungi cells may be transformed using various methods known in the art—such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of Aspergillus as a host microorganism is described in EP 0 238 023.

Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech Mar./Apr. 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

General teachings on the transformation of fungi, yeasts and plants are presented in following sections.

Transformed Fungus

A host organism may be a fungus—such as a mould. Examples of suitable such hosts include any member belonging to the genera Thermomyces, Acremonium, Aspergillus, Penicillium, Mucor, Neurospora, Trichoderma and the like.

In one embodiment, the host organism may be a filamentous fungus.

Transforming filamentous fungi is discussed in U.S. Pat. No. 5,741,665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to N. crassa is found, for example in Davis and de Serres, Methods Enzymol (1971) 17A: 79-143.

Further teachings which may also be utilised in transforming filamentous fungi are reviewed in U.S. Pat. No. 5,674,707.

In addition, gene expression in filamentous fungi is taught in Punt et al. (2002) Trends Biotechnol 2002 May; 20(5):200-6, Archer & Peberdy Crit Rev Biotechnol (1997) 17(4):273-306.

The present invention encompasses the production of transgenic filamentous fungi according to the present invention prepared by use of these standard techniques.

Suitably the host organism is a Trichoderma host organism, e.g. a Trichoderma reesei host organism.

In another embodiment, the host organism can be of the genus Aspergillus, such as Aspergillus niger.

A transgenic Aspergillus according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S. D., Kinghorn J. R. (Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).

Transformed Yeast

In another embodiment, the transgenic organism can be a yeast.

A review of the principles of heterologous gene expression in yeast are provided in, for example, Methods Mol Biol (1995), 49:341-54, and Curr Opin Biotechnol (1997) October; 8(5):554-60

In this regard, yeast—such as the species Saccharomyces cerevisiae or Pichia pastoris (see FEMS Microbiol Rev (2000 24(1):45-66), may be used as a vehicle for heterologous gene expression.

A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, “Yeast as a vehicle for the expression of heterologous genes”, Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

For the transformation of yeast, several transformation protocols have been developed. For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al., (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).

The transformed yeast cells may be selected using various selective markers—such as auxotrophic markers dominant antibiotic resistance markers.

Culturing and Production

Host cells transformed with the nucleotide sequence of the present invention may be cultured under conditions conducive to the production of the encoded polypeptide and which facilitate recovery of the polypeptide from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in questions and obtaining expression of the polypeptide.

The protein produced by a recombinant cell may be displayed on the surface of the cell.

The protein may be secreted from the host cells and may conveniently be recovered from the culture medium using well-known procedures.

Secretion

Often, it is desirable for the protein to be secreted from the expression host into the culture medium from where the protein may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the context of the present invention.

Typical examples of heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA—both 18 and 24 amino acid versions e.g. from Aspergillus), the a-factor gene (yeasts e.g. Saccharomyces, Kluyveromyces and Hansenula) or the α-amylase gene (Bacillus).

By way of example, the secretion of heterologous proteins in E. coli is reviewed in Methods Enzymol (1990) 182:132-43.

Post-Transcription and Post-Translational Modifications

Suitably the proline tolerant tripeptidyl peptidase and/or the endoprotease for use in the present invention may be encoded by any one of the nucleotide sequences taught herein. Depending upon the host cell used post-transcriptional and/or post-translational modifications may be made. It is envisaged that the enzymes (e.g. the proline tolerant tripeptidyl peptidase and/or the endoprotease) for use in the present methods and/or uses encompasses enzymes (e.g. the proline tolerant tripeptidyl peptidase and/or the endoprotease) which have undergone post-transcriptional and/or post-translational modification.

One non-limiting example of a post-transcriptional and/or post-translational modifications is “clipping” or “cleavage” of a polypeptide (e.g. of the proline tolerant tripeptidyl peptidase and/or the endoprotease).

In some embodiments the polypeptide (e.g. the tripeptidyl peptidase of the present invention e.g. proline tolerant tripeptidyl peptidase and/or the endoprotease) may be clipped or cleaved. This may result in the conversion of the proline tolerant tripeptidyl peptidase and/or the endoprotease from an inactive or substantially inactive state to an active state (i.e. capable of performing the activity described herein).

The proline tolerant tripeptidyl peptidase may be a pro-peptide which undergoes further post-translational modification to a mature peptide, i.e. a polypeptide which has the proline tolerant tripeptidyl peptidase activity.

By way of example only SEQ ID No. 1 is the same as SEQ ID No. 29 except that SEQ ID No. 1 has undergone post-translational and/or post-transcriptional modification to remove some amino acids, more specifically 197 amino acids from the N-terminus. Therefore the polypeptide shown herein as SEQ ID No. 1 could be considered in some circumstances (i.e. in some host cells) as a pro-peptide—which is further processed to a mature peptide (SEQ ID No. 29) by post-translational and/or post-transcriptional modification. The precise modifications, e.g. cleavage site(s), in respect of the post-translational and/or post-transcriptional modification may vary slightly depending on host species. In some host species there may be no post translational and/or post-transcriptional modification, hence the pro-peptide would then be equivalent to the mature peptide (i.e. a polypeptide which has the tripeptidyl peptidase activity of the present invention). Without wishing to be bound by theory, the cleavage site(s) may be shifted by a few residues (e.g. 1, 2 or 3 residues) in either direction compared with the cleavage site shown by reference to SEQ ID No. 29 compared with SEQ ID No. 1. In other words, rather than cleavage at position 197 (R) for example, the cleavage may be at position 196-A, 195-A, 194-A, 198Q, 199E, 200P for example. In addition or alternatively, the cleavage may result in the removal of about 197 amino acids, in some embodiments the cleavage may result in the removal of between 194 and 200 residues.

Other examples of post-transcriptional and/or post-translational modifications include but are not limited to myristoylation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation. The skilled person will appreciate that the type of post-transcriptional and/or post-translational modifications that may occur to a protein (e.g. the proline tolerant tripeptidyl peptidase and/or the endoprotease) may depend on the host organism in which the protein (e.g. the proline tolerant tripeptidyl peptidase and/or the endoprotease) is expressed.

Detection

A variety of protocols for detecting and measuring the expression of the amino acid sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays.

A number of companies such as Pharmacia Biotech (Piscataway, N.J.), Promega (Madison, Wis.), and US Biochemical Corp (Cleveland, Ohio) supply commercial kits and protocols for these procedures.

Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include U.S. Pat. No. 3,817,837; U.S. Pat. No. 3,850,752; U.S. Pat. No. 3,939,350; U.S. Pat. No. 3,996,345; U.S. Pat. No. 4,277,437; U.S. Pat. No. 4,275,149 and U.S. Pat. No. 4,366,241.

Also, recombinant immunoglobulins may be produced as shown in U.S. Pat. No. 4,816,567.

Fusion Proteins

The amino acid sequence for use according to the present invention may be produced as a fusion protein, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and (f-galactosidase). It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences.

Preferably, the fusion protein will not hinder the activity of the protein sequence.

Gene fusion expression systems in E. coli have been reviewed in Curr Opin Biotechnol (1995) 6(5):501-6.

In another embodiment of the invention, the amino acid sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

General Recombinant DNA Methodology Techniques

The present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, Irl Press; and, D. M. J. Lilley and J. E. Dahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

Dosages

The proline tolerant tripeptidyl peptidase and/or the endoprotease for use in the methods and/or uses of the present invention may be dosed in any suitable amount.

In one embodiment the proline tolerant tripeptidyl peptidase may be dosed in an amount of about 0.01 mg-100 mg; 0.5 mg-100 mg; 1 mg-50 mg; 5 mg-100 mg; 5 mg-20 mg, 10 mg-100 mg; 0.05 mg-50 mg; or 0.10 mg-10 mg of enzyme per kg of feed additive composition.

In certain embodiments the proline tolerant tripeptidyl peptidase may be dosed in an amount of about 0.01 g to 1000 g of enzyme per kg of feed additive composition, such as 0.1 g to 500 g, such as 0.5 g to 700 g, such as in an amount of about 0.01 g-200 g, 0.01 g-100 g; 0.5 g-100 g; 1 g-50 g; 5 g-100 g; 5 g-20 g, 5 g-15 g, 10 g-100 g; 0.05 g-50 g; or 0.10 g-10 g of enzyme per kg of feed additive composition.

In one preferred embodiment, the proline tolerant tripeptidyl peptidase may be dosed in an amount of about 5 mg-20 mg of enzyme per kg of feed additive composition,

The exact amount will depend on the particular type of composition employed and on the specific protease activity per mg of protein.

In another embodiment the proline tolerant tripeptidyl peptidase may be dosed in an amount of about 1 mg to about 1 kg of enzyme per kg of feed and/or feedstuff and/or premix. Suitably the proline tolerant tripeptidyl peptidase may be dosed at about 1 mg to about 250 g per kg of feed and/or feedstuff and/or premix. Preferably at about 1 mg to about 100 g (more preferably at about 1 mg to about 1 g) per kg of feed and/or feedstuff and/or premix.

The endoprotease may be dosed in an amount of less than about 6.0 g of enzyme per metric ton (MT) of feed.

Suitably, the endoprotease may be dosed in an amount of less than about 4.0 g of enzyme per MT, suitably less than about 2.0 g of enzyme per MT.

In another embodiment the endoprotease may be dosed at between about 0.5 g and about 5.0 g of enzyme per MT of feed. Suitably the endoprotease may be dosed at between about 0.5 g and about 3.0 g of enzyme per MT of feed. More suitably, the endoprotease may be dosed at about 1.0 g to about 2.0 g of enzyme per MT of feed.

In one embodiment the aminopeptidase may be dosed in an amount of between about 0.5 mg to about 2 g of enzyme per kg of protein substrate and/or feed additive composition. Suitably the aminopeptidase may be dosed in an amount of between about 1 mg to about 2 g of enzyme per kg of protein substrate and/or feed additive composition. More suitably in an amount of between about 5 mg to about 1.5 g of enzyme per kg of protein substrate and/or feed additive composition.

Animal

The term “animal”, as used herein, means an animal that is to be or has been administered with a feed additive composition according to the present invention or a feedstuff comprising said feed additive composition according to the present invention.

Preferably, the animal is a mammal, a ruminant animal, monogastric animal, fish or crustacean including for example livestock or a domesticated animal (e.g. a pet).

In one embodiment the “animal” is livestock.

The term “livestock”, as used herein refers to any farmed animal. Preferably, livestock is one or more of cows or bulls (including calves), pigs (including piglets, swine, growing pigs, sows), poultry (including broilers, chickens, egg layers and turkeys), birds, fish (including freshwater fish, such as salmon, cod, trout and carp, e.g. koi carp, and marine fish, such as sea bass), crustaceans (such as shrimps, mussels and scallops), horses (including race horses), sheep (including lambs).

In another embodiment the “animal” is a domesticated animal or pet or an animal maintained in a zoological environment.

The term “domesticated animal or pet or animal maintained in a zoological environment” as used herein refers to any relevant animal including canines (e.g. dogs), felines (e.g. cats), rodents (e.g. guinea pigs, rats, mice), birds, fish (including freshwater fish and marine fish), and horses.

In one embodiment the animal is a monogastric animal. In a preferred embodiment the monogastric animal may be poultry or pig (or a combination thereof).

In another embodiment the animal is a ruminant animal.

The term animal is not intended to refer to a human being.

Packaging

In one embodiment the feed additive composition and/or premix and/or feed or feedstuff according to the present invention is packaged.

In one preferred embodiment the feed additive composition and/or premix and/or feed or feedstuff is packaged in a bag, such as a paper bag.

In an alternative embodiment the feed additive composition and/or premix and/or feed or feedstuff may be sealed in a container. Any suitable container may be used.

Feed

The feed additive composition of the present invention may be used as—or in the preparation of—a feed.

The term “feed” is used synonymously herein with “feedstuff”.

The feed may be in the form of a solution or as a solid—depending on the use and/or the mode of application and/or the mode of administration.

When used as—or in the preparation of—a feed—such as functional feed—the composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.

In a preferred embodiment the feed additive composition of the present invention is admixed with a feed component to form a feedstuff.

The term “feed component” as used herein means all or part of the feedstuff. Part of the feedstuff may mean one constituent of the feedstuff or more than one constituent of the feedstuff, e.g. 2 or 3 or 4. In one embodiment the term “feed component” encompasses a premix or premix constituents.

In one embodiment a feed additive composition comprising a proline tolerant tripeptidyl peptidase and one or more ingredients selected from the group consisting of: a wheat carrier, a polyol, a sugar, a salt and a preservative (optionally in combination with an endoprotease) may be admixed with at least one protein or portion thereof is an animal protein or a vegetable protein (e.g. selected from one or more of a gliadin, a beta-casein, a beta-lactoglobulin or an immunogenic fragment of a gliadin, a beta-casein, a beta-lactoglobulin, glycinin, beta-conglycinin, cruciferin, napin, collagen, whey protein, fish protein or meal, meat protein or meal including meat bone meal, feather protein or meal, egg protein, soy protein or grain protein), preferably comprised in corn, soybean meal, corn dried distillers grains with solubles (DDGS), wheat, wheat proteins including gluten, wheat by products, wheat bran, corn by products including corn gluten meal, barley, oat, rye, triticale, full fat soy, animal by-product meals, an alcohol-soluble protein (preferably a zein (e.g. a maize zein maize) and/or a kafirin (e.g. from sorghum)), a protein from oil seeds (preferably from soybean seed proteins, sun flower seed proteins, rapeseed proteins, canola (rape) seed proteins or combinations thereof) or a combination thereof.

Preferably the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof. In one embodiment the feed additive composition according to the present invention may be admixed with a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder.

The term fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.

The term fodder includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes.

Fodder may be obtained from one or more of the plants selected from: alfalfa (Luceme), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy-grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.

The term “compound feed” means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble. Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.

Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins.

The main ingredients used in compound feed are the feed grains, which include corn, wheat, rye, maize, soybeans, sorghum, oats, and barley.

Suitably a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, antibiotics, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.

Vitamins for use in the present invention may include vitamin A, vitamin D3, vitamin E, vitamin K3, vitamin B1, vitamin B2, vitamin B6, vitamin B12, Niacin, Pantothenic acid or mixtures thereof.

Any feedstuff of the present invention may comprise one or more feed materials selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from plants, such as Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, citrus pulp, corn fibre, corn germ meal, corn bran, Hominy feed, corn gluten feed, gluten meal, wheat shorts, wheat middlings or combinations thereof; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola (rapeseed), fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins.

A feedstuff of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60% by weight corn and soybean meal or corn and full fat soy, or wheat meal or sunflower meal.

In addition or in the alternative, a feedstuff of the present invention may comprise at least one high fibre feed material and/or at least one by-product of the at least one high fibre feed material to provide a high fibre feedstuff. Examples of high fibre feed materials include: wheat, barley, rye, oats, by products from plants (e.g. cereals), such as Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, citrus pulp, corn fibre, corn germ meal, corn bran, Hominy feed, corn gluten feed, gluten meal, wheat shorts, wheat middlings or combinations thereof. Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.

In the present invention the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: corn, soybeans, sorghum, oats, barley, corn stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract.

The term “feed” in the present invention also encompasses in some embodiments pet food.

A pet food is plant or animal material intended for consumption by pets, such as dog food or cat food. Pet food, such as dog and cat food, may be either in a dry form, such as kibble for dogs, or wet canned form. Cat food may contain the amino acid taurine.

The term “feed” in the present invention also encompasses in some embodiments fish food. A fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health. Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the colour of ornamental fish.

The term “feed” in the present invention also encompasses in some embodiment bird food. Bird food includes food that is used both in birdfeeders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat).

As used herein the term “contacting” refers to the indirect or direct application of the composition of the present invention to the product (e.g. the feed). Examples of the application methods which may be used, include, but are not limited to, treating the product in a material comprising the feed additive composition, direct application by mixing the feed additive composition with the product, spraying the feed additive composition onto the product surface or dipping the product into a preparation of the feed additive composition.

In one embodiment the feed additive composition of the present invention is preferably admixed with the product (e.g. feedstuff). Alternatively, the feed additive composition may be included in the emulsion or raw ingredients of a feedstuff.

For some applications, it is important that the composition is made available on or to the surface of a product to be affected/treated. This allows the composition to impart one or more of the following favourable characteristics: biophysical characteristic is selected from the group consisting of one or more of the following: performance of the animal, growth performance of an animal, feed conversion ratio (FCR), ability to digest a raw material (e.g. nutrient digestibility, including starch, fat, protein, fibre digestibility), nitrogen digestibility (e.g. ileal nitrogen digestibility) and digestible energy (e.g. ileal digestible energy) nitrogen retention, carcass yield, growth rate, weight gain, body weight, mass, feed efficiency, body fat percentage, body fat distribution, growth, egg size, egg weight, egg mass, egg laying rate, lean gain, bone ash %, bone ash mg, back fat %, milk output, milk fat %, reproductive outputs such as litter size, litter survivability, hatchability % and environmental impact, e.g. manure output and/or nitrogen excretion.

The feed additive compositions of the present invention may be applied to intersperse, coat and/or impregnate a product (e.g. feedstuff or raw ingredients of a feedstuff) with a controlled amount of enzyme(s).

Preferably, the feed additive composition of the present invention will be thermally stable to heat treatment up to about 70° C.; up to about 85° C.; or up to about 95° C. The heat treatment may be performed for up to about 1 minute; up to about 5 minutes; up to about 10 minutes; up to about 30 minutes; up to about 60 minutes. The term thermally stable means that at least about 75% of the enzyme components that were present/active in the additive before heating to the specified temperature are still present/active after it cools to room temperature.

Preferably, at least about 80% of the enzyme components that were present and active in the additive before heating to the specified temperature are still present and active after it cools to room temperature.

In a particularly preferred embodiment the feed additive composition is homogenized to produce a powder.

In an alternative preferred embodiment, the feed additive composition is formulated to granules as described in WO2007/044968 (referred to as TPT granules) incorporated herein by reference.

In another preferred embodiment when the feed additive composition is formulated into granules the granules comprise a hydrated barrier salt coated over the protein core. The advantage of such salt coating is improved thermo-tolerance, improved storage stability and protection against other feed additives otherwise having adverse effect on the enzyme.

Preferably, the salt used for the salt coating has a water activity greater than 0.25 or constant humidity greater than 60% at 20° C.

Preferably, the salt coating comprises a Na₂SO₄.

The method of preparing a feed additive composition may also comprise the further step of pelleting the powder. The powder may be mixed with other components known in the art.

The powder, or mixture comprising the powder, may be forced through a die and the resulting strands are cut into suitable pellets of variable length.

Optionally, the pelleting step may include a steam treatment, or conditioning stage, prior to formation of the pellets. The mixture comprising the powder may be placed in a conditioner, e.g. a mixer with steam injection. The mixture is heated in the conditioner up to a specified temperature, such as from 60-100° C., typical temperatures would be 70° C., 80° C., 85° C., 90° C. or 95° C. The residence time can be variable from seconds to minutes and even hours. Such as 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minutes 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes and 1 hour.

It will be understood that the feed additive composition of the present invention is suitable for addition to any appropriate feed material.

As used herein, the term “feed material” refers to the basic feed material to be consumed by an animal. It will be further understood that this may comprise, for example, at least one or more unprocessed grains, and/or processed plant and/or animal material such as soybean meal or bone meal.

As used herein, the term “feedstuff” refers to a feed material to which one or more feed additive compositions have been added.

It will be understood by the skilled person that different animals require different feedstuffs, and even the same animal may require different feedstuffs, depending upon the purpose for which the animal is reared.

Preferably, the feedstuff may comprise feed materials comprising maize or corn, wheat, barley, triticale, rye, rice, tapioca, sorghum, and/or any of the by-products, as well as protein rich components like soybean mean, rape seed meal, canola (rapeseed) meal, cotton seed meal, sunflower seed mean, animal-by-product meals and mixtures thereof. More preferably, the feedstuff may comprise animal fats and/or vegetable oils.

Optionally, the feedstuff may also contain additional minerals such as, for example, calcium and/or additional vitamins.

Preferably, the feedstuff is a corn soybean meal mix.

In another aspect there is provided a method of preparing a feedstuff comprising contacting a feed component with a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′
  
  optionally in combination with at least one endoprotease.

There is also provided a feedstuff comprising a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a premix of the invention.

Feedstuff is typically produced in feed mills in which raw materials are first ground to a suitable particle size and then mixed with appropriate additives. The feedstuff may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and then the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool. Subsequently liquid additives such as fat and enzyme may be added. Production of feedstuff may also involve an additional step that includes extrusion or expansion prior to pelleting—in particular by suitable techniques that may include at least the use of steam.

The feedstuff may be a feedstuff for a monogastric animal, such as poultry (for example, broiler, layer, broiler breeders, turkey, duck, geese, water fowl), swine (all age categories), a pet (for example dogs, cats) or fish, preferably the feedstuff is for poultry.

By way of example only a feedstuff for chickens, e.g. broiler chickens may be comprises of one or more of the ingredients listed in the table below, for example in the % ages given in the table below:

Ingredients
Starter (%)
Finisher (%)

Maize
46.2
46.7

Wheat Middlings
6.7
10.0

Maize DDGS
7.0
7.0

Soyabean Meal 48% CP
32.8
26.2

An/Veg Fat blend
3.0
5.8

L-Lysine HCl
0.3
0.3

DL-methionine
0.3
0.3

L-threonine
0.1
0.1

Salt
0.3
0.4

Limestone
1.1
1.1

Dicalcium Phosphate
1.2
1.2

Poultry Vitamins and Micro-minerals
0.3
0.3

By way of example only the diet specification for chickens, such as broiler chickens, may be as set out in the Table below:

Diet specification

Crude Protein (%)
23.00
20.40

Metabolizable Energy Poultry
2950
3100

(kcal/kg)

Calcium (%)
0.85
0.85

Available Phosphorus (%)
0.38
0.38

Sodium (%)
0.18
0.19

Dig. Lysine (%)
1.21
1.07

Dig. Methionine (%)
0.62
0.57

Dig. Methionine + Cysteine (%)
0.86
0.78

Dig. Threonine (%)
0.76
0.68

By way of example only a feedstuff laying hens may be comprises of one or more of the ingredients listed in the table below, for example in the % ages given in the table below:

Ingredient
Laying phase (%)

Maize
10.0

Wheat
53.6

Maize DDGS
5.0

Soybean Meal 48% CP
14.9

Wheat Middlings
3.0

Soybean Oil
1.8

L-Lysine HCl
0.2

DL-methionine
0.2

L-threonine
0.1

Salt
0.3

Dicalcium Phosphate
1.6

Limestone
8.9

Poultry Vitamins and Micro-minerals
0.6

By way of example only the diet specification for laying hens may be as set out in the Table below:

Diet specification

Crude Protein (%)
16.10

Metabolizable Energy Poultry
2700

(kcal/kg)

Lysine (%)
0.85

Methionine (%)
0.42

Methionine + Cysteine (%)
0.71

Threonine (%)
0.60

Calcium (%)
3.85

Available Phosphorus (%)
0.42

Sodium (%)
0.16

By way of example only a feedstuff for turkeys may be comprises of one or more of the ingredients listed in the table below, for example in the % ages given in the table below:

Phase 1
Phase 2
Phase 3
Phase 4

Ingredient
(%)
(%)
(%)
(%)

Wheat
33.6
42.3
52.4
61.6

Maize DDGS
7.0
7.0
7.0
7.0

Soyabean Meal 48% CP
44.6
36.6
27.2
19.2

Rapeseed Meal
4.0
4.0
4.0
4.0

Soyabean Oil
4.4
4.2
3.9
3.6

L-Lysine HCl
0.5
0.5
0.4
0.4

DL-methionine
0.4
0.4
0.3
0.2

L-threonine
0.2
0.2
0.1
0.1

Salt
0.3
0.3
0.3
0.3

Limestone
1.0
1.1
1.1
1.0

Dicalcium Phosphate
3.5
3.0
2.7
2.0

Poultry Vitamins and
0.4
0.4
0.4
0.4

Micro-minerals

By way of example only the diet specification for turkeys may be as set out in the Table below:

Diet specification

Crude Protein (%)
29.35
26.37
22.93
20.00

Metabolizable Energy Poultry
2.850
2.900
2.950
3.001

(kcal/kg)

Calcium (%)
1.43
1.33
1.22
1.02

Available Phosphorus (%)
0.80
0.71
0.65
0.53

Sodium (%)
0.16
0.17
0.17
0.17

Dig. Lysine (%)
1.77
1.53
1.27
1.04

Dig. Methionine (%)
0.79
0.71
0.62
0.48

Dig. Methionine + Cysteine (%)
1.12
1.02
0.90
0.74

Dig. Threonine (%)
1.03
0.89
0.73
0.59

By way of example only a feedstuff for piglets may be comprises of one or more of the ingredients listed in the table below, for example in the % ages given in the table below:

Ingredient
Phase 1 (%)
Phase 2 (%)

Maize
20.0
7.0

Wheat
25.9
46.6

Rye
4.0
10.0

Wheat middlings
4.0
4.0

Maize DDGS
6.0
8.0

Soyabean Meal 48% CP
25.7
19.9

Dried Whey
10.0
0.0

Soyabean Oil
1.0
0.7

L-Lysine HCl
0.4
0.5

DL-methionine
0.2
0.2

L-threonine
0.1
0.2

L-tryptophan
0.03
0.04

Limestone
0.6
0.7

Dicalcium Phosphate
1.6
1.6

Swine Vitamins and Micro-minerals
0.2
0.2

Salt
0.2
0.4

By way of example only the diet specification for piglets may be as set out in the Table below:

Diet specification

Crude Protein (%)
21.50
20.00

Swine Digestible Energy
3380
3320

(kcal/kg)

Swine Net Energy (kcal/kg)
2270
2230

Calcium (%)
0.80
0.75

Digestible Phosphorus (%)
0.40
0.35

Sodium (%)
0.20
0.20

Dig. Lysine (%)
1.23
1.14

Dig. Methionine (%)
0.49
0.44

Dig. Methionine + Cysteine (%)
0.74
0.68

Dig. Threonine (%)
0.80
0.74

By way of example only a feedstuff for grower/finisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the % ages given in the table below:

Ingredient
Grower/Finisher (%)

Maize
27.5

Soyabean Meal 48% CP
15.4

Maize DDGS
20.0

Wheat bran
11.1

Rice bran
12.0

Canola seed meal
10.0

Limestone
1.6

Dicalcium phosphate
0.01

Salt
0.4

Swine Vitamins and Micro-minerals
0.3

Lysine-HCl
0.2

Vegetable oil
0.5

By way of example only the diet specification for grower/finisher pigs may be as set out in the Table below:

Diet specification

Crude Protein (%)
22.60

Swine Metabolizable Energy
3030

(kcal/kg)

Calcium (%)
0.75

Available Phosphorus (%)
0.29

Digestible Lysine (%)
1.01

Dig. Methionine + Cysteine (%)
0.73

Digestible Threonine (%)
0.66

Forms

The feed additive composition of the present invention and other components and/or the feedstuff comprising same may be used in any suitable form.

The feed additive composition of the present invention may be used in the form of solid or liquid preparations or alternatives thereof. Examples of solid preparations include powders, pastes, boluses, capsules, pellets, tablets, dusts, and granules which may be wettable, spray-dried or freeze-dried. Examples of liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions.

In some applications, feed additive composition of the present invention may be mixed with feed or administered in the drinking water.

Suitable examples of forms include one or more of: powders, pastes, boluses, pellets, tablets, pills, granules, capsules, ovules, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

By way of example, if the composition of the present invention is used in a solid, e.g. pelleted form, it may also contain one or more of: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates; granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia; lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Examples of nutritionally acceptable carriers for use in preparing the forms include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, liposomes, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.

Preferred excipients for the forms include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.

For aqueous suspensions and/or elixirs, the composition of the present invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, propylene glycol and glycerin, and combinations thereof.

Combination with Other Components

The feed additive composition, or feed ingredient, or feed or feedstuff or premix of the present invention may be used in combination with other components.

The combination of the present invention feed additive composition, or feed ingredient, or feed or feedstuff or premix of the present invention and another component which is suitable for animal consumption and is capable of providing a medical or physiological benefit to the consumer.

In one embodiment the “another component” may be one or more enzymes.

Suitable additional enzymes for use in the present invention may be one or more of the enzymes selected from the group consisting of: endoglucanases (E.C. 3.2.1.4); celliobiohydrolases (E.C. 3.2.1.91), β-glucosidases (E.C. 3.2.1.21), cellulases (E.C. 3.2.1.74), lichenases (E.C. 3.1.1.73), lipases (E.C. 3.1.1.3), lipid acyltransferases (generally classified as E.C. 2.3.1.x), phospholipases (E.C. 3.1.1.4, E.C. 3.1.1.32 or E.C. 3.1.1.5), phytases (e.g. 6-phytase (E.C. 3.1.3.26) or a 3-phytase (E.C. 3.1.3.8), alpha-amylases (E.C. 3.2.1.1), xylanases (E.C. 3.2.1.8, E.C. 3.2.1.32, E.C. 3.2.1.37, E.C. 3.1.1.72, E.C. 3.1.1.73), glucoamylases (E.C. 3.2.1.3), proteases (e.g. subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.x.x)) and/or mannanases (e.g. a β-mannanase (E.C. 3.2.1.78)).

Suitably the other component may be a phytase (e.g. a 6-phytase (E.C. 3.1.3.26) or a 3-phytase (E.C. 3.1.3.8)).

In one embodiment (particularly for feed applications) the other component may be one or more of the enzymes selected from the group consisting of xylanases (E.C. 3.2.1.8, E.C. 3.2.1.32, E.C. 3.2.1.37, E.C. 3.1.1.72, E.C. 3.1.1.73), an amylase (including α-amylases (E.C. 3.2.1.1), G4-forming amylases (E.C. 3.2.1.60), β-amylases (E.C. 3.2.1.2) and γ-amylases (E.C. 3.2.1.3); and/or a protease (e.g. subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.x.x)).

In one embodiment (particularly for feed applications) the other component may be a combination of an amylase (e.g. α-amylases (E.C. 3.2.1.1)) and a protease (e.g. subtilisin (E.C. 3.4.21.62)).

In one embodiment (particularly for feed applications) the other component may be a β-glucanase, e.g. an endo-1,3(4)-β-glucanases (E.C. 3.2.1.6).

In one embodiment (particularly for feed applications) the other component may be a mannanases (e.g. a β-mannanase (E.C. 3.2.1.78)).

In one embodiment (particularly for feed applications) the other component may be a lipase (E.C. 3.1.1.3), a lipid acyltransferase (generally classified as E.C. 2.3.1.x), or a phospholipase (E.C. 3.1.1.4, E.C. 3.1.1.32 or E.C. 3.1.1.5), suitably a lipase (E.C. 3.1.1.3).

In one embodiment (particularly for feed applications) the other component may be a protease (e.g. subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.x.x)).

In another embodiment the other component may be a further protease. Suitably, the further protease may be selected from the group consisting of: an aminopeptidase, and a carboxypeptidase.

The term “aminopeptidase” as used in this context refers to an exopeptidase which is able to cleave single amino acids, di-amino acids or combinations thereof from the N-terminus of a protein and/or peptide substrate. Preferably, an aminopeptidase is able to cleave single amino acids only from the N-terminus of a protein and/or peptide substrate.

The aminopeptidase may be obtainable (e.g. obtained) from Lactobacillus, suitably obtainable from Lactobacillus helveticus.

In one embodiment the aminopeptidase may be an aminopeptidase N (e.g. PepN) (EC 3.4.11.2).

In one embodiment the aminopeptidase may comprise the sequence shown as:

MAVKRFYKTFHPEHYDLRINVNRKNKTINGTSTITGDVIENPVFINQKFM

TIDSVKVDGKNVDFDVIEKDEAIKIKTGVTGKAVIEIAYSAPLTDTMMGI

YPSYYELEGKKKQIIGTQFETTFARQAFPCVDEPEAKATFSLALKWDEQD

GEVALANMPEVEVDKDGYHHFEETVRMSSYLVAFAFGELQSKTTHTKDGV

LIGVYATKAHKPKELDFALDIAKRAIEFYEEFYQTKYPLPQSLQLALPDF

SAGAMENWGLVTYREAYLLLDPDNTSLEMKKLVATVITHELAHQWFGDLV

TMKWWDNLWLNESFANMMEYLSVDGLEPDWHIWEMFQTSEAASALNRDAT

DGVQPIQMEINDPADIDSVFDGAIVYAKGSRMLVMVRSLLGDDALRKGLK

YYFDHHKFGNATGDDLWDALSTATDLDIGKIMHSWLKQPGYPVVNAFVAE

DGHLKLTQKQFFIGEGEDKGRQWQIPLNANFDAPKIMSDKEIDLGNYKVL

REEAGHPLRLNVGNNSHFIVEYDKTLLDDILSDVNELDPIDKLQLLQDLR

LLAEGKQISYASIVPLLVKFADSKSSLVINALYTTAAKLRQFVEPESNEE

KNLKKLYDLLSKDQVARLGWEVKPGESDEDVQIRPYELSASLYAENADSI

KAAHQIFTENEDNLEALNADIRPYVLINEVKNFGNAELVDKLIKEYQRTA

DPSYKVDLRSAVTSTKDLAAIKAIVGDFENADWKPQDLCDVVYRGLLANH

YGQQAAWDWIREDWDWLDKTVGGDMEFAKFITVTAGVFHTPERLKEFKEF

FEPKINVPLLSREIKMDVKVIESKVNLIEAEKDAVNDAVAKAID

The term “carboxypeptidase” as used herein has its usual meaning in the art and refers to an exopeptidase that is capable of cleaving n amino acids from the C-terminus of a peptide and/or protein substrate. In one embodiment n may be at least 1, suitably n may be at least 2. In other embodiments n may be at least 3, suitably at least 4.

In other embodiments, the proline tolerant tripeptidyl peptidase (optionally in combination with an endoprotease) may be used with one or more further exopeptidase

In one embodiment the proline tolerant tripeptidyl peptidase (optionally in combination with an endoprotease) is not combined with a proline-specific exopeptidase.

In a particularly preferred embodiment the proline tolerant tripeptidyl peptidase may not be combined with an enzyme having the following polypeptide sequence:

MRTAAASLTLAATCLFELASALMPRAPLIPAMKAKVALPSGNATFEQYID

HNNPGLGTFPQRYWYNPEFWAGPGSPVLLFTPGESDAADYDGFLTNKTIV

GRFAEEIGGAVILLEHRYWGASSPYPELTTETLQYLTLEGSIADLVHFAK

TVNLPFDEIHSSNADNAPWVMTGGSYSGALAAWTASIAPGTFWAYHASSA

PVQAIYDFWQYFVPWEGMPKNCSKDLNRWEYIDHVYESGDiERQQEIKEM

FGLGALKHFDDFAAAITNGPWLWQDMNFVSGYSRFYKFCDAVENVTPGAK

SVPGPEGVGLEKALQGYASWFNSTYLPGSCAEYKYWTDKDAVDCYDSYET

NSPIYTDKAVNNTSNKQWTWFLCNEPLFYWQDGAPKDESTIVSRIVSAEY

WQRQCHAYFPEVNGYTFGSANGKTAEDVNKWTKGWDLTNTTRLIWANGQF

DPWRDASVSSKTRPGGPLQSTEGAPVHVIPGGFHCSDQWLVYGEANAGVQ

KVIDEEVAQIKAWVAEYPKYRKP

In one embodiment the additional component may be a stabiliser or an emulsifier or a binder or carrier or an excipient or a diluent or a disintegrant.

The term “stabiliser” as used here is defined as an ingredient or combination of ingredients that keeps a product (e.g. a feed product) from changing over time.

The term “emulsifier” as used herein refers to an ingredient (e.g. a feed ingredient) that prevents the separation of emulsions. Emulsions are two immiscible substances, one present in droplet form, contained within the other. Emulsions can consist of oil-in-water, where the droplet or dispersed phase is oil and the continuous phase is water; or water-in-oil, where the water becomes the dispersed phase and the continuous phase is oil. Foams, which are gas-in-liquid, and suspensions, which are solid-in-liquid, can also be stabilised through the use of emulsifiers.

As used herein the term “binder” refers to an ingredient (e.g. a feed ingredient) that binds the product together through a physical or chemical reaction. During “gelation” for instance, water is absorbed, providing a binding effect. However, binders can absorb other liquids, such as oils, holding them within the product. In the context of the present invention binders would typically be used in solid or low-moisture products for instance baking products: pastries, doughnuts, bread and others. Examples of granulation binders include one or more of: polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, maltose, gelatin and acacia.

“Carriers” mean materials suitable for administration of the enzyme and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner.

In one embodiment, the present invention provides the use of a composition (e.g. a feed additive composition) comprising an enzyme of the present invention formulated with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na₂SO₄, Talc, polyvinyl alcohol (PVA), sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.

In a preferred embodiment the present invention provides a composition (e.g. a feed additive composition) or the use thereof and methods of making the same comprising an enzyme of the present invention formulated with a compound selected from one or more of the group consisting of a salt, polyol including sorbitol and glycerol, wheat or a wheat component, sodium acetate, sodium acetate trihydrate, potassium sorbate Talc, polyvinyl alcohol (PVA), benzoate, sorbiate, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, metabisulfite, formate or a combination thereof.

Examples of “excipients” include one or more of: microcrystalline cellulose and other celluloses, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine, starch, milk sugar and high molecular weight polyethylene glycols.

Examples of “disintegrants” include one or more of: starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates.

Examples of “diluents” include one or more of: water, ethanol, propylene glycol and glycerin, and combinations thereof.

The other components may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes) to the feed additive of the present invention.

In one embodiment preferably the feed additive composition, or feed ingredient, or feed or feedstuff or premix according to the present invention does not comprise chromium or organic chromium.

In one embodiment preferably the feed additive composition, or feed ingredient, or feed or feedstuff or premix according to the present invention does not contain sorbic acid.

Biophysical Characteristic

In one aspect there is provided a method for improving a biophysical characteristic of an animal or for improving protein digestibility of an animal which method comprises administering to an animal a feed additive composition obtainable (e.g. obtained) by a method or use of the invention or a feed additive composition, feedstuff or premix of the invention or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′.

The term “administering” as used herein may mean feeding the animal the proline tolerant tripeptidyl peptidase or said feed additive composition either before, after or simultaneously with a feedstuff (e.g. the animals usual diet). Alternatively the term “administering” as used herein may mean feeding the animal with a feedstuff or premix comprising said feed additive composition.

Suitably the at least one proline tolerant tripeptidyl peptidase may be capable of cleaving tri-peptides from the N-terminus of peptides having:

- (i) (A) Proline at P1; and
  - (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; and
- (ii) (a′) Proline at P1′; and
  - (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′.

In another aspect there is provided the use of a feed additive composition or feed ingredient of the invention or a feed additive composition obtainable (preferably obtained) by a method of the invention or a feed feedstuff or premix of the invention for improving a biophysical characteristic of an animal or for improving protein digestibility in an animal or at least one proline tolerant tripeptidyl peptidase predominantly having exopeptidase activity wherein said proline tolerant tripeptidyl peptidase is capable of cleaving tri-peptides from the N-terminus of peptides having:

(i) (A) Proline at P1; and

- (B) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1; or
  
  (ii) (a′) Proline at P1′; and
- (b′) An amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine or synthetic amino acids at P1′
  
  for improving protein digestibility in an animal or for improving a biophysical characteristic of an animal.

Suitably the method and/or use may further comprising administering to an animal at least one feed component, at least one mineral, at least one vitamin or combinations thereof. Alternatively or additionally the method and/or use may further comprise administering to an animal at least one endoprotease.

As used herein, “biophysical characteristic” means any biophysical property of an animal which improves its health and/or performance and/or output.

By way of example, the biophysical characteristic may be one or more selected from the group consisting of one or more of the following: performance of the animal, growth performance of an animal, feed conversion ratio (FCR), ability to digest a raw material (e.g. nutrient digestibility, including starch, fat, protein, fibre digestibility), nitrogen digestibility (e.g. ileal nitrogen digestibility) and digestible energy (e.g. ileal digestible energy), nitrogen retention, carcass yield, growth rate, weight gain, body weight, mass, feed efficiency, body fat percentage, body fat distribution, growth, egg size, egg weight, egg mass, egg laying rate, lean gain, bone ash %, bone ash mg, back fat %, milk output, milk fat %, reproductive outputs such as litter size, litter survivability, hatchability % and environmental impact, e.g. manure output and/or nitrogen excretion.

Suitably the biophysical characteristic may be one or more selected from the group consisting of: feed conversion ratio, nitrogen digestibility (e.g. ileal nitrogen digestibility) and digestible energy (e.g. ileal digestible energy).

In a preferred embodiment the biophysical characteristic may be the ability to digest a protein.

In one embodiment the biophysical characteristic of the animal means the performance of the animal.

Suitably, administering to an animal a feed additive composition and/or feed and/or feedstuff and/or feed ingredient and/or premix of the invention may not substantially increase the incidence of necrotic enteritis in the animal when compared to an animal not fed with the feed additive composition and/or feed and/or feedstuff and/or feed ingredient and/or premix of the invention.

The term “substantially increase the incidence of necrotic enteritis” as used herein means that the incidence is not increased by more than about 20%, suitably not increased by more than about 10%. Preferably it is meant that the incidence of necrotic enteritis is not increased by more than about 5%, more preferably more than about 1%.

Performance

As used herein, “performance of the animal” may be determined by the feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio and/or by the digestibility of a nutrient in a feed (e.g. amino acid digestibility) and/or digestible energy or metabolizable energy in a feed and/or by nitrogen retention.

Preferably “performance of the animal” is determined by feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio.

By “improved performance of the animal” it is meant that there is increased feed efficiency, and/or increased weight gain and/or reduced feed conversion ratio and/or improved digestibility of nutrients or energy in a feed and/or by improved nitrogen retention in the subject resulting from the use of feed additive composition of the present invention compared with feeding the animal a feed composition which does not contain the proline tolerant tripeptidyl peptidase in accordance with the present invention.

Preferably, by “improved animal performance” it is meant that there is increased feed efficiency and/or increased weight gain and/or reduced feed conversion ratio.

As used herein, the term “feed efficiency” refers to the amount of weight gain in an animal that occurs when the animal is fed ad-libitum or a specified amount of food during a period of time.

By “increased feed efficiency” it is meant that the use of a feed additive composition according the present invention in feed results in an increased weight gain per unit of feed intake compared with an animal fed with the feed composition which does not contain the proline tolerant tripeptidyl peptidase in accordance with the present invention.

Feed Conversion Ratio (FCR)

As used herein, the term “feed conversion ratio” refers to the amount of feed fed to an animal to increase the weight of the animal by a specified amount.

An improved feed conversion ratio means a lower feed conversion ratio.

By “lower feed conversion ratio” or “improved feed conversion ratio” it is meant that the use of the proline tolerant tripeptidyl peptidase or a feed additive composition in accordance with the present invention in feed results in a lower amount of feed being required to be fed to an animal to increase the weight of the animal by a specified amount compared to the amount of feed required to increase the weight of the animal by the same amount without said proline tolerant tripeptidyl peptidase or without said feed additive composition in accordance with the present invention.

Nutrient Digestibility

Nutrient digestibility as used herein means the fraction of a nutrient that disappears from the gastro-intestinal tract or a specified segment of the gastrointestinal tract, e.g. the small intestine. Nutrient digestibility may be measured as the difference between what is administered to the subject and what comes out in the faeces of the subject, or between what is administered to the subject and what remains in the digesta on a specified segment of the gastro intestinal tract, e.g. the ileum.

Nutrient digestibility as used herein may be measured by the difference between the intake of a nutrient and the excreted nutrient by means of the total collection of excreta during a period of time; or with the use of an inert marker that is not absorbed by the animal, and allows the researcher calculating the amount of nutrient that disappeared in the entire gastro-intestinal tract or a segment of the gastro-intestinal tract. Such an inert marker may be titanium dioxide, chromic oxide or acid insoluble ash. Digestibility may be expressed as a percentage of the nutrient in the feed, or as mass units of digestible nutrient per mass units of nutrient in the feed.

Nutrient digestibility as used herein encompasses starch digestibility, fat digestibility, protein digestibility, and amino acid digestibility.

Suitably use of a proline tolerant tripeptidyl peptidase according to the methods and/or uses or any of the aspects of the present invention (optionally in combination with at least one endoprotease) increases protein and/or amino acid digestibility in an animal fed with the feed additive composition and/or feed ingredient and/or feed and/or feedstuff and/or premix of the invention.

Energy digestibility as used herein means the gross energy of the feed consumed minus the gross energy of the faeces or the gross energy of the feed consumed minus the gross energy of the remaining digesta on a specified segment of the gastro-intestinal tract of the animal, e.g. the ileum. Metabolizable energy as used herein refers to apparent metabolizable energy and means the gross energy of the feed consumed minus the gross energy contained in the faeces, urine, and gaseous products of digestion. Energy digestibility and metabolizable energy may be measured as the difference between the intake of gross energy and the gross energy excreted in the faeces or the digesta present in specified segment of the gastro-intestinal tract using the same methods to measure the digestibility of nutrients, with appropriate corrections for nitrogen excretion to calculate metabolizable energy of feed.

Nitrogen Retention

Nitrogen retention as used herein means as subject's ability to retain nitrogen from the diet as body mass. A negative nitrogen balance occurs when the excretion of nitrogen exceeds the daily intake and is often seen when the muscle is being lost. A positive nitrogen balance is often associated with muscle growth, particularly in growing animals.

Nitrogen retention may be measured as the difference between the intake of nitrogen and the excreted nitrogen by means of the total collection of excreta and urine during a period of time. It is understood that excreted nitrogen includes undigested protein from the feed, endogenous proteinaceous secretions, microbial protein, and urinary nitrogen.

Carcass Yield and Meat Yield

The term carcass yield as used herein means the amount of carcass as a proportion of the live body weight, after a commercial or experimental process of slaughter. The term carcass means the body of an animal that has been slaughtered for food, with the head, entrails, part of the limbs, and feathers or skin removed. The term meat yield as used herein means the amount of edible meat as a proportion of the live body weight, or the amount of a specified meat cut as a proportion of the live body weight.

Weight Gain

The present invention further provides a method of increasing weight gain in a subject, e.g. poultry or swine, comprising feeding said subject a feedstuff comprising a feed additive composition according to the present invention.

An “increased weight gain” refers to an animal having increased body weight on being fed feed comprising a proline tolerant tripeptidyl peptidase or feed additive composition according to the present invention compared with an animal being fed a feed not comprising said proline tolerant tripeptidyl peptidase or said feed additive composition according to the present invention.

Advantages

The inventors have shown for the first time that such a proline tolerant tripeptidyl peptidase is highly advantageous for use in feed and feedstuffs and confers advantages to an animal fed the proline tolerant tripeptidyl peptidase or a feed and/or feedstuff and/or feed additive composition comprising the same.

The present invention also provides for proline tolerant tripeptidyl peptidase that, in addition to having the activities described above, may be tolerant of proline at position P2, P2′, P3 and P3′. This is advantageous as it allows the efficient cleavage of peptide and/or protein substrates having stretches of proline and allows cleavage of a wide range of peptide and/or protein substrates.

The present invention also provides for thermostable proline tolerant tripeptidyl peptidases which are less prone to being denatured and/or will therefore retain activity for a longer period of time in e.g. an animal when compared to a non-thermostable variant.

The proline tolerant tripeptidyl peptidases herein may be active at an acid pH.

Advantageously, a proline tolerant tripeptidyl peptidase having activity at an acidic pH can be active in the upper gastrointestinal tract of an animal (e.g. in the gizzard, proventriculus or stomach) and/or can digest a peptide and/or protein substrate in combination with endogenous proteases (e.g. pepsin) that are present in the gastrointestinal tract of the animal.

Many current feeding practices involve administering an alkaline protease active at a high pH (e.g. pH 8) to animals. Alkaline proteases are therefore only active lower down (e.g. later) in the gastrointestinal tract of an animal where the gastrointestinal tract becomes more alkaline, such as in the later part of the small intestine and the large intestine and caecum. Without wishing to be bound by theory, it is believed that producing oligopeptides in the later parts of the gastrointestinal tract increases populations of microbes which utilise the oligopeptides which in turn can lead to enteric disease challenges and/or reduced nutrients available for uptake by the animal. Additionally, later in the gastrointestinal tract (i.e. lower down) the mucosa is less well-protected than in the upper portions (e.g. the gizzard, proventriculus or stomach) and so is more easily damaged leading to inflammation. Advantageously, the use of a proline tolerant tripeptidyl peptidase having activity at an acid pH alleviates this problem as it is capable of digesting its substrate in the upper gastrointestinal tract thereby not substantially increasing populations of microbes and/or increasing the amount of nutrient (e.g. amino acids/peptides) available for uptake by an animal and/or reducing inflammation. Advantageously, the use of an endoprotease in combination with a proline tolerant tripeptidyl peptidase can increase the efficiency of substrate cleavage. Without wishing to be bound by theory, it is believed that an endoprotease is able to cleave a peptide and/or protein substrate at multiple regions away from the C or N-terminus, thereby producing more N-terminal ends for the proline tolerant tripeptidyl peptidase to use as a substrate, thereby advantageously increasing reaction efficiency and/or reducing reaction times.

Advantageously feeding a proline tolerant tripeptidyl peptidase to an animal results in increased body weight gain and/or a reduction in feed conversion ratio and/or increased nitrogen digestibility (e.g. ileal nitrogen digestibility) and/or increased energy digestion (e.g. ileal energy digestion).

In one embodiment the compositions and proline tolerant tripeptidyl peptidase of the present invention has been shown to be less harmful to cells (e.g. of the GI tract) compared with conventional proteases used in feed applications. Without wishing to be bound by theory, as ATP plays a central role in cellular metabolism, it is present in all metabolically active cells, and its intracellular level is regulated precisely in healthy cells. ATP has been used as a tool for the functional integrity of living cells since all cells require ATP to remain alive and carry out their specialized function. Most ATP is found within living cells and links catabolic and anabolic processes. Cell injury or oxygen/substrate depletion results in a rapid decrease in cytoplasmic ATP. The decrease in ATP indicates often either an injury in mitochondria, that produce the ATP, or an increase in level of ATPases that degrade ATP. ATPases are located for instance in transporters that couple transportation of a specific molecules to the transportation. However, peptide transportation in the intestine usually is mediated by sodium cotransport, or the sodium binds to the transporter along the peptide. After binding, the sodium ion then moves down its electrochemical gradient to the interior of the cell and pulls the amino acid or peptide along with it. Of course, after the peptide transportation, the sodium would be transported against the concentration gradient back outside the cells by utilising the ATP energy, but normally this decrease in ATP is restored quite rapidly (Normal, healthy cells produce ATP as fast as they use it). Thus ATP content can be used as an indicator of healthy cells. The present inventors have surprisingly found that commercially available proteases uses in the feed industry have a negative effect on living cells. In contrast with the proline tolerant tripeptidyl peptidases of the present invention such a negative effect was not observed.

Likewise a decrease in tight junction integrity was observed with commercially available proteases uses in the feed industry, which again was not the case with the proline tolerant tripeptidyl peptidases of the present invention.

Additional Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, N.Y. (1991) provide one of skill with a general dictionary of many of the terms used in this disclosure.

This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5′ to 3′ orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation.

The term “protein”, as used herein, includes proteins, polypeptides, and peptides.

The terms “protein” and “polypeptide” are used interchangeably herein. In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to understand that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a proline tolerant tripeptidyl peptidase”, “an endoprotease” or “an enzyme” includes a plurality of such candidate agents and reference to “the feed”, “the feedstuff”, “the premix” or “the feed additive composition” includes reference to one or more feeds, feedstuffs, premixes and equivalents thereof known to those skilled in the art, and so forth.

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

The invention will now be described, by way of example only, with reference to the following Figures and Examples.

EXAMPLES
Example 1

Cloning and Expression of Proline Tolerant Tripeptidyl Peptidases in Trichoderma reesei.

Synthetic genes encoding proline tolerant tripeptidyl peptidases were generated using preferred codons for expression in Trichoderma reesei except for TRI079 (SEQ ID No. 57) and TRI083 (SEQ ID No. 56) that were generated as genomic sequences. The predicted secretion signal sequences (SignalP 4.0: Discriminating signal peptides from transmembrane regions. Thomas Nordahl Petersen, Søren Brunak, Gunnar von Heijne & Henrik Nielsen. Nature Methods, 8:785-786, 2011) were replaced (except for TRI079 and TRI083) by the secretion signal sequence from the Trichoderma reesei acidic fungal protease (AFP) and an intron from a Trichoderma reesei glucoamylase gene (TrGA1) (see FIG. 7 lower panel). Synthetic genes were introduced into the destination vector pTTT-pyrG13 (as described in U.S. Pat. No. 8,592,194 B2 the teaching of which is incorporated herein by reference) using LR Clonase™ enzyme mix (Life Technologies) resulting in the construction of expression vectors pTTT-pyrG13 for the proline tolerant tripeptidyl peptidases herein. Expression vectors encoding SEQ ID No's 1, 2 and 29 are shown in FIG. 1 and encoding SEQ ID No's 12 and 39 are shown in FIG. 7. Expression vectors encoding SEQ ID No's 96 or 97 (TRI045) are shown in FIG. 2.

5-10 μg of the expression vectors were transformed individually into a suitable Trichoderma reesei strain using PEG mediated protoplast transformation essentially as described previously (U.S. Pat. No. 8,592,194 B2). Germinating spores were harvested by centrifugation, washed and treated with 45 mg/ml of lysing enzyme solution (Trichoderma harzianum, Sigma L1412) to lyse the fungal cell walls. Further preparation of protoplasts was performed by a standard method, as described by Penttilä et al. [Gene 61(1987) 155-164] the contents of which are incorporated herein by reference.

Spores were harvested using a solution of 0.85% NaCl, 0.015% Tween 80. Spore suspensions were used to inoculate liquid cultures Cultures were grown for 7 days at 28° C. and 80% humidity with shaking at 180 rpm. Culture supernatants were harvested by vacuum filtration and used to measure expression and enzyme performance.

Purification and Characterization
A. Purification of Proline Tolerant Tripeptidyl Peptidase

Desalting of samples was performed on PD10 column (GE Life Sciences, USA) equilibrated with 20 mM Na-acetate, pH 4.5 (buffer A). For ion exchange chromatography on Source S15 HR25/5 (GE Life Sciences, USA) the column was equilibrated with buffer A. The desalted sample (7 ml) was applied to the column at a flow rate of 6 ml/min and the column was washed with buffer A. The bound proteins were eluted with a linier gradient of 0-0.35 M NaCl in 20 mM Na-acetate, pH 4.5 (35 min). During the entire run 10 ml fractions were collected. The collected samples were assayed for tripeptidyl amino-activity as described below. Protein concentration was calculated based on the absorbance measure at 280 nm and the theoretical absorbance of the protein calculated using the ExPASy ProtParam tool (http://web.expasy.org/cgi-bin/protparam/protparam).

B. Determination of Proline Tolerant Tripeptidyl Peptidase and Endopeptidase Activity

The chromogenic peptide H-Ala-Ala-Ala-pNA (MW=387.82; Bachem, Switzerland) was used to determine the activity of proline tolerant tripeptidyl peptidase in the samples produced as described above. The assay was conducted as follows, 10 μL of the chromogenic peptide solution (10 mM dissolved in dimethly sulfoxide; DMSO) were added to 130 μl Na-acetate (20 mM, adjusted to pH 4.0 with acetic acid) in a microtiter plate and heated for 5 minutes at 40° C. 10 μL of appropriately diluted enzyme was added and the absorption was measured in an MTP reader (Versa max, Molecular Devices, Denmark) at 405 nm. One katal of proteolytic activity was defined as the amount of enzyme required to release 1 mole of p-nitroaniline per second.

Azoscasein Assay for Endoprotease Activity.

A modified version of the endoprotease assay described by Iversen and Jørgensen, 1995 is used. An enzyme sample of 50 μl is added to 250 μl of azocasein (0.25% w/v; from Sigma) in 4 times diluted McIlvaine buffer, pH 5 and incubated for 15 min at 40° C. with shaking (800 rpm). The reaction is terminated by adding 50 μl of 2 M TCA and centrifugation for 5 min at 20,000 g. To a 195 μl sample of the supernatant 65 μl of 1 M NaOH is added and absorbance at 450 nm is measured. One unit of endoprotease activity is defined as the amount which yields an increase in absorbance of 0.1 in 15 min at 40° C.

The proline tolerant tripeptidyl peptidase samples produced as described in Example 1 were found to be essentially free of endopeptidase side-activity. Upon purification as described in Example 2A, substantially no endopeptidase side activity was detected.

C. pH Profile

The proline tolerant tripeptidyl peptidase assay described with H-Ala-Ala-Ala-pNA substrate above with modification of using the buffers 20 mM Na-glycine (pH 2.0, 2.5, 3.0, 3.5 and 4.0) or 20 mM Na-acetate buffer (pH 4.0, 4.5 and 5.5) was used to determine the pH profile of proline tolerant tripeptidyl peptidase TRI083 (FIG. 2) and TRI045 (FIG. 24). Optimum pH of TRI083 and TRI045 was observed to be 4.0.

D. Temperature Profile

The proline tolerant tripeptidyl peptidase assay described above was used at temperatures 25, 50, 55, 60, 65, 70, 75, 80 and 85° C. The optimum temperature of proline tolerant tripeptidyl peptidase TRI083 was found to be 50° C., whereas no activity was found at 70° C. and higher temperatures (FIG. 3).

Protein Hydrolysis Using a Proline Tolerant Tripeptidyl Peptidase in Combination with an Endoprotease (Alphalase® AFP)

The enzymes: Alphalase® AFP and the proline tolerant tripeptidyl peptidase TRI083 expressed as described in Example 1.

Assay buffer: 50 mM NaOAc, pH 4.0, 3% dimethylhemoglobin, 37° C., 1 h incubation (100 μl reaction mixture per MTP well).

Stop/colour reagent: 0.05% trinitrobenzenesulfonic acid in 125 mM Na borate pH 8.6 (200 μl per well).

The plate was read at 450 nm using a Versa max microplate reader (Molecular Devices) after about 20 min incubation with stop/colour reagent. The results of the assay (FIG. 4) show a synergistic effect when an endoprotease (Alphalase® AFP) is used in combination with the proline tolerant tripeptidyl peptidase.

Hydrolysis of 33-Mer Gliadin Peptide

The tripeptidyl amino-peptidase was examined for its ability to hydrolyse a synthetic substrate from alpha gliadin (alpha-2-gliadin) by LC-MS and label-free quantification. It was found to cleave the substrate into tri-peptides irrespective of high proline content in the substrate.

Experimental Set-Up

The 33-mer of gliadin (alpha-2-gliadin) (aa56-88) H-LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF-OH (Zedira GmbH: D-64293 Darmstadt, Germany) C190H273N43O47 (MW=3911.46) (1 mg/ml; 0.26 mM) was incubated at 24 C in the presence of proline tolerant tripeptidyl peptidase (0.01 mg/ml) in a total volume of 1000 ul buffer (pH=4.5) (the ratio substrate/enzyme 100:1, w/w). Aliquots (100 ul) of enzyme reaction were stopped with 20 ul 5% trifluoroacetic acid (TFA) after 0, 1, 3, 5, 10, 15 and 30 minutes, respectively. The samples were then transferred to new vials and analyzed on the LTQ Orbitrap mass spectrometer.

Data Acquisition, Label Free Quantification and MS/MS Data Analysis

Nano LC-MS/MS analyses were performed using an Easy LC system (Thermo Scientific, Odense, DK) interfaced to a LTQ Orbitrap Classic hybrid mass spectrometer (Thermo Scientific, Bremen, Germany). Samples were loaded onto a custom-made 2 cm trap column (100 μm i.d., 375 μm o.d., packed with Reprosil C18, 5 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) connected to a 10 cm analytical column (75 μm i.d., 375 μm o.d., packed with Reprosil C18, 3 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) with a steel needle. Separation was performed at a flow rate of 300 nL/min using a 10 min gradient of 0-34% Solvent B (H2O/CH3CN/TFE/HCOOH (100/1800//100/1 v/v/v/v)) into the nanoelectrospray ion source (Thermo Scientific, Odense, DK). The LTQ Orbitrap Classic instrument was operated in a data-dependent MS/MS mode. The peptide masses were measured by the Orbitrap (MS scans were obtained with a resolution of 60 000 at m/z 400), and up to 2 of the most intense peptide m/z were selected and subjected to fragmentation using CID in the linear ion trap (LTQ). Dynamic exclusion was enabled with a list size of 500 masses, duration of 40 s, and an exclusion mass width of ±10 ppm relative to masses on the list.

The RAW files were accessed with the open source program Skyline 1.4.0.4421 (available from MacCoss Lab Software, University of Washington, Department of Genome Sciences, 3720 15^thAve NE Seattle, Wash., US) which can use the MS1 intensities to build chromatograms. The precursor isotopic import filter was set to a count of three, (M, M+1, and M+2) at a resolution of 60,000 and the most intense charge state was used. Peptide sequences of the two substrates as well as their cleavage products were typed into Skyline and intensities were calculated in each sample.

The LC-MS/MS data was manually annotated using GPMAW to calculate theoretical values of fragmentation.

The triple charged mass of the intact alpha-2-gliadin peptide was isolated and followed over time. The intact peptide was not detectable after 3 min and was very fast hydrolyzed (Table 1). Full hydrolysis of the 33-mer alpha-2-gliadin peptide would give the following tri-peptides: LQL′ QPF′ PQP′ QLP′ YPQ′ PQL′ PYP′ QPQ′ LPY′ PQP′ QPF. The intermediate product YPQPQLPYPQPQLPYPQPQPF resulting from cleaving off the four tri-peptides LQL, QPF, PQP and QLP from the alpha-2-gliadin substrate was found to accumulate and then to decrease (Table 1).

TABLE 1

Relative MS peak intensities of alpha-2-gliadin and derived peptides

0 min
1 min
3 min
5 min
10 min
15 min
30 min

Alpha-2 gliadin
100
10
0
0
0
0
0

YPQPQLPYPQPQLPYPQPQPF
79
100
52
23
23
23
20

LQL
3
91
88
94
94
100
100

QPF
0
4
55
7
129
26
100

PQL
8
21
30
32
42
58
100

PYR
4
7
12
15
28
48
101

LPY
5
21
46
62
90
100
94

The accumulation of most of the expected tri-peptides was detected. The underlined tri-peptides were found and confirmed based their MS/MS fragmentation: LQL′ QPF′ PQP′QLP′ YPQ′ PQL′ PYP′ QPQ′ LPY′ PQP′ QPF, whereas the QPF tri-peptides were found only based on their mass.

In conclusion, proline tolerant tripeptidyl peptidase was found to cleave the substrate alpha-2-gliadin consecutively into tri-peptides irrespective of a high proline content. During the hydrolysis proline was present in P3, P2, P1, P1′, P2′ and P3′ positions, respectively.

This is in contrast to that previously found tripeptidyl amino-peptidase do not cleave proline in P1 or P1′ positions (U.S. Pat. No. 7,972,808B2, U.S. Pat. No. 5,821,104. Reichard et al. 2006. Applied and Environmental Microbiology 72, 1739-1748).

Cleavage of AAPPA Peptide

Proline tolerant tripeptidyl peptidase was examined for its ability to hydrolyse a synthetic substrate AAPPA by LC-MS and label free quantification. The peptide H-AAPPA-NH2 (MW=424.49, from Schafer-N, Copenhagen) was dissolved in 20 mM MES buffer, pH=4.0 (1 mg/ml). 1000 ul of the H-AAPPA-NH2 solution was incubated with 200 ul proline tolerant tripeptidyl peptidase (TRI083) solution (40 ug/ml) (substrate/enzyme 100:0.8) at room temperature. At seven time points (0, 5, 15, 60, 180, 720 and 1440 min) 100 ul samples were withdrawn, diluted with 50 ul 5% TFA, heat inactivated (10 min at 80° C.) and kept at −20° C. until LC-MS analysis.

Nano LC-MS/MS analyses were performed using an Easy LC system (Thermo Scientific, Odense, DK) interfaced to a LTQ Orbitrap Classic hybrid mass spectrometer (Thermo Scientific, Bremen, Germany). Samples were loaded onto a custom-made 2 cm trap column (100 μm i.d., 375 μm o.d., packed with Reprosil C18, 5 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) connected to a 10 cm analytical column (75 μm i.d., 375 μm o.d., packed with Reprosil C18, 3 μm reversed phase particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) with a steel needle. Separation was performed at a flow rate of 300 nL/min using a 10 min gradient of 0-34% Solvent B (H2O/CH3CN/TFE/HCOOH (100/8001//100/1 v/v/v/v)) into the nanoelectrospray ion source (Thermo Scientific, Odense, DK). The LTQ Orbitrap Classic instrument was operated in a data-dependent MS/MS mode. The peptide masses were measured by the Orbitrap (MS scans were obtained with a resolution of 60 000 at m/z 400), and up to 2 of the most intense peptide m/z were selected and subjected to fragmentation using CID in the linear ion trap (LTQ). Dynamic exclusion was enabled with a list size of 500 masses, duration of 40 s, and an exclusion mass width of ±10 ppm relative to masses on the list.

The RAW files were accessed with the open source program Skyline 1.4.0.4421 which can use the MS1 intensities to build chromatograms. The precursor isotopic import filter was set to a count of three, (M, M+1, and M+2) at a resolution of 60,000 and the most intense charge state was used. Peptide sequences of the substrate as well as a cleavage product was typed into Skyline and intensities were calculated in each sample.

The analysis showed that proline tolerant tripeptidyl peptidase (TRI083) over time is able to degrade the peptide AAPPA (FIG. 5) and generate the product AAP (FIG. 6), indicating that the PP peptide bond in AAPPA is hydrolysed by proline tolerant tripeptidyl peptidase (TRI083).

Example 2
Materials and Methods
1. Enzyme Treatment of Cornsoy Feed.

Feed flour was sifted to a particle size less than 212 μm and suspended in water to 10% (w/w) slurry and pH adjusted to pH3.5. Then, 138 μL 10% this slurry was added to each well in 96 MTP well-plate using a Beckman Coulter Biomek NXp laboratory automation workstaton. Wide bore tips were used. Then 20 μl of enzyme solution containing proteases to be tested in 20 mM acetate pH 3.5 was added, after that 10 μL (1.14 U/μL) pepsin dissolved in water was added. The plate was incubated at 40° C. for 45 minutes in iEMS incubator/shaker at 1150 rpm. Then 34 μL pancreatin 1.126 mg/mL in 1M Na-bicarbonate was added and the plate was incubated at 40° C. for 60 minutes in iEMS at 1150 rpm. Afterwards, the plate was centrifuged at 5° C., 4000 rpm for 15 min, 10 μL supernatant was transferred to new plates (coming plate #3641 nonbinding) containing 190 μL water in each well to a 20× dilution. The obtained plates (master plates) were stored in the freezer −20° C.

2. Degree of Hydrolysis Measurements.

The method of analysis of degree of hydrolysis (DH) of soluble protein is based on the reaction of primary amino groups with o-phthaldialdehyde (OPA—assay). Reference: P. M. Nielsen, D. Petersen and C. Dambmann. Improved Method for Determining Food Protein Degree of Hydrolysis. Journal of Food Science. 66 (2001) 642-646.

For OPA assay the following procedure was carried on. 10-25 μl feed sample treated by enzyme from master plate was transferred to the new plate, then 175 μl of OPA reagent containing sodium borate, dodecyl sulfate and dithiothreitol, were added to the plate. The end point measurements of optical density at 340 nm were performed right after 2 min and 5 second mixing.

The Effect of Alphalase® AFP (an Acid Protease) on Cornsoy Feed in the Presence of Pepsin and Pancreatin. In Vitro Studies.

The composition of cornsoy feed is presented in the Table below (Interactions of phytate and myo-inositol phosphate esters (IP_1-5) including IP₅isomers with dietary protein and iron and inhibition of pepsin. S. Yu, A. Cowieson, C. Gilbert, P. Plumstead and S. Dalsgaard J. Anim. Sci. 90 (2012) 1824-1832. Supplementary Information).

Ingredient
Amount, %

Corn
60.01

Soybean meal
31.52

Soy oil
4.00

Salt
0.40

DL-Methionine
0.20

Limestone
1.16

Dicalcium Phosphate
1.46

Vitamin and mineral mixture
1.25

Cornsoy feed were treated with Alphalase® AFP (NSP24, available at Genencor Division, Food Enzymes) (herein referred to as “AFP”) at different concentrations (450, 1000 and 1500 ppm in relation to the cornsoy feed) in the presence of pepsin and pancreatin (FIG. 8). The results are presented below; the level of improvement of cornsoy feed DH is 4.5, 6.3 and 9.0%, respectively.

Example 3
The Effect of a Proline Tolerant Tripeptidyl Peptidase on Cornsoy Feed in the Presence of Pepsin and Pancreatin and in the Presence and in the Absence of Alphalase® AFP. In Vitro Studies.

In these studies Alphalase® AFP and proline tolerant tripeptidyl peptidase were used only at the dosages of 1000 and 450 ppm, respectively. The experiment was carried out as per Example 2. The results are presented in Table 2. In the control experiment only pepsin and pancreatin were used. Improvement of hydrolysis is the ratio between the treatment and control.

TABLE 2

The effect of proline tolerant tripeptidyl peptidase and Alphalase ® AFP

on hydrolysis of cornsoy feed.

Control
3PP
AFP
AFP + 3PP

Degree of
24.5 ± 2.0
25.5 ± 1.6
28.6 ± 3.6
32.3 ± 2.6

hydrolysis, %

Improvement of
100 ± 8.2
104 ± 6.5
117 ± 14.7
132 ± 10.7

hydrolysis, %.

As can be seen from Table 2 proline tolerant tripeptidyl peptidase on its own does not give sufficient benefit in cornsoy protein hydrolysis. The performance of Alphalase® AFP is similar to the results presented in the Example 2. However, the combination of proline tolerant tripeptidyl peptidase and Alphalase® AFP gives the maximal results and can be associated with the synergetic action of endo- and exo-proteases.

Example 4a

Validation of Dose Response of Proline Tolerant Tripeptidyl Peptidase (Sometimes Referred to Herein as 3PP) in Combination with Endo-Proteases on Cornsoy Feed Hydrolysis in the Absence of Pepsin and Pancreatin.

The aim of the work was to identify the origin of the enzymes performance and truly monitor possible additive or synergetic performance of endo- and exo-proteases. For this reason, the experiments were performed in the absence of pepsin and pancreatin and the results are summarized in FIG. 9. Otherwise the experiment was carried out as per Example 2.

As can be seen from FIG. 9, the degree of hydrolysis when proline tolerant tripeptidyl peptidase is used with endoproteases is very pronounced. It is clear that this phenomenon is synergetic, since the dose response depends on the level of proline tolerant tripeptidyl peptidase and the nature of endoprotease. In the case of Alphalase® the effect is much more pronounced.

Example 4b

Validation of Dose Response of 3PP in Combination with Different Dosages of AFP Endo-Proteases on Cornsoy Feed Hydrolysis in the Presence of Pepsin and Pancreatin.

To estimate the level of synergism between AFP and 3PP, the experiment carried out in accordance with Example 2 with different dosages of the enzymes and in the presence of pepsin and pancreatin were performed.

As can be seen from FIG. 10 the level of degree of hydrolysis increases with the inclusion of AFP at both 1000 and 2000 ppm. Addition of 3PP further increases the hydrolysis. This is the case for a reaction time of 100 and 200 min.

Example 5
The Stability of Proline Tolerant Tripeptidyl Peptidases in the Presence of Pepsin
Material and Methods

Pepsin solution: Swine pepsin from Sigma (P7000, 674 Sigma units/mg) was used in this example and was prepared in MilliQ water at 10000 Sigma unit/ml. The tripeptidyl peptidase pepsin pre-incubation mixture contained: 2.5 μl tripeptidyl peptidase sample, 95 μl GAT buffer (50 mM glycine-50 mM acetic acid-50 mM tris, pH3.5), 5 μl pepsin in milliQ water (10000 Sigma unit/ml) (final pepsin unit concentration: 500 Sigma unit/ml reaction mixture) in a half bottom area 96 well Corning MTP. For control, the pre-incubation mixture contained 5 μl water instead of 5 μl pepsin. The mixture was incubated at 40° C. for 60 min and then kept on ice. For residual activity, the assay mixture contained the pre-incubation mixture 5 μl, 0.1M acetic acid-sodium acetate (pH4.0) 85 μl, 5 μl substrate AAF-pNA (2.5 mg/ml)(H-Ala-Ala-Phe-pNA. BACHEM, L-1095). The 410 nm reading using a microplate reader (Power Wave X from Bio-Tek Instruments Inc.) was followed every 0.5 min at 30° C. N=2.

Results

Table 3 shows that under the assay conditions and pre-incubation at 40° C. for 60 min, the residual activity was found to be over 80% for all the tripeptidyl peptidases in the presence of 500 units pepsin/ml pre-incubation mixture.

TABLE 3

Activity recovery for tripeptidyl peptidases

Sam-

ples
TRI043
TRI050
TRI053
TRI071
TRI071
TRI071
TRI071

No
0.379
0.919
0.525
1.219
1.105
0.936
1.214

pep-

sin

With
0.529
0.880
0.588
1.118
1.127
0.924
1.091

pep-

sin

Ac-
140
96
112
112
102
99
90

tiv-

ity

re-

cov-

ery

(%)

Example 6

Analysis of Proline Tolerant Tripeptidyl Peptidases (3PP) for their Low pH Stability at pH 2.5 40° C. 60 Min

As a requirement for utilization of the enzymes in feed for monogastric animals, the enzymes should be active at lower pH. For this reason the number of tripeptidyl peptidases has been tested with the reaction on synthetic substrate AAF-pNA, at pH 2.5.

The tripeptide substrate AAF-pNA was prepared at 2.5 mg/ml in DMSO. Tripeptidyl peptidases were used as broth. The reaction mixture containing 2.5 μl enzyme and 90 μL GAT buffer (pH 2.5) was prepared in 96 well incubation plates.

The incubation plate was mixed and incubated at 40° C. for 60 min. Then 50 μl 0.2M Mes-NaOH pH6.0 was added to each well, mixed at 600 rpm for 2 min. After that, 5 μl of the incubation mixture were taken to 96 well assay plate already filled with 85 μl 0.1M acetic acid buffer, pH4.0 and 5 μl 2.5 mg/ml AAF-pNA solution.

The reaction mixture was stirred at 600 rpm for 2 min and read directly in a microplate reader at 410 nm at 30° C. every 0.5 min for 15 min.

To measure initial enzyme activity, similar procedure was performed except the step of enzyme incubation at 40° C. for 60 min.

The results of measuring initial and final activity with activity recovery are presented in Table 4.

TABLE 4

Initial, final activity and its recovery for tripeptidyl peptidases.

OD410 nm
OD410 nm
Activity

Protein name
(Initial)
(Final)
recovery (%)

TRI050.3 (SEQ ID No.
0.603
0.501
83

7/SEQ ID No. 34)

TRI053.1 (SEQ ID No.
0.345
0.356
103

10/SEQ ID No. 37)

29.9 Induction control

Morph 1.1 Background

TRI050 (SEQ ID No.
0.895
0.814
91

7/SEQ ID No. 34)

TRI071 (pool1) 2%
0.757
0.589
78

glu/soph (SEQ ID No.

12/SEQ ID No. 39)

TRI071 (pool1) 2%
0.815
0.672
82

glu/soph (SEQ ID No.

12/SEQ ID No. 39)

TRI071 (pool1) 4%
0.466
0.453
97

glu/soph (SEQ ID No.

12/SEQ ID No. 39)

TRI071 (pool1) 4%
0.67
0.6
90

glu/soph (SEQ ID No.

12/SEQ ID No. 39)

From Table 4 it can been seen that the tripeptidyl peptidases listed above are considerably stable at pH2.5 and 40° C. for 60 min since over 70% activities were retained. From these results it can be concluded that the proline tolerant tripeptidyl peptidases listed above are stale at low pH, for example in the upper digest tract of monogastrics.

Conclusions

This work demonstrated the activity of the enzymes under conditions mimicking the monogastric digestion system. It is shown that the tripeptidyl peptidases listed above are stable at low pH and in the presence of pepsin and thus are ideal for feed applications.

Example 7
Proline Tolerant Tripeptidyl Peptidase in Animal Feed

A total of 288 one day old Ross 308 male broiler chicks were purchased from a commercial hatchery. At study initiation, 8 birds were randomly allocated to battery cages according to respective treatments by blocks. Only healthy birds were selected for the experiment, and no birds were replaced throughout the course of the study. The study consisted of the following treatments (Table 5):

TABLE 5

Experimental design

Phytase

level

Dietary treatment
Protease inclusion
(FTU/kg)

1. Negative control (NC)
—
500

2. NC + commercial protease
0.2
g/kg
500

product A (trypsin family protease

75000 PROT/g activity)

3. NC + commercial protease
4000
U/kg
500

product B (subtilisin family

protease 2750-3500 GSU/g activity)

4. NC + tripeptidyl peptidase
0.01
g/kg
500

Commercial protease product A is a trypsin family protease and Commercial protease product B is a subtilisin family protease, neither of which are proline tolerant tripeptidyl peptidases in accordance with the present invention.

Bird weights were recorded at study initiation (d0), day 14, and at study termination (d21).

The cage is the experimental unit. Diets were fed in mash form and were formulated to meet or exceed NRC standards, except for Ca and AvP (Table 5). All feed was mixed using a Davis S-20 mixer, the mixer was flushed between each treatment to prevent cross contamination between rations. Samples were collected from each treatment diet from the beginning, middle and end of each batch and were minced together for analysis of enzyme activity in feed.

All birds were fed a corn soy base ration until day 14; from day 14 the treatment rations were fed. Phytase was added to all treatment rations. At the feed change, feeders were removed from the cages, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study (d21), feed and birds were weighed, to determine feed intake (FI) and body weight gain (BWG) for the experimental period. Pens were checked daily for mortality. When a bird was culled or found dead, the date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the possible cause of death. Feed conversion ratio (FCR) corrected for mortality was determined.

On d21, all birds per cage were euthanised by intracardial injection of sodium pentobarbitone and contents of the lower ileum were expressed by gentle flushing with distilled water. Digesta from birds within a cage were pooled, resulting in eight samples per dietary treatment. The digesta samples were frozen immediately after collection, lyophilised and processed. Diets and digesta samples were analysed for the marker, nitrogen (N) and gross energy to enable calculation of digestibility co-efficients.

TABLE 6

Diet formulations

Ingredient %
0-14 days
14-21 days

Maize
48.78
57.09

Soybean Meal, 48% CP
40.06
34.7

Canola meal
4
4

Soybean Oil
3
1.35

L-Lysine HCl
0.13
0.07

DL-methionine
0.28
0.22

L-threonine
0.03
0

Salt
0.33
0.33

Limestone
1
0.98

Dicalcium Phosphate
2.09
0.97

Poultry Vits/TE's
0.3
0.3

Calculated Analyses

PROTEIN %
24.98
22.97

MEP MJ/KG
12.4
12.34

CALCIUM %
1.05
0.76

AV PHOS %
0.5
0.3

ALYS %
1.27
1.1

AM + C %
0.94
0.84

ATHRE %
0.83
0.73

ATRYP %
0.26
0.23

Statistical Analysis

Data were analyzed using ANOVA, and means separation conducted to test differences between the different enzymes and enzyme dosages. Cage was used as the experimental unit.

Results

TABLE 7

Performance and digestibility results

Ileal

digestible

BWG
FI
FCR
Ileal N
energy

(g)
(g)
(kg/kg)
Digestibility %
(MJ/kg)

NC
386.3^b
576.3^a
1.496^a
79.6^b
12.45^b

NC + commercial protease A
414.1^ab
582^a
1.429^b
81.7^a
12.98^a

(trypsin family protease 75000

PROT/g activity)

NC + commercial protease B
386.2^b
572.2^a
1.486^a
80.3^b
12.89^a

(subtilisin family protease

2750-3500 GSU/g activity)

NC + tripeptidyl peptidase
420.8^a
597.7^a
1.422^b
81.7^a
13.12^a

SEM
11.1
9.4
0.018
0.4
0.112

Effect tests

Treatment
0.0627
0.2563
0.0092
0.0016
0.0011

Each value represents the mean of 9 replicates (8 birds per replicate).

^abMeans in a column not sharing a common superscript are different (P < 0.05).

Commercial protease A is a trypsin family protease and Commercial protease B is a subtilisin family protease, neither of which are proline tolerant tripeptidyl peptidases in accordance with the present invention.

Supplementation of the proline tolerant tripeptidyl peptidase resulted in a significant reduction in FCR compared to the negative control and commercial protease B and a numerical reduction in comparison to commercial protease A.

Proline tolerant tripeptidyl peptidase supplementation significantly increased BWG compared to the NC, this was not the case for either commercial protease A or commercial protease B.

Proline tolerant tripeptidyl peptidase significantly increased ileal N digestibility % compared to the control and commercial protease B (FIG. 11). Proline tolerant tripeptidyl peptidase also significantly increased the energy digested to a level significantly greater than the negative control and numerically greater than the two commercial proteases (FIG. 12).

Conclusions

In conclusion, supplementation of proline tolerant tripeptidyl peptidase resulted in significantly better bird performance than the NC and commercial protease B in terms of FCR and BWG. There was a numerical increase in BWG and reduction in FCR when proline tolerant tripeptidyl peptidase was supplemented compared to commercial protease A.

The improvements in bird performance ware driven by improved energy and protein (N) digestibility compared to the commercial proteases.

Example 8
Combination of Acid Fungal Protease (Alphalase® AFP) and Proline Tolerant Tripeptidyl Peptidase (TRI083) in Animal Feed

A total of 432 one day old Ross 308 male broiler chicks were purchased form a commercial hatchery. At study initiation, 8 birds were randomly allocated to battery cages according to respective treatments by blocks. Only healthy birds were selected for the experiment, and no birds were replaced throughout the course of the study. The study consisted of the following treatments (Table 8):

TABLE 8

Experimental design

Phytase

level

Dietary treatment
Protease inclusion
(FTU/kg)

1. Negative control (NC)
—
500

2. NC + commercial protease
0.2
g/kg
500

product A

3. NC + commercial protease
4000
U/kg
500

product B

4. NC + acid fungal protease (AFP)
0.0015 g/kg of AFP
500

5. NC + AFP + 0.0035 g/kg
0.0015 g/kg of AFP
500

tripeptidyl peptidase
0.0035 g/kg

tripeptidyl peptidase

8. NC + AFP + 0.007 g/MT
0.0015 g/kg of AFP
500

tripeptidyl peptidase
0.007 g/kg of

tripeptidyl peptidase

Bird weights were recorded at study initiation (d0), day 14, and at study termination (d21). The cage is the experimental unit. Diets were fed in mash form and were formulated to meet or exceed NRC standards, except for Ca and AvP (Table 9.2). All feed was mixed using a Davis S-20 mixer, the mixer was flushed between each treatment to prevent cross contamination between rations. Samples were collected from each treatment diet from the beginning, middle and end of each batch and were minced together for analysis of enzyme activity in feed.

TABLE 7

Diet formulations

Ingredient %
0-14 days
14-21 days

Maize
48.78
57.09

Soybean Meal, 48% CP
40.06
34.7

Canola meal
4
4

Soybean Oil
3
1.35

L-Lysine HCl
0.13
0.07

DL-methionine
0.28
0.22

L-threonine
0.03
0

Salt
0.33
0.33

Limestone
1
0.98

Dicalcium Phosphate
2.09
0.97

Poultry Vits/TE's
0.3
0.3

Calculated Analyses

PROTEIN %
24.98
22.97

MEP MJ/KG
12.4
12.34

CALCIUM %
1.05
0.76

AV PHOS %
0.5
0.3

ALYS %
1.27
1.1

AM + C %
0.94
0.84

ATHRE %
0.83
0.73

ATRYP %
0.26
0.23

All birds were fed a corn soy base ration until day 14; from day 14 the treatment rations were fed. Enzyme doses used in the study were selected for being most commercially relevant. Phytase was added to all treatment rations. At the feed change, feeders were removed from the cages, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study (d21), feed and birds were weighed, to determine feed intake (FI) and body weight gain (BWG) for the experimental period. Pens were checked daily for mortality. When a bird was culled or found dead, the date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the possible cause of death. Feed conversion ratio (FCR) corrected for mortality was determined.

Statistical Analysis

Data were analyzed using ANOVA, and means separation conducted to test differences between the different enzymes and enzyme dosages. Cage was used as the experimental unit.

Results

TABLE 8

Performance and digestibility results

Ileal

digestible

BWG
FI
FCR
Ileal N
energy

(g)
(g)
(kg/kg)
Digestibility %
(MJ/kg)

NC
386.3
576.3
1.496a
79.6c
12.45b

NC + commercial
414.1
582.0
1.429c
81.7a
12.98a

protease A

NC + commercial
386.2
572.2
1.486ab
80.3bc
12.89a

protease B

NC + acid fungal
391.2
575.8
1.475abc
79.8bc
12.67ab

protease (AFP)

NC + AFP + 0.0035 g/kg
418.1
595.9
1.428c
80.9ab
12.78a

tripeptidyl peptidase

NC + AFP + 0.007 g/MT
404.6
583.3
1.443bc
81.5a
12.92a

tripeptidyl peptidase

SEM
10.5
8.9
0.017
0.406
0.11

Effect tests

Treatment
0.1258
0.4891
0.021
0.0012
0.0144

Each value represents the mean of 9 replicates (8 birds per replicate).

abMeans in a column not sharing a common superscript are different (P < 0.05).

From Table 8 it can be seen that there was a significant effect of treatment on FCR, there was no significant difference between birds fed the NC diet and the AFP alone, even though there was a numerical reduction in FCR. However, diets supplemented with a combination of AFP and proline tolerant tripeptidyl peptidase significantly reduced FCR to a level lower than the control and commercial protease B.

There was a numerical increase in ileal N digestibility (%) when the NC diet was supplemented with AFP alone. There was a stepwise improvement in ileal N digestibility (%) as tripeptidyl peptidase dose increased on top of the AFP, with the combination of AFP and 0.007 g/MT tripeptidyl peptidase having significantly higher ileal N digestibility (%) than the NC, commercial protease B and the AFP alone.

Similarly there was a stepwise numerical increase in ileal energy digestibility as tripeptidyl peptidase was added in increasing doses on top of the AFP, in all cases the combination of AFP and tripeptidyl peptidase was significantly better than the negative control.

Conclusions

In conclusion, there is a beneficial effect of the combination of AFP and proline tolerant tripeptidyl peptidase on improving bird performance. This is driven by an increase in the ileal digestibility of N and energy in birds fed the combination rather than just the AFP enzyme alone. The combination of AFP and proline tolerant tripeptidyl peptidase conferred significantly higher levels of N and energy digestibility than some commercial proteases.

Example 9
Materials and Methods
Evaluation of the Protein Content in the Proteases

In order to add equivalent amounts of proteases into the tests, the protein contents of the proteases were measured using Pierce™ BCA protein assay kit. Enzymes stock solution was prepared, whereas rest of the enzymes were in the liquid form. Proteases were diluted 1:10, 1:100 and 1:1000 with MQ water, after which the protein content was measured according to the instructions in the kit.

In Vitro Digestion of the Feed with Proteases

In vitro digestions were performed by simulation of the upper gastrointestinal tract (UGIT) with soy-corn based feed to produce test material for HT-29 MTX E12 cell culture experiments. 5.0 g of pelletized chicken feed was crushed by a mortar and hydrated with 15 ml of MQ water. Proteases were added to the digestions according to Table 1, pH adjusted to 5.5, and the digestions were incubated at 39° C. water bath for 20 min by mixing the bottles at five minutes intervals. The conditions of proventriculus and gizzard were simulated by adding 2.5 ml of 1.5 M HCl and 2.5 ml of pepsin solution (1.8 mg/ml in MQ-water) to the digestions, adjusting pH to 2.5, and incubating the bottles at 39° C. water bath for 40 min with mixing at 5 min intervals. The condition of small intestine was simulated by adding 2.5 ml of NaHCO₃containing 18.5 mg pancreatin, adjusting the pH to 6.3-6.5, and incubating the bottles at 39° C. water bath for 60 min by mixing at 5 min intervals. Digestions were centrifuged at 30 000×g for 30 min and the supernatants were collected to new tubes. Digestive and protease enzymes were inactivated by incubating the supernatants in boiling water for 4 minutes. The digestions were cooled on ice and stored in freezer (−20° C.) for cell culture experiments.

The protein amount was adjusted so that for each protein the final concentration was about 1 μg/ml solution added to the cells.

TABLE 9

Amount of protease in the digestions

Treatment #
Protease product
Dose (microgram/g feed)

1
Control
0

2
Commercial Protease A
10

3
Commercial Protease B
1000

4
TRIO83
10

5
TRIO83 + Alphalase ® AFP
10 + 10

Cell Culture

HT-29 MTX E12 cells (HPA Cultures, Salisbury, England) were maintained in DMEM (high glucose) supplemented with 10% FBS, 1×MEM non-essential amino acids, 1× sodium pyruvate, 1× antibiotic-antimycotic at 37° C., in 8% CO₂atmosphere. All the media and supplements were purchased from Life Technologies.

For studies investigating the effects of proteases on tight junctions and inflammation markers on differentiated cells, the HT-29 MTX E12 cells were seeded at a density of 5.7×10⁴cells/well on cell culture inserts coated with rat tail collagen type I in complete cultivation medium and differentiated for 14 days. On the 4^thday of differentiation, the cells were moved to asymmetric serum-conditions using the serum-free cultivation medium on the apical side and the complete medium on the basal side of the insert. This condition was used until the end of the differentiation by changing the media at three days intervals. The test solutions were applied on the apical chamber of the cells.

ATP Measurements

HT-29 MTXE12 cells were seeded at a density of 2500 cells/well on white 96-well microplates with complete cultivation medium overnight, and then the serum-free medium was changed to the cells for yet another overnight incubation. On the third day of cultivation, the cells were treated with test materials and the ATP measurement was performed. As a test material, proteases were diluted as such 0.01, 0.1, 0.25, 0.5, 1, 2.5, and 5 μg/ml (based on their protein amount) in SFM. For combination of proline tolerant tripeptidyl peptidase (TRI083) and Alphalase) AFP, the amount of both enzymes was added the equal amount. When proteases in feed were used the feed supernatant was diluted 1:1 in SFM and equal amount of proteases were added as was in the in vitro digestion (table 3). The ATP content of the cells was measured using ATPLite™ monitoring system (Perkin Elmer) following the manufacturer's instructions after 15 min or 1 h from starting the experiment.

FITC-Dextran Permeability Assay

The effect of proteases on macromolecular permeability of epithelial layer was studied by monitoring the FITC dextran flux through the differentiated HT-29 MTX E12 cell layer. Differentiated cells were washed with HBSS medium and equilibrated in HBSS at +37° C., with for 30 minutes. HBSS medium was removed and 0.5 ml of test solutions were added to the cells. Test solutions were prepared by diluting the in vitro digested feed 1:1 with HBSS and adding two amounts of proteases into the samples (1 and 10 μg/ml). The FITC-Dextran (mol wt 10 000) was included in the test solutions as 1 mg/ml. The HBSS in the apical chambers of the cells were replaced with the test solutions, and the cells were placed in the incubator for 1 h. The cells were shaken with orbital shaker (30 rpm) during this time to minimize the effect of the unstirred water layer. After 1 h 200 μl samples were drawn from the basolateral chamber, and 200 μl of fresh HBSS was added into the basolateral side. This was continued for additional 3 hours. The final sample was drawn after 24 hours had gone from the beginning of the study. After that the fluorescence of the samples was measured, and the Papp calculated using the following formula:

$P_{app} = \frac{V ({cm}^{3})}{A ({cm}^{3})} \times \frac{Ci (100 µM)}{T \times Cf}$

TEER Measurements

The integrity of HT-29 MTXE12 cell monolayer was studied by measurement of Transepithelial Electrical Resistance (TEER) using Epithelial Voitohmmeter. TEER was measured before and after the treatment, the resistance of an empty filter without cells was subtracted from the measured values, multiplied with the surface area of the filter, and the results were expressed as Ω×cm². A percentual change in TEER after treatment was calculated by subtracting the TEER measured before treatment from the TEER measured after treatment, dividing this value with the TEER measured before treatment and multiplying with 100.

Results
Example 9.1
Effect of Proteases on ATP Content in the Cells Treated by Proteases

ATP deficiency is a marker for cytotoxicity but it also describes the overall situation in the energy reservoir of the cells. ATP content was measured from HT-29 MTXE12 cells after treatment with proteases mixed directly with cell cultivation medium by ATPLite™ system. Significant dose-dependent changes were observed after one hour treatment with Commercial Protease 1 and Commercial Protease 2 (FIG. 13). That would lead to the assumption that Commercial Protease 1 and Commercial Protease 2 have a negative effect on living cells.

Example 9.2

Effect of In Vitro Digested Feed with Proteases on Cellular ATP Content

ATP content was also measured from HT-29 MTXE12 cells after one-hour treatment using in vitro digested feed containing proteases. The highest amount of Commercial Protease 1 and Commercial Protease 2 are showing significant reduction in the amount of ATP compared to control in vitro digested feed, and thus leading to the possible cytotoxicity of cells. That would confirm the negative effect of high dosages of Commercial Protease 1 and Commercial Protease 2 on living cells (see FIG. 14).

Example 9.3
Permeability Assessment

The effect of the in vitro digested feed with proteases on macromolecular permeability was studied using FITC-Dextran permeability assay. For the after the heat inactivation of the digested feed 1 and 10 μg/ml of protease was added. In some of the assays medium with pH 6.5 was used in order to evaluate the effect of lower pH. For the FITC-Dextran permeability, the tracer was mixed with the in vitro digested feed and applied on the apical compartment. After the four hours the permeability was calculated (FIG. 15).

As can be seen from the figure that both Commercial Protease 1 and Commercial Protease 2 significantly increase the macromolecular permeability of cells, thus it has a negative effect on those cells. Neither TRI083 alone nor in combination with Alphalase® AFP induced such response.

A similar phenomenon was observed during the TEER measurement. A decrease in tight junction integrity was observed both for Commercial Protease 1 and Commercial Protease 2 (FIG. 16) which would also lead to the conclusion of negative effect of Commercial Protease 1 and Commercial protease 2 on living cells, while TRI083 alone or in combination with Alphalase® AFP does not contribute to any negative effects for the cells.

Example 10
Supplementation of Tripeptidyl Peptidase (TRIO83) in Animal Feed Improves Nutrient Digestibility

TABLE 10.1

Experimental design

Phytase

level

Dietary treatment
Protease inclusion
(FTU/kg)

1. Negative control (NC)
—
500

2. NC + commercial product A
0.2
g/kg
500

3. NC + commercial product B
4000
U/kg
500

4. NC + tripeptidyl
0.01 g/kg of TRIO83
500

peptidase (TRIO83)

Bird weights were recorded at study initiation (d0) on day 14, and at study termination (d21). The cage is the experimental unit. Diets were fed in mash form and were formulated to meet or exceed NRC standards, except for Ca and AvP (Table 10.2). All feed was mixed using a Davis S-20 mixer, the mixer was flushed between each treatment to prevent cross contamination between rations. Samples were collected from each treatment diet from the beginning, middle and end of each batch and were minced together for analysis of enzyme activity in feed.

TABLE 10.2

Diet formulations

Ingredient %
0-14 days
14-21 days

Maize
48.48
56.78

Soybean Meal 48% CP
40.06
34.7

Canola meal
4
4

Soybean Oil
3
1.35

L-Lysine HCl
0.13
0.07

DL-methionine
0.28
0.22

L-threonine
0.03
0

Salt
0.33
0.33

Limestone
1
0.98

Dicalcium Phosphate
2.09
0.97

Poultry Vits/TE's
0.3
0.3

Calculated Analyses

PROTEIN %
24.98
22.97

MEP MJ/KG
12.4
12.34

CALCIUM %
1.05
0.76

AV PHOS %
0.5
0.3

ALYS %
1.27
1.1

AM + C %
0.94
0.84

ATHRE %
0.83
0.73

ATRYP %
0.26
0.23

On d 21, all birds per cage were euthanised by intracardial injection of sodium pentobarbitone and contents of the lower ileum were expressed by gentle flushing with distilled water. Digesta from birds within a cage were pooled, resulting in eight samples per dietary treatment. The digesta samples were frozen immediately after collection, lyophilised and processed. Diets and digesta samples were analysed for the marker, nitrogen (N) and gross energy to enable calculation of digestibility co-efficients.

Statistical Analysis

Data were analyzed using ANOVA, and means separation conducted to test differences between the different enzymes and enzyme dosages. Cage was used as the experimental unit.

Results

TABLE 10.3

Performance and digestibility results

Ileal

digestible

BWG
FI
FCR
Ileal N
energy

(g)
(g)
(kg/kg)
Digestibility %
(MJ/kg)

NC
386.3^y
576.3
1.496^a
79.6^b
12.45^b

NC + commercial
414.1^xy
582.0
1.429^b
81.7^a
12.98^a

protease A

NC + commercial
386.2^y
572.2
1.486^a
80.3^b
12.89^a

protease B

NC + tripeptidyl
420.8^x
597.7
1.422^b
81.7^a
13.12^a

peptidase (TRIO83)

SEM
11.1
9.4
0.018
0.4
0.112

Effect tests

Treatment
0.0627
0.2563
0.0092
0.0016
0.0011

Each value represents the mean of 9 replicates (8 birds per replicate).

^abMeans in a column not sharing a common superscript are different (P < 0.05).

^xyMeans in a column not sharing a common superscript are different (P < 0.1)

There was a significant effect of treatment on FCR, birds fed the tripeptidyl peptidase (TRIO83) has significantly lower FCR than the NC diet and commercial protease A.

There was a significant increase in ileal N digestibility (%) when the NC diet was supplemented with tripeptidyl peptidase (TRI083). The increase in N digestibility % was comparable between tripeptidyl peptidase (TRIO83) and commercial protease A, both conferred significantly higher N digestibility than commercial protease B (FIG. 18). Similarly, there was a significant increase in ileal digestible energy versus the negative control when each of the protease enzymes was supplemented; ileal energy digestibility was numerically highest when tripeptidyl peptidase (TRIO83) was supplemented (FIG. 19).

Conclusions

In conclusion, there is a beneficial effect of tripeptidyl peptidase (TRIO83) on improving bird performance through reducing FCR. This is driven by an increase in the ileal digestibility of N and energy in birds fed tripeptidyl peptidase (TRIO83).

Tripeptidyl peptidase (TRI083) conferred significantly higher levels of N and energy digestibility than some commercial proteases.

Example 11
Supplementation of Tripeptidyl Peptidase (TRIO83) in Animal Feed Improves Broiler Performance

A total of 1600 one day old Ross 708 male broiler chicks were purchased from a commercial hatchery. At study initiation, 40 birds were randomly allocated to floor pens according to respective treatments by blocks. Only healthy birds were selected for the experiment, and no birds were replaced throughout the course of the study. The study consisted of the following treatments (Table 11.1):

TABLE 11.1

Experimental design

Phytase

level

Dietary treatment
Protease inclusion
(FTU/kg)

1. Positive control (PC)

500

2. Negative control (NC)
—
500

3. NC + commercial protease A
0.2
g/kg
500

4. NC + commercial protease B
4000
U/kg
500

5. NC + tripeptidyl
0.01 g/kg of TRIO83
500

peptidase (TRIO83)

Bird weights were recorded at study initiation (d0) and at diet changes on d10, d25 and at study termination (d42). The pen is the experimental unit. All diets were fed in mash form. The PC diets were formulated to meet or exceed NRC standards and the NC diets were down-specified by 50% of the undigested fraction of the amino acids in the PC diets (Table 11.2). All feed was mixed using a Davis S-20 mixer, the mixer was flushed between each treatment to prevent cross contamination between rations. Samples were collected from each treatment diet from the beginning, middle and end of each batch and were minced together for analysis of enzyme activity in feed.

TABLE 11.2

Diet formulations

Starter
Grower
Finisher

PC
NC
PC
NC
PC
NC

Maize
59.75
61.22
64.91
70.35
69.14
74.34

SBM 48% CP
30.99
27.82
25.31
21.70
21.23
17.95

Rapeseed Meal
4.00
4.00
4.00
4.00
4.00
4.00

Wheat Bran
0.00
2.78
0.00
0.00
0.00
0.00

Soybean Oil
1.03
0.00
2.15
0.24
2.26
0.33

L-Lysine HCl
0.310
0.314
0.280
0.304
0.247
0.272

DL-methionine
0.327
0.300
0.280
0.257
0.237
0.210

L-threonine
0.097
0.079
0.085
0.075
0.066
0.051

Sodium Bicarbonate
0.17
0.17
0.00
0.17
0.00
0.00

Salt
0.23
0.22
0.34
0.22
0.35
0.35

Limestone
1.26
1.27
1.05
1.06
1.03
1.04

Dicalcium
1.29
1.27
1.04
1.06
0.90
0.91

Phosphate

Poultry Vits/TE's
0.30
0.30
0.30
0.30
0.30
0.30

Enzymes
0.25
0.25
0.25
0.25
0.25
0.25

Calculated Nutrients

[VOLUME]
100.00
100.00
100.00
100.00
100.00
100.00

DRY_MAT
87.94
87.80
87.94
87.69
87.88
87.62

PROTEIN %
21.34
20.32
18.94
17.63
17.24
16.06

MEP MJ/KG
12.52
12.18
13.07
12.74
13.27
12.93

MEP Kcal/KG
2992
2911
3124
3045
3172
3090

TLYSINE %
1.40
1.33
1.22
1.14
1.08
1.01

ALYS %
1.27
1.20
1.10
1.03
0.97
0.91

METH %
0.67
0.63
0.60
0.56
0.53
0.49

AMETH %
0.64
0.60
0.57
0.53
0.51
0.47

M + C %
1.04
0.99
0.93
0.88
0.85
0.79

AM + C %
0.94
0.89
0.84
0.79
0.76
0.71

THREO %
0.96
0.89
0.84
0.78
0.76
0.69

ATHRE %
0.83
0.77
0.73
0.67
0.65
0.59

TRYPTO %
0.28
0.26
0.24
0.22
0.22
0.20

ATRYP %
0.27
0.25
0.23
0.21
0.20
0.18

ARGINI %
1.51
1.42
1.31
1.20
1.17
1.07

AARG %
1.31
1.21
1.14
1.04
1.02
0.93

ISOLEUC %
1.04
0.97
0.91
0.83
0.81
0.74

AISO %
0.95
0.87
0.82
0.75
0.73
0.67

VAL %
1.17
1.09
1.03
0.96
0.94
0.88

AVAL %
1.04
0.97
0.92
0.85
0.83
0.77

CALCIUM %
0.92
0.92
0.77
0.77
0.72
0.72

TPHOS %
0.63
0.64
0.56
0.55
0.52
0.51

AV PHOS %
0.35
0.35
0.30
0.30
0.27
0.27

NA %
0.16
0.16
0.16
0.16
0.16
0.16

K %
0.82
0.80
0.73
0.68
0.67
0.62

CL %
0.23
0.23
0.30
0.23
0.29
0.30

All birds were fed treatment rations throughout the study. Enzyme doses used in the study were selected for being most commercially relevant. Phytase was added to all treatment rations at 500 FTU/kg. At the feed change, feeders were removed from the cages, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study (d42), feed and birds were weighed, to determine feed intake (FI) and body weight gain (BWG) for the experimental period. Pens were checked daily for mortality. When a bird was culled or found dead, the date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the possible cause of death. Feed conversion ratio (FCR) corrected for mortality was determined.

Statistical Analysis

Data were analyzed using ANOVA, and means separation conducted to test differences between the different enzymes and enzyme dosages. Pen was used as the experimental unit.

Results

TABLE 11.3

Performance results

BWG
FI
FCR

(g/bird)
(kg/pen)
(kg/kg)

PC
2235^a
159.37
1.870^b

NC
2135^c
158.75
1.957^a

NC + commercial protease A
2145^c
157.70
1.940^a

NC + commercial protease B
2160^bc
159.52
1.949^a

NC + tripeptidyl
2215^ab
158.82
1.888^b

peptidase (TRIO83)

SEM
23.4
2.4
0.018

Effect tests

Treatment
0.01
0.986
0.004

Each value represents the mean of 9 replicates (8 birds per replicate).

^abMeans in a column not sharing a common superscript are different (P < 0.05).

There was a significant effect of treatment on BWG; birds fed the NC diet had significantly lower bodyweights than birds fed the PC diet. Enzyme treatment with commercial proteases A+B numerically increased bodyweight but not to a level significantly different to the NC birds. Supplementation with tripeptidyl peptidase (TRIO83) significantly increased bodyweight gain of birds compared to the NC to a level not significantly different to the PC birds (FIG. 20).

Similarly, FCR in NC birds was significantly higher than the PC birds. There was no significant effect of commercial protease A+B on FCR compared to the NC. Tripeptidyl peptidase (TRIO83) significantly reduced FCR compared to the NC birds to a level not significantly different to the PC birds (FIG. 21).

Conclusions

In conclusion, there is a beneficial effect of tripeptidyl peptidase (TRI083) on improving bird performance through reducing FCR and increasing BWG in nutrient deficient diets.

Tripeptidyl peptidase (TRIO83) increased BWG and reduced FCR to greater levels than commercial proteases A+B.

Example 12
Stability of TRI045 (SEQ ID No. 99) Tripeptidyl Peptidase in the Presence of Pepsin
Material and Methods

Pepsin solution: Swine pepsin from Sigma (P7000, 674 Sigma units/mg, www.sigma.com) was used in this example and prepared in MilliQ water at 10000 Sigma unit/ml at 10000 Sigma unit/mL.

Pre-incubation mixture contained: 2.5 μl sedolisin sample, 95 μl GAT buffer (50 mM glycine-50 mM acetic acid-50 mM Tris, pH3.5), 5 μl pepsin in milliQ water (10000 Sigma unit/ml) (final pepsin unit concentration: 500 Sigma unit/ml reaction mixture) in a half bottom area 96 well Corning MTP. For control, the pre-incubation mixture contained 5 μl water instead of 5 μl pepsin. The mixture was incubated at 40° C. for 60 min and then kept on ice. For assaying the residual activity, the assay mixture contained the pre-incubation mixture 5 μl, 0.1 M acetic acid-sodium acetate (pH4.0) 85 μl, 5 μl H-Ala-Ala-Phe-pNA (2.5 mg/ml) from BACHEM.com (L-1095.0250). The 410 nm reading was followed in a microplate reader every 0.5 min at 30° C. N=2.

Results

Under the assay conditions and pre-incubation at 40° C. for 60 min, the residual activity was found to be over 90% for TRI045 in the presence of 500 units pepsin/mL pre-incubation mixture.

Example 13
TRI045 (SEQ ID No. 99) as Feed Enzyme to Promote Feed Protein Hydrolysis

Animals produce and secrete proteases into their digestive tracts for feed digestion. These proteases include endoproteases of pepsin, trypsin and chymotrypsin and the exopeptidases of Carboxypeptidase A and B etc. However, animals do not produce aminopeptidases as digestive enzymes or at least not in appreciable amount. As shown in this example, the addition of the tripeptidyl peptidase TRI045 (sedolisin) promotes protein digestion in an in vitro system for corn soy based feed. This example shows that TRI045 had high activity between pH 4 and 6.5

Material and Methods

The tripeptide substrate H-Ala-Ala-Phe-pNA (AAF-pNA from BACHEM.com, L-1095.0250) for sedolisin was prepared at 2.5 mg/ml in DMSO. The reaction was prepared by mixing 8.5 μl AAF-pNA, 7 μl DMSO, 32 μl water and 50 μl buffer with pH4.14-6.57, and 0.8 μl or 1.5 ul TRI045. The reaction was started at 30° C. by the addition of the enzyme TRI045. The initial reaction rate was recorded using a microplate reader at every 0.5 min interval at 410 nm in 96 well plate.

Results

Table 12 shows that TRI045 had optimal activity around pH5.0, but still had around 50% activity at around pH4 and pH6.5, which is ideal for gastric feed digestion. FIG. 22 furthers shows that the final reaction degree reached at pH5, pH5.5 and pH6 are very similar. The high pH optimum is ideal for animal feed as in such situation pancreatin would have time to make more oligopeptide substrates for TRI045.

TABLE 12

Effect of pH on the TRI045 activity using H-Ala-Ala-Phe-pNA

as substrate (values are the average one test with 0.8 μl TRI045

(n = 2) and one test with 1.5 μl TRI045 dose (n = 1).

0.1M
0.1M
0.1M
0.1M
0.1M
0.1M

HAC-
HAC-
HAC-
HAC-
Mes-
Mes-

Buffer
NaAC
NaAC
NaAC
NaAC
NaOH
NaOH

pH
4.1
4.6
5.0
5.6
6.0
6.6

Relative
59.4
81.7
100.0
80.7
72.2
48.5

activity with

pH 5.01

as 100%

Example 14
Effect of TRI045 (SEQ ID No. 99) Plus Pepsin and Pancreatin on Hydrolysis of Corn Soy Feed Substrate.

The in vitro reaction system contained 140 μl 10% (w/v) corn soy feed slurry (14 mg corn soy feed), 10 μl TRI045 in 50 m M MES-NaOH pH 6.0, 10 μl swine pepsin (1,14 U/μL in water). The reaction was incubated with shaking at 40° C. for 45 min and subsequently 34 μl swine pancreatin (0.4636 mg/mL in 1M Na-bicarbonate) were added and further incubated for additional 60 min. After incubation, the 96-well plate was centrifuged and supernatants were used for residual TRI045 activity assay and for OPA and BCA assays (see below).

The degree of Hydrolysis measurements of soluble protein is based on the reaction of primary amino groups with o-phthaldialdehyde (OPA—assay). Reference: P. M. Nielsen, D. Petersen and C. Dambmann. Improved Method for Determining Food Protein Degree of Hydrolysis. Journal of Food Science. 66 (2001) 642-646.

For OPA assay the following procedure was carried out. 10-25 μl feed sample treated by enzyme from master plate was transferred to the new plate, then 175 μl of OPA reagent containing sodium borate, dodecyl sulfate and dithiothreitol, were added to the plate. The end point measurements of optical density at 340 nm were performed right after 2 min and 5 second mixing.

To quantify the protein concentrations of each protease samples, the Pierce BCA Protein Assay Reagent Kit (Thermo Scientific, cat no. 23228) was used. The TRI045 sample was not purified before quantification. The Pierce BCA Protein Assay Kit is a detergent-compatible formulation based on bicinchoninic acid (BCA) for colorimetric detection and quantification of total proteins. This method combines the well-known reduction of Cu²⁺ to Cu¹⁺ by protein in an alkaline medium with the highly sensitive and selective colorimetric detection of the cuprous cat ion (Cu⁺¹) using a unique reagent containing bicinchoinic acid. The purple-coloured reaction product of this assay is formed by the chelation of two molecules of BCA with one cuprous ion. This water soluble complex exhibits a strong absorbance at 562 nm that is nearly linear with increasing protein concentration over a broad working range (20-2000 μg/mL). The macromolecular structure of protein, the number of peptide bonds and the presence of four particular amino acids Cysteine, Cystine, Trytophan and Tyrosine are reported to be responsible for colour formation with BCA.

For OPA (total amino group released) and BCA (total protein in the soluble fraction) determinations the supernatants were diluted 20 times and 10 ul was used.

In the system containing TRI045 at 1000 ppm, in the presence of swine pepsin and pancreatin, the release of free amino groups from corn soy feed (as a measure of protein hydrolysis (OPA value)) increased by 9% and the protein solubility increased by 5%.

In order to test the stability of TRI045 under the in vitro assay conditions described above (incubation in the presence of pepsin at pH3 for 45 min at 40° C. and subsequently in the presence of pancreatin for 60 min at 40° C.). The residual activity of TRI045 was subsequently assayed. The reaction mixture contained 50 μl buffer 0.1M HAC-NaAC (pH5.0), 10 μl the supernatant, and 5 μl AAF-pNA (5 mg/ml in DMSO). The reaction rate was followed at 410 nm and 30° C. every 30 seconds using a microplate reader. As a control, a commercial protease at the same concentration of 1000 ppm was used.

Conclusion for Examples 12-14

The reaction rate for the control (pepsin and pancreatin only) was 4.3 mOD/min, for the commercial protease it was 11.0 mOD/min, and for TRI045 it was 19.3 mOD/min. After the subtraction of the control (4.3 mOD/min), the residual activity of TRI045 on AAF-pNA substrate was 2.2 times higher than for the commercial protease. These results indicate that TRI045 is stable to pepsin and pancreatin at 40° C. for at least 100 minutes.

In conclusion, this example demonstrates that TRI045 is stable to pepsin and pancreatin when incubated for 105 min at 40° C. in the presence of corn soy feed at a pH range of 3 to 7. It has also the additional effect of increasing protein solubilization and protein hydrolysis in the presence of pepsin and pancreatin when corn soy feed was used as the substrate under conditions mimicking the monogastric digestion system (BEDFORD, M. R., & CLASSEN, H. L. (1993) “An in vitro assay for prediction of broiler intestinal viscosity and growth when fed rye-based diets in the presence of exogenous enzymes”. Poultry Science, 72: 137-143), i.e., the reaction was carried out at 40° C. at pH3.0-3.3 in the presence of pepsin for 45 min and then pH raised to pH6.5-7.0 and addition of pancreatin for additional 60 min incubation,

Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

Number	Date	Country
62068282	Oct 2014	US
62068264	Oct 2014	US
62068243	Oct 2014	US
62093301	Dec 2014	US

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

PCT Information

Provisional Applications (4)